WorldWideScience

Sample records for bnct treatment planning

  1. BNCT-RTPE: BNCT radiation treatment planning environment

    Energy Technology Data Exchange (ETDEWEB)

    Wessol, D.E.; Wheeler, F.J. [Idaho National Engineering Lab., Idaho Fall, ID (United States); Babcock, R.S. [and others

    1995-11-01

    Several improvements have been developed for the BNCT radiation treatment planning environment (BNCT-Rtpe) during 1994. These improvements have been incorporated into Version 1.0 of BNCT-Rtpe which is currently installed at the INEL, BNL, Japanese Research Center (JRC), and Finland`s Technical Research Center. Platforms supported by this software include Hewlett-Packard (HP), SUN, International Business Machines (IBM), and Silicon Graphics Incorporated (SGI). A draft version of the BNCT-Rtpe user manual is available. Version 1.1 of BNCT-Rtpe is scheduled for release in March 1995. It is anticipated that Version 2.x of BNCT-Rtpe, which includes the nonproprietary NURBS library and data structures, will be released in September 1995.

  2. Implementation of BNCT treatment planning procedures

    International Nuclear Information System (INIS)

    Estimation of radiation doses delivered during boron neutron capture therapy (BNCT) requires combining data on spatial distribution of both the thermal neutron fluence and the 10B concentration, as well as the relative biological effectiveness of various radiation dose components in the tumor and normal tissues. Using the treatment planning system created at Idaho National Engineering and Environmental Laboratory and the procedures we had developed for clinical trials, we were able to optimize the treatment position, safely deliver the prescribed BNCT doses, and carry out retrospective analyses and reviews. In this paper we describe the BNCT treatment planning process and its implementation in the ongoing dose escalation trials at Brookhaven National Laboratory. (author)

  3. Treatment Planning Systems for BNCT Requirements and Peculiarities

    CERN Document Server

    Daquino, G G

    2003-01-01

    The main requirements and peculiarities expected from the BNCT-oriented treatment planning system (TPS) are summarized in this paper. The TPS is a software, which can be integrated or composed by several auxiliary programs. It plays important roles inside the whole treatment planning of the patient's organ in BNCT. However, the main goal is the simulation of the irradiation, in order to obtain the optimal configuration, in terms of neutron spectrum, patient positioning and dose distribution in the tumour and healthy tissues. The presence of neutrons increases the level of complexity, because much more nuclear reactions need to be monitored and properly calculated during the simulation of the patient's treatment. To this purposes several 3D geometry reconstruction techniques, generally based on the CT scanning data, are implemented and Monte Carlo codes are normally used. The TPSs are expected to show also the results (basically doses and fluences) in a proper format, such as isocurves (or isosurfaces) along t...

  4. Voxel model in BNCT treatment planning: performance analysis and improvements

    Science.gov (United States)

    González, Sara J.; Carando, Daniel G.; Santa Cruz, Gustavo A.; Zamenhof, Robert G.

    2005-02-01

    In recent years, many efforts have been made to study the performance of treatment planning systems in deriving an accurate dosimetry of the complex radiation fields involved in boron neutron capture therapy (BNCT). The computational model of the patient's anatomy is one of the main factors involved in this subject. This work presents a detailed analysis of the performance of the 1 cm based voxel reconstruction approach. First, a new and improved material assignment algorithm implemented in NCTPlan treatment planning system for BNCT is described. Based on previous works, the performances of the 1 cm based voxel methods used in the MacNCTPlan and NCTPlan treatment planning systems are compared by standard simulation tests. In addition, the NCTPlan voxel model is benchmarked against in-phantom physical dosimetry of the RA-6 reactor of Argentina. This investigation shows the 1 cm resolution to be accurate enough for all reported tests, even in the extreme cases such as a parallelepiped phantom irradiated through one of its sharp edges. This accuracy can be degraded at very shallow depths in which, to improve the estimates, the anatomy images need to be positioned in a suitable way. Rules for this positioning are presented. The skin is considered one of the organs at risk in all BNCT treatments and, in the particular case of cutaneous melanoma of extremities, limits the delivered dose to the patient. Therefore, the performance of the voxel technique is deeply analysed in these shallow regions. A theoretical analysis is carried out to assess the distortion caused by homogenization and material percentage rounding processes. Then, a new strategy for the treatment of surface voxels is proposed and tested using two different irradiation problems. For a parallelepiped phantom perpendicularly irradiated with a 5 keV neutron source, the large thermal neutron fluence deviation present at shallow depths (from 54% at 0 mm depth to 5% at 4 mm depth) is reduced to 2% on average

  5. Voxel model in BNCT treatment planning: performance analysis and improvements

    International Nuclear Information System (INIS)

    In recent years, many efforts have been made to study the performance of treatment planning systems in deriving an accurate dosimetry of the complex radiation fields involved in boron neutron capture therapy (BNCT). The computational model of the patient's anatomy is one of the main factors involved in this subject. This work presents a detailed analysis of the performance of the 1 cm based voxel reconstruction approach. First, a new and improved material assignment algorithm implemented in NCTPlan treatment planning system for BNCT is described. Based on previous works, the performances of the 1 cm based voxel methods used in the MacNCTPlan and NCTPlan treatment planning systems are compared by standard simulation tests. In addition, the NCTPlan voxel model is benchmarked against in-phantom physical dosimetry of the RA-6 reactor of Argentina. This investigation shows the 1 cm resolution to be accurate enough for all reported tests, even in the extreme cases such as a parallelepiped phantom irradiated through one of its sharp edges. This accuracy can be degraded at very shallow depths in which, to improve the estimates, the anatomy images need to be positioned in a suitable way. Rules for this positioning are presented. The skin is considered one of the organs at risk in all BNCT treatments and, in the particular case of cutaneous melanoma of extremities, limits the delivered dose to the patient. Therefore, the performance of the voxel technique is deeply analysed in these shallow regions. A theoretical analysis is carried out to assess the distortion caused by homogenization and material percentage rounding processes. Then, a new strategy for the treatment of surface voxels is proposed and tested using two different irradiation problems. For a parallelepiped phantom perpendicularly irradiated with a 5 keV neutron source, the large thermal neutron fluence deviation present at shallow depths (from 54% at 0 mm depth to 5% at 4 mm depth) is reduced to 2% on average

  6. Investigation of development and management of treatment planning systems for BNCT at foreign facilities

    International Nuclear Information System (INIS)

    A new computational dosimetry system for BNCT: JCDS is developed by JAERI in order to carry out BNCT with epithermal neutron beam at present. The development and management situation of computational dosimetry system, which are developed and are used in BNCT facilities in foreign countries, were investigated in order to accurately grasp functions necessary for preparation of the treatment planning and its future subjects. In present state, 'SERA', which are developed by Idaho National Engineering and Environmental Laboratory (INEEL), is used in many BNCT facilities. Followings are necessary for development and management of the treatment planning system. (1) Reliability confirmation of system performance by verification as comparison examination of calculated value with actual experimental measured value. (2) Confirmation systems such as periodic maintenance for retention of the system quality. (3) The improvement system, which always considered relative merits and demerits with other computational dosimetry system. (4) The development of integrated system with patient setting. (author)

  7. Investigation of development and management of treatment planning systems for BNCT at foreign facilities

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2001-03-01

    A new computational dosimetry system for BNCT: JCDS is developed by JAERI in order to carry out BNCT with epithermal neutron beam at present. The development and management situation of computational dosimetry system, which are developed and are used in BNCT facilities in foreign countries, were investigated in order to accurately grasp functions necessary for preparation of the treatment planning and its future subjects. In present state, 'SERA', which are developed by Idaho National Engineering and Environmental Laboratory (INEEL), is used in many BNCT facilities. Followings are necessary for development and management of the treatment planning system. (1) Reliability confirmation of system performance by verification as comparison examination of calculated value with actual experimental measured value. (2) Confirmation systems such as periodic maintenance for retention of the system quality. (3) The improvement system, which always considered relative merits and demerits with other computational dosimetry system. (4) The development of integrated system with patient setting. (author)

  8. A treatment planning comparison of BPA- or BSH-based BNCT of malignant gliomas

    Energy Technology Data Exchange (ETDEWEB)

    Capala, J.; Coderre, J.A.; Chanana, A.D.

    1996-12-31

    Accurate delivery of the prescribed dose during clinical BNCT requires knowledge (or reasonably valid assumptions) about the boron concentrations in tumor and normal tissues. For conversion of physical dose (Gy) into photon-equivalent dose (Gy-Eq), relative biological effectiveness (RBE) and/or compound-adjusted biological effectiveness (CBE) factors are required for each tissue. The BNCT treatment planning software requires input of the following values: the boron concentration in blood and tumor, RBEs in brain, tumor and skin for the high-LET beam components, the CBE factors for brain, tumor, and skin, and the RBE for the gamma component.

  9. Some recent developments in treatment planning software and methodology for BNCT

    International Nuclear Information System (INIS)

    Over the past several years/the Idaho National Engineering Laboratory (INEL) has led the development of a unique, internationally-recognized set of software modules (BNCT rtpe) for computational dosimetry and treatment planning for Boron Neutron Capture Therapy (BNCT). The computational capability represented by this software is essential to the proper administration of all forms of radiotherapy for cancer. Such software addresses the need to perform pretreatment computation and optimization of the radiation dose distribution in the target volume. This permits the achievement of the optimal therapeutic ratio (tumor dose relative to critical normal tissue dose) for each individual patient via a systematic procedure for specifying the appropriate irradiation parameters to be employed for a given treatment. These parameters include angle of therapy beam incidence, beam aperture and shape,and beam intensity as a function of position across the beam front. The INEL software is used for treatment planning in the current series of human glioma trials at Brookhaven National Laboratory (BNL) and has also been licensed for research and developmental purposes to several other BNCT research centers in the US and in Europe

  10. Co-registration of the BNCT treatment planning images for clinical practice

    International Nuclear Information System (INIS)

    We have co-registered MRI, CT and FBPA-PET images for BNCT in clinical practice. Co-registration improves the spatial accuracy of the treatment planning by enabling use of information from all the co-registered modalities. The multimodal co-registration has been implemented as a service product provided by the Imaging Center of Helsinki University Central Hospital to other departments. To increase the accuracy of co-registration and patient positioning in the head area BNCT, a patient-specific fixation mask suitable for PET, MRI and CT was developed. The goal of the fixation mask is to normalize the orientation of the patient's head and neck. Co-registration is performed at the image processing unit by using a rigid body model, mutual-information based algorithms and partly in-house developed software tools. The accuracy of co-registration is verified by comparing the locations of the external skin markers and anatomical landmarks in different modalities. After co-registration, the images are transformed and covered into a format required by the BNCT dose-planning software and set to the dose-planning unit of the hospital. So far co-registration has been done for 22 patients. The co-registration protocol has proved to be reliable and efficient. Some registration errors are seen on some patients in the neck area because the rigid-body model used in co-registration is not fully valid for the brain-neck entity. The registration accuracy in this area could likely be improved by implementing a co-registration procedure utilizing a partly non-rigid body model. (author)

  11. Assessment of dose rate scaling factors used in NCTPlan treatment planning code for the BNCT beam of THOR

    International Nuclear Information System (INIS)

    Tsing Hua open-pool reactor (THOR) at Tsing Hua University in Taiwan has been used to investigate the feasibility and to enhance the technology of boron neutron capture therapy (BNCT) for years. A rebuilt epithermal beam port for BNCT at THOR was finished in the summer of 2004, and then researches and experiments were performed to hasten the first clinical treatment case of BNCT in Taiwan in the near future. NCTPlan, a Monte Carlo-based clinical treatment planning code, was used to calculate the dose-rate distributions of BNCT in this work. A self-made Snyder head phantom with a servo-motor control system was irradiated in front of the THOR BNCT beam exit. The phantom was made from a 3 mm shell of quartz wool impregnated with acrylic casting resin mounted on an acrylic base, and was filled with water. Gold foils (bare and cadmium-covered) and paired ion chambers (one with graphite wall and filled with CO2 gas, another with A-150 plastic tissue equivalent wall and filled with tissue equivalent gas) were placed inside the Snyder phantom to measure and estimate the depth-dose distributions in the central axis of the beam. Dose components include the contribution of thermal neutrons, fast neutrons, photons and emitted α particles from 10B(n,α)7Li reaction. Comparison and analysis between computed and measured results of depth-dose distributions were made in this work. Dose rate scaling factors (DRSFs) were defined as normalization factors derived individually for each dose component in the BNCT in-phantom radiation field that provide the best agreement between measured and computed data. This paper reports the in-phantom calculated and experimental dosimetry and the determined DRSFs used in NCTPlan code for the BNCT beam of THOR.

  12. BDTPS The BNCT Treatment Planning System jointly developed at DIMNP and JRC/IE

    CERN Document Server

    Daquino, G G; Mazzini, M; Moss, R; Muzi, L; International Workshop on "Neutron Capture Therapy: State of the art"

    2003-01-01

    The idea to couple the Treatment Planning System (TPS) to the information on the real boron distribution in the patient is the main added value of the new methodology set-up at DIMNP of University of Pisa, in collaboration with the JRC of Petten (NL). The methodology has been implemented in the new TPS, called BDTPS (Boron Distribution Treatment Planning System), which takes into account the actual boron distribution in the patient brain, while the standard TPS assumes a uniform boron distribution, absolutely far from the reality. Nowadays, Positron Emission Tomography (PET) is able to provide this in vivo information. The new TPS, based on the Monte Carlo technique, has been validated comparing the main BNCT parameters (thermal flux, boron dose, etc.) as measured during the irradiation of a special heterogeneous boron phantom (HEBOM), ad hoc designed, as calculated by the BDTPS and by the standard TPS SERA. An evident SERA overestimation of the thermal neutron flux, as well as the boron dose, has been detect...

  13. Development and verification of THORplan—A BNCT treatment planning system for THOR

    International Nuclear Information System (INIS)

    THORplan is a treatment planning system under continuous development and refinement at Tsing Hua University, Taiwan, for BNCT purpose. New features developed for homogeneous model calculation include material grouping model, and voxel data reconstruction model. Material grouping model is a two-step grouping method, tissue-volume-percent grouping method followed by atom-gram-density grouping method. The root mean square difference of neutron flux due to material grouping is <0.8%. In the voxel data reconstruction model, voxel neutron dose is calculated based on the material composition and dose of individual atom of each voxel, which is calculated by linear interpolation from the dose of individual atom of neighboring cells tallied in MCNP calculation. The detailed voxel model is used to benchmark the accuracy of the new features developed for the homogeneous model calculation. The maximum error of the neutron flux and dose of voxels using the homogeneous cell model is 5% and 7%, respectively. Big improvement of accuracy of voxel dose over the original dose calculation model based on F6 tally is observed at locations containing very heterogeneous compositions.

  14. Introducing BNCT treatment in new treatment facilities

    International Nuclear Information System (INIS)

    The physical and radiobiological studies that should be performed before the initiation of BNCT are discussed. The need for dose-escalation versus response studies in large animal models is questioned. These studies are time consuming, expensive and legally difficult in some countries and may be dispensable. (author)

  15. Dose estimation of the THOR BNCT treatment room

    International Nuclear Information System (INIS)

    BNCT beam of Tsing Hua Open-pool Reactor (THOR) was designed and constructed since 1998. A treatment room for the newly modified THOR BNCT beam was constructed for the next clinical-stage trials in 2004. Dose distribution in a patient (or a phantom) is important as irradiated with the BNCT beam. The dose distributions for different type of radiations such as neutron and photons in the treatment room are strongly becoming the index or reference of success for a BNCT facility. An ART head phantom was placed in front of the THOR BNCT beam port and was irradiated. In each section of the head phantom, numbers of small holes are inside and separated uniformly. Dual detector: TLD-600 and TLD-700 chips were placed inside these holes within the phantom to distinct doses of neutron and photon. Besides, Dual-TLD chips were latticed placed in the horizontal plane of beam central axis, in the treatment room to estimate the spatial dose distribution of neutron and photon. Gold foils were assisted in TLD dose calibrations. Neutron and photon dose distributions in phantom and spatial dose distributions in the THOR BNCT treatment room were both estimated in this work. Testing and improvement in THOR BNCT beam were continuative during these years. Results of this work could be the reference and be helpful for the further clinical trials in nearly future. (author)

  16. Summary of recent BNCT Polish programme and future plans.

    Science.gov (United States)

    Gryziński, M A; Maciak, M; Wielgosz, M

    2015-12-01

    In this work we present Polish achievements on the ground of BNCT research. Starting from preliminary built therapeutic stand at MARIA reactor going through designing of unique detectors for in-phantom and in-beam measurements for mixed radiation fields and finally coming to boron carriers synthesizing and examination in cellular and animal models. Now it is planned to restart research on boron compounds in specially designed BIMA line, to set up epithermal neutron irradiation facility for BNCT research and education and to improve recombination detectors for neutron beams characterisation. PMID:26293009

  17. Boron determination in liver tissue by combining quantitative neutron capture radiography (QNCR) and histological analysis for BNCT treatment planning at the TRIGA Mainz.

    Science.gov (United States)

    Schütz, C; Brochhausen, C; Altieri, S; Bartholomew, K; Bortolussi, S; Enzmann, F; Gabel, D; Hampel, G; Kirkpatrick, C J; Kratz, J V; Minouchehr, S; Schmidberger, H; Otto, G

    2011-09-01

    The typical primary malignancies of the liver are hepatocellular carcinoma and cholangiocarcinoma, whereas colorectal liver metastases are the most frequently occurring secondary tumors. In many cases, only palliative treatment is possible. Boron neutron capture therapy (BNCT) represents a technique that potentially destroys tumor tissue selectively by use of externally induced, locally confined secondary particle irradiation. In 2001 and 2003, BNCT was applied to two patients with colorectal liver metastases in Pavia, Italy. To scrutinize the rationale of BNCT, a clinical pilot study on patients with colorectal liver metastases was carried out at the University of Mainz. The distribution of the (10)B carrier (p-borono-phenylalanine) in the liver and its uptake in cancerous and tumor-free tissue were determined, focusing on a potential correlation between the uptake of p-borono-phenylalanine and the biological characteristics of cancerous tissue. Samples were analyzed using quantitative neutron capture radiography of cryosections combined with histological analysis. Methodological aspects of the combination of these techniques and results from four patients enrolled in the study are presented that indicate that the uptake of p-borono-phenylalanine strongly depends on the metabolic activity of cells. PMID:21692653

  18. “Sequential” Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model

    Energy Technology Data Exchange (ETDEWEB)

    Ana J. Molinari; Emiliano C. C. Pozzi; Andrea Monti Hughes; Elisa M. Heber; Marcela A. Garabalino; Silvia I. Thorp; Marcelo Miller; Maria E. Itoiz; Romina F. Aromando; David W. Nigg; Jorge Quintana; Gustavo A. Santa Cruz; Veronica A. Trivillin; Amanda E. Schwint

    2011-04-01

    In the present study we evaluated the therapeutic effect and/or potential radiotoxicity of the novel “Tandem” Boron Neutron Capture Therapy (T-BNCT) for the treatment of oral cancer in the hamster cheek pouch model at RA-3 Nuclear Reactor. Two groups of animals were treated with “Tandem BNCT”, i.e. BNCT mediated by boronophenylalanine (BPA) followed by BNCT mediated by sodium decahydrodecaborate (GB-10) either 24 h (T-24h-BNCT) or 48 h (T-48h-BNCT) later. A total tumor dose-matched single application of BNCT mediated by BPA and GB-10 administered jointly [(BPA + GB-10)-BNCT] was administered to an additional group of animals. At 28 days post-treatment, T-24h-BNCT and T-48h-BNCT induced, respectively, overall tumor control (OTC) of 95% and 91%, with no statistically significant differences between protocols. Tumor response for the single application of (BPA + GB-10)-BNCT was 75%, significantly lower than for T-BNCT. The T-BNCT protocols and (BPA + GB-10)-BNCT induced reversible mucositis in dose-limiting precancerous tissue around treated tumors, reaching Grade 3/4 mucositis in 47% and 60% of the animals respectively. No normal tissue radiotoxicity was associated to tumor control for any of the protocols. “Tandem” BNCT enhances tumor control in oral cancer and reduces or, at worst, does not increase, mucositis in dose-limiting precancerous tissue.

  19. Computational dosimetry of a simulated combined standard X-Rays and BNCT treatment

    Energy Technology Data Exchange (ETDEWEB)

    Casal, M.R., E-mail: mcasal@cnea.gov.ar [Instituto de Oncologia ' Angel H. Roffo' , Universidad de Buenos Aires, Av. San Martin 5481, Bs.As. (Argentina)] [Comision Nacional de Energia Atomica, Av. General Paz 1499, San Martin, Buenos Aires (Argentina); Herrera, M.S., E-mail: mariettaherrera@gmail.com [Comision Nacional de Energia Atomica, Av. General Paz 1499, San Martin, Buenos Aires (Argentina)] [Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) Av. Rivadavia 191, Buenos Aires (Argentina)] [Escuela de Ciencia y Tecnologia, Universidad de General San Martin, 25 de Mayo and M. de Irigoyen, San Martin (Argentina); Gonzalez, S.J., E-mail: srgonzal@cnea.gov.ar [Comision Nacional de Energia Atomica, Av. General Paz 1499, San Martin, Buenos Aires (Argentina)] [Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) Av. Rivadavia 191, Buenos Aires (Argentina)

    2011-12-15

    There has been increasing interest in combining Boron Neutron Capture Therapy (BNCT) with standard radiotherapy, either concomitantly or as a BNCT treatment of a recurrent tumor that was previously irradiated with a medical electron linear accelerator (LINAC). In this work we report the simulated dosimetry of treatments combining X-rays and BNCT

  20. Accelerator-based BNCT

    International Nuclear Information System (INIS)

    The activity in accelerator development for accelerator-based BNCT (AB-BNCT) both worldwide and in Argentina is described. Projects in Russia, UK, Italy, Japan, Israel, and Argentina to develop AB-BNCT around different types of accelerators are briefly presented. In particular, the present status and recent progress of the Argentine project will be reviewed. The topics will cover: intense ion sources, accelerator tubes, transport of intense beams, beam diagnostics, the 9Be(d,n) reaction as a possible neutron source, Beam Shaping Assemblies (BSA), a treatment room, and treatment planning in realistic cases. - Highlights: • The activity in accelerator development for accelerator-based BNCT (AB-BNCT) both worldwide and in Argentina is described. • Projects in Russia, UK, Italy, Japan, Israel, and Argentina to develop AB-BNCT around different types of accelerators are briefly presented. • The present status and recent progress of the Argentine project will be reviewed. • Topics cover intense ion sources, accelerator tubes, transport of intense beams and beam diagnostics, among others

  1. BNCT treatment planning for superficial and deep-seated tumors: Experience from clinical trial of recurrent head and neck cancer at THOR.

    Science.gov (United States)

    Liu, Yen-Wan Hsueh; Chang, Chih-Ting; Yeh, Lan-Yun; Wang, Ling-Wei; Lin, Tzung-Yi

    2015-12-01

    Under the collaboration between National Tsing Hua University and Taipei Veterans General Hospital, clinical trial of recurrent head-and-neck cancer by Boron neutron capture therapy at Tsing Hua open-pool reactor started on August 11, 2010. Up to January 2014, 17 patients were treated. Based on the treatment planning experiences of clinical trials using in-house designed THORplan, different setups should be used for superficial and deep-seated tumors. Superficial tumor treatment gains benefits from the use of patient collimator, while direct irradiation is a better choice for deep-seated tumor. PMID:26278349

  2. TIDBIT - the INEL database of BNCT information and treatment

    Energy Technology Data Exchange (ETDEWEB)

    Mancuso, C.A.

    1995-11-01

    The INEL Database of BNCT Information and Treatment (TIDBIT) has been under development for several years. Late in 1993, a new software development team took over the project and did and assessment of the current implementation status, and determined that the user interface was unsatisfactory for the expected users and that the data structures were out of step with the current state of reality. The team evaluated several tools that would improve the user interface to make the system easier to use. Uniface turned out to be the product of choice. During 1994, TIDBIT got its name, underwent a complete change of appearance, had a major overhaul to the data structures that support the application, and system documentation was begun. A prototype of the system was demonstrated in September 1994.

  3. Photoneutron source for in-hospital BNCT treatment. Feasibility study

    International Nuclear Information System (INIS)

    Some recent studies in Italy have focused on the possibility of exploiting high energy electron linear accelerators, normally used in gamma radiotherapy, as photo-neutrons source for in-hospital medical applications. Neutrons are produced by Giant Dipole Resonance (GDR) reactions from high energy photons on high Z targets; by proper material and geometry optimization, interesting fluence rates of thermalized neutrons can be made available, with minimized fast neutron and gamma backgrounds, for a fractionated type of Boron Neutron Capture Therapy (BNCT) devoted to external treatment of some specific tumors. A photoneutron converter, constituted by high Z core and surrounded by Low Z materials, is shaped to produce thermal beam inside an irradiation cavity. A feasibility study on Beam Shaping Assembly using MCNPGN simulation code is performed on various geometrical shapes and material selection. A first prototype of the photoconverter has been realized and tested at some hospital high energy medical LINAC facilities. In this paper the preliminary experimental results of neutron fluence rate and neutron spectra produced by the photoconverter prototype are compared to the simulation data. (author)

  4. Quality assurance of BNCT dosimetry

    International Nuclear Information System (INIS)

    The Phase I clinical trials for boron neutron capture therapy (BNCT) started in May 1999 in Otaniemi, Espoo. For BNCT no uniform international guidance for the quality assurance of dosimetry exists, so far. Because of the complex dose distribution with several different dose components, the international recommendations on conventional radiotherapy dosimetry are not applicable in every part. Therefore, special guidance specifically for BNCT is needed. To obtain such guidelines a European collaboration project has been defined. The aim of the project is a generally accepted Code of Practice for use by all European BNCT centres. This code will introduce the traceability of the dosimetric methods to the international measurement system. It will also ensure the comparability of the results in various BNCT beams and form the basis for the comparison of the treatment results with the conventional radiotherapy or other treatment modalities. The quality assurance of the dosimetry in BNCT in Finland covers each step of the BNCT treatment, which include dose planning imaging, dose planning, boron infusion, boron kinetics, patient positioning, monitoring of the treatment beam, characterising the radiation spectrum, calibration of the beam model and the dosimetric measurements both in patients (in viva measurements) and in various phantoms. The dose planning images are obtained using a MR scanner with MRI sensitive markers and the dose distribution is computed with a dose planning software BNCTRtpe. The program and the treatment beam (DORT) model used have been verified with measurements and validated with MCNP calculations in phantom. Dosimetric intercomparison has been done with the Brookhaven BNCT beam (BMRR). Before every patient irradiation the relationship between the beam monitor pulse rate and neutron fluence rate in the beam is checked by activation measurements. Kinetic models used to estimate the time-behavior of the blood boron concentration have been verified

  5. Computational study of room scattering influence in the THOR BNCT treatment room

    International Nuclear Information System (INIS)

    BNCT dosimetry has often employed heavy Monte Carlo calculations for the beam characterization and the dose determination. However, these calculations commonly ignored the scattering influence between the radiations and the room structure materials in order to facilitate the calculation speed. The aim of this article attempts to explore how the room scattering affects the physical quantities such as the capture reaction rate and the gamma-ray dose rate under in-phantom and free-air conditions in the THOR BNCT treatment room. The geometry and structure materials of the treatment room were simulated in detail. The capture reaction rates per atom, as well as the gamma-ray dose rate were calculated in various sizes of phantoms and in the free-air condition. Results of this study showed that the room scattering has significant influence on the physical quantities, whether in small phantoms or in the free-air condition. This paper may be of importance in explaining the discrepancies between measurements and calculations in the BNCT dosimetry using small phantoms, in addition to provide a useful consideration with a better understanding of how the room scattering influence acts in a BNCT facility. - Highlights: • The room scattering effect at THOR BNCT room was discussed in this paper. • The room scattering factors of 4 different sizes of PMMA phantoms were calculated. • The room scattering effect was significant in small size phantom. • The room scattering neutron and gamma-ray spectra were calculated free-in-air. • The room scattering contributions of supporting table and materials were discussed

  6. Postoperative treatment of glioblastoma with BNCT at the Petten Irradiation Facility (EORTC Protocol 11961)

    International Nuclear Information System (INIS)

    The boron neutron capture therapy is based on the reaction occurring between the isotope 10B and thermal neutrons. A low energy neutron is captured by the nucleus and it disintegrates into two densely ionising particles, Li nucleus and He nucleus (α particle), with high biological effectiveness. On the basis of comprehensive preclinical investigations in the frame of the European Collaboration with Na2B12H11SH (BSH), as boron delivery agent, the first European phase I, clinical trial was designed at the only available epithermal beam in Europe, at the High Flux Reactor, Petten, in the Netherland. The goal of this study is to establish the safe BNCT dose for cranial tumors under defined conditions. BNCT is applied as postoperative radiotherapy in 4 fractions, after removal of the tumor for a group of patients suffering from glioblastoma, who would have no benefit from conventional treatment, but have sufficient life expectancy to detect late radiation morbidity due to BNCT. The starting dose is set at 80% of the dose where neurological effects occured in preclinical large animal experiments following a single fraction. The radiation dose will be escalated, by constant boron concentration in blood, in 4 steps for cohorts of ten patients, after an observation period of at least 6 months after the end of BNCT of the last patient of a cohort. The adverse events on healthy tissues due to BSH and due to the radiotherapy will be analysed in order to establish the maximal tolerated dose and dose limiting toxicity. Besides of the primary aim of this study the survival will be recorded. The first patient was treated in October 1997, and further four patients have been irradiated to date. The protocol design proved to be well applicable, establishing the basis for scientific evaluation, for performance of safe patient treatment in a very complex situation and for opening the possibility to perform further clinical research work on BNCT. (orig.)

  7. Design of epithermal neutron beam for clinical BNCT treatment at Slovenian TRIGA research reactor

    International Nuclear Information System (INIS)

    The Monte Carlo feasibility study of development of epithermal neutron beam for BNCT clinical trials on Jozef Stefan Institute (JSI) TRIGA reactor is presented. The investigation of the possible use of fission converter for the purpose of enhancement of neutron beam, as well as the set-up of TRIGA reactor core is performed. The optimization of the irradiation facility components is carried out and the configuration with the most favorable cost/performance ratio is proposed. The simulation results prove that a BNCT irradiation facility with performances, comparable to existing beams throughout the world, could be installed in the thermalizing column of the TRIGA reactor, quite suitable for the clinical treatments of human patients. (author)

  8. Design of epithermal neutron beam for clinical BNCT treatment at Slovenian TRIGA research reactor

    Energy Technology Data Exchange (ETDEWEB)

    Maucec, Marko [Jozef Stefan Institute, Reactor Physics Division, Lubljana (Slovenia). E-mail: marko.mauce@ijs.si

    1999-07-01

    The Monte Carlo feasibility study of development of epithermal neutron beam for BNCT clinical trials on Jozef Stefan Institute (JSI) TRIGA reactor is presented. The investigation of the possible use of fission converter for the purpose of enhancement of neutron beam, as well as the set-up of TRIGA reactor core is performed. The optimization of the irradiation facility components is carried out and the configuration with the most favorable cost/performance ratio is proposed. The simulation results prove that a BNCT irradiation facility with performances, comparable to existing beams throughout the world, could be installed in the thermalizing column of the TRIGA reactor, quite suitable for the clinical treatments of human patients. (author)

  9. 'Sequential' Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality that involves the selective accumulation of 10B carriers in tumors followed by irradiation with a thermal or epithermal neutron beam. The minor abundance stable isotope of boron, 10B, interacts with low energy (thermal) neutrons to produce high linear energy transfer (LET) a-particles and 7Li ions. These disintegration products are known to have a high relative biological effectiveness (RBE). Their short range (<10 (micro)m) would limit the damage to cells containing 10B (1,2). Thus, BNCT would target tumor tissue selectively, sparing normal tissue. Clinical trials of BNCT for the treatment of glioblastoma multiforme and/or melanoma and, more recently, head and neck tumors and liver metastases, using boronophenylalanine (BPA) or sodium mercaptoundecahydrododecaborane (BSH) as the 10B carriers, have been performed or are underway in Argentina, Japan, the US and Europe (e.g. 3-8). To date, the clinical results have shown a potential, albeit inconclusive, therapeutic advantage for this technique. Contributory translational studies have been carried out employing a variety of experimental models based on the implantation of tumor cells in normal tissue (e.g. 5).

  10. "Sequential” Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model

    Energy Technology Data Exchange (ETDEWEB)

    Ana J. Molinari; Andrea Monti Hughes; Elisa M. Heber; Marcela A. Garabalino; Veronica A. Trivillin; Amanda E. Schwint; Emiliano C. C. Pozzi; Maria E. Itoiz; Silvia I. Thorp; Romina F. Aromando; David W. Nigg; Jorge Quintana; Gustavo A. Santa Cruz

    2011-04-01

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality that involves the selective accumulation of 10B carriers in tumors followed by irradiation with a thermal or epithermal neutron beam. The minor abundance stable isotope of boron, 10B, interacts with low energy (thermal) neutrons to produce high linear energy transfer (LET) a-particles and 7Li ions. These disintegration products are known to have a high relative biological effectiveness (RBE). Their short range (<10 {micro}m) would limit the damage to cells containing 10B (1,2). Thus, BNCT would target tumor tissue selectively, sparing normal tissue. Clinical trials of BNCT for the treatment of glioblastoma multiforme and/or melanoma and, more recently, head and neck tumors and liver metastases, using boronophenylalanine (BPA) or sodium mercaptoundecahydrododecaborane (BSH) as the 10B carriers, have been performed or are underway in Argentina, Japan, the US and Europe (e.g. 3-8). To date, the clinical results have shown a potential, albeit inconclusive, therapeutic advantage for this technique. Contributory translational studies have been carried out employing a variety of experimental models based on the implantation of tumor cells in normal tissue (e.g. 5).

  11. Effective dose evaluation for BNCT brain tumor treatment based on voxel phantoms

    International Nuclear Information System (INIS)

    For BNCT treatments, in addition to tumor target doses, non-negligible doses will result in all the remaining organs of the body. This work aims to evaluate the effective dose as well as the average absorbed doses of each of organs of patients with brain tumor treated in the BNCT epithermal neutron beam at THOR. The effective doses were evaluated according to the definitions of ICRP Publications 60 and 103 for the reference male and female computational phantoms developed in ICRP Publication 110 by using the MCNP5 Monte Carlo code with the THOR-Y09 beam source. The effective dose acquired in this work was compared with the results of our previous work calculated for an adult hermaphrodite mathematical phantom. It was found that the effective dose for the female voxel phantom is larger than that for the male voxel phantom by a factor of 1.2–1.5 and the effective dose for the voxel phantom is larger than that for the mathematical phantom by a factor of 1.3–1.6. For a typical brain tumor BNCT, the effective dose was calculated to be 1.51 Sv and the average absorbed dose for eye lenses was 1.07 Gy. - Highlights: • For a typical brain tumor BNCT, the effective dose was calculated to be 1.51 Sv. • The average absorbed dose for eye lenses was 1.07 Gy. • The effective doses for both male and female voxel phantoms were calculated. • The effective doses were compared between voxel and mathematical phantoms

  12. Application of BNCT to the treatment of HER2+ breast cancer recurrences: Research and developments in Argentina

    International Nuclear Information System (INIS)

    In the frame of the Argentine BNCT Project a new research line has been started to study the application of BNCT to the treatment of locoregional recurrences of HER2+ breast cancer subtype. Based on former studies, the strategy considers the use of immunoliposomes as boron carriers nanovehicles to target HER2 overexpressing cells. The essential concerns of the current stage of this proposal are the development of carriers that can improve the efficiency of delivery of boron compounds and the dosimetric assessment of treatment feasibility. For this purpose, an specific pool of clinical cases that can benefit from this application was determined. In this work, we present the proposal and the advances related to the different stages of current research. - Highlights: • A new proposal of BNCT for HER2+ breast cancer treatment is introduced. • The proposal considers development of immunoliposomes as boron carrier nanovehicles. • Locoregional recurrences after treatment were identified as candidates for initial BNCT studies. • First analysis show acceptable neutron flux distributions provided by RA-6 BNCT facility

  13. Experimental approach to the BNCT treatment of human liver

    International Nuclear Information System (INIS)

    The research program named Taormina, is concerned with an attempt to set up a method to use Boron neutron capture therapy for liver metastases in diffused tumours. According to our project, the liver will be explanted, treated with a solution of organic Boron compound, then irradiated in a thermal neutron field. Such modalities give the significant advantage to preserve the remaining patient organs from damage. A collaboration including nuclear physicists and surgeons of the University of Pavia planned the original research project. Researchers in the fields of chemistry and anatomy gave contributions during the experiment in their particular fields of competence. The conditions which must be satisfied to get a safe neutron treatment are given. The Thermal Column (TC) of the reactor Triga Mark II of the University of Pavia was modified to reach the objectives. The possibility to get useful values of T parameter by searching the modalities to take the greatest possible advantage from the so called blood-brain barrier is investigated. Such a barrier effect, due to the particular metabolism of tumour cells, produces Boron accumulation into tumour tissues while Boron solutions are circulating inside the blood channels. The results of processing of 24 rats are given. The rather poor statistics do not allow meaningful conclusions but only some optimistic hope

  14. Estimation of photon and neutron dose distributions in the THOR BNCT treatment room using dual TLD method

    International Nuclear Information System (INIS)

    Dual detector dosimetry using the paired detectors, TLD-600 and TLD-700 chips, were selected in this study to distinguish the doses of neutrons and photons in Tsing Hua Open-pool Reactor (THOR) boron neutron capture therapy (BNCT) preclinical test. Since the neutron response of TLD is dependent on the neutron spectrum, responses of TLD-600 and TLD-700 for neutrons and photons were estimated by irradiation methods and in addition the effect of the neutron spectrum on the TLD response was studied by Monte Carlo simulations in present work. A sectional ART head phantom was used to be irradiated with the THOR BNCT beam. TLD-600 and TLD-700 chips were placed inside the phantom to measure and distinct the doses of neutrons from photons. Besides, dual TLD chips were placed in plane of the room space area to estimate the spatial dose distributions in the THOR BNCT treatment room. A cube water phantom was used to consider the deviation between the two algorithms used in this work. In the results, neutron and photon dose distributions in phantom and the spatial dose distributions in THOR BNCT treatment room were estimated; characteristics and the treatment indexes for BNCT were also assessed

  15. Preliminary evaluations of the undesirable patient dose from a BNCT treatment at the ENEA-TAPIRO reactor

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is an experimental technique for the treatment of certain kinds of tumors. Research in BNCT is performed utilizing both thermal and epithermal neutron beams. Epithermal neutrons (0.4 eV-10 keV) penetrate more deeply into tissue and are thus used in non-superficial clinical applications such as the brain glioma. In the last few years, the fast reactor TAPIRO (ENEA-Casaccia Rome) has been employed as a neutron source for research into BNCT applications. Recently, an 'epithermal therapeutic column' has been designed and its construction has been completed. The Monte Carlo code MCNPX was employed to optimize the design of the column and to evaluate the dose profiles and the therapeutic parameters in the cranium of the anthropomorphic phantom ADAM. In the same context, some preliminary evaluations of the undesirable doses to the patient were performed with MCNPX. A hermaphrodite phantom derived from ADAM and EVA was employed to evaluate the energy deposition in some organs during a standard BNCT treatment. The total dose consists of the contributions from the primary neutron beam, the neutron interactions with boron and the neutron induced photons generated in the epithermal column structures and in the patient's tissues. The paper summarizes the computational procedure and provides a general dosimetric framework of the patient radiological protection aspects related to a BNCT treatment scenario at the TAPIRO reactor. (authors)

  16. Design of a beam shaping assembly and preliminary modelling of a treatment room for accelerator-based BNCT at CNEA

    International Nuclear Information System (INIS)

    This work reports on the characterisation of a neutron beam shaping assembly (BSA) prototype and on the preliminary modelling of a treatment room for BNCT within the framework of a research programme for the development and construction of an accelerator-based BNCT irradiation facility in Buenos Aires, Argentina. The BSA prototype constructed has been characterised by means of MCNP simulations as well as a set of experimental measurements performed at the Tandar accelerator at the National Atomic Energy Commission of Argentina. - Highlights: ► Characterisation of a neutron beam shaping assembly for accelerator-based BNCT. ► Measurements: total and epi-cadmium neutron fluxes and beam homogeneity. ► Calculations: Monte Carlo simulations with the MCNP code. ► Measured and calculated figure-of-merit parameters in agreement with those of IAEA. ► Initial MCNP dose calculations for a treatment room to define future design actions.

  17. INEL BNCT Research Program annual report 1994

    International Nuclear Information System (INIS)

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1994. Contributions from the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor studies, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, ICP-AES analysis of biological samples), physics (treatment planning software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of BSH and BPA is presented and results of 21 spontaneous tumor bearing dogs that have been treated with BNCT at Brookhaven National Laboratory (BNL) are discussed. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors is presented. Highlights from the First International Workshop on Accelerator-Based Neutron Sources for BNCT are included

  18. Effective dose evaluation for BNCT treatment in the epithermal neutron beam at THOR

    International Nuclear Information System (INIS)

    This paper aims to evaluate the effective dose as well as equivalent doses of several organs of an adult hermaphrodite mathematical phantom according to the definition of ICRP Publication 60 for BNCT treatments of brain tumors in the epithermal neutron beam at THOR. The MCNP5 Monte Carlo code was used for the calculation of the average absorbed dose of each organ. The effective doses for a typical brain tumor treatment with a tumor treatment dose of 20 Gy-eq were evaluated to be 0.59 and 0.35 Sv for the LLAT and TOP irradiation geometries, respectively. In addition to the stochastic effect, it was found that it is also likely to produce deterministic effects, such as cataracts and depression of haematopoiesis.

  19. Building of scientific information system for sustainable development of BNCT in Bulgaria

    International Nuclear Information System (INIS)

    Building a boron neutron capture therapy (BNCT) facility is foreseen within the reconstruction of the Research Reactor IRT (IRT) of the Institute for Nuclear Research and Nuclear Energy of the Bulgaria Academy of Sciences (INRNE). The development of BNCT at IRT plays a very significant role in the plan for sustainable application of the reactor. A centralized scientific information system on BNCT is being built at the INRNE with the purpose to collect and sort new information as knowledge accumulated during more than thirty years history of BNCT. This BNCT information system will help the creation and consolidation of a well informed and interconnected interdisciplinary team of physicists, chemists, biologists, and radio-oncologists for establishing BNCT cancer treatment in Bulgaria. It will strengthen more intensive development of the national network as well as its enlargement to the Balkan region countries. Furthermore, to acquaint the public at large with the opportunity for BNCT cancer treatment will be addressed. Human, social, and economics results due to BNCT for many patients from Balkan region are expected.

  20. Building of scientific information system for sustainable development of BNCT in Bulgaria

    Energy Technology Data Exchange (ETDEWEB)

    Mitev, M. [Institute for Nuclear Research and Nuclear Energy of the Bulgarian Academy of Sciences, Boul. Tsarigradsko shossee 72, Sofia (Bulgaria)], E-mail: mlmitev@inrne.bas.bg; Ilieva, K.; Apostolov, T. [Institute for Nuclear Research and Nuclear Energy of the Bulgarian Academy of Sciences, Boul. Tsarigradsko shossee 72, Sofia (Bulgaria)

    2009-07-15

    Building a boron neutron capture therapy (BNCT) facility is foreseen within the reconstruction of the Research Reactor IRT (IRT) of the Institute for Nuclear Research and Nuclear Energy of the Bulgaria Academy of Sciences (INRNE). The development of BNCT at IRT plays a very significant role in the plan for sustainable application of the reactor. A centralized scientific information system on BNCT is being built at the INRNE with the purpose to collect and sort new information as knowledge accumulated during more than thirty years history of BNCT. This BNCT information system will help the creation and consolidation of a well informed and interconnected interdisciplinary team of physicists, chemists, biologists, and radio-oncologists for establishing BNCT cancer treatment in Bulgaria. It will strengthen more intensive development of the national network as well as its enlargement to the Balkan region countries. Furthermore, to acquaint the public at large with the opportunity for BNCT cancer treatment will be addressed. Human, social, and economics results due to BNCT for many patients from Balkan region are expected.

  1. SBNCT plan: A 3-dimensional treatment planning system for boron neutron capture therapy

    International Nuclear Information System (INIS)

    The need for accurate and comprehensive 3-dimensional treatment planning for boron neutron capture therapy (BNCT) has been debated for the past several years. Although many argue against the need for elaborate and expensive treatment planning programs which mimic conventional radiotherapy planning systems, it is clear that in order to realize significant gains over conventional fractionated radiation therapy, patients must be treated to the edge of normal tissue tolerance. Just how close to this edge is dictated by the uncertainties in dosimetry. Hence the focus of BNCT planning is the determination of dose distribution throughout normal tissue volumes. Although precise geometric manipulation of the epithermal neutron beam is not achievable, the following variables play an important role in BNCT optimization: patient orientation, dose fractionation, number of fields, megawatt-minutes per fraction, use of surface bolus, and use of collimation. Other variables which are not as easily adjustable and would not, therefore, be part of treatment planning optimization, include external patient contour, internal patient heterogeneities, boron compound distributions, and RBE's. The boron neutron capture therapy planning system developed at SUNY Stony Brook (SBNCT-Plan) was designed as an interactive graphic tool to assist the radiation oncologist in generating the optimum plan for a neutron capture treatment

  2. First clinical results from the EORTC phase I Trial ''postoperative treatment of glioblastoma with BNCT at the Petten irradiation facility''

    International Nuclear Information System (INIS)

    Based on the pre-clinical work of the European Collaboration on Boron Neutron Capture Therapy a study protocol was prepared in 1995 to initiate Boron Neutron Capture Therapy (BNCT) in patients at the High Flux Reactor (HFR) in Petten. Bio-distribution and pharmacokinetics data of the boron drug Na2B12H11SH (BSH) as well as the radiobiological effects of BNCT with BSH in healthy brain tissue of dogs were considered in designing the strategy for this clinical Phase I trial. The primary goal of the radiation dose escalation study is the investigation of possible adverse events due to BNCT; i.e. to establish the dose limiting toxicity and the maximal tolerated dose. The treatment is delivered in 4 fractions at a defined average boron concentration in blood. Cohorts of 10 patients are treated per dose group. The starting dose was set at 80% of the dose at which neurological symptoms occurred in preclinical dog experiments following a single fraction. After an observation period of at least 6 months, the dose is increased by 10% for the next cohort if less then three severe side effects related to the treatment occurred. The results of the first cohort are presented here. The evaluated dose level can be considered safe. (author)

  3. Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: application to the treatment of experimental oral cancer.

    Science.gov (United States)

    Pozzi, E; Nigg, D W; Miller, M; Thorp, S I; Heber, E M; Zarza, L; Estryk, G; Monti Hughes, A; Molinari, A J; Garabalino, M; Itoiz, M E; Aromando, R F; Quintana, J; Trivillin, V A; Schwint, A E

    2009-07-01

    The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1 x 10(9) n cm(-2)s(-1) and the fast neutron flux was 2.5 x 10(6) n cm(-2)s(-1), indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in (6)Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated. PMID:19380233

  4. Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: Application to the treatment of experimental oral cancer

    International Nuclear Information System (INIS)

    The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1x109 n cm-2 s-1 and the fast neutron flux was 2.5x106 n cm-2 s-1, indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in 6Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.

  5. Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: Application to the treatment of experimental oral cancer

    Energy Technology Data Exchange (ETDEWEB)

    Pozzi, E. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina)], E-mail: epozzi@cnea.gov.ar; Nigg, D.W. [Idaho National Laboratory, Idaho Falls (United States); Miller, M.; Thorp, S.I. [Instrumentation and Control Department, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Heber, E.M. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Zarza, L.; Estryk, G. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Monti Hughes, A.; Molinari, A.J.; Garabalino, M. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Itoiz, M.E. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires (Argentina); Aromando, R.F. [Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires (Argentina); Quintana, J. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Trivillin, V.A.; Schwint, A.E. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina)

    2009-07-15

    The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1x10{sup 9} n cm{sup -2} s{sup -1} and the fast neutron flux was 2.5x10{sup 6} n cm{sup -2} s{sup -1}, indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in {sup 6}Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.

  6. Monte Carlo simulation to study the doses in an accelerator BNCT treatment

    International Nuclear Information System (INIS)

    In this work the 7Li(p, n)7Be reaction has been studied as a neutron source for accelerator-based BNCT (Boron Neutron Capture Therapy). In order to optimize the design of the neutron production target and the beam shaping assembly, extensive MCNP simulations have been performed. These simulations include a thick Li metal target, a whole-body phantom, a moderator-reflector assembly (Al/AlF3 as moderator and graphite as reflector) and the treatment room. The doses were evaluated for two proton bombarding energies of 1.92 MeV (near to the threshold of the reaction) and 2.3 MeV (near to the resonance of the reaction) and for three Al/ALF3 moderator thicknesses (18, 26 and 34 cm). To assess the doses, a comparison using a Tumor Control Probability (TCP) model was done. In a second instance, the effect of the specific skin radiosensitivity (an RBE of 2.5 for the 10B(n,α)7Li reaction) and a 10B uptake of 17 ppm was considered for the scalp. Finally, the simulations show the advantage of irradiating with near-resonance-energy protons (2.3 MeV) because of the high neutron yield at this energy, leading to the lowest treatment times. Moreover, the 26 cm Al/AlF3 moderator has shown the best performance among the studied cases. (author)

  7. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma

    International Nuclear Information System (INIS)

    Introduction: To plan the optimal BNCT for patients with malignant cerebral glioma, estimation of the ratio of boron concentration in tumor tissue against that in the surrounding normal brain (T/N ratio of boron) is important. We report a positron emission tomography (PET) imaging method to estimate T/N ratio of tissue boron concentration based on pharmacokinetic analysis of amino acid probes. Methods: Twelve patients with cerebral malignant glioma underwent 60 min dynamic PET scanning of brain after bolus injection of 18F-borono-phenyl-alanine (FBPA) with timed arterial blood sampling. Using kinetic parameter obtained by this scan, T/N ratio of boron concentration elicited by one-hour constant infusion of BPA, as performed in BNCT, was simulated on Runge-Kutta algorithm. 11C-methionine (MET) PET scan, which is commonly used in worldwide PET center as brain tumor imaging tool, was also performed on the same day to compare the image characteristics of FBPA and that of MET. Result: PET glioma images obtained with FBPA and MET are almost identical in all patients by visual inspection. Estimated T/N ratio of tissue boron concentration after one-hour constant infusion of BPA, T/N ratio of FBPA on static condition, and T/N ratio of MET on static condition showed significant linear correlation between each other. Conclusion: T/N ratio of boron concentration that is obtained by constant infusion of BPA during BNCT can be estimated by FBPA PET scan. This ratio can also be estimated by MET-PET imaging. As MET-PET study is available in many clinical PET center, selection of candidates for BNCT may be possible by MET-PET images. Accurate planning of BNCT may be performed by static images of FBPA PET. Use of PET imaging with amino acid probes may contribute very much to establish an appropriate application of BNCT for patients with malignant glioma.

  8. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma

    Energy Technology Data Exchange (ETDEWEB)

    Nariai, Tadashi [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo (Japan)], E-mail: nariai.nsrg@tmd.ac.jp; Ishiwata, Kiichi [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Nakacho, Itabashi-ku, Tokyo (Japan); Kimura, Yuichi [Molecular Imaging Center, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba (Japan); Inaji, Motoki; Momose, Toshiya [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo (Japan); Yamamoto, Tetsuya; Matsumura, Akira [Department of Neurosurgery, University of Tsukuba, Tennodai, Tsukuba, Igaraki (Japan); Ishii, Kenji [Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Nakacho, Itabashi-ku, Tokyo (Japan); Ohno, Kikuo [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo (Japan)

    2009-07-15

    Introduction: To plan the optimal BNCT for patients with malignant cerebral glioma, estimation of the ratio of boron concentration in tumor tissue against that in the surrounding normal brain (T/N ratio of boron) is important. We report a positron emission tomography (PET) imaging method to estimate T/N ratio of tissue boron concentration based on pharmacokinetic analysis of amino acid probes. Methods: Twelve patients with cerebral malignant glioma underwent 60 min dynamic PET scanning of brain after bolus injection of {sup 18}F-borono-phenyl-alanine (FBPA) with timed arterial blood sampling. Using kinetic parameter obtained by this scan, T/N ratio of boron concentration elicited by one-hour constant infusion of BPA, as performed in BNCT, was simulated on Runge-Kutta algorithm. {sup 11}C-methionine (MET) PET scan, which is commonly used in worldwide PET center as brain tumor imaging tool, was also performed on the same day to compare the image characteristics of FBPA and that of MET. Result: PET glioma images obtained with FBPA and MET are almost identical in all patients by visual inspection. Estimated T/N ratio of tissue boron concentration after one-hour constant infusion of BPA, T/N ratio of FBPA on static condition, and T/N ratio of MET on static condition showed significant linear correlation between each other. Conclusion: T/N ratio of boron concentration that is obtained by constant infusion of BPA during BNCT can be estimated by FBPA PET scan. This ratio can also be estimated by MET-PET imaging. As MET-PET study is available in many clinical PET center, selection of candidates for BNCT may be possible by MET-PET images. Accurate planning of BNCT may be performed by static images of FBPA PET. Use of PET imaging with amino acid probes may contribute very much to establish an appropriate application of BNCT for patients with malignant glioma.

  9. INEEL BNCT research program. Annual report, January 1, 1996--December 31, 1996

    International Nuclear Information System (INIS)

    This report is a summary of the progress and research produced for the Idaho National Engineering and Environmental Laboratory (INEEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1996. Contributions from the individual investigators about their projects are included, specifically, physics: treatment planning software, real-time neutron beam measurement dosimetry, measurement of the Finnish research reactor epithermal neutron spectrum, BNCT accelerator technology; and chemistry: analysis of biological samples and preparation of 10B enriched decaborane

  10. Liposome and co-spray-dried PVP / o-carborane formulations for BNCT treatment of cancer

    OpenAIRE

    Olusanya, Temidayo; Stich, Theresia; Higgins, Samantha Caroline; Lloyd, Rhiannon Eleanor Iris; Pilkington, Geoffrey John; Fatouros, Dimitrios; Calabrese, Gianpiero; Smith, James Richard; Tsibouklis, John

    2015-01-01

    Purpose: Boron neutron capture therapy (BNCT) is a method for selectively destroying malignant (normally glioma) cells whilst sparing normal tissue. Irradiation of 10B (large neutron capture cross-section) with thermal neutrons effects the nuclear fission reaction: 10B + 1n → → 7Li+ + α + γ; where the penetration of α-particles and 7Li+ is only 8 and 5 µm, respectively, i.e., within a single cell thickness. Poor selectivity is the main reason why BNCT has not become a mainstream cancer therap...

  11. BNCT of canine osteosarcoma

    International Nuclear Information System (INIS)

    A dog was diagnosed with osteosarcoma (8x6x5cm) in the right wing of ilium by radiography, radionuclide scintigraphy and histological study of biopsy material. The treatment plan was as follows: γ-therapy in combination with chemotherapy; prevention of hematogenous pulmonary metastases by the transfusion of 130 ml of allogenic marrow from a healthy donor; administration of 11.4g 10B-boronphenylalanine into the right iliac artery; resection of the right iliac wing with the osteosarcoma lesion; neutron irradiation (MEPhI Reactor) of the bone fragment (dose on healthy osteocytes - 15±4 Gy (W), on tumor - 50±9 Gy (W); reimplantation and fixation of the fragment; three courses of adjuvant chemotherapy. The doses were determined in full-scale calculations of the reactor radiation fields with a model of the bone under the code RADUGA. The 10B concentration (μg/g) in the bone was: normal tissue - 9±3, tumor - 28±5. In 24 hours post operation the dog was able to walk using the treated limb, and 6 months later it moved freely. The patient has been under observation for 30 months. The results of the research demonstrate complete cure. The use of similar treatment plans improves the therapeutic efficiency of BNCT. (author)

  12. Improvements in patient treatment planning systems

    International Nuclear Information System (INIS)

    The Boron Neutron Capture Therapy, Radiation treatment planning environment (BNCT-Rtpe) software system is used to develop treatment planning information. In typical use BNCT-Rtpe consists of three main components: (1) Semi-automated geometric modeling of objects (brain, target, eyes, sinus) derived from MRI, CT, and other medical imaging modalities, (2) Dose computations for these geometric models with rtt-MC, the INEL Monte Carlo radiation transport computer code, and (3) Dose contouring overlaid on medical images as well as generation of other dose displays. We continue to develop a planning system based on three-dimensional image-based reconstructions using Bspline surfaces. Even though this software is in an experimental state, it has been applied for large animal research and for an isolated case of treatment for a human glioma. Radiation transport is based on Monte Carlo, however there will be implementations of faster methods (e.g. diffusion theory) in the future. The important thing for treatment planning is the output which must convey, to the radiologist, the deposition of dose to healthy and target tissue. Many edits are available such that one can obtain contours registered to medical image, dose/volume histograms and most information required for treatment planning and response assessment. Recent work has been to make the process more automatic and easier to use. The interface, now implemented for contouring and reconstruction, utilizes the Xwindowing system and the MOTIF graphical users interface for effective interaction with the planner. Much work still remains before the tool can be applied in a routine clinical setting

  13. An in-phantom comparison of neutron fields for BNCT

    International Nuclear Information System (INIS)

    Previously, the authors have developed the in-phantom neutron field assessment parameters T and D (Tumor) for the evaluation of epithermal neutron fields for use in BNCT. These parameters are based on an energy-spectrum-dependent neutron normal-tissue RBE and the treatment planning methodology of Gahbauer and his co-workers, which includes the effects of dose fractionation. In this paper, these neutron field assessment parameters were applied to The Ohio State University (OSU) design of an Accelerator Based Neutron Source (ABNS) (hereafter called the OSU-ABNS) and the Brookhaven Medical Research Reactor (BMRR) epithermal neutron beam (hereafter called the BMRR-ENB), in order to judge the suitability of the OSU-ABNS for BNCT. The BMRR-ENB was chosen as the basis for comparison because it is presently being used in human clinical trials of BNCT and because it is the standard to which other neutron beams are most often compared

  14. INEEL BNCT Research Program Annual Report, CY-2000

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, James Robert

    2001-03-01

    This report is a summary of the activities conducted in conjunction with the Idaho National Engineering and Environmental Laboratory (INEEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 2000. Applications of supportive research and development, as well as technology deployment in the fields of chemistry, radiation physics and dosimetry, neutron source design and demonstration, and support the Department of Energy’s (DOE) National BNCT Program goals are the goals of this Program. Contributions from the individual contributors about their projects are included, specifically described are the following, chemistry: analysis of biological samples and an infrared blood-boron analyzer, and physics: progress in the patient treatment planning software, measurement of neutron spectra for the Argentina RA-6 reactor, and recalculation of the Finnish research reactor FiR 1 neutron spectra, BNCT accelerator technology, and modification to the research reactor at Washington State University for an epithermal-neutron beam.

  15. TL detectors in BNCT dosimetry

    International Nuclear Information System (INIS)

    The main detectors for characterising and controlling of BNCT beams are activation foils and paired ionisation chambers. Thermoluminescent (TL) dosimeters are also of interest because of their following advantages: i) small physical size, ii) no need for high voltage or cables, i.e. stand alone character, and iii) suitability for large scale measurements; with TL dosimeters it is possible to measure depth dose curves and profiles at the same time, with one irradiation. Also, TL dosimeters may be possible detectors for in vivo use. At the Finnish BNCT facility, a TL detector MTS-Ns of TLD Niewiadomski and Co. (Krakow, Poland) with an ultrathin active LiF:Mg,Ti layer for small self-shielding of thermal neutrons was selected for use as a neutron sensitive dosimeter. A TL detector MCP-7s (7LiF:Mg,Cu,P) of the same manufacturer was used for gamma detection because of its high sensitivity to gamma radiation compared to that to high LET radiation. The gamma dose and neutron fluence distributions have been measured in PMMA, water and brain substitute liquid phantoms at the BNCT beam. Gamma dose and neutron fluence profiles measured with TL detectors correlate with those calculated using DORT (Two Dimensional Discrete Ordinates Transport Code) and measured with ionisation chambers. NITS-Ns TL detectors were found to measure accurately (8%, 1 S.D.) the relative neutron fluence, and therefore to be a useful addition to the activation foils in BNCT neutron dosimetry. Due to the high uncertainty of the thermal neutron sensitivity of the MCP-7s TL detectors, the absorbed gamma doses can be measured with MCP-7s detectors within 20% in the mixed neutron-gamma field of BNCT. The treatments of glioma patients at the Finnish BNCT facility will start in the spring 1999. The doses to the target volume and sensitive organs, i.e. brain, will be calculated individually in the dose planning. Since it is also necessary to monitor the absorbed doses to the head and to the body, in vivo

  16. Accelerator technology and SPECT developments for BNCT

    International Nuclear Information System (INIS)

    Accelerator-Based BNCT (AB-BNCT) is establishing itself worldwide as the future modality to start the phase of in-hospital facilities. There are projects in Russia, UK, Italy, Japan, Israel, and Argentina to develop AB-BNCT around different types of accelerators. They will be briefly mentioned. In particular, the present status and recent progress of the Argentine project will be presented. The topics will cover: high power ion sources, power and voltage generation systems for a Tandem- Electrostatic Quadrupole (TES Q) accelerator, acceleration tubes, transport of intense beams, beam diagnostics, control systems, high power targets, the 9Be(d,n) reaction as a possible neutron source, Beam Shaping Assemblies (BSA.s), treatment room design, treatment planning assessment of clinical cases, etc. A complete test stand has been built and commissioned for intense proton beam production and characterization. Beams of 10 to 30 m A have been produced and transported during variable periods of operation by means of a pre accelerator and an electrostatic quadrupole doublet to a suppressed Faraday cup. The beam diagnostics has been performed through the observation with digital cameras of induced fluorescence in the residual gas. A 200 kV TES Q accelerator prototype has been constructed and tested and a 600 keV prototype is under construction. Self consistent space charge beam transport simulations have been performed and compared with experimental results. In addition to the traditional 7Li(p,n)7Be reaction, 9Be(d,n)10B using a thin Be target has been thoroughly studied as a candidate for a possible neutron source for deep seated tumors, showing a satisfactory performance. BSA.s and production targets and a treatment room complying with regulations have also been designed. Realistic clinical treatment planning cases for AB-BNCT have been studied showing very good results. Finally we will present advances in the development of a Single Photon Emission Computed Tomography (SPECT

  17. INEL BNCT Research Program annual report 1994

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1995-11-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1994. Contributions from the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor studies, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, ICP-AES analysis of biological samples), physics (treatment planning software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of BSH and BPA is presented and results of 21 spontaneous tumor bearing dogs that have been treated with BNCT at Brookhaven National Laboratory (BNL) are discussed. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors is presented. Highlights from the First International Workshop on Accelerator-Based Neutron Sources for BNCT are included. Selected papers have been indexed separately for inclusion in the Energy Science and Technology Database.

  18. Depth-dose evaluation for lung and pancreas cancer treatment by BNCT using an epithermal neutron beam

    International Nuclear Information System (INIS)

    The depth-dose distributions were evaluated for possible treatment of both lung and pancreas cancers using an epithermal neutron beam. The MCNP calculations showed that physical dose in tumors were 6 and 7 Gy/h, respectively, for lung and pancreas, attaining an epithermal neutron flux of 5x108 ncm-2s-1. The boron concentrations were assumed at 100 ppm and 30 ppm, respectively, for lung and pancreas tumors and normal tissues contains 1/10 tumor concentrations. The dose ratios of tumor to normal tissue were 2.5 and 2.4, respectively, for lung and pancreas. The dose evaluation suggests that BNCT could be applied for both lung and pancreas cancer treatment. (author)

  19. Combination of fractionated photon radiation and BNCT

    International Nuclear Information System (INIS)

    Because of the relatively low normal brain dose, BNCT allows additional photon radiation sufficient to maintain a total normal brain dose below the tolerance limit. We started a new protocol with a combination of fractionated, extended local photon radiation, and BPA- and BSH-mediated BNCT. In this protocol, newly diagnosed glioblastoma were treated with BPA (250 mg/kg) - and BSH (100 mg/kg) - mediated BNCT followed by fractionated photon radiation. The BNCT dose for the normal brain was restricted to less than 13 GyEq. The fractionated photon radiation at a dose of 30/15 fr or 30.6 Gy/17 fr was planned to irradiate a T2 high-intensity area of post-BNCT MRI. So far, 6 patients have been treated by this protocol. The clinical course, dose distribution, tumor response, and adverse events will be discussed herein. (author)

  20. Clinical treatment planning for subjects undergoing boron neutron capture therapy at Harvard-MIT

    International Nuclear Information System (INIS)

    Treatment planning is a crucial component of the Harvard-MIT boron neutron capture therapy (BNCT) clinical trials. Treatment planning can be divided into five stages: (1) pre-planning, based on CT and MRI scans obtained when the subject arrives at the hospital and on assumed boron-10 distribution parameters; (2) subject set-up, or simulation, in the MITR-II medical therapy room to determine the boundary conditions for possible set-up configurations; (3) re-planning, following the subject simulation; (4) final localization of the subject in the medical therapy room for BNCT; and (5) final post facto recalculation of the doses delivered based on firm knowledge of the blood boron-10 concentration profiles and the neutron flux histories from precise online monitoring. The computer-assisted treatment planning is done using a specially written BNCT treatment planning code called MacNCTPLAN. The code uses the Los Alamos National Laboratory's Monte Carlo n-particle radiation transport code MCNPv.4b as the dose calculation engine and advanced anatomical model simulation based on an automatic evaluation of CT scan data. Results are displayed as isodose contours and dose-volume histograms, the latter correlated precisely with corresponding anatomical CT or MRI image planes. Examples of typical treatment planning scenarios will be presented. (author)

  1. Whole-body dose evaluation with an adaptive treatment planning system for boron neutron capture therapy

    International Nuclear Information System (INIS)

    Dose evaluation for out-of-field organs during radiotherapy has gained interest in recent years. A team led by University of Tsukuba is currently implementing a project for advancing boron neutron capture therapy (BNCT), along with a radiation treatment planning system (RTPS). In this study, the authors used the RTPS (the 'Tsukuba-Plan') to evaluate the dose to out-of-field organs during BNCT. Computed tomography images of a whole-body phantom were imported into the RTPS, and a voxel model was constructed for the Monte Carlo calculations, which used the Particle and Heavy Ion Transport Code System. The results indicate that the thoraco-abdominal organ dose during BNCT for a brain tumour and maxillary sinus tumour was 50-360 and 120-1160 mGy-Eq, respectively. These calculations required ∼29.6 h of computational time. This system can evaluate the out-of-field organ dose for BNCT irradiation during treatment planning with patient-specific irradiation conditions. (authors)

  2. Dose calculation for the BNCT treatment room at THOR by the TORT-coupled MCNP4C technique

    International Nuclear Information System (INIS)

    This study investigates the radiation shielding design of the boron neutron capture therapy (BNCT) treatment room at THOR using Monte Carlo method. Since the size of the treatment room including the concrete walls surrounding is very large, effective variance reduction technique is required to make the calculation feasible within reasonable time. The TORT-coupled MCNP4C technique based on CADIS theory is used in this study. The results show that the computing efficiency can be improved by two orders of magnitude, which makes the calculation feasible using a single PC in reasonable computing time. The main contribution to the dose outside the treatment room is found to be from the neutron-induced secondary gamma rays produced near the detector point. When patient is treated or water phantom is presented in front of the beam exit, the dose rate outside the treatment room is well below the safety limit. When the beam is on and with nothing placed in front of the beam exit, the dose rate outside door of the treatment room is two times higher than the recommended value. The shielding design should be further revised. (authors)

  3. Clinical results of boron neutron capture therapy (BNCT) for glioblastoma

    International Nuclear Information System (INIS)

    The purpose of this study was to evaluate the clinical outcome of BSH-based intra-operative BNCT (IO-BNCT) and BSH and BPA-based non-operative BNCT (NO-BNCT). We have treated 23 glioblastoma patients with BNCT without any additional chemotherapy since 1998. The median survival time (MST) of BNCT was 19.5 months, and 2-year, 3-year and 5-year survival rates were 26.1%, 17.4% and 5.8%, respectively. This clinical result of BNCT in patients with GBM is superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment. - Highlights: ► In this study, we evaluate the clinical outcome of boron neutron capture therapy (BNCT) for malignant brain tumors. ► We have treated 23 glioblastoma (GBM) patients with BNCT without any additional chemotherapy. ► Clinical results of BNCT in patients with GBM are superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment.

  4. A clinical trial protocol for second line treatment of malignant brain tumors with BNCT at University of Tsukuba

    Energy Technology Data Exchange (ETDEWEB)

    Aiyama, H. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Nakai, K., E-mail: knakai@Neurosurg-tsukuba.com [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Yamamoto, T. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan)] [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Nariai, T. [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyouku (Japan); Kumada, H. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Ishikawa, E. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Isobe, T. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Endo, K.; Takada, T.; Yoshida, F.; Shibata, Y.; Matsumura, A. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan)

    2011-12-15

    We have evaluated the efficacy and safety of boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor using a new protocol. One of the two patients enrolled in this trial is a man with recurrent glioblastoma and the other is a woman with anaplastic meningioma. Both are still alive and no severe adverse events have been observed. Our findings suggest that NCT will be safe as a palliative therapy for malignant brain tumors. - Highlights: Black-Right-Pointing-Pointer Boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor. Black-Right-Pointing-Pointer Two cases with recurrent glioblastoma and anaplastic meningioma. Black-Right-Pointing-Pointer No severe adverse events have been observed using BNCT. Black-Right-Pointing-Pointer BNCT has a possibility of a safe palliative therapy for malignant brain tumors.

  5. The time-of-flight epithermal neutron spectrum measurement from accelerator based BNCT facility

    International Nuclear Information System (INIS)

    Results of epithermal neutrons spectrum measurement by time-of-flight method for different beam shaping assembly designed for BNCT purposes are presented. Discuss method to realize time-of-flight measurement at accelerator. Results looks are important for beam shaping assembly optimization and accurate and reliable treatment planning. (author)

  6. Accelerator based-boron neutron capture therapy (BNCT)-clinical QA and QC

    International Nuclear Information System (INIS)

    Alpha-particle and recoil Li atom yielded by the reaction (10B, n), due to their high LET properties, efficiently and specifically kill the cancer cell that has incorporated the boron. Efficacy of this boron neutron capture therapy (BNCT) has been demonstrated mainly in the treatment of recurrent head/neck and malignant brain cancers in Kyoto University Research Reactor Institute (KUR). As the clinical trial of BNCT is to start from 2009 based on an accelerator (not on the Reactor), this paper describes the tentative outline of the standard operation procedure of BNCT for its quality assurance (QA) and quality control (QC) along the flow of its clinical practice. Personnel concerned in the practice involve the attending physician, multiple physicians in charge of BNCT, medical physicists, nurses and reactor stuff. The flow order of the actual BNCT is as follows: Pre-therapeutic evaluation mainly including informed consent and confirmation of the prescription; Therapeutic planning including setting of therapy volume, and of irradiation axes followed by meeting for stuffs' agreement, decision of irradiating field in the irradiation room leading to final decision of the axis, CT for the planning, decision of the final therapeutic plan according to Japan Atomic Energy Agency-Computational Dosimetry System (JCDS) and meeting of all related personnel for the final confirmation of therapeutic plan; and BNCT including the transport of patient to KUR, dripping of boronophenylalanine, setting up of the patient on the machine, blood sampling for pharmacokinetics, boron level measurement for decision of irradiating time, switch on/off of the accelerator, confirmation of patient's movement in the irradiated field after the neutron irradiation, blood sampling for confirmation of the boron level, and patient's leave from the room. The QA/QC check is principally to be conducted with the two-person rule. The purpose of the clinical trial is to establish the usefulness of BNCT, and

  7. An optimum source neutron spectrum and holder shape for extra-corporal treatment of liver cancer by BNCT

    International Nuclear Information System (INIS)

    In extra-corporal treatment of liver cancer by BNCT, it is desired to have an as homogeneous as possible thermal neutron field throughout the organ. Previous work has shown that when using an epithermal neutron beam, the shape of the holder in which the liver is placed is the critical factor. This study develops the notion further as to what is the optimum neutron spectrum to perform such treatments. In the design calculations, when using Monte Carlo techniques, it is shown that when the expected contributions of the source neutrons in every part of the liver is calculated, a linear optimization scheme such as the Simplex method results in a mix of thermal and epithermal source neutrons to get the highest homogeneity for the thermal neutron field. This optimisation method is demonstrated in 3 holder shapes: cuboid, cylindrical and spherical with each 3 volumes of 2, 4 and 6 litres. A 10 cm thick cuboid model, irradiated from both sides gives the highest homogeneity. The spherical (rotating) holder has the lowest homogeneity but the highest contribution of every source neutron to the thermal neutrons in the liver. This can be advantageous when using a relatively small sized neutron beam with a low strength. (author)

  8. First clinical results on the finnish study on BPA-mediated BNCT in glioblastoma

    Energy Technology Data Exchange (ETDEWEB)

    Kankaanranta, L. [Helsinki University Hospital, Dept. of Oncology, Helsinki (Finland); Seppaelae, T. [University of Helsinki, Department of Physics, Helsinki (Finland); Kallio, M. [Helsinki University Hospital, Dept. of Neurology, Helsinki (Finland)] [and others

    2000-10-01

    An open phase I dose-escalation boron neutron capture therapy (BNCT) study on glioblastoma multiforme (GBM) was initiated at the BNCT facility FiR 1, Espoo, Finland, in May 1999. The aim of the study is to investigate the safety of boronophenylalanine (BPA)-mediated BNCT. Ten GBM patients were treated with a 2-field treatment plan using one fraction. BPA-F was used as the {sup 10}B carrier infused as a fructose solution 290 mg BPA/kg over 2-hours prior to irradiation with epithermal neutrons. Average doses to the normal brain, contrast enhancing tumour, and the target ranged from 3.0 to 5.6 Gy (W), from 35.1 to 66.7 Gy (W), and from 29.6 to 53.6 Gy (W), respectively. BNCT was associated with acceptable toxicity. The median follow-up is 9 months (range, 3 to 16 months) post diagnosis in July 2000. Seven of the 10 patients have recurrent or persistent GBM, and the median time to progression is 8 months. Only one patient has died, and the estimated 1-year overall survival is 86%. Five of the recurrent tumours were treated with external beam photon radiation therapy to the total dose of 30-40 Gy with few acute side-effects. These preliminary findings suggest that acute toxicity of BPA-mediated BNCT is acceptable when average brain doses of 5.6 Gy (W) or less are used. The followup time is too short to evaluate survival, but the estimated 1-year survival of 86% achieved with BNCT followed by conventional photon irradiation at the time of tumour progression is encouraging and emphasises the need of further investigation of BPA-mediated BNCT. (author)

  9. Tumor control and normal tissue complications in BNCT treatment of nodular melanoma: A search for predictive quantities

    International Nuclear Information System (INIS)

    A previous work concerning tumor control and skin damage in cutaneous melanoma treatments with BNCT has been extended to include doses, volumes and responses of 104 subcutaneous lesions from all patients treated in Argentina. Acute skin reactions were also scored for these patients, and cumulative dose-area histograms and dose-based figures of merit for skin were calculated. Broadening the tumor response analysis with the latest data showed that the (minimum or mean) tumor dose is not a good predictor of the observed clinical outcome by itself. However, when the tumor volume was included in the model as second explicative variable, the dose increases its significance and becomes a critical variable jointly with the volume (p-values3) doses greater than 20 Gy-Eq produce a high tumor control (> 80%). However, when tumor volumes are larger than 0.1 cm3, control is moderate (< 40%) even for minimum doses up to 40 Gy-Eq. Some quantities based on skin doses, areas and complication probabilities were proposed as candidates for predicting the severity of the early skin reactions. With the current data, all the evaluated figures of merit derived similar results: ulceration is present among the cases for which these quantities take the highest values.

  10. Medical set-up of boron neutron capture therapy (BNCT) for malignant glioma at the Japan research reactor (JRR)-4

    International Nuclear Information System (INIS)

    The University of Tsukuba project for boron neutron capture therapy (BNCT) was initiated at the Japan Atomic Energy Research Institute (JAERI) in 1992. The clinical study for BNCT began at the Japan Research Reactor (JRR)-2 of the JAERI in November 1995. By the end of 1998, a new medical irradiation facility had been installed in JRR-4 of that included a new medical treatment room and patient-monitoring area adjacent to the irradiation room. The medical treatment room was built to reflect a hospital-type operation room that includes an operating table with a carbon head frame, anesthesia apparatus with several cardiopulmonary monitors, etc. Following craniotomy in the treatment room, a patient under anesthesia is transported into the irradiation room for BNCT. The boron concentration in tissue is measured with prompt gamma ray analysis (PGA) and simultaneously by inductively coupled plasma atomic emission spectroscopy (ICP-AES) methods. For the immediate pre- and post-BNCT care, a collaborating neurosurgical department of the University of Tsukuba was prepared in the vicinity of the JAERI. The long term follow-up is done at the University of Tsukuba Hospital. Epithermal neutron beam also became available at the new JRR-4. By changing the thickness and/or the configuration of heavy water, a cadmium plate, and a graphite reflector, the JRR-4 provides a variety of neutron beams, including three typical beams (Epithermal mode and Thermal modes I and II). Intraoperative BNCT using the thermal beam is planned to study at the beginning of the clinical trial. The ongoing development of the JAERI Computational Dosimetry System (JCDS) and radiobiological studies have focused in the application of the epithermal beam for BNCT. After obtaining these basic data, we are planning to use the epithermal beam for intraoperative BNCT. (author)

  11. The relationship between boron neutron capture therapy (BNCT) and positron emission tomography (PET) for malignant brain tumors

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is a particle irradiation therapy that is theoretically available for selective radiation of tumor cells. Boronophenylalanine-positron emission tomography (18F-BPA-PET) was used in this study. Boron is used as a tracer compound for the neutron capture reaction and has been particularly useful for the recent noncraniotomy BNCT. In this report, we introduce this type of PET as a principal axis in BNCT and relationship with PET. We calculated the drug accumulation to the tumor before neutron irradiation to individualize the treatment. We decided the indication for BNCT on the basis of a PET study and are now expanding the indications to other systemic cancers, including head and neck, lung, and liver cancers. In addition, other irradiation modalities have developed a radiation plan on the basis of a PET study, and several studies attempted improving the results; however, the lesion is exposed to high radiation doses and appear as high accumulation on BPA-PET during BNCT. We determined the neutron exposure time from the dosage for normal tissue in the actual treatment, but the lesion/normal tissue ratio obtained from BPA-PET is for evaluating the tumor dose and following the treatment plan. We also found that a PET study was useful in the follow-up stage to aid in diagnosis of pathologic conditions such as increase in tumor volume, recurrence, or radiation necrosis and for patients who had already been treated for malignant brain tumor. (author)

  12. The BNCT project in the Czech Republic

    International Nuclear Information System (INIS)

    The start of clinical trials is expected before NCT Osaka 2000. The experiences from different part of project are presented. The BNCT facility at LVR-15 reactor of NRI consists of epithermal neutron beam with improved construction (6.98 x 108/cm2s with acceptable background of fast neutrons and gammas) and irradiation and control rooms equipped by appropriate devices. Internationally-recognized software MacNCTPLAN is utilized for computational dosimetry and treatment planning. In the part of protocol the following parameters have been assessed: patient selection, BSH dosage, fractionation, starting dose, dose escalation steps. At the LVR-15, at horizontal channel, a prompt gamma ray analysis (PGRA) system has been developed and is operated for BNCT purposes. Some human blood samples were analyzed and compared with classical ICP method. During the process of licensing the experience was obtained, some notes are discussed in the paper. The first results were received for the study of biological effect of the LVR source for small animal model. (author)

  13. Computerized radiation treatment planning

    International Nuclear Information System (INIS)

    Following a general introduction, a chain consisting of three computer programs which has been developed for treatment planning of external beam radiotherapy without manual intervention is described. New score functions used for determination of optimal incidence directions are presented and the calculation of the position of the isocentre for each optimum combination of incidence directions is explained. A description of how a set of applicators, covering fields with dimensions of 4 to 20 cm, for the 6 to 20 MeV electron beams of a MEL SL75-20 linear accelerator was developed, is given. A computer program for three dimensional electron beam treatment planning is presented. A microprocessor based treatment planning system for the Selectron remote controlled afterloading system for intracavitary radiotherapy is described. The main differences in treatment planning procedures for external beam therapy with neutrons instead of photons is discussed. A microprocessor based densitometer for plotting isodensity lines in film dosimetry is described. A computer program for dose planning of brachytherapy is presented. Finally a general discussion about the different aspects of computerized treatment planning as presented in this thesis is given. (Auth.)

  14. Measurement and simulation of the TRR BNCT beam parameters

    Science.gov (United States)

    Bavarnegin, Elham; Sadremomtaz, Alireza; Khalafi, Hossein; Kasesaz, Yaser; Golshanian, Mohadeseh; Ghods, Hossein; Ezzati, Arsalan; Keyvani, Mehdi; Haddadi, Mohammad

    2016-09-01

    Recently, the configuration of the Tehran Research Reactor (TRR) thermal column has been modified and a proper thermal neutron beam for preclinical Boron Neutron Capture Therapy (BNCT) has been obtained. In this study, simulations and experimental measurements have been carried out to identify the BNCT beam parameters including the beam uniformity, the distribution of the thermal neutron dose, boron dose, gamma dose in a phantom and also the Therapeutic Gain (TG). To do this, the entire TRR structure including the reactor core, pool, the thermal column and beam tubes have been modeled using MCNPX Monte Carlo code. To measure in-phantom dose distribution a special head phantom has been constructed and foil activation techniques and TLD700 dosimeter have been used. The results show that there is enough uniformity in TRR thermal BNCT beam. TG parameter has the maximum value of 5.7 at the depth of 1 cm from the surface of the phantom, confirming that TRR thermal neutron beam has potential for being used in treatment of superficial brain tumors. For the purpose of a clinical trial, more modifications need to be done at the reactor, as, for example design, and construction of a treatment room at the beam exit which is our plan for future. To date, this beam is usable for biological studies and animal trials. There is a relatively good agreement between simulation and measurement especially within a diameter of 10 cm which is the dimension of usual BNCT beam ports. This relatively good agreement enables a more precise prediction of the irradiation conditions needed for future experiments.

  15. Completion of treatment planning

    International Nuclear Information System (INIS)

    The outline of the lecture included the following topics: entering prescription; plan printout; print and transfer DDR; segment BEV; export to R and V; physician approval; and second check. Considerable attention, analysis and discussion. The summary is as follows: Treatment planning completion is a very responsible process which requires maximum attention; Should be independently checked by the planner, physicist, radiation oncologist and a therapist; Should not be done in a last minute rush; Proper communication between team members; Properly set procedure should prevent propagation of an error by one individual to the treatment: the error should be caught by somebody else. (P.A.)

  16. INEL BNCT research program: Annual report, 1995

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1996-04-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1995. Contributions from the principal investigators about their individual projects are included, specifically, physics (treatment planning software, real-time neutron beam measurement dosimetry), and radiation biology (large animal models efficacy studies). Design of a reactor based epithermal neutron extraction facility is discussed in detail. Final results of boron magnetic resonance imagining is included for both borocaptate sodium (BSH) and boronophenylalanine (BPA) in rats, and BSH in humans. Design of an epithermal neutron facility using electron linear accelerators is presented, including a treatise on energy removal from the beam target. Information on the multiple fraction injection of BSH in rats is presented.

  17. INEL BNCT research program: Annual report, 1995

    International Nuclear Information System (INIS)

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1995. Contributions from the principal investigators about their individual projects are included, specifically, physics (treatment planning software, real-time neutron beam measurement dosimetry), and radiation biology (large animal models efficacy studies). Design of a reactor based epithermal neutron extraction facility is discussed in detail. Final results of boron magnetic resonance imagining is included for both borocaptate sodium (BSH) and boronophenylalanine (BPA) in rats, and BSH in humans. Design of an epithermal neutron facility using electron linear accelerators is presented, including a treatise on energy removal from the beam target. Information on the multiple fraction injection of BSH in rats is presented

  18. Might iodomethyl-{alpha}-tyrosine be a surrogate for BPA in BNCT?

    Energy Technology Data Exchange (ETDEWEB)

    Miura, Michiko; Micca, P.L.; Nawrocky, M.M.; Slatkin, D.N.

    1996-12-31

    A single-photon emission computed tomography [SPECT] imaging agent that is an analogue of a boron carrier for boron neutron-capture therapy [BNCT] of cerebral gliomas would be useful for assessing the kinetics of boron uptake in tumors and in the surrounding brain tissues noninvasively. BNCT is based on the interaction of thermalized neutrons with {sup 10}B nuclei in the targeted tumor. For BNCT of brain tumors, it is crucial that {sup 10}B concentrations in radiosensitive regions of the brain be minimal since malignant cells and vital brain tissues are often inter-mingled at the margins of the tumor. Currently, boronophenylalanine [BPA]-mediated BNCT is undergoing preliminary clinical study for postoperative radiotherapy of glioblastorna multiforme at Brookhaven National Laboratory. Investigators in Japan are developing {sup 18}F-fluoroboronophenylaianine [FBPA] as a positron {sup 18}F (T{sub 1/2} = 110 min), which is usually emission tomography [PET] surrogate for BPA. generated at a cyclotron dedicated to PET, is generally a minimally perturbing substitute for the 2-H on the aromatic ring because of its small size and the strong covalent bond it forms with carbon. However, SPECT has potential advantages over PET: (1) SPECT is clinically more widely available at lower cost; (2) most radioisotopes for the synthesis of SPECT agents can be purchased; (3) SPECT is less difficult to implement. It is thought that the quality of images derived from the two techniques would each be sufficiently informative for BNCT treatment planning purposes, provided that the SPECT and PET agents being considered were both pharmacokinetic surrogates for BPA. This study evaluated the use of {sup 123}I alpha methyltyrosine as a surrogate for BPA in BNCT.

  19. Might iodomethyl-α-tyrosine be a surrogate for BPA in BNCT?

    International Nuclear Information System (INIS)

    A single-photon emission computed tomography [SPECT] imaging agent that is an analogue of a boron carrier for boron neutron-capture therapy [BNCT] of cerebral gliomas would be useful for assessing the kinetics of boron uptake in tumors and in the surrounding brain tissues noninvasively. BNCT is based on the interaction of thermalized neutrons with 10B nuclei in the targeted tumor. For BNCT of brain tumors, it is crucial that 10B concentrations in radiosensitive regions of the brain be minimal since malignant cells and vital brain tissues are often inter-mingled at the margins of the tumor. Currently, boronophenylalanine [BPA]-mediated BNCT is undergoing preliminary clinical study for postoperative radiotherapy of glioblastorna multiforme at Brookhaven National Laboratory. Investigators in Japan are developing 18F-fluoroboronophenylaianine [FBPA] as a positron 18F (T1/2 = 110 min), which is usually emission tomography [PET] surrogate for BPA. generated at a cyclotron dedicated to PET, is generally a minimally perturbing substitute for the 2-H on the aromatic ring because of its small size and the strong covalent bond it forms with carbon. However, SPECT has potential advantages over PET: (1) SPECT is clinically more widely available at lower cost; (2) most radioisotopes for the synthesis of SPECT agents can be purchased; (3) SPECT is less difficult to implement. It is thought that the quality of images derived from the two techniques would each be sufficiently informative for BNCT treatment planning purposes, provided that the SPECT and PET agents being considered were both pharmacokinetic surrogates for BPA. This study evaluated the use of 123I alpha methyltyrosine as a surrogate for BPA in BNCT

  20. The first main steps for development of BNCT neutron sources at the Ukrainian and Uzbek Research Reactors

    International Nuclear Information System (INIS)

    Both in Ukraine and in Uzbekistan, epithermal neutron irradiation facilities for Boron Neutron Capture Therapy (BNCT) are under consideration, as the need for them is very large. Based on information from medical cancer treatment institutions of the total number of patients identified with cancer, about 5000 have brain tumours. The most prospective method of their treatment is BNCT. Both in Ukraine and in Uzbekistan, this method can be implemented on existing research reactors. Modification of research reactors may be a relatively straightforward and inexpensive way to develop a BNCT neutron source, especially in comparison with construction of new reactors specialized for BNCT. However, prior to any reactor modification, careful calculations need to be performed, which take into account all the peculiarities of the specific reactor system. Based on the world experience in epithermal neutron beam development, it is very clear that the research reactors in Kyiv (Kyiv Research Reactor-KRR) and Tashkent (Tashkent Research Reactor-TRR) may be reconstructed into epithermal irradiation facilities. Selection of the most suitable materials for moderator, collimator, shielding, etc., demands carrying out calculations considering their individual characteristics. Since the KRR and TRR are the same kind of research reactors, with for example similar thermal columns, the development of a BNCT neutron source at these research reactors may be achieved in a like manner. The development plan and the first experience in this direction (using preliminary MCNP calculation results) are presented here. (author)

  1. Neutron-photon mixed field dosimetry by TLD-700 glow curve analysis and its implementation in dose monitoring for Boron Neutron Capture Therapy (BNCT) treatments

    Energy Technology Data Exchange (ETDEWEB)

    Boggio, E. F.; Longhino, J. M. [Centro Atomico Bariloche, Departamento de Fisica de Reactores y Radiaciones / CNEA, Av. E. Bustillo Km 9.5, R8402AGP San Carlos de Bariloche (Argentina); Andres, P. A., E-mail: efboggio@cab.cnea.gov.ar [Centro Atomico Bariloche, Division Proteccion Radiologica / CNEA, Av. E. Bustillo Km 9.5, R8402AGP San Carlos de Bariloche (Argentina)

    2015-10-15

    BNCT is a cancerous cells selective, non-conventional radiotherapy modality to treat malignant tumors such as glioblastoma, melanoma and recurrent head and neck cancer. It consists of a two-step procedure: first, the patient is injected with a tumor localizing drug containing a non-radioactive isotope (Boron-10) with high slow neutron capture cross-section. In a second step, the patient is irradiated with neutrons, which are absorbed by the Boron-10 agent with the subsequently nuclear reaction B- 10(n,a)Li-7, thereby resulting in dose at cellular level due to the high-Let particles. The neutron fields suitable for BNCT are characterized by high neutron fluxes and low gamma dose. Determination of each component is not an easy task, especially when the volume of measurement is quite small or inaccessible for a miniature ionization chamber, for example. A method of measuring the photon and slow neutron dose(mainly by N-14 and B-10) from the glow curve (GC) analysis of a single {sup 7}LiF thermoluminescence detector is evaluated. This method was suggested by the group headed by Dr. Grazia Gambarini. The dosemeters used were TLD-600 ({sup 6}LiF:Mg,Ti with 95.6% {sup 6}Li) and TLD-700 ({sup 7}LiF:Mg,Ti with 99.9% {sup 7}LiF) from Harshaw. Photon dose measurement using the GC analysis method with TLD-700 in mixed fields requires the relation of the two main peaks of a TLD-600 GC shape obtained from an exposition to the same neutron field, and a photon calibrated GC with TLD-700. The requirements for slow neutron dose measurements are similar. In order to properly apply the GC analysis method at the Ra-6 Research Reactor BNCT facility, measurements were carried out in a standard water phantom, fully characterized on the BNCT beam by conventional techniques (activation detectors and paired ionization chambers technique). Next, the method was implemented in whole body dose monitoring of a patient undergoing a BNCT treatment, using a Bo MAb (Bottle Manikin Absorption) phantom

  2. Neutron-photon mixed field dosimetry by TLD-700 glow curve analysis and its implementation in dose monitoring for Boron Neutron Capture Therapy (BNCT) treatments

    International Nuclear Information System (INIS)

    BNCT is a cancerous cells selective, non-conventional radiotherapy modality to treat malignant tumors such as glioblastoma, melanoma and recurrent head and neck cancer. It consists of a two-step procedure: first, the patient is injected with a tumor localizing drug containing a non-radioactive isotope (Boron-10) with high slow neutron capture cross-section. In a second step, the patient is irradiated with neutrons, which are absorbed by the Boron-10 agent with the subsequently nuclear reaction B- 10(n,a)Li-7, thereby resulting in dose at cellular level due to the high-Let particles. The neutron fields suitable for BNCT are characterized by high neutron fluxes and low gamma dose. Determination of each component is not an easy task, especially when the volume of measurement is quite small or inaccessible for a miniature ionization chamber, for example. A method of measuring the photon and slow neutron dose(mainly by N-14 and B-10) from the glow curve (GC) analysis of a single 7LiF thermoluminescence detector is evaluated. This method was suggested by the group headed by Dr. Grazia Gambarini. The dosemeters used were TLD-600 (6LiF:Mg,Ti with 95.6% 6Li) and TLD-700 (7LiF:Mg,Ti with 99.9% 7LiF) from Harshaw. Photon dose measurement using the GC analysis method with TLD-700 in mixed fields requires the relation of the two main peaks of a TLD-600 GC shape obtained from an exposition to the same neutron field, and a photon calibrated GC with TLD-700. The requirements for slow neutron dose measurements are similar. In order to properly apply the GC analysis method at the Ra-6 Research Reactor BNCT facility, measurements were carried out in a standard water phantom, fully characterized on the BNCT beam by conventional techniques (activation detectors and paired ionization chambers technique). Next, the method was implemented in whole body dose monitoring of a patient undergoing a BNCT treatment, using a Bo MAb (Bottle Manikin Absorption) phantom, with representative

  3. Radiotherapy treatment planning

    International Nuclear Information System (INIS)

    A teaching text on external beam radiotherapy treatment planning is presented. Chapters are included on machines, radiation units, the physics of a single radiation field, the multiple-field isodose curve pattern, electron beam therapy, manual addition of isodose curves and dose calculation methods. (U.K.)

  4. Radiation Dosimetry in the BNCT Patient Treatment Room at the Brookhaven Medical Research Reactor

    International Nuclear Information System (INIS)

    The BMRR was a 3 MW light water reactor that had an epithermal neutron beam that was used to perform clinical trials on patients with malignant brain tumors. A series of measurements and calculations had been performed in the treatment room both prior to the trials and during the trials. The details of the measurements and the Monte Carlo calculations are presented and compared.

  5. Feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis

    International Nuclear Information System (INIS)

    Purpose: To investigate the feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma (MPM) from a viewpoint of dose distribution analysis using Simulation Environment for Radiotherapy Applications (SERA), a currently available BNCT treatment planning system. Methods and Materials: The BNCT treatment plans were constructed for 3 patients with MPM using the SERA system, with 2 opposed anterior-posterior beams. The 1B concentrations in the tumor and normal lung in this study were assumed to be 84 and 24 ppm, respectively, and were derived from data observed in clinical trials. The maximum, mean, and minimum doses to the tumors and the normal lung were assessed for each plan. The doses delivered to 5% and 95% of the tumor volume, D05 and D95, were adopted as the representative dose for the maximum and minimum dose, respectively. Results: When the D05 to the normal ipsilateral lung was 5 Gy-Eq, the D95 and mean doses delivered to the normal lung were 2.2-3.6 and 3.5-4.2 Gy-Eq, respectively. The mean doses delivered to the tumors were 22.4-27.2 Gy-Eq. The D05 and D95 doses to the tumors were 9.6-15.0 and 31.5-39.5 Gy-Eq, respectively. Conclusions: From a viewpoint of the dose-distribution analysis, BNCT has the possibility to be a promising treatment for MPM patients who are inoperable because of age and other medical illnesses

  6. BNCT for malignant brain tumors in children

    International Nuclear Information System (INIS)

    BSH-based intra-operative BNCT as an initial treatment underwent in 4 children with malignant brain tumors since 1998. There were 2 glioblastomas, one primitive neuroectodermal tumor (PNET) and one anaplastic ependymoma patient. They included two children under 3-year-old. All GBM patients were died of CSF dissemination without tumor regrowth in the primary site. Another PNET and anaplastic ependymoma patients are still alive without tumor recurrence. We can consider BNCT is optimal treatment modality for malignant brain tumor in children. (author)

  7. Treatment planning systems

    International Nuclear Information System (INIS)

    All aspects of treatment planning in radiotherapy are discussed in detail. Included are, among others, machine data and their acquisition, photon dose calculations and tests thereof, criteria of acceptability, sources of uncertainties, from 2D to 3D and from 3D to IMRT, dosimetric measurements for RTP validation, frequency of QA tests and suggested tolerances for TPS, time and staff requirements, model based segmentation, multi-dimensional radiotherapy (MDCRT), and biological IMRT process. (P.A.)

  8. The studsvik BNCT project: structure and the proposed protocols

    International Nuclear Information System (INIS)

    The BNCT facility at Studsvik is now ready for clinical trials. Scientific operations of the Studsvik BNCT project are overseen by the Scientific Advisory Board comprised of representatives of all major universities in Sweden. Furthermore, special task groups for clinical and preclinical studies have been formed to facilitate collaboration with academia and to assure the quality of the research. Proposed clinical Phase II trials for glioblastoma are sponsored by the Swedish National Neuro-Oncology Group and, initially, will involve two protocols: Protocol no.1. BNCT for glioblastoma patients who have not received any therapy other than surgery (including stereotactic biopsy only). Protocol no.2. BNCT as a palliative treatment for patients with recurrent glioblastoma following conventional therapies or BNCT. In both protocols, BPA, administered by a 6 hour i.v. infusion, will be used as the boron delivery agent. (author)

  9. BNCT Technology Development on HANARO Reactor

    International Nuclear Information System (INIS)

    So as to establish the biological effects of BNCT in the HANARO Reactor, biological damages in cells and animals with treatment of boron/neutron were investigated. And 124I-BPA animal PET image, analysis technology of the boron contents in the mouse tissues by ICP-AES was established. A Standard clinical protocol, a toxicity evaluation report and an efficacy investigation report of BNCT has been developed. Based on these data, the primary permission of clinical application was acquired through IRB of our hospital. Three cases of pre-clinical experiment for boron distribution and two cases of medium-sized animal simulation experiment using cat with verifying for 2 months after BNCT was performed and so the clinical demonstration with a patient was prepared. Also neutron flux, fast neutron flux and gamma ray dose of BNCT facility were calculated and these data will be utilized good informations for clinical trials and further BNCT research. For the new synthesis of a boron compound, o-carboranyl ethylamine, o-carboranylenepiperidine, o-carboranyl-THIQ and o-carboranyl-s-triazine derivatives were synthesized. Among them, boron uptake in the cancer cell of the triazine derivative was about 25 times than that of BPA and so these three synthesized methods of new boron compounds were patented

  10. BNCT Technology Development on HANARO Reactor

    Energy Technology Data Exchange (ETDEWEB)

    Chun, Ki Jung; Park, Kyung Bae; Whang, Seung Ryul; Kim, Myong Seop

    2007-06-15

    So as to establish the biological effects of BNCT in the HANARO Reactor, biological damages in cells and animals with treatment of boron/neutron were investigated. And 124I-BPA animal PET image, analysis technology of the boron contents in the mouse tissues by ICP-AES was established. A Standard clinical protocol, a toxicity evaluation report and an efficacy investigation report of BNCT has been developed. Based on these data, the primary permission of clinical application was acquired through IRB of our hospital. Three cases of pre-clinical experiment for boron distribution and two cases of medium-sized animal simulation experiment using cat with verifying for 2 months after BNCT was performed and so the clinical demonstration with a patient was prepared. Also neutron flux, fast neutron flux and gamma ray dose of BNCT facility were calculated and these data will be utilized good informations for clinical trials and further BNCT research. For the new synthesis of a boron compound, o-carboranyl ethylamine, o-carboranylenepiperidine, o-carboranyl-THIQ and o-carboranyl-s-triazine derivatives were synthesized. Among them, boron uptake in the cancer cell of the triazine derivative was about 25 times than that of BPA and so these three synthesized methods of new boron compounds were patented.

  11. Production of epithermal neutron beams for BNCT

    CERN Document Server

    Bisceglie, E; Colonna, N; Paticchio, V; Santorelli, P; Variale, V

    2002-01-01

    The use of boron neutron capture therapy (BNCT) for the treatment of deep-seated tumors requires neutron beams of suitable energy and intensity. Simulations indicate the optimal energy to reside in the epithermal region, in particular between 1 and 10 keV. Therapeutic neutron beams with high spectral purity in this energy range could be produced with accelerator-based neutron sources through a suitable neutron-producing reaction. Herein, we report on different solutions that have been investigated as possible sources of epithermal neutron beams for BNCT. The potential use of such sources for a hospital-based therapeutic facility is discussed.

  12. Integral multidisciplinary rehabilitation treatment planning

    OpenAIRE

    Braaksma, A.; Kortbeek, Nikky; Post, Gerhard; Nollet, Frans

    2012-01-01

    This paper presents a methodology to plan treatments for rehabilitation outpatients. These patients require a series of treatments by therapists from various disciplines. In current practice, when treatments are planned, a lack of coordination between the different disciplines, along with a failure to plan the entire treatment plan at once, often occurs. This situation jeopardizes both the quality of care and the logistical performance. The multidisciplinary nature of the rehabilitation proce...

  13. Experimental Studies of Boronophenylalanine (10BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment

    International Nuclear Information System (INIS)

    Purpose: Patients with the same histopathologic diagnosis of cutaneous melanoma treated with identical protocols of boron neutron capture therapy (BNCT) have shown different clinical outcomes. The objective of the present studies was to evaluate the biodistribution of boronophenilalanina (10BPA) for the potential application of BNCT for the treatment of melanoma on an individual basis. Methods and Materials: The boronophenilalanine (BPA) uptake was evaluated in 3 human melanoma cell lines: MEL-J, A375, and M8. NIH nude mice were implanted with 4 106 MEL-J cells, and biodistribution studies of BPA (350 mg/kg intraperitoneally) were performed. Static infrared imaging using a specially modified infrared camera adapted to measure the body infrared radiance of small animals was used. Proliferation marker, Ki-67, and endothelial marker, CD31, were analyzed in tumor samples. Results: The in vitro studies demonstrated different patterns of BPA uptake for each analyzed cell line (P<.001 for MEL-J and A375 vs M8 cells). The in vivo studies showed a maximum average boron concentration of 25.9 ± 2.6 μg/g in tumor, with individual values ranging between 11.7 and 52.0 μg/g of 10B 2 hours after the injection of BPA. Tumor temperature always decreased as the tumors increased in size, with values ranging between 37°C and 23°C. A significant correlation between tumor temperature and tumor-to-blood boron concentration ratio was found (R2 = 0.7, rational function fit). The immunohistochemical studies revealed, in tumors with extensive areas of viability, a high number of positive cells for Ki-67, blood vessels of large diameter evidenced by the marker CD31, and a direct logistic correlation between proliferative status and boron concentration difference between tumor and blood (R2 = 0.81, logistic function fit). Conclusion: We propose that these methods could be suitable for designing new screening protocols applied before melanoma BNCT treatment for each individual

  14. Experimental Studies of Boronophenylalanine ({sup 10}BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment

    Energy Technology Data Exchange (ETDEWEB)

    Carpano, Marina; Perona, Marina; Rodriguez, Carla [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); Nievas, Susana; Olivera, Maria; Santa Cruz, Gustavo A. [Department of Boron Neutron Capture Therapy, National Atomic Energy Commission, San Martín (Argentina); Brandizzi, Daniel; Cabrini, Romulo [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); School of Dentistry, University of Buenos Aires, Buenos Aires (Argentina); Pisarev, Mario [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); National Research Council of Argentina, Buenos Aires (Argentina); Department of Human Biochemistry, School of Medicine, University of Buenos Aires, Buenos Aires (Argentina); Juvenal, Guillermo Juan [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); National Research Council of Argentina, Buenos Aires (Argentina); Dagrosa, Maria Alejandra, E-mail: dagrosa@cnea.gov.ar [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); National Research Council of Argentina, Buenos Aires (Argentina)

    2015-10-01

    Purpose: Patients with the same histopathologic diagnosis of cutaneous melanoma treated with identical protocols of boron neutron capture therapy (BNCT) have shown different clinical outcomes. The objective of the present studies was to evaluate the biodistribution of boronophenilalanina ({sup 10}BPA) for the potential application of BNCT for the treatment of melanoma on an individual basis. Methods and Materials: The boronophenilalanine (BPA) uptake was evaluated in 3 human melanoma cell lines: MEL-J, A375, and M8. NIH nude mice were implanted with 4 10{sup 6} MEL-J cells, and biodistribution studies of BPA (350 mg/kg intraperitoneally) were performed. Static infrared imaging using a specially modified infrared camera adapted to measure the body infrared radiance of small animals was used. Proliferation marker, Ki-67, and endothelial marker, CD31, were analyzed in tumor samples. Results: The in vitro studies demonstrated different patterns of BPA uptake for each analyzed cell line (P<.001 for MEL-J and A375 vs M8 cells). The in vivo studies showed a maximum average boron concentration of 25.9 ± 2.6 μg/g in tumor, with individual values ranging between 11.7 and 52.0 μg/g of {sup 10}B 2 hours after the injection of BPA. Tumor temperature always decreased as the tumors increased in size, with values ranging between 37°C and 23°C. A significant correlation between tumor temperature and tumor-to-blood boron concentration ratio was found (R{sup 2} = 0.7, rational function fit). The immunohistochemical studies revealed, in tumors with extensive areas of viability, a high number of positive cells for Ki-67, blood vessels of large diameter evidenced by the marker CD31, and a direct logistic correlation between proliferative status and boron concentration difference between tumor and blood (R{sup 2} = 0.81, logistic function fit). Conclusion: We propose that these methods could be suitable for designing new screening protocols applied before melanoma BNCT

  15. BNCT. Computational Analysis; BNCT. Analisis computacional

    Energy Technology Data Exchange (ETDEWEB)

    Caro, R.

    2004-07-01

    The BNCT (Boron Neutron Capture Therapy) is a new oncologic radiotherapy technique in the process of research which consists of injecting a non-poisonous pharmacovector into an ill patient in such a way that the tumor receives isotope boron-10, so that the tumoral area can later be bombarded with a beam of neutrons, many of which are captured the isotope in question. (Author)

  16. In vivo BNCT in experimental and spontaneous tumors at RA-1 reactor

    International Nuclear Information System (INIS)

    Within the search for new applications of Boron Neutron Capture Therapy (BNCT) and the basic research oriented towards the study of BNCT radiobiology to optimize its therapeutic gain, we previously proposed and validated the hamster cheek pouch oral cancer model and showed, for the first time, the success of BNCT to treat oral cancer in an experimental model. The staff of the Ra-1 Reactor (Constituyentes Atomic Center) adapted the thermal beam and physical set-up to perform in vivo BNCT of superficial tumors in small animals. We preformed a preliminary characterization of the thermal beam, performed beam only irradiation of normal and tumor bearing hamsters and in vivo BNCT of experimental oral squamous cell carcinomas in hamsters mediated by boron phenylalanine (BPA) and GB-10 (Na210B10H10). Having demonstrated the absence of radio toxic effects in healthy tissue and a therapeutic effect of in vivo BNCT in hamster cheek pouch tumors employing the Ra-1 thermal beam, we performed a feasibility study of the treatment by BNCT of 3 terminal cases of spontaneous head and neck squamous cell carcinoma in cats following the corresponding biodistribution studies. This was the first treatment of spontaneous tumors by BNCT in our country and the first treatment by BNCT in cats worldwide. This preclinical study in terminal cases showed significant tumor control by BNCT with no damage to normal tissue. (author)

  17. Design, construction and application of a neutron shield for the treatment of diffuse lung metastases in rats using BNCT

    International Nuclear Information System (INIS)

    A model of multiple lung metastases in BDIX rats is under study at CNEA (Argentina) to evaluate the feasibility of BNCT for multiple, non-surgically resectable lung metastases. A practical shielding device that comfortably houses a rat, allowing delivery of a therapeutic, uniform dose in lungs while protecting the body from the neutron beam is presented. Based on the final design obtained by numerical simulations, the shield was constructed, experimentally characterized and recently used in the first in vivo experiment at RA-3. - Highlights: • A practical shielding device that comfortably houses a rat is presented. • The shield allows a uniform and useful dose in the rat thoracic area. • A novel computational dosimetry in animals based on Multicell is presented. • Experimental characterization evidences the good performance of the shield. • An irradiation based on a diffuse lung metastases model in rats was performed

  18. Integral multidisciplinary rehabilitation treatment planning

    NARCIS (Netherlands)

    Braaksma, A.; Kortbeek, Nikky; Post, Gerhard; Nollet, Frans

    2012-01-01

    This paper presents a methodology to plan treatments for rehabilitation outpatients. These patients require a series of treatments by therapists from various disciplines. In current practice, when treatments are planned, a lack of coordination between the different disciplines, along with a failure

  19. Integral multidisciplinary rehabilitation treatment planning

    NARCIS (Netherlands)

    Braaksma, A.; Kortbeek, N.; Post, G.F.; Nollet, F.

    2014-01-01

    This paper presents a methodology to plan treatments for rehabilitation outpatients. These patients require a series of treatments by therapists from various disciplines. In current practice, when treatments are planned, a lack of coordination between the different disciplines, along with a failure

  20. Design of a BNCT facility at HANARO

    International Nuclear Information System (INIS)

    Based on the feasibility study of the BNCT at HANARO, it was confirmed that only thermal BNCT is possible at the IR beam tube if appropriate filtering system be installed. Medical doctors in Korea Cancer Center Hospital agreed that the thermal BNCT facility would be worthwhile for the BNCT technology development in Korea as well as superficial cancer treatment. For the thermal BNCT to be effective, the thermal neutron flux should be high enough for patient treatment during relatively short time and also the fast neutron and gamma-ray fluxes should be as low as possible. In this point of view, the following design requirements are set up: 1) thermal neutron flux at the irradiation position should be higher than 3x109 n/cm2-sec, 2) ratio of the fast neutrons and gamma-rays to the thermal neutrons should be minimized, and 3) patient treatment should be possible without interrupt to the reactor operation. To minimize the fast neutrons and gamma-rays with the required thermal neutrons at the irradiation position, a radiation filter consisting of single crystals of silicon and bismuth at liquid nitrogen temperature is designed. For the shielding purpose around the irradiation position, polyethylene, lead, LiF, etc., are appropriately arranged around the radiation filter. A water shutter in front of the radiation filter is adopted so as to avoid interrupt to the reactor operation. At present, detail design of the radiation filter is ongoing. Cooling capabilities of the filter will be tested through a mockup experiment. Dose rate distributions around the radiation filter and a prompt gamma-ray activation analysis system for the analyses of boron content in the biological samples are under design. The construction of this facility will be started from next year if it is permitted from the regulatory body this year. Some other future works exist and are described in the paper. (author)

  1. INEL BNCT Program

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.)

    1991-08-01

    This Bulletin presents a summary of accomplishments and highlights in the Idaho National Engineering Laboratory's (INEL) Boron Neutron Capture Therapy (BNCT) Program for August 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, and updates to the animal data charts.

  2. New EORTC clinical trials for BNCT

    International Nuclear Information System (INIS)

    Due to ethical reasons, a separated optimization of the two components of BNCT in the frame of clinical investigations can only be performed applying the whole binary system. The ongoing trial at HFR (High Flux Reactor Petten) has proven the feasibility of BNCT under defined conditions. On that basis the European Commission supported a comprehensive research project on boron imaging including three further clinical studies. In the first trial the boron uptake related to the blood boron concentration and surrounding normal tissue in various solid tumours will be examined using BSH (Sodiumborocaptate), BPA (Boronophenylalanine) or both in order to explore tumour entities, which may gain benefit from BNCT. The major objectives of the second trial are to define the maximum tolerated single and cumulative dose, and the dose limiting toxicity of BSH. The third clinical trial, a phase II study is designed to evaluate the anti-tumour effect of fractionated BNCT at the Petten treatment facility against cerebral metastasis of malignant melanoma using BPA. (author)

  3. Design and testing of a rotating, cooled device for extra-corporate treatment of liver cancer by BNCT in the epithermal neutron beam at the HFR Petten

    International Nuclear Information System (INIS)

    As part of the joint project on extra-corporal treatment of liver cancer by BNCT between JRC Petten and the University Hospital Essen, a facility has been designed and built to contain the liver during its irradiation treatment at the HFR Petten. The design consists of a rotating spheroid shaped PMMA holder, manufactured to open at the equator and closed by screwing together, surrounded by PMMA and graphite blocks. A validation exercise has been performed regarding both the nuclear conditions and the physical conditions. For the former, activation foil sets of Au, Cu and Mn, were irradiated at positions inside the liver holder filled with water, whilst a second measurement campaign has been performed using gel dosimetry. For the physical test, it is required to operate (rotate) the facility for up to 4 hours and to maintain the liver at approximately 4degC. The latter test was performed using 'cold gun sprays' that inject cold air near the liver holder. Both the nuclear and physical validation tests were performed successfully. (author)

  4. Characteristics of the new THOR epithermal neutron beam for BNCT

    International Nuclear Information System (INIS)

    A characterization of the new Tsing Hua open-pool reactor (THOR) epithermal neutron beam designed for boron neutron capture therapy (BNCT) has been performed. The facility is currently under construction and expected in completion in March 2004. The designed epithermal neutron flux for 1 MW power is 1.7x109 n cm-2 s-1 in air at the beam exit, accompanied by photon and fast neutron absorbed dose rates of 0.21 and 0.47 mGy s-1, respectively. With 10B concentrations in normal tissue and tumor of 11.4 and 40 ppm, the calculated advantage depth dose rate to the modified Snyder head phantom is 0.53 RBE-Gy min-1 at the advantage depth of 85 mm, giving an advantage ratio of 4.8. The dose patterns determined by the NCTPlan treatment planning system using the new THOR beam for a patient treated in the Harvard-MIT clinical trial were compared with results of the MITR-II M67 beam. The present study confirms the suitability of the new THOR beam for possible BNCT clinical trials

  5. In-phantom dosimetry for BNCT with Fricke and normoxic-polymer gels

    Science.gov (United States)

    Gambarini, G.; Agosteo, S.; Carrara, M.; Gay, S.; Mariani, M.; Pirola, L.; Vanossi, E.

    2006-05-01

    Measurements of in-phantom dose distributions and images are important for Boron Neutron Capture Therapy treatment planning. The method for spatial determination of absorbed doses in thermal or epithermal neutron fields, based on Fricke-xylenol-orange-infused gel dosimeters in form of layers, has revealed to be very reliable, as gel layer dosimeters give the possibility of obtaining spatial dose distributions and measurements of each dose contribution in neutron fields, by means of a properly studied procedure. Quite recently, BNCT has been applied to treat liver metastases; in this work the results of in-phantom dosimetry for explanted liver in BNCT treatments are described. Moreover, polyacrylamide gel (PAG) dosimeters in which a polymerization process appears as a consequence of absorbed dose, have been recently tested, because of their characteristic absence of diffusion. In fact, due to the diffusion of ferric ions, Fricke-gel dosimeters require prompt analysis after exposure to avoid spatial information loss. In this work the preliminary results of a study about the reliability of polymer gel in BNCT dosimetry are also discussed. Gel layers have been irradiated in a phantom exposed in the thermal column of the TRIGA MARK II reactor (Pavia). The results obtained with the two kinds of gel dosimeter have been compared.

  6. BNCT and dose fractionation

    International Nuclear Information System (INIS)

    Some portion of the radiation dose received by a patient during BNCT consists of primary and secondary gammas. The biological effect of that portion of the dose will depend upon the time history of the delivered dose. The well-known models for relating time-dose effects to clinical experience, are of questionable value in understanding dose effects in the time regime of a few hours, and for doses of less than tolerance. In order to examine the time-dose effect in the regime of interest to BNCT a simple phenomenological model was developed and normalized to the accepted body of clinical experience. The model has been applied to the question of fractionation of BNCT and the results are presented. The model is simply a linear healing model with two time constants. In other words, a first hit of radiation is assumed to wound (or potentiate) a cell. Given time, the cell will fully repair itself. If a second hit occurs before the cell has healed, the cell is killed. Apparently, there are two kinds of healing, one which occurs in 30 to 60 minutes, the other in two to four days. A small fraction of the cells will die on the first hit

  7. An Accelerator Neutron Source for BNCT

    International Nuclear Information System (INIS)

    The overall goal of this project was to develop an accelerator-based neutron source (ABNS) for Boron Neutron Capture Therapy (BNCT). Specifically, our goals were to design, and confirm by measurement, a target assembly and a moderator assembly that would fulfill the design requirements of the ABNS. These design requirements were (1) that the neutron field quality be as good as the neutron field quality for the reactor-based neutron sources for BNCT, (2) that the patient treatment time be reasonable, (3) that the proton current required to treat patients in reasonable times be technologically achievable at reasonable cost with good reliability, and accelerator space requirements which can be met in a hospital, and finally (4) that the treatment be safe for the patients

  8. An Accelerator Neutron Source for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Blue, Thomas, E

    2006-03-14

    The overall goal of this project was to develop an accelerator-based neutron source (ABNS) for Boron Neutron Capture Therapy (BNCT). Specifically, our goals were to design, and confirm by measurement, a target assembly and a moderator assembly that would fulfill the design requirements of the ABNS. These design requirements were 1) that the neutron field quality be as good as the neutron field quality for the reactor-based neutron sources for BNCT, 2) that the patient treatment time be reasonable, 3) that the proton current required to treat patients in reasonable times be technologially achievable at reasonable cost with good reliability, and accelerator space requirements which can be met in a hospital, and finally 4) that the treatment be safe for the patients.

  9. A new NEDO research project towards hospital based accelerator BNCT using advanced DDS system

    International Nuclear Information System (INIS)

    A new national project of developing a hospital based accelerator for boron neutron capture therapy (BNCT) with advanced drug delivery system (DDS) has been started in 2005. In this paper, the outline of the new project will be introduced. The project includes two main topics: 1) a hospital based accelerator for BNCT will be developed by a research consortium of Universities and companies. A fixed field alternating gradient (FFAG) type of accelerator with internal target is planned. 2) New boronated DDS using different methods including porphyrins, virus envelope vector, and liposome are planned. BNCT may become a first line charged particle therapy if the hospital based accelerator become feasible due to broadening the opportunity to use the neutron source. Due to such clinical convenience, there will be also possibility to spread the indication of BNCT for the diseases (cancer and other diseases) which has not been the candidate for BNCT in the nuclear-reactor era. (author)

  10. Isodose Curves and Treatment Planning for Boron Neutron Capture Therapy.

    Science.gov (United States)

    Liu, Hungyuan B.

    The development of Boron Neutron Capture Therapy (BNCT) has been progressing in both ^{10 }B compound development and testing and neutron beam delivery. Animal tests are now in progress with several ^{10}B compounds and once the results of these animal tests are promising, patient trials can be initiated. The objective of this study is to create a treatment planning method based on the dose calculations by a Monte Carlo code of a mixed radiation field to provide linkage between phantom dosimetry and patient irradiation. The research started with an overall review of the development of BNCT. Three epithermal neutron facilities are described, including the operating Brookhaven Medical Research Reactor (BMRR) beam, the designed Missouri University Research Reactor (MURR) beam, and a designed accelerator based neutron source. The flux and dose distributions in a head model have been calculated for irradiation by these neutron beams. Different beam parameters were inter -compared for effectiveness. Dosimetric measurements in an elliptical lucite phantom and a cylindrical water phantom were made and compared to the MCNP calculations for irradiation by the BMRR beam. Repeated measurements were made and show consistent. To improve the statistical results calculated by MCNP, a neutron source plane was designed to start neutrons at the BMRR irradiation port. The source plane was used with the phantoms for dosimetric calculations. After being verified by different phantom dosimetry and in-air flux measurements at the irradiation port, the source plane was used to calculate the flux and dose distributions in the head model. A treatment planning program was created for use on a PC which uses the MCNP calculated results as input. This program calculates the thermal neutron flux and dose distributions of each component of radiation in the central coronal section of the head model for irradiation by a neutron beam. Different combinations of head orientations and irradiation

  11. Requirements for BNCT at a nuclear research reactor. Results from a BNCT workshop organized by the European Commission in Prague, November 2005

    International Nuclear Information System (INIS)

    As part of the European Commission's Enlargement and Integration Action (E and IA), which is intended to improve exchange and relationship within the extended European Union (EU), a Workshop was organized in Prague in November 2005. The purpose of the workshop was to present and discuss technical and organisational requirements in setting up a BNCT facility at a research reactor. Topics included: treatment of a patient by BNCT; organisational aspects and regulatory affairs; BNCT from the nuclear perspective and BNCT from the clinician's perspective. Presentations were given by BNCT experts in their particular field, whilst eleven different national nuclear research centres from the New Member States and Accession Countries, interested in developing a BNCT programme, presented the status of their preparations. The conclusions of the Workshop were that an early and close collaboration between nuclear and medical groups is the basis for BNCT, that a local effort to build a BNCT facility should be supported by a national research programme including basic and clinical science and that the JRC and its partners are ready to support national initiatives within the EU and candidate countries. (author)

  12. Determining and reporting the doses in the treatments of glioma patients in the epithermal neutron beam at the Finnish BNCT facility (FIR 1)

    International Nuclear Information System (INIS)

    The clinical trials of glioma patients at the Finnish boron neutron capture therapy (BNCT) facility (FiR 1) started in May 1999. The doses of the patient in tumour, target volume and sensitive tissues are calculated individually. The calculated doses are calibrated to the reference monitor units according to the ratio of the independently measured and calculated 197Au(n,g) reactions rates at the depth of 20 mm on the central axis of a cylindrical PMMA phantom chosen as the reference geometry. Absorbed doses to the head and body are monitored individually using in vivo dosimeters. In BNCT the total dose is the weighted sum of the absorbed doses originating from the neutron and gamma interactions in tissues. The material compositions of the head model for the neutron-gamma transport calculation and kerma factors are based on the ICRU report 46. The doses in the clinical research of BNCT should be reported in such a way that the doses are comparable, traceable and can be recalculated, if underlying information, like weighting factors for dose components, are replaced by new ones. The minimum, maximum, average and reference doses are reported for the tumour, target and normal brain. In addition to the total weighted doses the dose components (boron, gamma, nitrogen and fast neutron dose), weighting factors and estimated boron concentration in these tissues are reported. There are no international recommendations available for BNCT dose calculation or reporting. Therefore the BNCT doses reported in the literature may not be comparable and a careless use of values can lead to over- or underdosing. There is an obvious need for standardisation in the medical application of BNCT. In this paper the methods of dose calculation and reporting of the glioma patients at FiR 1 are described. (author)

  13. Treatment planning in conservative dentistry

    OpenAIRE

    Andamuthu Sivakumar; Vinod Thangaswamy; Vaiyapuri Ravi

    2012-01-01

    A patient attending for treatment of a restorative nature may present for a variety of reasons. The success is built upon careful history taking coupled with a logical progression to diagnosis of the problem that has been presented. Each stage follows on from the preceding one. A fitting treatment plan should be formulated and should involve a holistic approach to what is required.

  14. BNCT irradiation facility at the JRR-4

    Energy Technology Data Exchange (ETDEWEB)

    Torii, Y.; Kishi, T.; Kumada, H.; Yamamoto, K.; Sakurai, F.; Takayanagi, M. [Japan Atomic Energy Research Inst., Tokai, Ibaraki (Japan). Tokai Research Establishment

    2000-10-01

    The JRR--4 was modified for fuel enrichment reducing and reactor equipment renewal. And also a medical irradiation facility for the Boron Neutron Capture Therapy (BNCT) was installed at the JRR--4 in that time. The medical irradiation facility has been composed of a heavy water tank, a collimator and an irradiation room. The heavy water tank has four layers of heavy water for spectrum shifter and 75cm-thickness aluminum for the shield of fast neutron. The collimator is for collimating thermal neutron and epithermal neutron using polyethylene with lithium-fluoride and shielding gamma ray by bismuth. The irradiation room has sufficient space at exit side of the beam, to accommodate a large working area for setting the patient. Both of the medical treatment room and the patient-monitoring area were prepared adjacent to the irradiation room. The medical irradiation facility in the JRR-4 is designed to permit selection of neutron energies from thermal neutron to epithermal neutron by changing the thickness of heavy water layers. Therefore it is available to continue the same kind of BNCT with thermal neutron used to perform in the JRR-2, as well as to commence the research and development of BNCT with epithermal neutron, which will make the brain tumor treatment possible at a deep part of brain. The full power operation of the JRR-4 was resumed with LEU fuel in October 1998 and currently performing some experiments to measure the neutron fluxes and physical doses for determinate characterization of the medical irradiation facility. The first medical irradiation for BNCT was carried out on 25th October 1999. The patient was treated by Tsukuba University group using thermal neutron beam included epi-thermal neutrons. (author)

  15. Design of a BNCT facility at HANARO

    International Nuclear Information System (INIS)

    Based on the feasibility study of the BNCT at HANARO, it was confirmed that only thermal BNCT is possible at the IR beam tube if appropriate filtering system be installed. Medical doctors in Korea Cancer Center Hospital agreed that the thermal BNCT facility would be worthwhile for the BNCT technology development in Korea as well as superficial cancer treatment. For the thermal BNCT to be effective, the thermal neutron flux should be high enough for patient treatment during relatively short time and also the fast neutron and gamma-ray fluxes should be as low as possible to avoid high dose on the patient during treatment. In this point of view, the following design requirements are set up; 1) thermal neutron flux at the irradiation position should be higher than 2 X 109 n/cm2 . sec, 2) ration of the fast neutrons and gamma-rays to the thermal neutrons should be minimized, and 3) patient treatment should be possible during reactor operation. To minimize the fast neutrons and gamma-rays with the required thermal neutrons at the irradiation position, a radiation filter consisting of single crystals of silicon and bismuth at liquid nitrogen temperature is design d. For the shielding purpose around the irradiation position, polyethylene, lead, LiF, etc., are appropriately arranged around the radiation filter. A water shutter in front of the radiation filter is adopted so as to avoid interrupt to the reactor operation. While the shutter is filled in water during on power, the radiation level in the irradiation room is sufficiently low for the preparation work for patient irradiation including temporary surgery. At present, detail design of the radiation filter is ongoing. cooling capabilities of the filter will be tested through a mockup experiment. Dose rate distributions around the radiation filter are under analysis for the configuration of the irradiation room. A prompt gamma-ray activation analysis system for the analyses of boron content in the biological samples, is

  16. Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: An experimental study that supports a potential new application of BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Monti Hughes, A.; Heber, E.M. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Pozzi, E. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Department of Research and Production Reactors, Ezeiza Atomic Center, CNEA, Buenos Aires (Argentina); Nigg, D.W. [Idaho National Laboratory, Idaho Falls, Idaho (United States); Calzetta, O.; Blaumann, H.; Longhino, J. [Department of Nuclear Engineering, Bariloche Atomic Center, CNEA, Rio Negro (Argentina); Nievas, S.I. [Department of Chemistry, CNEA, Buenos Aires (Argentina); Aromando, R.F. [Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, Buenos Aires (Argentina); Itoiz, M.E. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, Buenos Aires (Argentina); Trivillin, V.A. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Schwint, A.E. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina)], E-mail: schwint@cnea.gov.ar

    2009-07-15

    We previously demonstrated the efficacy of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-10 (Na{sub 2}{sup 10}B{sub 10}H{sub 10}) and (GB-10+BPA) to control tumors, with no normal tissue radiotoxicity, in the hamster cheek pouch oral cancer model. Herein we developed a novel experimental model of field-cancerization and precancerous lesions (globally termed herein precancerous tissue) in the hamster cheek pouch to explore the long-term potential inhibitory effect of the same BNCT protocols on the development of second primary tumors from precancerous tissue. Clinically, second primary tumor recurrences occur in field-cancerized tissue, causing therapeutic failure. We performed boron biodistribution studies followed by in vivo BNCT studies, with 8 months follow-up. All 3 BNCT protocols induced a statistically significant reduction in tumor development from precancerous tissue, reaching a maximum inhibition of 77-100%. The inhibitory effect of BPA-BNCT and (GB-10+BPA)-BNCT persisted at 51% at the end of follow-up (8 months), whereas for GB-10-BNCT it faded after 2 months. Likewise, beam-only elicited a significant but transient reduction in tumor development. No normal tissue radiotoxicity was observed. At 8 months post-treatment with BPA-BNCT or (GB-10+BPA)-BNCT, the precancerous pouches that did not develop tumors had regained the macroscopic and histological appearance of normal (non-cancerized) pouches. A potential new clinical application of BNCT would lie in its capacity to inhibit local regional recurrences.

  17. Radiation treatment planning system verification

    International Nuclear Information System (INIS)

    Optimum radiotherapy requires accurate and consistent radiation doses. To fulfil this requirement, it is necessary to make quality checks of the equipment and software included in the planning process. Treatment planning system is used to calculate monitor units required to deliver prescribed dose to a designated volume with acceptable distribution of radiation dose. The aim of this study was to verify the Theraplan Plus treatment program used in our Department to calculate treatment times for radiation therapy with 60Co unit. To run a Theraplan Plus system, it is necessary to input data describing mechanical and radiation aspects of treatment unit. One of the checks included a comparison of the measured depth doses and off-axis ratios with those calculated using the treatment program. The second step included the measurement of the dose using ionisation chamber and thermoluminescent dosimeters (TLD), which was then compared with calculated values for several treatment scenarios (central axis dose on specified depth of square fields, elongated fields, under the block and wedges etc.). The third step involved the comparison between the dose calculated for a specific treatment plan with the doses measured with TLD dosimeters in the Alderson phantom.(author)

  18. Extra-corporeal liver BNCT for the treatment of diffuse metastases: What was learned and what is still to be learned

    Energy Technology Data Exchange (ETDEWEB)

    Zonta, A. [Department of Surgery, University of Pavia, Pavia (Italy)], E-mail: aris.zonta@pv.infn.it; Pinelli, T. [Department of Nuclear and Theoretical Physics, University of Pavia, Pavia (Italy); National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy); Prati, U.; Roveda, L. [Oncologic Surgery, Cancer Center of Excellence Fond. ' T. Campanella' , Catanzaro (Italy); Ferrari, C.; Clerici, A.M.; Zonta, C. [Department of Surgery, University of Pavia, Pavia (Italy); Mazzini, G. [Department of Animal Biol., IGM-CNR Histochemistry and Cytometry Section, Pavia (Italy); Dionigi, P. [Department of Surgery, University of Pavia, Pavia (Italy); Altieri, S.; Bortolussi, S. [Department of Nuclear and Theoretical Physics, University of Pavia, Pavia (Italy); National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy); Bruschi, P. [Department of Nuclear and Theoretical Physics, University of Pavia, Pavia (Italy); Fossati, F. [Department of Nuclear and Theoretical Physics, University of Pavia, Pavia (Italy); National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy)

    2009-07-15

    Almost eight years ago, in December 2001, we performed for the first time in the world thermal neutron irradiation on an isolated liver of a patient. The organ was affected by diffuse metastases of a colon carcinoma and had been previously loaded with a {sup 10}B compound. In July 2003, the same procedure was applied again on a patient for the treatment of unresectable and incurable hepatic metastases of a carcinoma of the rectum. Both patients are dead at present. Now we can analyze in depth the clinical history of these patients and evaluate the effectiveness of this therapy. From this exciting experience we learned much, and we also found out about complications till then unknown, which need to be studied and addressed experimentally. Unfortunately we can base our conclusions just on the experience we had with these two patients. We could have been much more detailed and firm in our statements if the number of clinical cases was larger. The BNCT Pavia project has been suspended, but it is more than likely to resume in a short time. Good findings were many. The procedure is feasible; the original concept of complete immersion of the diseased liver in a homogeneous neutron field proved effective and winning. The tumor masses resulted completely necrotic and unknown metastases too appeared radically treated; healthy hepatic tissue was preserved from both morphological and functional points of view; no symptoms of cirrhosis appeared even four years after treatment. For the long term surviving patient, quality of life was excellent. Other findings require to be tackled in depth. The 'post-irradiation syndrome' we observed in both patients, with identical symptoms and biochemical derangements, creates a dramatic-even though totally reversible-clinical condition, that is the probable cause of death for our second patient, suffering from cardiomyopathy, 33 days after treatment. For the first patient, recurrences were a late yet fatal complication, for which

  19. 9Be(d,n)10B-based neutron sources for BNCT

    International Nuclear Information System (INIS)

    In the frame of accelerator-based BNCT, the 9Be(d,n)10B reaction was investigated as a possible source of epithermal neutrons. In order to determine the configuration in terms of bombarding energy, target thickness and Beam Shaping Assembly (BSA) design that results in the best possible beam quality, a systematic optimization study was carried out. From this study, the optimal configuration resulted in tumor doses ≥40 Gy-Eq, with a maximum value of 51 Gy-Eq at a depth of about 2.7 cm, in a 60 min treatment. The optimal configuration was considered for the treatment planning assessment of a real Glioblastoma Multiforme case. From this, the resulted dose performances were comparable to those obtained with an optimized 7Li(p,n)-based neutron source, under identical conditions and subjected to the same clinical protocol. - Highlights: • Study of the 9Be(d,n)10B reaction as a source of epithermal neutrons for BNCT. • Evaluation of the optimal configuration of target thickness, deuteron energy and BSA design. • Computational dose assessment for brain tumor treatments using the MCNP code. • Treatment planning assessment of a particular clinical Glioblastoma Multiforme case. • Dose performances were comparable to those obtained with an optimized 7Li(p,n)-based source

  20. Concepts of radiotherapy treatment planning

    International Nuclear Information System (INIS)

    Full text: Radiotherapy treatment planning (RTP) relies heavily on medical imaging. Until recently, the most important planning tool was the treatment simulator. The kilovoltage radiographic capabilities in a treatment simulator enabled the boundaries of treatment fields to be visualized with respect to bony anatomic landmarks. Perhaps the most important advance in treatment planning in recent years is the ability to visualize the passage of the beams with respect to a more accurate geometrical representation of the tumor and other soft tissue structures. This 'virtual simulation' uses a computer-based representation of a patient to determine the extent of the disease and the location of radiation sensitive normal tissue. Computer tomographic (CT) imaging produces a high-resolution three-dimensional representation of anatomy that can be correlated with other image sets such as magnetic resonance images (MRI) of function. Positron emission tomographic (PET) imaging is beginning to be used to determine tumor proliferation and the presence of distant disease. It is likely that accurate RTP in conjunction with CT simulators will eliminate traditional treatment simulators in the future. Traditionally, patient dose calculation algorithms have been based on correcting measured dose in water phantoms to take into account beam modifiers, patient surface contours and internal tissue inhomogeneities. Recently, model-based algorithms have been computing the dose directly in the patient representation using the CT to obtain a voxel-by-voxel density map. The convolution/superposition method, which uses a Monte Carlo-derived transport kernel, is the current state-of-the-art algorithm for dose computation. Soon direct Monte Carlo simulation will be used in model-based dose computation. Model-based dose computations enable a simpler monitor unit calculation formulation. The other major breakthrough in RTP is computer-based optimization. The goals of the treatment are specified as

  1. Boron neutron capture therapy (BNCT) for glioblastoma multiforme using the epithermal neutron beam at the Brookhaven Medical Research Reactor

    Energy Technology Data Exchange (ETDEWEB)

    Capala, J. [Brookhaven National Lab., Upton, NY (United States); Diaz, A.Z.; Chadha, M. [Univ. Hospital, State Univ. of New York, NY (United States)] [and others

    1997-12-31

    The abstract describes evaluation of boron neutron capture therapy (BNCT) for two groups of glioblastoma multiforme patients. From September 1994 to February 1996 15 patients have been treated. In September 1997 another 34 patients were examined. Authors determined a safe starting dose for BNCT using epithermal neutrons and BPA-F. They have also evaluated adverse effects of BNCT at this starting dose. Therapeutic effectiveness of this starting dose has been evaluated. No significant side effects from BPA-F infusion or BNCT treatment were observed in normal brains.

  2. An analysing of heat treatment process planning

    OpenAIRE

    B. Smoljan

    2007-01-01

    Purpose: Process planning of heat treatment has been investigated. The established approach of heat treatingprocess planning is suitable for effective integration of heat treatment in computer added manufacturing.Design/methodology/approach: Process plan of heat treating process has been established based on fundamentalprocess planning principals. The heat treatment was treated in the same as other manufacture processes.Findings: The general approach for process planning of heat treatment pro...

  3. Shielding design of a treatment room for an accelerator-based epithermal neutron irradiation facility for BNCT

    International Nuclear Information System (INIS)

    Protecting the facility personnel and the general public from radiation exposure is a primary safety concern of an accelerator-based epithermal neutron irradiation facility. This work makes an attempt at answering the questions open-quotes How much?close quotes and open-quotes What kind?close quotes of shielding will meet the occupational limits of such a facility. Shielding effectiveness is compared for ordinary and barytes concretes in combination with and without borated polyethylene. A calculational model was developed of a treatment room, patient open-quotes scatterer,close quotes and the epithermal neutron beam. The Monte Carlo code, MCNP, was used to compute the total effective dose equivalent rates at specific points of interest outside of the treatment room. A conservative occupational effective dose rate limit of 0.01 mSv h-1 was the guideline for this study. Conservative Monte Carlo calculations show that constructing the treatment room walls with 1.5 m of ordinary concrete, 1.2 m of barytes concrete, 1.0 m of ordinary concrete preceded by 10 cm of 5% boron-polyethylene, or 0.8 m of barytes concrete preceded by 10 cm of 5% boron-polyethylene will adequately protect facility personnel. 20 refs., 8 figs., 2 tabs

  4. Radiation shielding evaluation of the BNCT treatment room at THOR: A TORT-coupled MCNP Monte Carlo simulation study

    International Nuclear Information System (INIS)

    This study investigates the radiation shielding design of the treatment room for boron neutron capture therapy at Tsing Hua Open-pool Reactor using 'TORT-coupled MCNP' method. With this method, the computational efficiency is improved significantly by two to three orders of magnitude compared to the analog Monte Carlo MCNP calculation. This makes the calculation feasible using a single CPU in less than 1 day. Further optimization of the photon weight windows leads to additional 50-75% improvement in the overall computational efficiency

  5. Clinical practice in BNCT to the brain

    International Nuclear Information System (INIS)

    Our concept of Boron Neutron Capture Therapy (BNCT) is to selectively destroy tumour cells using the high LET particles yielded from the 10B(n,α)7Li reactions. The effort of clinical investigators has concentrated on how to escalate the radiation dose at the target point. BNCT in Japan combines thermal neutrons and BSH (Na2B12H11SH). The radiation dose is determined by the neutron fluence at the target point and the boron concentration in the tumour tissue. According to the recent analysis, the ratio of boron concentration (BSH) in tumour tissue and blood is nearly stable at around 1.2 to 1.69. Escalation of the radiation dose was carried out by means of improving the penetration of the thermal neutron beam. Since 1968, 175 patients with glioblastoma (n=83), anaplastic astrocytoma (n=44), low grade astrocytoma (n=16) or other types of tumour (n=32) were treated by BNCT at 5 reactors (HTR n=13, JRR-3 n=1, MulTR n=98, KUR n=30, JRR-2 n=33). The retrospective analysis revealed that the important factors related to the clinical results and QOL of the patients were minimum tumour volume radiation dose, more than 18Gy of physical dose and maximum vascular radiation dose (less than 15Gy) in the normal cortex. We have planned several trials to escalate the target radiation dose. One trial makes use of a cavity in the cortex following debulking surgery of the tumour tissue to improve neutron penetration. The other trial is introduction of epithermal neutron. KUR and JRR-4 were reconstructed and developed to be able to irradiate using epithermal neutrons. The new combination of surgical procedure and irradiation using epithermal neutrons should remarkably improve the target volume dose compared to the radiation dose treated by thermal neutrons. (author)

  6. Treatment planning optimization for linear accelerator radiosurgery

    International Nuclear Information System (INIS)

    Purpose: Linear accelerator radiosurgery uses multiple arcs delivered through circular collimators to produce a nominally spherical dose distribution. Production of dose distributions that conform to irregular lesions or conformally avoid critical neural structures requires a detailed understanding of the available treatment planning parameters. Methods and Materials: Treatment planning parameters that may be manipulated within a single isocenter to provide conformal avoidance and dose conformation to ellipsoidal lesions include differential arc weighting and gantry start/stop angles. More irregular lesions require the use of multiple isocenters. Iterative manipulation of treatment planning variables can be difficult and computationally expensive, especially if the effects of these manipulations are not well defined. Effects of treatment parameter manipulation are explained and illustrated. This is followed by description of the University of Florida Stereotactic Radiosurgery Treatment Planning Algorithm. This algorithm organizes the manipulations into a practical approach for radiosurgery treatment planning. Results: Iterative treatment planning parameters may be efficiently manipulated to achieve optimal treatment plans by following the University of Florida Treatment Planning Algorithm. The ability to produce conformal stereotactic treatment plans using the algorithm is demonstrated for a variety of clinical presentations. Conclusion: The standard dose distribution produced in linear accelerator radiosurgery is spherical, but manipulation of available treatment planning parameters may result in optimal dose conformation. The University of Florida Treatment Planning Algorithm organizes available treatment parameters to efficiently produce conformal radiosurgery treatment plans

  7. Automatic planning of head and neck treatment plans

    DEFF Research Database (Denmark)

    Hazell, Irene; Bzdusek, Karl; Kumar, Prashant;

    2016-01-01

    overall treatment qual-ity since consistent, high-quality plans are generated which even can be further optimized, if necessary. This makes it possible for the dosimetrist to focus more time on difficult dose planning goals and to spend less time on the more tedious parts of the planning process.......Treatment planning is time-consuming and the outcome depends on the person performing the optimization. A system that automates treatment planning could potentially reduce the manual time required for optimization and could also pro-vide a method to reduce the variation between persons performing...... radiation dose planning (dosimetrist) and potentially improve the overall plan quality. This study evaluates the performance of the Auto-Planning module that has recently become clinically available in the Pinnacle3 radiation therapy treatment planning system. Twenty-six clinically delivered head and neck...

  8. Dose-rate scaling factor estimation of THOR BNCT test beam

    International Nuclear Information System (INIS)

    In 1998, an epithermal neutron test beam was designed and constructed at the Tsing Hua Open-Pool Reactor (THOR) for the purpose of preliminary dosimetric experiments in boron neutron capture therapy (BNCT). A new epithermal neutron beam was designed at this facility, and is currently under construction, with clinical trials targeted in late 2004. Depth dose-rate distributions for the THOR BNCT test beam have been measured by means of activation foil and dual ion chamber techniques. Neutron and structure-induced gamma spectra measured at the test beam exit were configured into a source function for the Monte Carlo-based treatment planning code NCTPlan. Dose-rate scaling factors (DRSFs) were determined to normalize computationally derived dose-rate distributions with experimental measurements in corresponding mathematical and physical phantoms, and to thus enable accurate treatment planning using the NCTPlan code. A similar approach will be implemented in characterizing the new THOR epithermal beam in preparation for clinical studies. This paper reports the in-phantom calculated and experimental dosimetry comparisons and derived DRSFs obtained with the THOR test beam

  9. Successful BNCT for patients with cutaneous and mucosal melanomas. Report of 4 cases

    International Nuclear Information System (INIS)

    Since 2003 we have conducted BNCT clinical trials on melanomas at the Kyoto University Research Reactor (KUR) and Japan Research Reactor No.4 (JRR-4). We report 4 patients given BNCT for malignant melanomas: 2 with superficial spreading types on the heel, 1 with mucosal melanoma in the nasal cavity, and 1 with a melanoma on the vulva and in the vagina. The two cutaneous melanomas and the nasal cavity mucosal melanoma showed a complete response (CR) by 6 months after BNCT. The residual melanoma showed a partial response (PR) by 3 months after treatment and no regrowth since then. Although two patients experienced normal-tissue damage that exceeded the tolerance level, all the participants were cured within a few months of treatment. BNCT was shown to be a promising treatment for mucosal, as well as for cutaneous, melanomas. (author)

  10. FiR 1 Reactor in Service for Boron Neutron Capture Therapy (BNCT) and Isotope Production

    International Nuclear Information System (INIS)

    The FiR 1 reactor, a 250 kW Triga reactor, has been in operation since 1962. The main purpose to run the reactor is now the Boron Neutron Capture Therapy (BNCT). Although BNCT dominates the current utilization of the reactor, it also has an important national role in providing local enterprises and research institutions in the fields of industrial measurements, pharmaceuticals, electronics, etc. with isotope produc- tion and activation analysis services. The whole reactor building has been renovated, creating a dedicated clinical BNCT facility at the reactor. Close to 30 patients have been treated since May 1999, when the licence for patient treatment was granted to the responsible BNCT treatment organization. The treatment organization has a close connection to the Helsinki University Central Hospital. (author)

  11. Carborane-containing metalloporphyrins for BNCT

    International Nuclear Information System (INIS)

    For BNCT of malignant brain tumors, it is crucial that there be relatively high boron concentrations in tumor compared with normal tissues within the neutron-irradiated treatment volume. Fairchild and Bond estimated that major advances in BNCT should be possible if ratios of 10B concentrations in tumor to those in normal tissue (e.g. brain and blood) were at least 5: 1. Given that the only current boron carrier being tested clinically in the U.S., p-boronophenyl-alanine[BPA], yields tumor blood and tumor brain ratios of about 3:1, the criteria for new boronated compounds should be to at least match these ratios and maintain tumor boron concentrations greater than 30 μg B/g. Although previously tested boronated porphyrins have not only matched but surpassed these ratios, it was at a cost of greater toxicity. Chemical and hematological assays of blood analytes; showed marked thrombocytopenia, a decrease to about one-tenth the normal concentration of platelets circulating in the blood, in addition to abnormalities in concentrations of circulating enzymes, that indicated liver toxicity. The physical appearance and behavior of the affected mice were different from those of mice injected with solvent only. Although thrombocytopenia and other toxic effects had disappeared after a few days, previously tested porphyrins would not be safe to infuse into patients for BNCT of potentially hemorrhagic malignant tumors in the brain such as glioblastoma multiforme and metastatic melanoma. We synthesized a different boronated porphyrin, tetracarboranylphenylporphyrin, [TCP] and inserted nickel, copper, or manganese into its coordination center. Biological studies of NiTCP in mice and of CuTCP in rats show that these compounds elicit little or no toxicity when given at potentially therapeutic doses

  12. Carborane-containing metalloporphyrins for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Miura, Michiko; Joel, D.D.; Nawrocky, M.M.; Micca, P.L. [and others

    1996-12-31

    For BNCT of malignant brain tumors, it is crucial that there be relatively high boron concentrations in tumor compared with normal tissues within the neutron-irradiated treatment volume. Fairchild and Bond estimated that major advances in BNCT should be possible if ratios of {sup 10}B concentrations in tumor to those in normal tissue (e.g. brain and blood) were at least 5: 1. Given that the only current boron carrier being tested clinically in the U.S., p-boronophenyl-alanine[BPA], yields tumor blood and tumor brain ratios of about 3:1, the criteria for new boronated compounds should be to at least match these ratios and maintain tumor boron concentrations greater than 30 {mu}g B/g. Although previously tested boronated porphyrins have not only matched but surpassed these ratios, it was at a cost of greater toxicity. Chemical and hematological assays of blood analytes; showed marked thrombocytopenia, a decrease to about one-tenth the normal concentration of platelets circulating in the blood, in addition to abnormalities in concentrations of circulating enzymes, that indicated liver toxicity. The physical appearance and behavior of the affected mice were different from those of mice injected with solvent only. Although thrombocytopenia and other toxic effects had disappeared after a few days, previously tested porphyrins would not be safe to infuse into patients for BNCT of potentially hemorrhagic malignant tumors in the brain such as glioblastoma multiforme and metastatic melanoma. We synthesized a different boronated porphyrin, tetracarboranylphenylporphyrin, [TCP] and inserted nickel, copper, or manganese into its coordination center. Biological studies of NiTCP in mice and of CuTCP in rats show that these compounds elicit little or no toxicity when given at potentially therapeutic doses.

  13. QA of treatment planning systems

    International Nuclear Information System (INIS)

    Protocols for commissioning and performance of treatment planning systems have been proposed and performed at several occasions. These tests are valuable, but it is evident that we need a more comprehensive QA for the planning systems. International bodies are working on this subject today, and recommendations will soon appear. However, very little results and experiences are published from running QA protocols. In our department we have been using an in house 2D system for many years, and as both developer and user we needed a QA protocol. Two years ago we bought a commercial 3D system, and a new QA protocol had to be set up for this situation. This protocol include: 1) description of duties for responsible persons, 2) education/competence levels for users, 3) acceptance tests for both system and treatment unit data, and 4) constancy tests for the same. Experience so far reveals that a QA protocol is necessary for use of sophisticated 3D systems, even though no error in the system itself have been found that would have given erroneous dosage. Clear definitions of who is responsible for the different aspects of using the system has proven essential. An introductory course have to be given to all new users to avoid misuse. Acceptance tests of system is necessary, not only to accept the system but also to learn how to use it correctly and detect its limitations. Acceptance tests of basic treatment unit data is mandatory before they can be taken into clinical use. Also constancy tests have proven necessary when modifications are done. The experience with such a protocol gives lot of input back to the manufacturer too. It also raises principal questions about what should be checked and what is the responsibility of the manufacturers. More details will be presented in the meeting

  14. Histological and biochemical analysis of DNA damage after BNCT in rat model

    International Nuclear Information System (INIS)

    To understand the mechanism of tumor cell death induced by boron neutron capture therapy (BNCT) and to optimize BNCT condition, we used rat tumor graft models and histological and biochemical analyses were carried out focusing on DNA damage response. Rat lymphosarcoma cells were grafted subcutaneously into male Wister rats. The rats with developed tumors were then treated with neutron beam irradiation 45 min after injection of 330 mg/kg bodyweight boronophenylalanine (10BPA) (+BPA) or saline control (–BPA). BNCT was carried out in the National Nuclear Center of the Republic of Kazakhstan (neutron flux: 1×109 nvt/s, fluence: 6×1011 nvt) with the presence of background γ-irradiation of 33 Gy. 6 and 20 h after BNCT treatment, tumors were resected, fixed and subjected to immunohistochemistry and biochemical analyses. Immunostaining of nuclei showed that double strand break (DSB) marker gamma H2AX staining was high in 20 h/+BPA sample but not in 20 h/–BPA samples. Poly(ADP-ribose), DSB and single strand break markers of DNA, also demonstrated this tendency. These two markers were observed at low levels in unirradiated tissues or 6 h after BNCT either under −BPA and +BPA conditions. HMGB1 level increased in 6 h/+BPA but not in 6 h/−BPA or 20 h/+BPA samples. The persistent staining of γH2AX and poly(ADP-ribose) in +BPA group suggests accumulated DSB damage after BNCT. The early HMGB1 upregulation and γH2AX and poly(ADP-ribose) observed later might be the markers for monitoring the DNA damage induced by BNCT. - Highlights: • We used rat tumor graft models and DNA damage response in BNCT was analyzed. • HMGB1 upregulation was suggested to be an early marker for BNCT. • The persistent presence of γH2AX and PAR in the nuclei might serve as late markers

  15. Boron neutron capture therapy (BNCT) selectively destroys human clear cell sarcoma in mouse model

    International Nuclear Information System (INIS)

    Clear cell sarcoma of tendons and aponeuroses (CCS) is a rare malignant tumor with no effective treatment. This study demonstrates the efficacy of BNCT with the use of human CCS-bearing nude mice. Groups A and C were administered saline, and groups B and D were injected with p-borono-L-phenylalanine-fructose complex. Groups C and D were then irradiated with thermal neutrons. The tumors in only group D disappeared, demonstrating that BNCT is a potentially new option for the treatment of human CCS. - Highlights: ► Human clear cell sarcoma (CCS)-bearing nude mice were used in this study. ► The human CCS in the nude mice disappeared after BNCT. ► The efficacy of BNCT for human CCS is demonstrated here for the first time

  16. Quality assurance of treatment planning systems

    International Nuclear Information System (INIS)

    In Finland the inspections (site visits) of the Finnish Centre for Radiation and Nuclear Safety (STUK) represent quality audit procedures for the treatment machines and simulators, but at present do not cover treatment planning and CT imaging. The centre has now planned to extend the quality audit program to include the whole treatment chain. The preliminary step of this program was the intercomparison of radiotherapy treatment planning system. As the next step, a special phantom has been designed in order to check the whole treatment chain from treatment planning to dose delivery. (author). 2 figs, 1 tab

  17. Dosimetric feasibility study for an extracorporeal BNCT application on liver metastases at the TRIGA Mainz.

    Science.gov (United States)

    Blaickner, M; Kratz, J V; Minouchehr, S; Otto, G; Schmidberger, H; Schütz, C; Vogtländer, L; Wortmann, B; Hampel, G

    2012-01-01

    This study investigates the dosimetric feasibility of Boron Neutron Capture Therapy (BNCT) of explanted livers in the thermal column of the research reactor in Mainz. The Monte Carlo code MCNP5 is used to calculate the biologically weighted dose for different ratios of the (10)B-concentration in tumour to normal liver tissue. The simulation results show that dosimetric goals are only partially met. To guarantee effective BNCT treatment the organ has to be better shielded from all gamma radiation. PMID:21872481

  18. Application of HVJ envelope system to boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) has been used clinically for the treatment of malignant tumors. Two drugs, p-boronophenylalanine (BPA) and sulfhydral borane (BSH), have been used as boron delivery agents. These drugs seem to be taken up preferentially in solid tumors, but it is uncertain whether therapeutic quantities of boron atoms are taken up by micro-invasive or distant tumor cells. High accumulation and high selective delivery of boron into tumor tissues are the most important requirements to achieve efficient BNCT for malignant tumor. The HVJ envelope (HVJ-E) vector system is a novel fusion-mediated gene delivery system based on inactivated hemagglutinating virus of Japan (HVJ; Sendai virus). Although we developed this vector system for gene transfer, it can also deliver proteins, synthetic oligonucleotides, and drugs. HVJ-liposome, which is liposome fused with HVJ-E, has higher boron trapping efficiency than HVJ-E alone. We report the boron delivery into cultured cells with HVJ-liposome systems. The cellular 10B concentration after 60 min incubation with HVJ-E containing BSH was 24.9 μg/g cell pellet for BHK-21 cells (baby hamster kidney cells) and 19.4 μg/g cell pellet for SCC VII cells (murine squamous cell carcinoma). These concentrations are higher than that of 60 min incubated cells with BSH containing (100μg 10B/ml) medium. These results indicate the HVJ-E fused with tumor cell membrane and rapidly delivered boron agents, and that the HVJ-E-mediated delivery system could be applicable to BNCT. Plans are underway to begin neutron radiation experiments in vivo and in vitro. (author)

  19. Fractionated BNCT for locally recurrent head and neck cancer: Experience from a phase I/II clinical trial at Tsing Hua Open-Pool Reactor

    International Nuclear Information System (INIS)

    To introduce our experience of treating locally and regionally recurrent head and neck cancer patients with BNCT at Tsing Hua Open-Pool Reactor in Taiwan, 12 patients (M/F=10/2, median age 55.5 Y/O) were enrolled and 11 received two fractions of treatment. Fractionated BNCT at 30-day interval with adaptive planning according to changed T/N ratios was feasible, effective and safe for selected recurrent head and neck cancer in this trial. - Highlights: • We treated 12 patients with recurrent Head and Neck (H and N) cancer after radical surgery and radiotherapy since 2010. • Four complete response (CR) and 3 partial response (PR) were found. Total response rate was 58%. • Two patients had local control longer than one year. • No grade 4 or higher toxicity was noted for both acute and chronic effects

  20. Boron neutron capture therapy (BNCT) for glioblastoma multiforme (GBM), using the epithermal neutron beam at the Brookhaven National Laboratory

    International Nuclear Information System (INIS)

    Objective: BNCT is a binary treatment modality based on the nuclear reactions that occur when boron (10B) is exposed to thermal neutrons. Preclinical studies have demonstrated the therapeutic efficacy of p-boronophenylalanine (BPA)-based BNCT. The objective of the Phase I/II trial was to evaluate BPA-fructose (BPA-F) as a boron delivery agent for GBM and to study the feasibility and safety of a single-fraction of BNCT. Materials and Methods: The trial design required i) a BPA-F biodistribution study performed at the time of craniotomy; and ii) BNCT within 4 weeks of the craniotomy. From September 94 to July 95, 10 patients with biopsy proven GBM were treated. All but 1 patient underwent a biodistribution study receiving IV BPA-F at the time of craniotomy. Multiple tissue samples and concurrent blood and urine samples were collected for evaluation of the boron concentration and clearance kinetics. For BNCT all patients received 250 mg/kgm of BPA-F (IV infusion over 2 hrs) followed by neutron irradiation. The blood 10B concentration during irradiation was used to calculate the time of neutron exposure. The 3D treatment planning was done using the BNCT treatment planning software developed at the Idaho National Engineering Laboratory. The BNCT dose is expressed as the sum of the physical dose components corrected for both the RBE and the 10B localization factor with the unit Gy-Eq. The photon-equivalent dose, where the thermal neutron fluence reaches a maximum, is the peak-dose equivalent. A single-fraction of BNCT was delivered prescribing 10.5 Gy-Eq (9 patients) and 13.8 Gy-Eq (1 patient) as the peak dose-equivalent to the normal brain. The peak dose rate was kept below 27 cGy-Eq/min. Results: Biodistribution data: The maximum blood 10B concentration was observed at the end of the infusion and scaled as a linear function of the administered dose. The 10B concentration in the scalp and in the GBM tissue was higher than in blood by 1.5 x and at least 3.5 x

  1. Effect of different BNCT protocols on DNA synthesis in precancerous and normal tissues in an experimental model of oral cancer

    International Nuclear Information System (INIS)

    We previously reported the therapeutic success of different BNCT protocols in the treatment of oral cancer, employing the hamster cheek pouch model. The aim of the present study was to evaluate the effect of these BNCT protocols on DNA synthesis in precancerous and normal tissue in this model and assess the potential lag in the development of second primary tumors in precancerous tissue. The data are relevant to potential control of field cancerized tissue and tolerance of normal tissue. We evaluated DNA synthesis in precancerous and normal pouch tissue 1-30 days post-BNCT mediated by BPA, GB-10 or BPA + GB-10 employing incorporation of bromo-deoxyuridine as an end-point. The BNCT-induced potential lag in the development of second primary tumors in precancerous tissue was monitored. A drastic, statistically significant reduction in DNA synthesis occurred in pacancerous tissue as early as 1 day post-BNCT and was sustained at virtually all time points until 30 days post-BNCT for all protocols. The histological categories evaluated individually within precancerous tissue (dysplasia, hyperplasia and NUMF [no unusual microscopic features]) responded similarly. DNA synthesis in normal tissue treated with BNCT oscillated around the very low pre-treatment values. A BNCT-induced lag in the development of second primary tumors was observed. BNCT induced a drastic fall in DNA synthesis in precancerous tissue that would be associated to the observed lag in the development of second primary tumors. The minimum variations in DNA synthesis in BNCT-treated normal tissue would correlate with the absence of normal tissue radiotoxicity. The present data would contribute to optimize therapeutic efficacy in the treatment of field-cancerized areas. (author)

  2. Diagnostic reasoning and treatment planning: II. Treatment.

    Science.gov (United States)

    Nurcombe, B

    1987-12-01

    The concepts of therapy-oriented and problem-oriented plans are discussed and their advantages and disadvantages considered. Goal-directed planning is proposed as an alternative to intuitive decision making. Goal-directed planning involves the abstraction of pivotal problems from a diagnostic formulation, the restatement of problems as goals, the selection of appropriate therapy, the designation of a target date, the stipulation of objectives, the selection of methods of evaluation and the monitoring of progress. Systematic goal-directed planning fosters teamwork, promotes accountability, obviates therapeutic drift and enhances outcome evaluation. Its chief disadvantage is its unfamiliarity. PMID:3502386

  3. Boron Neutron Capture Therapy at the TRIGA Mark II of Pavia, Italy - The BNCT of the diffuse tumours

    Energy Technology Data Exchange (ETDEWEB)

    Altieri, S.; Bortolussi, S.; Stella, S.; Bruschi, P.; Gadan, M.A. [University of Pavia (Italy); INFN - National Institute for Nuclear Physics, of Pavia (Italy)

    2008-10-29

    The selectivity based on the B distribution rather than on the irradiation field makes Boron neutron Capture Therapy (BNCT) a valid option for the treatment of the disseminated tumours. As the range of the high LET particles is shorter than a cell diameter, the normal cells around the tumour are not damaged by the reactions occurring in the tumoral cells. PAVIA 2001: first treatment of multiple hepatic metastases from colon ca by BNCT and auto-transplantation technique: TAOrMINA project. The liver was extracted after BPA infusion, irradiated in the Thermal Column of the Pavia TRIGA Mark II reactor, and re-implanted in the patient. Two patients were treated, demonstrating the feasibility of the therapy and the efficacy in destroying the tumoral nodules sparing the healthy tissues. In the last years, the possibility of applying BNCT to the lung tumours using epithermal collimated neutron beams and without explanting the organ, is being explored. The principal obtained results of the BNCT research are presented, with particular emphasis on the following aspects: a) the project of a new thermal column configuration to make the thermal neutron flux more uniform inside the explanted liver, b) the Monte Carlo study by means of the MCNP code of the thermal neutron flux distribution inside a patient's thorax irradiated with epithermal neutrons, and c) the measurement of the boron concentration in tissues by (n,{alpha}) spectroscopy and neutron autoradiography. The dose distribution in the thorax are simulated using MCNP and the anthropomorphic model ADAM. To have a good thermal flux distribution inside the lung epithermal neutrons must be used, which thermalize crossing the first tissue layers. Thermal neutrons do not penetrate and the obtained uniformity is poor. In the future, the construction of a PGNAA facility using a horizontal channel of the TRIGA Mark II is planned. With this method the B concentration can be measured also in liquid samples (blood, urine) and

  4. The Finnish Boron neutron capture therapy (BNCT) project

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is a new, binary radiotherapy, which has been developed especially for severe brain tumours, incurable by the present means. A suitable 10B containing carrier compound is injected into the blood circulation and taken up selectively by the cancer cells. When these cells are subjected to a thermal neutron field, the 10B atoms capture the neutrons and undergo fission reaction. The energy thereby released is killing the cancerous cell. The Finnish BNCT research and development project is in the situation where all the basic conditions exist to start clinical trials. An epithermal neutron irradiation facility has been constructed at the Finnish research reactor (FiR 1) operated by VTT in Otaniemi. This article is an overview over the developments within the Finnish BNCT project. A research project to carry out clinical application of BNCT was established in Finland in the early 1990's. It was motivated both by the need to create new uses for FiR 1 and by the ideas to start research and production of new boron carriers for BNCT in Finland. Soon also other medical, medical physics and chemistry disciplines joined the project. Now the project involves scientists from different departments of University of Helsinki (HU), Helsinki University Central Hospital (HUCH), Technical Research Centre of Finland (VTT), Finnish Radiation and Nuclear Safety Authority (STUK) and of the Helsinki University of Technology (HUT) and other Finnish universities. The aim of this project has been to start BNC-treatment of malignant brain tumours in Finland by the end of the century

  5. BNCT and Targeted Radiotherapy (TRT) developments in Romania

    International Nuclear Information System (INIS)

    There are a number of treatment modalities for cancer including surgery, chemotherapy and radiation therapy. However, these treatments are not always effective. The search for new and more efficient ways to combat cancer has opened new perspectives. Boron neutron capture therapy (BNCT) is a new approach in cancer treatment that has been proposed to combat glioblastomas of the brain, neck cancer and malignant melanomas, tumors that are resistant to traditional cancer therapies. BNCT is based on the 10B(n,α)7Li nuclear reaction, which can potentially deliver a very high and fatal radiation dose to cancerous cells by concentrating boron in them. It is a promising, though complicated treatment. This type of therapy offers a number of potentially significant advantages compared to traditional radiation therapy. Treatment is better targeted to cancerous cells so that when a tumour is irradiated with neutrons, the damage to normal tissue is respectively less. It is also less demanding for the patient as treatment is only one to two sessions, compared to conventional radiation therapy where patients can be treated up to 30 times. It provides an excellent example of the importance of innovation in the search for a cure to cancer. The recent developments in BNCT in Romania as well as the major drawbacks will be presented. (authors)

  6. BNCT facility development in HANARO

    International Nuclear Information System (INIS)

    An irradiation facility for boron neutron capture therapy (BNCT) was developed using one of the typical tangential beam tubes in HANARO. Thermal neutron was chosen because of the impossibility of sufficient epithermal neutrons for BNCT at the exit of the beam tube. The facility is designed not only for BNCT study but also for dynamic neutron radiography (DNR) and other experiments requiring pure thermal neutrons. Silicon and bismuth single crystals cooled by liquid nitrogen are selected to filter out fast neutrons and γ-rays and to penetrate the thermal neutrons as much as possible. A water shutter is installed in front of the radiation filter to keep the radiation level low in the irradiation room while it is filled with water. A prompt gamma neutron activation analysis (PGNAA) system was also developed to measure the boron concentration quickly from patient's blood samples. A spare neutron beam from a dedicated beam instrument was diffracted upward using pyrolytic graphite to obtain almost pure thermal neutrons at the target position. (author)

  7. Microdosimetry study of THOR BNCT beam using tissue equivalent proportional counter

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is a cancer treatment modality using a nuclear reactor and a boron compound drug. In Taiwan, Tsing Hua open-pool reactor (THOR) has been modulated for the basic research of BNCT for years. A new BNCT beam port was built in 2004 and used to prepare the first clinical trial in the near future. This work reports the microdosimetry study of the THOR BNCT beam by means of the tissue equivalent proportional counter (TEPC). Two self-fabricated TEPCs (the boron-doped versus the boron-free counter wall) were introduced. These dual TEPCs were applied to measure the lineal energy distributions in air and water phantom irradiated by the THOR BNCT mixed radiation field. Dose contributions from component radiations of different linear energy transfers (LETs) were analyzed. Applying a lineal energy dependent biological weighting function, r(y), to the total and individual lineal energy distributions, the effective relative biological effectiveness (RBE), neutron RBE, photon RBE, and boron capture RBE (BNC RBE) were all determined at various depths of the water phantom. Minimum and maximum values of the effective RBE were 1.68 and 2.93, respectively. The maximum effective RBE occurred at 2 cm depth in the phantom. The average neutron RBE, photon RBE, and BNC RBE values were 3.160±0.020, 1.018±0.001, and 1.570±0.270, respectively, for the THOR BNCT beam.

  8. Monte Carlo Treatment Planning for Advanced Radiotherapy

    DEFF Research Database (Denmark)

    Cronholm, Rickard

    validation of a Monte Carlo model of a medical linear accelerator (i), converting a CT scan of a patient to a Monte Carlo compliant phantom (ii) and translating the treatment plan parameters (including beam energy, angles of incidence, collimator settings etc) to a Monte Carlo input file (iii). A protocol...... more sophisticated than previous algorithms since it uses delineations of structures in order to include and/or exclude certain media in various anatomical regions. This method has the potential to reduce anatomically irrelevant media assignment. In house MATLAB scripts translating the treatment plan...... presented. Comparison between dose distribution for clinical treatment plans generated by a commercial Treatment Planning System and by the implemented Monte Carlo Treatment Planning workflow were conducted. Good agreement was generally found, but for regions involving large density gradients differences of...

  9. Inverse planning and class solutions for brachytherapy treatment planning

    International Nuclear Information System (INIS)

    Brachytherapy or interventional radiooncology is a method of radiation therapy. It is a method, where a small encapsulated radioactive source is placed near to / in the tumour and therefore delivers high doses directly to the target volume. Organs at risk (OARs) are spared due to the inverse square dose fall-off. In the past years there was a slight stagnation in the development of techniques for brachytherapy treatment. While external beam radiotherapy became more and more sophisticated, in brachytherapy traditional methods have been still used. Recently, 3D imaging was considered also as the modality for brachytherapy and more precise brachytherapy could expand. Nowadays, an image guided brachytherapy is state-of-art in many centres. Integration of imaging methods lead to the dose distribution individually tailored for each patient. Treatment plan optimization is mostly performed manually as an adaptation of a standard loading pattern. Recently, inverse planning approaches have been introduced into brachytherapy. The aim of this doctoral thesis was to analyze inverse planning and to develop concepts how to integrate inverse planning into cervical cancer brachytherapy. First part of the thesis analyzes the Hybrid Inverse treatment Planning and Optimization (HIPO) algorithm and proposes a workflow how to safely work with this algorithm. The problem of inverse planning generally is that only the dose and volume parameters are taken into account and spatial dose distribution is neglected. This fact can lead to unwanted high dose regions in a normal tissue. A unique implementation of HIPO into the treatment planning system using additional features enabled to create treatment plans similar to the plans resulting from manual optimization and to shape the high dose regions inside the CTV. In the second part the HIPO algorithm is compared to the Inverse Planning Simulated Annealing (IPSA) algorithm. IPSA is implemented into the commercial treatment planning system. It

  10. Assessment tool for planning fallback Tomotherapy treatment plans

    International Nuclear Information System (INIS)

    Interruption of radiotherapy treatments in an increase the total time of the same to the detriment of tumour control. In centers that have a unique special unit as the TomoTherapy, is emphasized the difficulty to resume treatment at another unit, since the technique of helical TomoTherapy is not portable to conventional accelerators and therefore requires the planning of new dosimetry distributions emulating the initially obtained and accepted. This work evaluates the ability of an automatic planning tool to mimic TomoTherapy plans. (Author)

  11. Towards a new therapy protocol for liver metastases. Effect of boron compounds and BNCT on normal liver regeneration

    International Nuclear Information System (INIS)

    The Taormina project developed a new method for BNCT treatment of multifocal unresectable liver metastases based on whole liver autograft. The Roffo Institute liver surgeons propose a new technique based on partial liver autograft that would pose less risk to the patient but would require significant healthy liver regeneration following BNCT. The aim of the present study was to assess the effect of BPA, GB-10 (Na210B10H10) and (GB-10 + BPA) and of BNCT mediated by these boron compounds on normal liver regeneration in the Wistar rat. Normal liver regeneration, body weight, hemogram, liver and kidney function were assessed following partial hepatectomy post administration of BPA, GB-10 or (GB-10 + BPA) and post in vivo BNCT at the RA-6 Reactor. These end-points were evaluated 9 days following partial hepatectomy, the time at which complete liver regeneration occurs in untreated controls. The corresponding biodistribution studies were conducted to perform dosimetric calculations. BPA, GB-10 and (GB-10 + PBA) and in vivo BNCT mediated by these boron compounds in dose ranges compatible with therapy did not cause alterations in the outcome of normal liver regeneration, and did not induce alterations in body weight, hemogram, liver or kidney function. The experimental data available to date support the development of a new BNCT protocol for the treatment of liver metastases that requires the regeneration of normal liver past-BNCT. (author)

  12. Clinical BNCT, where are we and where should we be going?

    International Nuclear Information System (INIS)

    The future in cancer treatment is with dedicated targeted therapies, selectively destroying tumour cells whilst sparing surrounding healthy tissue, so leading to increased efficacy and decreased toxicity. Boron Neutron Capture Therapy (BNCT) is a radiotherapeutic modality that through the limited spatial distribution of its effects provides a highly selective delivery of dose. It exploits the ability of the non-radioactive isotope boron-10 to readily capture thermal neutrons, to immediately produce particles with high Linear Energy Transfer, high Relative Biological Effectiveness and a limited range in tissue of 10 microns. In addition BNCT offers physical targeting methods such as optimised beam delivery and extra-corporal irradiation, which makes the global approach even more likely to succeed than cellular targeting based on a drug only approach. To be effective, B-10 has to be delivered selectively to the target cells, which is not the case at present in BNCT. Currently, clinical BNCT has been proven feasible using different neutron beams and clinical approaches (intraoperative, external beam and extracorporal irradiation), pharmacokinetic studies including tissue uptake evaluation and phase I trials have been performed using the drugs BSH and BPA. The efficacy of BNCT has been shown in single cases and phase II trials are now open for patient recruitment. In order to develop BNCT further, dedicated trial strategies have to be developed that allow the investigation of this binary treatment modality. Special emphasis has to be spent to the development of new targeting compounds, which is especially difficult because the drugs by themselves do not have any effect. If one day BNCT has been proven to be in specific situations superior to conventional treatments, then cheap and hospital based neutron sources must become available in order to introduce it in routine

  13. Development of an accelerator based BNCT facility. Following the Ibaraki BNCT project development process

    International Nuclear Information System (INIS)

    An accelerator-based BNCT (Boron Neutron Capture Therapy) facility is being constructed at the Ibaraki Neutron Medical Research Center. It consists of a proton linac (8 MeV energy and 10 mA average current), a beryllium target, and a moderator system to provide an epi-thermal neutron flux for patient treatment. The technology choices for this present system were driven by the need to site the facility in a hospital and where low residual activity is essential. The maximum neutron energy produced from an 8 MeV-proton is 6 MeV, which is below the threshold energy of the main nuclear reactions which produce radioactive products. The down side of this technology choice is that it produces a high density heat load on the target so that cooling and hydrogen blistering amelioration prevent sever challenges requiring successful R and D progress. The latest design of the target and moderator system shows that a flux of 2.5x109 epi-thermal neutrons/cm2/sec can be obtained. This is two times higher than the flux from the existing nuclear reactor based BNCT facility at JAEA (JRR-4). (author)

  14. An analysing of heat treatment process planning

    Directory of Open Access Journals (Sweden)

    B. Smoljan

    2007-01-01

    Full Text Available Purpose: Process planning of heat treatment has been investigated. The established approach of heat treatingprocess planning is suitable for effective integration of heat treatment in computer added manufacturing.Design/methodology/approach: Process plan of heat treating process has been established based on fundamentalprocess planning principals. The heat treatment was treated in the same as other manufacture processes.Findings: The general approach for process planning of heat treatment processes has been established. Heattreatment processes have to be designed into operations and sub-operations with the same principles that are alsovalid for other manufacturing processes.Research limitations/implications: The further research should be focused on development of methods for thebetter application of achieved results.Practical implications: This way of heat treatment process planning is more appropriate for integral trends ofmanufacturing, i.e., with the trend of introducing the modern systems in all parts of industrial manufacturing.Originality/value: The global approach of process planning of heat treatment processes was established andbetter unification with other manufacturing processes was achieved.

  15. In vitro biological models in order to study BNCT

    International Nuclear Information System (INIS)

    Undifferentiated thyroid carcinoma (UTC) lacks an effective treatment. Boron neutron capture therapy (BNCT) is based on the selective uptake of 10B-boronated compounds by some tumours, followed by irradiation with an appropriate neutron beam. The radioactive boron originated (11B) decays releasing 7Li, gamma rays and alpha particles, and these latter will destroy the tumour. In order to explore the possibility of applying BNCT to UTC we have studied the biodistribution of BPA. In vitro studies: the uptake of p-10borophenylalanine (BPA) by the UTC cell line ARO, primary cultures of normal bovine thyroid cells (BT) and human follicular adenoma (FA) thyroid was studied. No difference in BPA uptake was observed between proliferating and quiescent ARO cells. The uptake by quiescent ARO, BT and FA showed that the ARO/BT and ARO/FA ratios were 4 and 5, respectively (p< 0.001). The present experimental results open the possibility of applying BNCT for the treatment of UTC. (author)

  16. BNCT with linac, feasibility study

    International Nuclear Information System (INIS)

    High energy photon beams from Medical Linear Accelerators (linacs) which are used in radiotherapy produce undesirable neutrons, beside the clinically useful electron and photon beams. Neutrons are produced from the photonuclear reaction (γ,n) of high energy photons with high Z-materials which compose the accelerator head. In this paper the possible use of these undesirable neutrons for BNCT is investigated, making use of high energy linacs already installed in hospitals, primarily for high energy electron and photon therapy and applying them in the context of BNCT. The photoneutron components emitted by the accelerator is the source for Monte Carlo simulations of the interactions that take place within the head of a voxel-based phantom. The neutron flux across the phantom head is calculated using different moderator arrangements and different techniques in the aim of increasing the thermal neutron flux at the targeted site. Also, we shall test different configurations of the linac head to maximize the exposure of high-Z materials to the photon beam, including the removal of the flattening filter, so as to boost the photoneutron production in the linac head. Experimental work will be conducted in hospitals to validate the Monte Carlo simulations. To make use of linacs for BNCT will be advantageous in the sense that the setting in a hospital department is much more acceptable by the public than a reactor installation. This will mean less complications regarding patient positioning and movement with respect to the beams, additional patient transportation and management will be more cost effective. (author)

  17. Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases in BDIX rats

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases in BDIX rats Introduction: Boron Neutron Capture Therapy (BNCT) is based on selective tumor uptake of boron compounds, followed by neutron irradiation. BNCT was proposed for the treatment of unresectable, diffuse lung metastases. The aim of the present study was to perform BNCT studies in an experimental model of lung metastases. Materials and Methods: 3 x 106/0.5 ml colon carcinoma cells (DHD/K12/TRb) were injected iv in syngeneic BDIX rats. Three weeks post-inoculation, rats with diffuse lung metastases were used for in vivo BNCT studies in the RA-3 Nuclear Reactor. Based on previous biodistribution studies and computational dosimetry with Monte Carlo simulation, 2 doses were prescribed, i.e. 4 Gy and 8 Gy minimum absorbed dose to tumor. The animals were assigned to 5 experimental groups (n= 4 to 8) at each dose level: T0 (euthanized pre-treatment), BPA-BNCT, Comb-BNCT (BPA+GB-10), Beam only (background dose) and Sham (same manipulation, no treatment). Boron concentration was measured in a blood sample taken pre-irradiation to verify that the value was in the range established in previous biodistribution studies. The animals were followed clinically for 2 weeks after neutron irradiation and then euthanized to assess the response of tumor and normal lung, macroscopically and histologically. To date we have evaluated the end-point weight of lung (normal lung + metastases) and % lung weight/body weight as an indicator of tumor growth. Results: The statistical analysis (ANOVA) of % lung weight/body weight showed statistically significant differences (p<0.05) between groups T0 (0.79 ± 0.38) and Sham (1.87 ± 0.91). No statistically significant differences were observed between the Beam only groups (at both dose levels) and Sham. Similar and statistically significant tumor control was induced in the groups BPA-BNCT Low dose (LD) (0.56 ± 0.11), BPA-BNCT High dose (HD) (0.80 ± 0.16), Comb-BNCT

  18. Training Psychotherapists in Hierarchical Treatment Planning

    OpenAIRE

    MAKOVER, RICHARD B.

    1992-01-01

    Treatment planning is a central and persistent challenge in psychotherapy. This paper outlines a four-level planning hierarchy that encourages the therapist to conceptualize a desired overall outcome (the "aim") that can be realized through subsidiary objectives (the "goals"). The "strategies" by which goals are pursued and the "tactics" that carry out those strategies are subordinate and instrumental elements of the treatment process. Greater emphasis on this type of ...

  19. Normalisation: ROI optimal treatment planning - SNDH pattern

    International Nuclear Information System (INIS)

    Dose precision maximally to the target / ROI (Region of Interest), taking care of tolerance dose of normal tissue is the aim of ideal treatment planning. This goal is achieved with advanced modalities such as, micro MLC, simulator and 3-dimensional treatment planning system. But SNDH PATTERN uses minimum available resources as, ALCYON II Telecobalt unit, CT Scan, MULTIDATA 2-dimensional treatment planning system to their maximum utility and reaches to the required precision, same as that with advance modalities. Among the number of parameters used, 'NORMALISATION TO THE ROI' will achieve the aim of the treatment planning effectively. This is dealing with an example of canal of esophagus modified treatment planning based on SNDH pattern. Results are attractive and self explanatory. By implementing SNDH pattern, the QUALITY INDEX of treatment plan will reach to greater than 90%, with substantial reduction in dose to the vital organs. Aim is to utilize the minimum available resources efficiently to achieve highest possible precision for delivering homogenous dose to ROI while taking care of tolerance dose to vital organs

  20. Medical setup of intraoperative BNCT at JRR-4

    International Nuclear Information System (INIS)

    Since October 1999, we have been performing clinical trials of intraoperative boron neutron capture therapy (IOBNCT) using a mixed thermal-epithermal beam at the Japan Research Reactor No. 4 (JRR-4). For immediate pre-BNCT care, including administration of a boron compound as well as post-BNCT care, a collaborating neurosurgical department of the University of Tsukuba was prepared in the vicinity of JRR-4. Following craniotomy in the treatment room, anesthetized patients were transported into the irradiation room for BNCT. The boron concentration in tissue was measured by the PGA and ICP-AES methods. The long-term follow-up was done at the University of Tsukuba Hospital. IOBNCT is a complex clinical procedure, which requires sophisticated operating team and co-medical staffs and also cooperation with physicist team. IOBNCT is a complex clinical procedure requiring a high level of cooperation among the operating team, co-medical staff, and physicists. For the safe and successful performance of IOBNCT, we have made the program including critical pathway and prepared various equipments for IOBNCT. To ensure the safe and successful performance of IOBNCT, we developed a critical pathway for use during the procedure, and prepared various apparatus for IOBNCT. (author)

  1. A Tandem-electrostatic-quadrupole for accelerator-based BNCT

    International Nuclear Information System (INIS)

    A project to develop a Tandem-electrostatic-quadrupole (TESQ) accelerator for accelerator-based boron neutron capture therapy (AB-BNCT) is described. A folded Tandem, with 1.25 MV terminal voltage, combined with an electrostatic quadrupole (ESQ) chain is being proposed. The project goal is a machine capable of delivering 30 mA of 2.5 MeV protons to be used in conjunction with a neutron production target based on the 7Li(p, n)7Be reaction slightly beyond its resonance at 2.25 MeV. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7Li(p, n)7Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is the technologically simplest and cheapest solution for optimized AB-BNCT

  2. Tandem-ESQ for accelerator-based BNCT

    International Nuclear Information System (INIS)

    A project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) is described. A folded tandem, with 1.25 MV terminal voltage, combined with an ElectroStatic Quadrupole (ESQ) chain is being proposed. The project goal is a machine capable of delivering 30 mA of 2.5 MeV protons to be used in conjunction with a neutron production target based on the 7Li(p,n)7Be reaction beyond its resonance at 2.25 MeV. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the '7Li(p,n)7Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is the technologically simplest and cheapest solution for optimized AB-BNCT. (author)

  3. Preliminary modeling of BNCT beam tube on IRT in Sofia

    Energy Technology Data Exchange (ETDEWEB)

    Belousov, S. [Institute for Nuclear Research and Nuclear Energy (INRNE) of the Bulgarian Academy of Sciences, Tsarigradsko 72, Sofia (Bulgaria)], E-mail: belousov@inrne.bas.bg; Ilieva, K. [Institute for Nuclear Research and Nuclear Energy (INRNE) of the Bulgarian Academy of Sciences, Tsarigradsko 72, Sofia (Bulgaria)

    2009-07-15

    The technical design of the research reactor IRT in Sofia is in progress. It includes an arrangement for a BNCT facility for tumor treatment. Modeling of geometry and material composition of filter/collimator for the BNCT beam tube on IRT has been carried out following the beam tube configuration of the Massachusetts Institute of Technology Reactor [Harling et al., 2002. The fission converter-based epithermal neutron irradiation facility at the Massachusetts Institute of Technology Reactor. Nucl. Sci. Eng. 140, 223-240.] and taking into account an ability to include the tube into the IRT reactor geometry. The results of neutron and gamma transport calculations performed for the model have shown that the facility will be able to supply an epithermal neutron flux of about 5x10{sup 9} n cm{sup -2} s{sup -1}, with low contamination from fast neutrons and gamma rays that would be among the best facilities currently available. An optimiziation study has been performed for the beam collimator, following similar studies for the TAPIRO research reactor in Italy. [Nava et al., 2005. Monte Carlo optimization of a BNCT facility for treating brain gliomas at the TAPIRO reactor. Radiat. Prot. Dosim. 116 (1-4), 475-481.].

  4. Preliminary modeling of BNCT beam tube on IRT in Sofia

    International Nuclear Information System (INIS)

    The technical design of the research reactor IRT in Sofia is in progress. It includes an arrangement for a BNCT facility for tumor treatment. Modeling of geometry and material composition of filter/collimator for the BNCT beam tube on IRT has been carried out following the beam tube configuration of the Massachusetts Institute of Technology Reactor [Harling et al., 2002. The fission converter-based epithermal neutron irradiation facility at the Massachusetts Institute of Technology Reactor. Nucl. Sci. Eng. 140, 223-240.] and taking into account an ability to include the tube into the IRT reactor geometry. The results of neutron and gamma transport calculations performed for the model have shown that the facility will be able to supply an epithermal neutron flux of about 5x109 n cm-2 s-1, with low contamination from fast neutrons and gamma rays that would be among the best facilities currently available. An optimiziation study has been performed for the beam collimator, following similar studies for the TAPIRO research reactor in Italy. [Nava et al., 2005. Monte Carlo optimization of a BNCT facility for treating brain gliomas at the TAPIRO reactor. Radiat. Prot. Dosim. 116 (1-4), 475-481.

  5. Feasibility study of using laser-generated neutron beam for BNCT

    International Nuclear Information System (INIS)

    The feasibility of using a laser-accelerated proton beam to produce a neutron source, via (p,n) reaction, for Boron Neutron Capture Therapy (BNCT) applications has been studied by MCNPX Monte Carlo code. After optimization of the target material and its thickness, a Beam Shaping Assembly (BSA) has been designed and optimized to provide appropriate neutron beam according to the recommended criteria by International Atomic Energy Agency. It was found that the considered laser-accelerated proton beam can provide epithermal neutron flux of ∼2×106 n/cm2 shot. To achieve an appropriate epithermal neutron flux for BNCT treatment, the laser must operate at repetition rates of 1 kHz, which is rather ambitious at this moment. But it can be used in some BNCT researches field such as biological research. - Highlights: • Feasibility of using laser-accelerated proton beam for BNCT has been investigated. • The considered beam can provide epithermal neutron flux of ~2×106 (n/cm2.shot). • For BNCT treatment, the laser must operate at repetition rates of 1 kHz

  6. Emergency Planning for Municipal Wastewater Treatment Facilities.

    Science.gov (United States)

    Lemon, R. A.; And Others

    This manual for the development of emergency operating plans for municipal wastewater treatment systems was compiled using information provided by over two hundred municipal treatment systems. It covers emergencies caused by natural disasters, civil disorders and strikes, faulty maintenance, negligent operation, and accidents. The effects of such…

  7. Upgrading of JRR-3/JRR-4 neutron beam utilities - for cold neutron beam and BNCT

    International Nuclear Information System (INIS)

    We proposed two plans to promote the medical application of nuclear energy in Japan. One is the enhancement of the cold neutron beam intensity for Japan Research Reactor No.3 (JRR-3) and the other one is the progress of Boron Neutron Capture Therapy (BNCT) for JRR-4. We are expecting to achieve 10 times the present intensity in our maximum extent so that the good complementary relation with J-PARC (Japan Proton Accelerator Complex) in one site can be established with JRR-3. More specifically the optimization of the cold neutron source vessel could increase the cold neutron beam intensity twice and the replacement of neutron guides with high efficiency mirror could increase it twice. Although BNCT in JRR-4 has been mainly applied to therapy against brain tumor so far, technical developments such as the development of a new collimator has enabled us to apply BNCT to head and neck cancer

  8. Clinical experience of BNCT for brain and skin tumors at Kyoto University Reactor

    International Nuclear Information System (INIS)

    The research nuclear reactor of Kyoto University (KUR), which was established in 1963, has the power of 5 MW and has rendered services to scientists in various fields including biology and medicine. The first clinical application was carried out on a brain tumor patient by Professor Hatanaka in 1974. Eight Japanese, 2 German and one American patients were treated. The ages of patients were 9-66 years and all were male. Skin tumors were irradiated at KUR to measure 10B content in the tissues by Nickel Mirror Neutron Guide Tube (NMNGT) attached to KUR, before BNCT. Except in a few cases, patients had recurrent tumours after previous treatment by chemotherapy, radiotherapy or surgical treatments. The absorbed dose used in the previous radiotherapy before BNCT was a curative dose. The time intervals between previous radiotherapy and BNCT varied. The treated skin tumours included various grades of melanoma. Some cases appeared to be astrocytoma grade IV

  9. The Boron Neutron Capture Therapy (BNCT) Project at the TRIGA Reactor in Mainz, Germany

    Energy Technology Data Exchange (ETDEWEB)

    Hampel, G.; Grunewald, C.; Schutz, C.; Schmitz, T.; Kratz, J.V. [Nuclear Chemistry, University of Mainz, D-55099 Mainz (Germany); Brochhausen, C.; Kirkpatrick, J. [Department of Pathology, University of Mainz, D-55099 Mainz (Germany); Bortulussi, S.; Altieri, S. [Department of Nuclear and Theoretical Physics University of Pavia, Pavia (Italy); National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy); Kudejova, P. [Forschungs-Neutronenquelle Heinz Maier-Leibnitz (FRM II), Technische Universitaet Muenchen, D-85748 Garching (Germany); Appelman, K.; Moss, R. [Joint Research Centre (JRC) of the European Commission, NL-1755 ZG Petten (Netherlands); Bassler, N. [University of Aarhus, Norde Ringade, DK-8000, Aarhus C (Denmark); Blaickner, M.; Ziegner, M. [Molecular Medicine, Health and Environment Department, AIT Austrian Institute of Technology GmbH (Austria); Sharpe, P.; Palmans, H. [National Physical Laboratory, Teddington TW11 0LW, Middlesex (United Kingdom); Otto, G. [Department of Hepatobiliary, Pancreatic and Transplantation Surgery, University of Mainz, D-55099 Mainz (Germany)

    2011-07-01

    The thermal column of the TRIGA reactor in Mainz is being used very effectively for medical and biological applications. The BNCT (boron neutron capture therapy) project at the University of Mainz is focussed on the treatment of liver tumours, similar to the work performed in Pavia (Italy) a few years ago, where patients with liver metastases were treated by combining BNCT with auto-transplantation of the organ. Here, in Mainz, a preclinical trial has been started on patients suffering from liver metastases of colorectal carcinoma. In vitro experiments and the first animal tests have also been initiated to investigate radiobiological effects of radiation generated during BNCT. For both experiments and the treatment, a reliable dosimetry system is necessary. From work elsewhere, the use of alanine detectors appears to be an appropriate dosimetry technique. (author)

  10. Dosimetric feasibility study for an extracorporeal BNCT application on liver metastases at the TRIGA Mainz

    International Nuclear Information System (INIS)

    This study investigates the dosimetric feasibility of Boron Neutron Capture Therapy (BNCT) of explanted livers in the thermal column of the research reactor in Mainz. The Monte Carlo code MCNP5 is used to calculate the biologically weighted dose for different ratios of the 10B-concentration in tumour to normal liver tissue. The simulation results show that dosimetric goals are only partially met. To guarantee effective BNCT treatment the organ has to be better shielded from all gamma radiation. - Highlights: ► Monte Carlo simulations demonstrate the potential for BNCT treatment at TRIGA Mainz. ► Simulation shows the necessity of gamma shielding for the organ from all sides. ► Secondary photons induced within the graphite contribute considerably to gamma dose.

  11. BNCT activities at Slovenian TRIGA research reactor

    International Nuclear Information System (INIS)

    It has been reported that satisfactory thermal/epithermal neutron beams for Boron Neutron Capture Therapy (BNCT) could be designed at TRIGA research reactors These reactors are generally perceived as being safe to install and operate in populated areas. This contribution presents the most recent BNCT research activities on the 'Jozef Stefan' Institute, where epithermal neutron beam for 'in-vitro' irradiation has been developed and experimentally verified. Furthermore, The Monte Carlo feasibility study of development of the epithermal neutron beam for BNCT clinical trials of human patients in thermalising column (TC) of TRIGA reactor has been carried out. The simulation results prove, that a BNCT irradiation facility with performances, comparable to existing beam throughout the world, could be installed in TC of the TRIGA reactor. (author)

  12. Automatic Treatment Planning with Convex Imputing

    International Nuclear Information System (INIS)

    Current inverse optimization-based treatment planning for radiotherapy requires a set of complex DVH objectives to be simultaneously minimized. This process, known as multi-objective optimization, is challenging due to non-convexity in individual objectives and insufficient knowledge in the tradeoffs among the objective set. As such, clinical practice involves numerous iterations of human intervention that is costly and often inconsistent. In this work, we propose to address treatment planning with convex imputing, a new-data mining technique that explores the existence of a latent convex objective whose optimizer reflects the DVH and dose-shaping properties of previously optimized cases. Using ten clinical prostate cases as the basis for comparison, we imputed a simple least-squares problem from the optimized solutions of the prostate cases, and show that the imputed plans are more consistent than their clinical counterparts in achieving planning goals.

  13. Clinical results of BNCT for malignant meningiomas

    International Nuclear Information System (INIS)

    Malignant meningiomas is difficult pathology to be controlled as well as GBM. Since June of 2005, we applied BNCT for 7 cases of malignancy related meningiomas with 13 times neutron irradiation. Five were anaplastic, one was atypical meningiomas and one was sarcoma transformed from meningioma with cervical lymph node metastasis. All cases were introduced after repetitive surgeries and XRT or SRS. Follow-up images were available for 6 cases with observation duration between 2 to 9 months. We applied F-BPA-PET before BNCT in 6 out of 7 cases. One case was received methionine-PET. Five out of 6 cases who received BPA-PET study showed good BPA uptake more than 3 of T/N ratio. One atypical meningiomas cases showed 2.0 of T/N ratio. Original tumor sizes were between 9.2 to 92.7 ml. Two out of 5 anaplastic meningiomas showed CR and all six cases showed radiographic improvements. Clinical symptoms before BNCT such as hemiparesis and facial pain were improved after BNCT, except one case. An huge atypical meningiomas which arisen from tentorium and extended bilateral occipital lobes and brain stem, visual problems were worsened after repetitive BNCT with increase of peritumoral edema. Malignant meningiomas are seemed to be good candidate for BNCT. (author)

  14. Boron neutron capture therapy (BNCT) for liver metastasis in an experimental model: dose–response at five-week follow-up based on retrospective dose assessment in individual rats

    Energy Technology Data Exchange (ETDEWEB)

    Emiliano C. C. Pozzi; Veronica A. Trivilin; Lucas L. Colombo; Andrea Monti Hughes; Silvia I. Thorp; Jorge E. Cardoso; Marcel A. Garabalino; Ana J. Molinari; Elisa M. Heber; Paula Curotto; Marcelo Miller; Maria E. Itoiz; Romina F. Aromando; David W. Nigg; Amanda E. Schwint

    2013-11-01

    Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. Employing an experimental model of liver metastases in rats, we recently demonstrated that BNCT mediated by boronophenylalanine (BPA-BNCT) at 13 Gy prescribed to tumor is therapeutically useful at 3-week follow-up. The aim of the present study was to evaluate dose–response at 5-week follow-up, based on retrospective dose assessment in individual rats. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA-BNCT (n = 19), Beam only (n = 8) and Sham (n = 7) (matched manipulation, no treatment). For each rat, neutron flux was measured in situ and boron content was measured in a pre-irradiation blood sample for retrospective individual dose assessment. For statistical analysis (ANOVA), individual data for the BPA-BNCT group were pooled according to absorbed tumor dose, BPA-BNCT I: 4.5–8.9 Gy and BPA-BNCT II: 9.2–16 Gy. At 5 weeks post-irradiation, the tumor surface area post-treatment/pre-treatment ratio was 12.2 +/- 6.6 for Sham, 7.8 +/- 4.1 for Beam only, 4.4 +/- 5.6 for BPA-BNCT I and 0.45 +/- 0.20 for BPA-BNCT II; tumor nodule weight was 750 +/- 480 mg for Sham, 960 +/- 620 mg for Beam only, 380 +/- 720 mg for BPA-BNCT I and 7.3 +/- 5.9 mg for BPA-BNCT II. The BPA-BNCT II group exhibited statistically significant tumor control with no contributory liver toxicity. Potential threshold doses for tumor response and significant tumor control were established at 6.1 and 9.2 Gy, respectively.

  15. The evolution of brachytherapy treatment planning

    International Nuclear Information System (INIS)

    Brachytherapy is a mature treatment modality that has benefited from technological advances. Treatment planning has advanced from simple lookup tables to complex, computer-based dose-calculation algorithms. The current approach is based on the AAPM TG-43 formalism with recent advances in acquiring single-source dose distributions. However, this formalism has clinically relevant limitations for calculating patient dose. Dose-calculation algorithms are being developed based on Monte Carlo methods, collapsed cone, and solving the linear Boltzmann transport equation. In addition to improved dose-calculation tools, planning systems and brachytherapy treatment planning will account for material heterogeneities, scatter conditions, radiobiology, and image guidance. The AAPM, ESTRO, and other professional societies are working to coordinate clinical integration of these advancements. This Vision 20/20 article provides insight into these endeavors.

  16. The evolution of brachytherapy treatment planning

    Energy Technology Data Exchange (ETDEWEB)

    Rivard, Mark J.; Venselaar, Jack L. M.; Beaulieu, Luc [Department of Radiation Oncology, Tufts University School of Medicine, Boston, Massachusetts 02111 (United States); Department of Medical Physics, Instituut Verbeeten, P.O. Box 90120, 5000 LA Tilburg (Netherlands); Departement de Radio-Oncologie et Centre de Recherche en Cancerologie de l' Universite Laval, Centre Hospitalier Universitaire de Quebec, 11 Cote du Palais, Quebec, Quebec G1R 2J6 (Canada) and Departement de Physique, de Genie Physique et d' Optique, Universite Laval, Quebec, Quebec G1K 7P4 (Canada)

    2009-06-15

    Brachytherapy is a mature treatment modality that has benefited from technological advances. Treatment planning has advanced from simple lookup tables to complex, computer-based dose-calculation algorithms. The current approach is based on the AAPM TG-43 formalism with recent advances in acquiring single-source dose distributions. However, this formalism has clinically relevant limitations for calculating patient dose. Dose-calculation algorithms are being developed based on Monte Carlo methods, collapsed cone, and solving the linear Boltzmann transport equation. In addition to improved dose-calculation tools, planning systems and brachytherapy treatment planning will account for material heterogeneities, scatter conditions, radiobiology, and image guidance. The AAPM, ESTRO, and other professional societies are working to coordinate clinical integration of these advancements. This Vision 20/20 article provides insight into these endeavors.

  17. Towards in vivo monitoring of neutron distributions for quality control of BNCT

    Science.gov (United States)

    Verbakel, W. F. A. R.; Hideghety, K.; Morrissey, J.; Sauerwein, W.; Stecher-Rasmussen, F.

    2002-04-01

    Dose delivery in boron neutron capture therapy (BNCT) is complex because several components contribute to the dose absorbed in tissue. This dose is largely determined by local boron concentration, thermal neutron distribution and patient positioning. In vivo measurements of these factors would considerably improve quality control and safety. During therapy, a γ-ray telescope measures the γ-rays emitted following neutron capture by hydrogen and boron in a small volume of the head of a patient. Scans of hydrogen γ-ray emissions could be used to verify the actual distribution of thermal neutrons during neutron irradiation. The method was first tested on different phantoms. These measurements showed good agreement with calculations based on thermal neutron distributions derived from a treatment planning program and from Monte Carlo N-particle (MCNP) simulations. Next, the feasibility of telescope scans during patient irradiation therapy was demonstrated. Measurements were reproducible between irradiation fractions. In theory, this method can be used to verify the positioning of the patient in vivo and the delivery of thermal neutrons in tissue. However, differences between measurements and calculations based on a routine treatment planning program were observed. These differences could be used to refine the treatment planning. Further developments will be necessary for this method to become a standard quality control system.

  18. Dose estimation of animal experiments at the THOR BNCT beam by NCTPlan and Xplan

    International Nuclear Information System (INIS)

    Dose estimation of animal experiments affects many subsequent derived quantities, such as RBE and CBE values. It is important to ensure the trustiness of calculated dose of the irradiated animals. However, the dose estimation was normally calculated using simplified geometries and tissue compositions, which led to rough results. This paper introduces the use of treatment planning systems NCTplan and Xplan for the dose estimation. A mouse was taken as an example and it was brought to hospital for micro-PET/CT scan. It was found that the critical organ doses of an irradiated mouse calculated by simplified model were unreliable in comparison to Xplan voxel model. The difference could reach the extent of several tenths percent. It is recommended that a treatment planning system should be introduced to future animal experiments to upgrade the data quality. - Highlights: • This study presents the new BNCT treatment planning system Xplan for animal experiments. • Xplan is based on a pixel-to-pixel conversion which has the same resolution as the CT images. • NCTplan and a simplified geometry for rat were used for the sake of comparison. • The spatial resolution applied in calculation is crucial to the reliability of estimated dose

  19. Design, construction and installation of an epithermal neutron beam for BNCT at the High Flux Reactor Petten

    International Nuclear Information System (INIS)

    Following the formation in 1987, of both the European Collaboration group on Boron Neutron Capture Therapy (BNCT) and the Petten BNCT group, steps were taken to design and implement an epithermal neutron beam for BNCT applications at the High Flux Reactor (HFR) at Petten. The installation would serve as a European facility, while once the modality of BNCT is proven would be the pathfinder for implementation of BNCT at other European nuclear sites. Due to its favorable nuclear and geometric characteristics, the beam tube HB11 was chosen as the candidate beam tube for BNCT applications. To reconfigure the beam tube to produce the required epithermal neutrons, it was first necessary to remove the existing mirror system and then to install the appropriate filter materials. Due to the fixed operating schedule of the HFR, with only one long shut-down period per year during the summer weeks for maintenance and upgrading actions, installation of the new facility was planned for the summer stop period in 1990

  20. Three-dimensional teletherapy treatment planning

    International Nuclear Information System (INIS)

    This thesis deals with physical/mathematical backgrounds of computerized teletherapy treatment planning. The subjects discussed in this thesis can be subdivided into three main categories: a) Three-dimensional treatment planning. A method is evaluated which can be used for the purpose of simulation and optimization of dose distributions in three dimensions. b) The use of Computed Tomography. The use of patient information obtained from Computed Tomography for the purpose of dose computations is evaluated. c) Dose computational models for photon- and electron beams. Models are evaluated which provide information regarding the way in which the radiation dose is distributed in the patient (viz. is absorbed and/or dispersed). (Auth.)

  1. Construction of a BNCT facility using an 8-MeV high power proton linac in Ibaraki

    International Nuclear Information System (INIS)

    An accelerator-based BNCT (Boron Neutron Capture Therapy) facility is now under construction and the entire system including the patient treatment system will be installed in the Ibaraki Neutron Advanced Medical Research Center (tentative name). BNCT is expected to give good results for inoperable cancers. In BNCT, pharmaceuticals carry a neutron capture agent containing 10B (Boron 10) selectively into tumor cells. Next thermal or epi-thermal neutrons interact with the 10B and produce α and 7Li-particles. Both of these particles have a very high Linear Energy Transfer (LET) and therefore lose almost all of their energy within a distance comparable to the size of a tumor cell. So far, BNCT has been provided only by nuclear reactors. The promising results shown there by BNCT give the hope that it may become an indispensable treatment modality for many types of cancers. From solely the neutron intensity point of view, nuclear reactors are excellent neutron sources. But as nuclear reactors regularly require long maintenance shut-downs and are subject to strict regulations, hospital operation is completely impractical. Thus we recognize the desirability of an accelerator-based BNCT facility well adapted for use by hospitals. We are aiming at the design and construction of a 'Hospital and Patient friendly' BNCT system. The development of such a BNCT requires multi-disciplinary input and collaboration from a wide spectrum of scientific and technical specialties. To obtain the needed breath and strength, we have organized our team with contributing specialists from diverse institutes and companies. The Ibaraki Medical Center for Advanced Neutron Therapy will be on the IQBRC (Ibaraki Quantum Beam Research Center) campus, which is near the JAEA and KEK Tokai campuses. The building for the BNCT is now under renovation by the Ibaraki prefectural government. We are tentatively calling this project 'I-BNCT' because of the Ibaraki prefectural sponsorship. Investigation of an 8

  2. Spatial and spectral characteristics of a compact system neutron beam designed for BNCT facility

    International Nuclear Information System (INIS)

    The development of suitable neutron sources and neutron beam is critical to the success of Boron Neutron Capture Therapy (BNCT). In this work a compact system designed for BNCT is presented. The system consists of 252Cf fission neutron source and a moderator/reflector/filter/shield assembly. The moderator/reflector/filter arrangement has been optimized to maximize the epithermal neutron component which is useful for BNCT treatment of deep seated tumors with the suitably low level of beam contamination. The MCMP5 code has been used to calculate the different components of neutrons, secondary gamma rays originating from 252Cf source and the primary gamma rays emitted directly by this source at the exit face of the compact system. The fluence rate distributions of such particles were also computed along the central axis of a human head phantom

  3. Spatial and spectral characteristics of a compact system neutron beam designed for BNCT facility

    Energy Technology Data Exchange (ETDEWEB)

    Ghassoun, J. [EPRA, Departement de Physique, Faculte des Sciences Semlalia, B.P. 2390, 40000 Marrakech (Morocco)], E-mail: ghassoun@ucam.ac.ma; Chkillou, B.; Jehouani, A. [EPRA, Departement de Physique, Faculte des Sciences Semlalia, B.P. 2390, 40000 Marrakech (Morocco)

    2009-04-15

    The development of suitable neutron sources and neutron beam is critical to the success of Boron Neutron Capture Therapy (BNCT). In this work a compact system designed for BNCT is presented. The system consists of {sup 252}Cf fission neutron source and a moderator/reflector/filter/shield assembly. The moderator/reflector/filter arrangement has been optimized to maximize the epithermal neutron component which is useful for BNCT treatment of deep seated tumors with the suitably low level of beam contamination. The MCMP5 code has been used to calculate the different components of neutrons, secondary gamma rays originating from {sup 252}Cf source and the primary gamma rays emitted directly by this source at the exit face of the compact system. The fluence rate distributions of such particles were also computed along the central axis of a human head phantom.

  4. Spatial and spectral characteristics of a compact system neutron beam designed for BNCT facility.

    Science.gov (United States)

    Ghassoun, J; Chkillou, B; Jehouani, A

    2009-04-01

    The development of suitable neutron sources and neutron beam is critical to the success of Boron Neutron Capture Therapy (BNCT). In this work a compact system designed for BNCT is presented. The system consists of (252)Cf fission neutron source and a moderator/reflector/filter/shield assembly. The moderator/reflector/filter arrangement has been optimized to maximize the epithermal neutron component which is useful for BNCT treatment of deep seated tumors with the suitably low level of beam contamination. The MCMP5 code has been used to calculate the different components of neutrons, secondary gamma rays originating from (252)Cf source and the primary gamma rays emitted directly by this source at the exit face of the compact system. The fluence rate distributions of such particles were also computed along the central axis of a human head phantom. PMID:19168369

  5. Characterisation of an accelerator-based neutron source for BNCT versus beam energy

    CERN Document Server

    Agosteo, S; D'Errico, F; Nath, R; Tinti, R

    2002-01-01

    Neutron capture in sup 1 sup 0 B produces energetic alpha particles that have a high linear energy transfer in tissue. This results in higher cell killing and a higher relative biological effectiveness compared to photons. Using suitably designed boron compounds which preferentially localize in cancerous cells instead of healthy tissues, boron neutron capture therapy (BNCT) has the potential of providing a higher tumor cure rate within minimal toxicity to normal tissues. This clinical approach requires a thermal neutron source, generally a nuclear reactor, with a fluence rate sufficient to deliver tumorcidal doses within a reasonable treatment time (minutes). Thermal neutrons do not penetrate deeply in tissue, therefore BNCT is limited to lesions which are either superficial or otherwise accessible. In this work, we investigate the feasibility of an accelerator-based thermal neutron source for the BNCT of skin melanomas. The source was designed via MCNP Monte Carlo simulations of the thermalization of a fast ...

  6. Radiotherapy treatment planning linear-quadratic radiobiology

    CERN Document Server

    Chapman, J Donald

    2015-01-01

    Understand Quantitative Radiobiology from a Radiation Biophysics PerspectiveIn the field of radiobiology, the linear-quadratic (LQ) equation has become the standard for defining radiation-induced cell killing. Radiotherapy Treatment Planning: Linear-Quadratic Radiobiology describes tumor cell inactivation from a radiation physics perspective and offers appropriate LQ parameters for modeling tumor and normal tissue responses.Explore the Latest Cell Killing Numbers for Defining Iso-Effective Cancer TreatmentsThe book compil

  7. Conceptual design of epithermal neutron beam for BNCT in the thermalizing column of TRIGA reactor

    International Nuclear Information System (INIS)

    The Monte Carlo feasibility study of development of the epithermal neutron beam for BNCT clinical trials in thermalising column (TC) of TRIGA reactor is presented. The investigation of the possible use of fission converter as well as the set-up of TRIGA reactor core is performed. The optimization of the irradiation facility components is carried out and the configuration with the most favorable cost/performance ratio is proposed. The results prove, that a BNCT irradiation facility with performances, comparable to existing beams throughout the world, could be installed in TC/DC of the TRIGA reactor, quite suitable for the clinical treatments of human patients.(author)

  8. The Boron Neutron Capture Therapy (BNCT) Project at the TRIGA Reactor in Mainz, Germany

    DEFF Research Database (Denmark)

    Hampel, G.; Grunewald, C.; Schütz, C.;

    2011-01-01

    years ago, where patients with liver metastases were treated successfully by combining BNCT with auto-transplantation of the organ. Here, in Mainz, a preclinical trial has been started on patients suffering from liver metastases of colorectal carcinoma. In vitro experiments and the first animal tests...... have also been initiated to investigate radiobiological effects of radiation generated during BNCT. For both experiments and treatment, a reliable dosimetry system is necessary. From work elsewhere, the use of alanine detectors appear to be an appropriate dosimetry technique....

  9. Study of the potential of using 9B(p,n) for BNCT clinical trials

    International Nuclear Information System (INIS)

    The potential of using a 30-MeV proton accelerator utilizing the 9Be(p,n)9B reaction as a neutron source for BNCT (Boron Neutron Capture Therapy) was investigated. MCNPX (Monte Carlo Neutron Photon-transport code X) was used to calculated neutron spectra and yields for comparison against existing experimental data and for the moderator optimization. Moderator performance was assessed using MCNPX and clinical efficacy was assessed using BNCT-RTPE to estimate in-phantom dose distributions and neutron fluences. The optimized source and moderator gave comparable tumor doses and treatment times to the clinical trials recently completed at the Brookhaven Medical Research Reactor (BMRR). (author)

  10. Cost-Effective Fuel Treatment Planning

    Science.gov (United States)

    Kreitler, J.; Thompson, M.; Vaillant, N.

    2014-12-01

    The cost of fighting large wildland fires in the western United States has grown dramatically over the past decade. This trend will likely continue with growth of the WUI into fire prone ecosystems, dangerous fuel conditions from decades of fire suppression, and a potentially increasing effect from prolonged drought and climate change. Fuel treatments are often considered the primary pre-fire mechanism to reduce the exposure of values at risk to wildland fire, and a growing suite of fire models and tools are employed to prioritize where treatments could mitigate wildland fire damages. Assessments using the likelihood and consequence of fire are critical because funds are insufficient to reduce risk on all lands needing treatment, therefore prioritization is required to maximize the effectiveness of fuel treatment budgets. Cost-effectiveness, doing the most good per dollar, would seem to be an important fuel treatment metric, yet studies or plans that prioritize fuel treatments using costs or cost-effectiveness measures are absent from the literature. Therefore, to explore the effect of using costs in fuel treatment planning we test four prioritization algorithms designed to reduce risk in a case study examining fuel treatments on the Sisters Ranger District of central Oregon. For benefits we model sediment retention and standing biomass, and measure the effectiveness of each algorithm by comparing the differences among treatment and no treat alternative scenarios. Our objective is to maximize the averted loss of net benefits subject to a representative fuel treatment budget. We model costs across the study landscape using the My Fuel Treatment Planner software, tree list data, local mill prices, and GIS-measured site characteristics. We use fire simulations to generate burn probabilities, and estimate fire intensity as conditional flame length at each pixel. Two prioritization algorithms target treatments based on cost-effectiveness and show improvements over those

  11. Improvements at the biological shielding of BNCT research facility in the IEA-R1 reactor

    International Nuclear Information System (INIS)

    The technique of neutron capture in boron is a promising technique in cancer treatment, it uses the high LET particles from the reaction 10B (n, α) 7Li to destroy cancer cells.The development of this technique began in the mid-'50s and even today it is the object of study and research in various centers around the world, Brazil has built a facility that aims to conduct research in BNCT, this facility is located next to irradiation channel number three at the research nuclear reactor IEA-R1 and has a biological shielding designed to meet the radiation protection standards. This biological shielding was developed to allow them to conduct experiments with the reactor at maximum power, so it is not necessary to turn on and off the reactor to irradiate samples. However, when the channel is opened for experiments the background radiation in the experiments salon increases and this background variation makes it impossible to perform measurements in a neutron diffraction research that utilizes the irradiation channel number six. This study aims to further improve the shielding in order to minimize the variation of background making it possible to perform the research facility in BNCT without interfering with the action of the research group of the irradiation channel number six. To reach this purpose, the code MCNP5, dosimeters and activation detectors were used to plan improvements in the biological shielding. It was calculated with the help of the code an improvement that can reduce the average heat flow in 71.2% ± 13 and verified experimentally a mean reduce of 70 ± 9% in dose due to thermal neutrons. (author)

  12. Quality management in BNCT at a nuclear research reactor

    International Nuclear Information System (INIS)

    Each medical intervention must be performed respecting Health Protection directives, with special attention to Quality Assurance (QA) and Quality Control (QC). This is the basis of safe and reliable treatments. BNCT must apply QA programs as required for performance and safety in (conventional) radiotherapy facilities, including regular testing of performance characteristics (QC). Furthermore, the well-established Quality Management (QM) system of the nuclear reactor used has to be followed. Organization of these complex QM procedures is offered by the international standard ISO 9001:2008.

  13. 64: 3-D treatment planning. 4

    International Nuclear Information System (INIS)

    A full function brachytherapy treatment planning program has been developed as part of the 3-D treatment planning system U-MPlan. This program integrates more conventional brachytherapy planning with multi-modality imaging. As a result, source locations can be derived from and displayed over a variety of images including CT, MR, and digitized radiographs. Derived three-dimensional anatomical data can be used to help in designing and evaluating dose distributions. Cross-sectional calculational planes can be defined relative to the anatomy or modified to be oriented with respect to the implant symmetry. Special utilities are provided for designing stereotactic brain implants. Calculational results can be viewed both two- and three-dimensionally relative to axonometric views of image cross-sections and derived anatomical structures. Isodose surfaces can be generated and displayed as well as dose displays across anatomical surfaces. Dose-volume histograms and composite or subtracted plans can be used to evaluate and/or compare rival plans. 5 refs.; 4 figs

  14. Advances in boron neutron capture therapy (BNCT) at kyoto university - From reactor-based BNCT to accelerator-based BNCT

    Science.gov (United States)

    Sakurai, Yoshinori; Tanaka, Hiroki; Takata, Takushi; Fujimoto, Nozomi; Suzuki, Minoru; Masunaga, Shinichiro; Kinashi, Yuko; Kondo, Natsuko; Narabayashi, Masaru; Nakagawa, Yosuke; Watanabe, Tsubasa; Ono, Koji; Maruhashi, Akira

    2015-07-01

    At the Kyoto University Research Reactor Institute (KURRI), a clinical study of boron neutron capture therapy (BNCT) using a neutron irradiation facility installed at the research nuclear reactor has been regularly performed since February 1990. As of November 2014, 510 clinical irradiations were carried out using the reactor-based system. The world's first accelerator-based neutron irradiation system for BNCT clinical irradiation was completed at this institute in early 2009, and the clinical trial using this system was started in 2012. A shift of BCNT from special particle therapy to a general one is now in progress. To promote and support this shift, improvements to the irradiation system, as well as its preparation, and improvements in the physical engineering and the medical physics processes, such as dosimetry systems and quality assurance programs, must be considered. The recent advances in BNCT at KURRI are reported here with a focus on physical engineering and medical physics topics.

  15. First tomographic image of neutron capture rate in a BNCT facility

    International Nuclear Information System (INIS)

    This work discusses the development of online dosimetry of the boron dose via Single Photon Emission Computed Tomography (SPECT) during a BNCT treatment irradiation. Such a system will allow the online computation of boron dose maps without the large current uncertainties in the assessment of the boron concentration in different tissues. The first tomographic boron dose image with a SPECT prototype is shown.

  16. Inverse treatment planning for targeted radionuclide therapy

    International Nuclear Information System (INIS)

    Full text: A method for inverse treatment planning was developed for targeted radionuclide therapy. Taking into account the fact that the efficacy of targeting radionuclide therapy is affected by nonuniformity dose and dose rate distributions in tumors, we introduce the equivalent uniform biologically effective dose (EUBED) concept on treatment planning for targeting radionuclide therapy. The EUBED model converts the spatial biologically effective dose (BED) distribution into an equivalent uniform biologically effective dose value that would produce a biological response similar to that expected from de original BED distribution. According to this, the treatment planning must quantify the relationship between administered activity and the absorbed dose distribution that expressed in terms of biological effect maximizing the EUBED in tumor while the mean dose in dose-limiting normal organs is maintained within accepted values. The method is based on calculation of the absorbed dose distribution using patient-specific imaging data, incorporating radiobiologic modeling to account for effects of dose rate distribution for better prediction of tumor response. For BED calculation, we use a BED model based on cell repair and proliferation during the internal irradiation at low dose rate with beta emitters. The inverse planning process consists in the estimation of activity to be administered from treatment prescription in terms of tumor control probability (TCP), assuming that each amount of administered activity produces the same biological effect, for treatment schemes that uses multiple activity administrations equally time-spaced. From SPECT images of absorbed dose distribution at voxel level in Gy/GBq, the differential dose volume histogram is obtained and used together with the mean absorbed dose of the dose-limiting organ as input parameters. From prescribed TCP, the corresponding EUBED is calculated and divided by the number of activity administrations to

  17. Automatic liver contouring for radiotherapy treatment planning.

    Science.gov (United States)

    Li, Dengwang; Liu, Li; Kapp, Daniel S; Xing, Lei

    2015-10-01

    To develop automatic and efficient liver contouring software for planning 3D-CT and four-dimensional computed tomography (4D-CT) for application in clinical radiation therapy treatment planning systems.The algorithm comprises three steps for overcoming the challenge of similar intensities between the liver region and its surrounding tissues. First, the total variation model with the L1 norm (TV-L1), which has the characteristic of multi-scale decomposition and an edge-preserving property, is used for removing the surrounding muscles and tissues. Second, an improved level set model that contains both global and local energy functions is utilized to extract liver contour information sequentially. In the global energy function, the local correlation coefficient (LCC) is constructed based on the gray level co-occurrence matrix both of the initial liver region and the background region. The LCC can calculate the correlation of a pixel with the foreground and background regions, respectively. The LCC is combined with intensity distribution models to classify pixels during the evolutionary process of the level set based method. The obtained liver contour is used as the candidate liver region for the following step. In the third step, voxel-based texture characterization is employed for refining the liver region and obtaining the final liver contours.The proposed method was validated based on the planning CT images of a group of 25 patients undergoing radiation therapy treatment planning. These included ten lung cancer patients with normal appearing livers and ten patients with hepatocellular carcinoma or liver metastases. The method was also tested on abdominal 4D-CT images of a group of five patients with hepatocellular carcinoma or liver metastases. The false positive volume percentage, the false negative volume percentage, and the dice similarity coefficient between liver contours obtained by a developed algorithm and a current standard delineated by the expert group

  18. Automatic liver contouring for radiotherapy treatment planning

    Science.gov (United States)

    Li, Dengwang; Liu, Li; Kapp, Daniel S.; Xing, Lei

    2015-09-01

    To develop automatic and efficient liver contouring software for planning 3D-CT and four-dimensional computed tomography (4D-CT) for application in clinical radiation therapy treatment planning systems. The algorithm comprises three steps for overcoming the challenge of similar intensities between the liver region and its surrounding tissues. First, the total variation model with the L1 norm (TV-L1), which has the characteristic of multi-scale decomposition and an edge-preserving property, is used for removing the surrounding muscles and tissues. Second, an improved level set model that contains both global and local energy functions is utilized to extract liver contour information sequentially. In the global energy function, the local correlation coefficient (LCC) is constructed based on the gray level co-occurrence matrix both of the initial liver region and the background region. The LCC can calculate the correlation of a pixel with the foreground and background regions, respectively. The LCC is combined with intensity distribution models to classify pixels during the evolutionary process of the level set based method. The obtained liver contour is used as the candidate liver region for the following step. In the third step, voxel-based texture characterization is employed for refining the liver region and obtaining the final liver contours. The proposed method was validated based on the planning CT images of a group of 25 patients undergoing radiation therapy treatment planning. These included ten lung cancer patients with normal appearing livers and ten patients with hepatocellular carcinoma or liver metastases. The method was also tested on abdominal 4D-CT images of a group of five patients with hepatocellular carcinoma or liver metastases. The false positive volume percentage, the false negative volume percentage, and the dice similarity coefficient between liver contours obtained by a developed algorithm and a current standard delineated by the expert group

  19. Electron Density Calibration for Radiotherapy Treatment Planning

    Science.gov (United States)

    Herrera-Martínez, F.; Rodríguez-Villafuerte, M.; Martínez-Dávalos, A.; Ruiz-Trejo, C.; Celis-López, M. A.; Lárraga-Gutiérrez, J. M.; García-Garduño, A.

    2006-09-01

    Computed tomography (CT) images are used as basic input data for most modern radiosurgery treatment planning systems (TPS). CT data not only provide anatomic information to delineate target volumes, but also allow the introduction of corrections for tissue inhomogeneities into dose calculations during the treatment planning procedure. These corrections involve the determination of a relationship between tissue electron density (ρe) and their corresponding Hounsfield Units (HU). In this work, an elemental analysis of different commercial tissue equivalent materials using Scanning Electron Microscopy was carried out to characterize their chemical composition. The tissue equivalent materials were chosen to ensure a large range of ρe to be included in the CT scanner calibration. A phantom was designed and constructed with these materials to simulate the size of a human head.

  20. Heavy charged-particle treatment planning

    International Nuclear Information System (INIS)

    An essential element of the heavy-ion radiotherapy program is the development of a computerized treatment planning system. A computerized tomographic (CT) based system is currently in operation, where sequential scans are first displayed on a dedicated raster graphics display unit. Target contours in appropriate slices are then entered via cursor by the radiotherapist. After the entry angle and ion type are chosen, the treatment planning program uses CT data on a pixel-by-pixel basis to (1) design appropriate compensators to contour the stopping region of the therapy beams, (2) select an appropriate spread Bragg peak for the irradiation, (3) design a collimator aperture for each entry portal, and (4) generate isoeffect and physical dose distributions overlayed on the CT image. In this section, we review progress in the area of clinical physics, and outline future lines of investigation

  1. Comparative dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for brain tumors

    OpenAIRE

    Samia de Freitas Brandao; Tarcisio Passos Ribeiro de Campos

    2013-01-01

    Objective Comparative analysis of dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for treatment of brain tumors. Materials and Methods Simulations of intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT were performed with the MCNP5 code, modeling the treatment of a brain tumor on a voxel computational phantom representing a human head. Absorbed dose rates were converted int...

  2. Simple Case Treatment Planning: Diastema Closure.

    Science.gov (United States)

    Calamia, Vincent; Pantzis, Alexandria

    2015-07-01

    This article demonstrates the use of a smile evaluation form as an adjunct in arriving at diagnosis and developing a treatment plan for a patient desiring Diastema closure. It also shows the importance of the diagnostic wax-up for temporization and visualization of case outcome. The case also demonstrates the use of soft tissue lasers to create a gingival harmony that enhanced the resulting esthetics. Feldspathic porcelain was used for the final restorations because they provide optimal esthetics and translucency. PMID:26140972

  3. Treatment planning system for carbon ion radiotherapy

    International Nuclear Information System (INIS)

    This paper describes the treatment planning (TP) and its peripheral system for carbon ion therapy that has been developed and in clinical use in recent two years at our institution. A new treatment planning system which is FOCUS customized to our irradiation system will be launched in clinical use soon. A new DICOM based PACS has been developed and in use. Now MRI, PET images are ready to be utilized for patient definition with image fusion functionality of radiotherapy TP. We implemented the exchange functionality of TP data specified by RTOG 3D QA Center in FOCUS, Pinnacle3 and heavy ion TP. Target volume and normal structure contours and dose distributions are exchangeable. A database system of carbon ion therapy dedicated to analysis of therapy data has been designed and implemented. All accessible planning data and treatment records of more than 1000 patients treated for seven and half years have been archived. The system has a DICOM RT sever and a database for miscellaneous text data. Limited numbers of private attributes were introduced for ion therapy specific objects. On-line as well as manual registration along with edit functionalities is prepared. Standard web browser is used to search and retrieve information. A DICOM RT viewer has been developed to view and retrieve RT images, dose distributions and structure set. These system described above are all designed to conform to the up-to-date standards of radiation therapy so as to be bases of the future development of the therapy at our institution. (author)

  4. Radiobiological aspects of radiotherapy treatment planning

    International Nuclear Information System (INIS)

    The aim of an oncological treatment is to eradicate the tumor without inducing unacceptable side effects. The optimization of a dose distribution with external beams requires the selection of the radiation type and energy, the number of fields, their sizes and incidence angles of the beams and then the possible use of wedges or compensating filters. The goal of optimal treatment planning is to provide maximum tumor killing while sparing normal tissues as much as possible. New, more sophisticated planning systems, based on three dimensional dose distribution calculations, require simplified data interpretation techniques. Dose volume histograms represent a convenient and useful tool to summarize dose distribution information through the entire volume of a given anatomic structure and to quickly highlight characteristics such as dose uniformity and hot and cold spots. It is difficult however to choose among competing histograms concerning different organs when they cross one another. This paper discusses the development of a computerized treatment planning system in which dose volume histograms are used to estimate tumor control and normal tissue complication probabilities

  5. Real-time interactive treatment planning

    International Nuclear Information System (INIS)

    The goal of this work is to develop an interactive treatment planning platform that permits real-time manipulation of dose distributions including DVHs and other dose metrics. The hypothesis underlying the approach proposed here is that the process of evaluating potential dose distribution options and deciding on the best clinical trade-offs may be separated from the derivation of the actual delivery parameters used for the patient’s treatment. For this purpose a novel algorithm for deriving an Achievable Dose Estimate (ADE) was developed. The ADE algorithm is computationally efficient so as to update dose distributions in effectively real-time while accurately incorporating the limits of what can be achieved in practice. The resulting system is a software environment for interactive real-time manipulation of dose that permits the clinician to rapidly develop a fully customized 3D dose distribution. Graphical navigation of dose distributions is achieved by a sophisticated method of identifying contributing fluence elements, modifying those elements and re-computing the entire dose distribution. 3D dose distributions are calculated in ∼2–20 ms. Including graphics processing overhead, clinicians may visually interact with the dose distribution (e.g. ‘drag’ a DVH) and display updates of the dose distribution at a rate of more than 20 times per second. Preliminary testing on various sites shows that interactive planning may be completed in ∼1–5 min, depending on the complexity of the case (number of targets and OARs). Final DVHs are derived through a separate plan optimization step using a conventional VMAT planning system and were shown to be achievable within 2% and 4% in high and low dose regions respectively. With real-time interactive planning trade-offs between Target(s) and OARs may be evaluated efficiently providing a better understanding of the dosimetric options available to each patient in static or adaptive RT. (paper)

  6. Peripheral CT angiography for interventional treatment planning

    International Nuclear Information System (INIS)

    Lower extremity CT angiography (CTA) has evolved into a very effective, widely available and robust imaging modality for patients with peripheral arterial occlusive disease (PAOD). In this article we briefly review the acquisition and contrast administration techniques for 4- through 64-channel peripheral CTA. Visualization of atherosclerotic disease with CTA in general requires 'angiography-like' 3D images (such as volume rendered or maximum intensity projection images), but-notably in the presence of vessel wall calcifications and stents-cross-sectional views (such as curved planar reformations, CPR) are also required to accurately assess the flow lumen of the aorta down to the pedal arteries. Adequate visualization and mapping of atherosclerotic lesions in patients with PAOD is not only a prerequisite for generating a dictated report, but more importantly, standardized postprocessed images are the key to communicating the findings to the treating physician, and they also serve as a treatment planning tool. Treatment decisions (surgical versus transluminal revascularization, or conservative treatment), and percutaneous treatment planning (access site, antegrade versus retrograde puncture) can be made in the majority of patients with PAOD based on lower extremity CT angiograms. (orig.)

  7. Optimization of the BNCT filter

    International Nuclear Information System (INIS)

    The Czech Boron Neutron Capture Therapy (BNCT) facility works by an epithermal neutron beam installed at the LVR-15 reactor at Rez near Prague. Several configurations of moderating and shielding materials have been designed in order to ensure appropriate parameters of the beam. The beam filter consists of cylindrical layers of Al, AlF3 and Ti. To decrease the gamma two layers of Pb are implemented. The filter geometry and composition has been optimized with the aim to increase the epithermal neutron fluence rate and decrease the fast neutron dose rate using the MCNP-4B Monte Carlo code with the DLC-189 library. Suitable patterns of the reactor core were also studied especially in regard to a possible installation of fuel units close to the filter input. Results of calculations show that the optimized variant of the reactor core is able to increase the intensity of the fast neutron source incident to the filter by a factor of 2.0. An experimental verification of the beam parameters was performed using different measurement techniques. The neutron energy spectrum was measured with a set of activation foils, by a Bonner spheres spectrometer and a fast neutron spectrometer with a stilbene crystal. The fast neutron kerma rate was calculated from the spectral measurement. Al-P TLD were used to measure the photon absorbed dose. The beam parameters were measured at 10 MW and were found as follows: the epithermal neutron fluence rate (an energy range from 1 eV to 10 keV) of 9.29 x 1012 m-2 s-1, the fast neutron kerma rate in tissue of 2.63 Gy h-1 and the incident gamma dose rate in tissue of 29 Gy h-1. (author)

  8. 3-D CT for cardiovascular treatment planning

    Energy Technology Data Exchange (ETDEWEB)

    Wildermuth, S.; Leschka, S.; Duru, F.; Alkadhi, H. [Inst. for Diagnostic Radiology, Univ. Hospital Zurich (Switzerland)

    2005-11-15

    The recently developed 64-slice CT scanner together with the use of 2-D and 3-D reconstructions can aid the cardiovascular surgeon and interventional radiologist in visualizing exact geometric relationships to plan and execute complex procedures via minimally invasive or standard approaches.Cardiac 64-slice CT considerably benefits from the high temporal and spatial resolution allowing the reliable depiction of small coronary segments. Similarly, abdominal vascular 64-slice CT became possible within short examination times and allowing an optimal arterial contrast bolus exploitation. We demonstrate four representative cardiac and abdominal examples using the new 64-slice CT technology which reveal the impact of the new scanner generation for cardiovascular treatment planning. (orig.)

  9. INEL BNCT Program: Volume 5, No. 9

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.)

    1991-01-01

    This Bulletin presents a summary of accomplishments and highlights of the Idaho National Engineering Laboratory's (INEL) Boron Neutron Capture Therapy (BNCT) Program for September 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, and updates to the animal data charts.

  10. Synthesis and evaluation of boron folates for Boron-Neutron-Capture-Therapy (BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Kettenbach, Kathrin; Schieferstein, Hanno; Grunewald, Catrin; Hampel, Gabriele; Schuetz, Christian L. [Mainz Univ. (Germany). Inst. of Nuclear Chemistry; Iffland, Dorothee; Bings, Nicolas H. [Mainz Univ. (Germany). Inst. of Inorganic Chemistry and Analytical Chemistry; Reffert, Laura M. [Hannover Medical School (Germany). Radiopharmaceutical Chemistry; Ross, Tobias L. [Mainz Univ. (Germany). Inst. of Nuclear Chemistry; Hannover Medical School (Germany). Radiopharmaceutical Chemistry

    2015-07-01

    Boron neutron capture therapy (BNCT) employs {sup 10}B-pharmaceuticals administered for the treatment of malignancies, and subsequently irradiated with thermal neutrons. So far, clinical established pharmaceuticals like boron phenylalanine (BPA) or sodium boron mercaptate (BSH) use imperfect (BPA) or passive (BSH) targeting for accumulation at target sites. Due to the need of a selective transportation of boron drugs into cancer cells and sparing healthy tissues, we combined the BNCT approach with the specific and effective folate receptor (FR) targeting concept. The FR is overexpressed on many human carcinomas and provides a selective and specific target for molecular imaging as well as for tumor therapy. We synthesized and characterized a carborane-folate as well as a BSH-folate to study their in vitro characteristics and their potential as new boron-carriers for BNCT. Uptake studies were carried out using human KB cells showing a significant increase of the boron content in cells and demonstrating the successful combination of active FR-targeting and BNCT.

  11. Dentofacial Asymmetries: Challenging Diagnosis and Treatment Planning.

    Science.gov (United States)

    Agrawal, Manish; Agrawal, Jiwan Asha; Nanjannawar, Lalita; Fulari, Sangamesh; Kagi, Vishwal

    2015-07-01

    Dentofacial asymmetry is quite common and when sufficiently severe can require surgical orthodontic intervention. Asymmetries can be classified according to the structures involved into skeletal, dental and functional. In diagnosing asymmetries, a thorough clinical examination and radiographic survey are essential to determine the extent of soft tissue, skeletal, dental and functional involvement. Dental asymmetries, as well as a variety of functional deviations, can be managed orthodontically, whereas significant structural facial asymmetries require a comprehensive orthodontic and orthognathic management. With less severe dental, skeletal and soft tissue deviations the advisability of treatment should be carefully considered. The following article also contains a case report highlighting the importance of proper diagnosis in treatment plan for management of dentofacial asymmetry. PMID:26229387

  12. Verification of ophthalmic brachytherapy treatment planning

    International Nuclear Information System (INIS)

    Ophthalmic brachytherapy dose calculations were performed as an independent verification of commercial dosimetry software (BEBIG Plaque Simulator). Excel spreadsheets were constructed to follow the formalism of the AAPM Task Group No. 43. As a software commissioning tool, TG43 seed-based coordinates were reformatted to be compatible with plaque-based BEBIG dose tables for centrally positioned seeds. Plaque central axis doses were also calculated for rings of seeds. Close agreement with BEBIG doses was obtained in both cases. Tailored spreadsheet versions were subsequently created to verify patient treatment plans. Treatment time and dose to a specified central-axis point are calculated for ROPES plaques fully loaded with I-125 model 6702 seeds. Copyright (2001) Australasian College of Physical Scientists and Engineers in Medicine

  13. BNCT-Project at the Finnish TRIGA Reactor

    International Nuclear Information System (INIS)

    An epithermal neutron irradiation station for the Boron Neutron Capture Therapy (BNCT) will be constructed in the thermal column of the Finnish Triga reactor. The first target of the BNCT at FiR 1 is the treatment of malignant brain tumors. The epithermal neutrons have the capability to penetrate deep into the brain tissue thermalizing at the same time. The thermal neutrons are captured by 10B-nuclei situated ideally in the tumor cells only and thus the reaction products destroy selectively only the tumor cells. The graphite filling of the thermal column will be replaced by a special moderator material: Al+AlF3. The moderator material and its thickness has been chosen so that the system produces as much as possible epithermal neutrons with low fast neutron and gamma contamination. Both fast neutrons and gamma radiation are harmful for the patient. To reduce the gamma radiation there is a lead-bismuth gamma shield at the outer end of the moderator block. In spite of the low power (250 kW) of the reactor the needed epithermal neutron dose to destroy the tumor will be accumulated in a reasonable time e.g. 0.5 to 1.5 h. This is possible because of the rather short distance between the reactor core and the irradiation target. (author)

  14. Mass spectral investigations of boron neutron capture therapy (BNCT) agents

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is a promising technique for the treatment of selected types of brain tumor and potentially for other tumor types. In this therapy, a 10B-enriched species is administered to the bloodstream and selectively deposited in the tumor. The selective deposition in the tumor is due to either the breakdown of the blood-grain barrier or to the chemical nature of the boron-containing compounds. Once a sufficient concentration of boron is attained in the tumor (approximately 25 ppm), the tumor is irradiated with a controlled energy neutron beam (preferable epithermal, 1 eV to 10 keV), at which time neutrons are captured by the incorporated boron atoms. The capture results in the reaction, 10B(n, ) Li, which produces a localized nuclear reaction capable of destroying the tumor cell containing the boron. A variety of boron containing compounds have been evaluated for use in BNCT. This paper addresses some of the most promising of the compounds, the disodium salt of mercaptoundecahydrododecaborate (Na2B12H11SH), commonly referred to as BSH

  15. Recovery post treatment: plans, barriers and motivators

    Directory of Open Access Journals (Sweden)

    Duffy Paul

    2013-01-01

    Full Text Available Abstract Background The increasing focus on achieving a sustained recovery from substance use brings with it a need to better understand the factors (recovery capital that contribute to recovery following treatment. This work examined the factors those in recovery perceive to be barriers to (lack of capital or facilitators of (presence of capital sustained recovery post treatment. Methods A purposive sample of 45 participants was recruited from 11 drug treatment services in northern England. Semi-structured qualitative interviews lasting between 30 and 90 minutes were conducted one to three months after participants completed treatment. Interviews examined key themes identified through previous literature but focused on allowing participants to explore their unique recovery journey. Interviews were transcribed and analysed thematically using a combination of deductive and inductive approaches. Results Participants generally reported high levels of confidence in maintaining their recovery with most planning to remain abstinent. There were indications of high levels of recovery capital. Aftercare engagement was high, often through self referral, with non substance use related activity felt to be particularly positive. Supported housing was critical and concerns were raised about the ability to afford to live independently with financial stability and welfare availability a key concern in general. Employment, often in the substance use treatment field, was a desire. However, it was a long term goal, with substantial risks associated with pursuing this too early. Positive social support was almost exclusively from within the recovery community although the re-building of relationships with family (children in particular was a key motivator post treatment. Conclusions Addressing internal factors and underlying issues i.e. ‘human capital’, provided confidence for continued recovery whilst motivators focused on external factors such as family and

  16. 49: 3-D treatment planning. 3

    International Nuclear Information System (INIS)

    For practical 3-D treatment planning, one of the most important perspectives to be used is the 'beam's-eye-view' (BEV), since it displays the relationship of the target volume with the proposed radiation beams. Several BEV features comprise the 3-D planning system U-MPlan, including BEV displays which include contour and shaded solid surfaces of defined anatomy, block entry using joystick and digitizer tablet, automatic block and multi-leaf collimator design, output of block coordinates to hard copy devices, direct output to a computer-controlled block and compensator cutter, use of video digitized radiographs as a backdrop for the BEV graphics, image analysis of digitized films, complete image correlation between BEV-type imaging and CT, MR, PET, etc., and a photon dose calculation algorithm which makes accurate and fast calculations in BEV planes and under blocks. The correlation and use of radiographs and other BEV-type images with CT-type information allows a new degree of precision to be incorporated into radiation therapy planning. 9 refs.; 3 figs

  17. Initial evaluation of automated treatment planning software.

    Science.gov (United States)

    Gintz, Dawn; Latifi, Kujtim; Caudell, Jimmy; Nelms, Benjamin; Zhang, Geoffrey; Moros, Eduardo; Feygelman, Vladimir

    2016-01-01

    Even with advanced inverse-planning techniques, radiation treatment plan opti-mization remains a very time-consuming task with great output variability, which prompted the development of more automated approaches. One commercially available technique mimics the actions of experienced human operators to pro-gressively guide the traditional optimization process with automatically created regions of interest and associated dose-volume objectives. We report on the initial evaluation of this algorithm on 10 challenging cases of locoreginally advanced head and neck cancer. All patients were treated with VMAT to 70 Gy to the gross disease and 56 Gy to the elective bilateral nodes. The results of post-treatment autoplanning (AP) were compared to the original human-driven plans (HDP). We used an objective scoring system based on defining a collection of specific dosimetric metrics and corresponding numeric score functions for each. Five AP techniques with different input dose goals were applied to all patients. The best of them averaged the composite score 8% lower than the HDP, across the patient population. The difference in median values was statistically significant at the 95% confidence level (Wilcoxon paired signed-rank test p = 0.027). This result reflects the premium the institution places on dose homogeneity, which was consistently higher with the HDPs. The OAR sparing was consistently better with the APs, the differences reaching statistical significance for the mean doses to the parotid glands (p < 0.001) and the inferior pharyngeal constrictor (p = 0.016), as well as for the maximum doses to the spinal cord (p = 0.018) and brainstem (p = 0.040). If one is prepared to accept less stringent dose homogeneity criteria from the RTOG 1016 protocol, nine APs would comply with the protocol, while providing lower OAR doses than the HDPs. Overall, AP is a promising clinical tool, but it could benefit from a better process for shifting the balance between the target dose

  18. FIR 1 reactor in service for boron neutron capture therapy (BNCT) and isotope production

    International Nuclear Information System (INIS)

    Full text: The FIR 1-reactor, a 250 kW Triga reactor, has been in operation since 1962. The main purpose for the existence of the reactor is now the Boron Neutron Capture Therapy (BNCT). The BNCT work dominates the current utilization of the reactor: three or four days per week are reserved for BNCT purposes and the rest for other purposes such as isotope production and neutron activation analysis. In the 1990's a BNCT treatment facility was build at the FiR1 reactor located at Technical Research Centre of Finland. A special new neutron moderator material FluentalTM (Al+AlF3+Li) developed at VTT ensures the superior quality of the neutron beam. Also the treatment environment is of world top quality. The ground floor of the reactor hall was provided with a new entrance, easily accessible by any patient vehicle, a radio therapy control room and rooms for patient preparation and laboratories. The top of the reactor tank was separated from the reactor hall in order to confine contamination in case of a leakage from irradiation samples or fuel elements. The ventilation of the building, emergency power supply system, heat exchangers and the secondary cooling circuit of the reactor including cooling towers were completely redesigned and rebuilt. The expenditure of designing and accomplishing the construction work described was about 4 million euros. The costs were partly financed with venture capital via Radtek Ltd., particularly established for this enterprise. Close to thirty patients have been treated at FiR 1 since May 1999, when the license for patient treatment was granted to the responsible BNCT treatment organization, Boneca Corporation. VTT as the reactor operator has a long term contract with the Boneca Corp. to provide the facility and irradiation services for the patient treatments. The BNCT facility has been licensed for clinical use and is being surveyed by several national public health authorities including the Finnish Nuclear and Radiation Safety

  19. A colorimetric determination of boron in biological sample for boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    The boron neutron capture therapy (BNCT) has shown better prognosis in the treatment of glyemas and gluoblastomas grade III and IV than other therapies. During the treatment the levels of Na210B12H11SH must be known in several compartiments of the organism and with this purpose the method of colorimetric determination of boron using curcumine was established. This method is simple, reprodutible and adequate sensitivity for this control. (author)

  20. An economic model to assess the cost-benefit of BNCT.

    Science.gov (United States)

    Kulvik, Martti; Hermans, Raine; Linnosmaa, Ismo; Shalowitz, Joel

    2015-12-01

    We have constructed a formal model on cost-benefit of new technology in health care, and apply it on boron neutron capture therapy (BNCT). We assume that the patient health benefit from getting cured in acute treatment is always higher than the patient utility resulting from any long term treatment or death. This assumption makes it possible to evaluate the monetary cost impacts of a new technology and relate these measures to the patient health benefit. PMID:26365901

  1. A preclinical study of boron neutron capture therapy (BNCT) of spontaneous tumors in cats at RA-6 in Argentina

    International Nuclear Information System (INIS)

    BNCT is a binary treatment modality that combines irradiation with a thermal or epithermal neutron beam with tumor-seeking, boron containing drugs to produce selective irradiation of tumor tissue. Having demonstrated that BNCT mediated by boronophenylalanine (BPA) induced control of experimental squamous cell carcinomas (SCC) of the hamster cheek pouch mucosa with no damage to normal tissue we explored the feasibility and safety of treating spontaneous head and neck tumors, with particular focus on SCC, of terminal feline patients with low dose BPA-BNCT employing the thermal beam of RA-1. Having demonstrated partial tumor control with no radio toxic effects, the aim of the present study was to evaluate the effect of BPA-BNCT on tumor and normal tissue in 3 cases of spontaneous SCC in feline patients employing a higher neutron fluence than in the previous study. The present study was performed at RA-6 with the thermalized epithermal neutron beam. All three irradiations were successful. Except for an initial, moderate and reversible mucositis, no significant radio toxic effects were observed in terms of clinical follow-up, histological examination, biochemical analysis and assessment of autopsy material. Partial tumor control was evidenced in terms of growth inhibition and partial necrosis and improvement in the quality of life during the survival period. Optimization of the therapeutic efficacy of BNCT would require improvement in boron tumor targeting and strategies to increase in-depth dose in large tumors. (author)

  2. Investigating a multi-purpose target for electron linac based photoneutron sources for BNCT of deep-seated tumors

    Energy Technology Data Exchange (ETDEWEB)

    Masoudi, S. Farhad, E-mail: masoudi@kntu.ac.ir; Rasouli, Fatemeh S.

    2015-08-01

    Recent studies in BNCT have focused on investigating appropriate neutron sources as alternatives for nuclear reactors. As the most prominent facilities, the electron linac based photoneutron sources benefit from two consecutive reactions, (e, γ) and (γ, n). The photoneutron sources designed so far are composed of bipartite targets which involve practical problems and are far from the objective of achieving an optimized neutron source. This simulation study deals with designing a compact, optimized, and geometrically simple target for a photoneutron source based on an electron linac. Based on a set of MCNPX simulations, tungsten is found to have the potential of utilizing as both photon converter and photoneutron target. Besides, it is shown that an optimized dimension for such a target slows-down the produced neutrons toward the desired energy range while keeping them economy, which makes achieving the recommended criteria for BNCT of deep-tumors more available. This multi-purpose target does not involve complicated designing, and can be considered as a significant step toward finding application of photoneutron sources for in-hospital treatments. In order to shape the neutron beam emitted from such a target, the beam is planned to pass through an optimized arrangement of materials composed of moderators, filters, reflector, and collimator. By assessment with the recommended in-air parameters, it is shown that the designed beam provides high intensity of desired neutrons, as well as low background contamination. The last section of this study is devoted to investigate the performance of the resultant beam in deep tissue. A typical simulated liver tumor, located within a phantom of human body, was subjected to the irradiation of the designed spectrum. The dosimetric results, including evaluated depth-dose curves and carried out in-phantom parameters show that the proposed configuration establishes acceptable agreement between the appropriate neutron intensity, and

  3. Noncoplanar VMAT for nasopharyngeal tumors: Plan quality versus treatment time

    International Nuclear Information System (INIS)

    Purpose: The authors investigated the potential of optimized noncoplanar irradiation trajectories for volumetric modulated arc therapy (VMAT) treatments of nasopharyngeal patients and studied the trade-off between treatment plan quality and delivery time in radiation therapy. Methods: For three nasopharyngeal patients, the authors generated treatment plans for nine different delivery scenarios using dedicated optimization methods. They compared these scenarios according to dose characteristics, number of beam directions, and estimated delivery times. In particular, the authors generated the following treatment plans: (1) a 4π plan, which is a not sequenced, fluence optimized plan that uses beam directions from approximately 1400 noncoplanar directions and marks a theoretical upper limit of the treatment plan quality, (2) a coplanar 2π plan with 72 coplanar beam directions as pendant to the noncoplanar 4π plan, (3) a coplanar VMAT plan, (4) a coplanar step and shoot (SnS) plan, (5) a beam angle optimized (BAO) coplanar SnS IMRT plan, (6) a noncoplanar BAO SnS plan, (7) a VMAT plan with rotated treatment couch, (8) a noncoplanar VMAT plan with an optimized great circle around the patient, and (9) a noncoplanar BAO VMAT plan with an arbitrary trajectory around the patient. Results: VMAT using optimized noncoplanar irradiation trajectories reduced the mean and maximum doses in organs at risk compared to coplanar VMAT plans by 19% on average while the target coverage remains constant. A coplanar BAO SnS plan was superior to coplanar SnS or VMAT; however, noncoplanar plans like a noncoplanar BAO SnS plan or noncoplanar VMAT yielded a better plan quality than the best coplanar 2π plan. The treatment plan quality of VMAT plans depended on the length of the trajectory. The delivery times of noncoplanar VMAT plans were estimated to be 6.5 min in average; 1.6 min longer than a coplanar plan but on average 2.8 min faster than a noncoplanar SnS plan with comparable

  4. Noncoplanar VMAT for nasopharyngeal tumors: Plan quality versus treatment time

    Energy Technology Data Exchange (ETDEWEB)

    Wild, Esther, E-mail: e.wild@dkfz.de; Bangert, Mark [Department of Medical Physics in Radiation Oncology, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg (Germany); Nill, Simeon [Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London SM2 5NG (United Kingdom); Oelfke, Uwe [Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London SM2 5NG, United Kingdom and Department of Medical Physics in Radiation Oncology, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg (Germany)

    2015-05-15

    Purpose: The authors investigated the potential of optimized noncoplanar irradiation trajectories for volumetric modulated arc therapy (VMAT) treatments of nasopharyngeal patients and studied the trade-off between treatment plan quality and delivery time in radiation therapy. Methods: For three nasopharyngeal patients, the authors generated treatment plans for nine different delivery scenarios using dedicated optimization methods. They compared these scenarios according to dose characteristics, number of beam directions, and estimated delivery times. In particular, the authors generated the following treatment plans: (1) a 4π plan, which is a not sequenced, fluence optimized plan that uses beam directions from approximately 1400 noncoplanar directions and marks a theoretical upper limit of the treatment plan quality, (2) a coplanar 2π plan with 72 coplanar beam directions as pendant to the noncoplanar 4π plan, (3) a coplanar VMAT plan, (4) a coplanar step and shoot (SnS) plan, (5) a beam angle optimized (BAO) coplanar SnS IMRT plan, (6) a noncoplanar BAO SnS plan, (7) a VMAT plan with rotated treatment couch, (8) a noncoplanar VMAT plan with an optimized great circle around the patient, and (9) a noncoplanar BAO VMAT plan with an arbitrary trajectory around the patient. Results: VMAT using optimized noncoplanar irradiation trajectories reduced the mean and maximum doses in organs at risk compared to coplanar VMAT plans by 19% on average while the target coverage remains constant. A coplanar BAO SnS plan was superior to coplanar SnS or VMAT; however, noncoplanar plans like a noncoplanar BAO SnS plan or noncoplanar VMAT yielded a better plan quality than the best coplanar 2π plan. The treatment plan quality of VMAT plans depended on the length of the trajectory. The delivery times of noncoplanar VMAT plans were estimated to be 6.5 min in average; 1.6 min longer than a coplanar plan but on average 2.8 min faster than a noncoplanar SnS plan with comparable

  5. Preliminary computational model for BNCT for breast cancer

    International Nuclear Information System (INIS)

    For the large number of women who are diagnosed with breast cancer every year, the available treatment options are effective, though physically and mentally taxing. This work begins a study of the efficacy of boron neutron capture therapy as an alternative treatment for this type of cancer. Using HER2-specific monoclonal antibodies coupled with a boron rich oligomeric phosphate diester, it may be possible to deliver large amounts of boron-10 to a tumor of the breast, which would allow for selective cell destruction via irradiation with a thermal neutron beam. A preliminary computational model (MCNP) of a deep-seated breast tumor is described as well as the calculated thermal neutron distribution within the tumor resulting from a thermal neutron source similar to those used for BNCT. A linear decrease in flux across the tumor volume is observed due to attenuation within the tissue prior to the tumor. Suggestions for future work are included. (author)

  6. Alopecia areata: a new treatment plan

    Directory of Open Access Journals (Sweden)

    Alsantali A

    2011-07-01

    Full Text Available Adel AlsantaliDepartment of Dermatology, King Fahd Armed Forces Hospital, Jeddah, Saudi ArabiaAbstract: Many therapeutic modalities have been used to treat alopecia areata, with variable efficacy and safety profiles. Unfortunately, none of these agents is curative or preventive. Also, many of these therapeutic agents have not been subjected to randomized, controlled trials, and, except for topical immunotherapy, there are few published studies on long-term outcomes. The treatment plan is designed according to the patient's age and extent of disease. In this paper, the therapeutic agents are organized according to their efficacy and safety profiles into first-line, second-line, and third-line options.Keywords: alopecia areata, corticosteroids, immunotherapy, intralesional, phototherapy, sulfasalazine

  7. Federal Facilities Compliance Act, Draft Site Treatment Plan: Compliance Plan Volume. Part 2, Volume 2

    International Nuclear Information System (INIS)

    This document presents the details of the implementation of the Site Treatment Plan developed by Ames Laboratory in compliance with the Federal Facilities Compliance Act. Topics discussed in this document include: implementation of the plan; milestones; annual updates to the plan; inclusion of new waste streams; modifications of the plan; funding considerations; low-level mixed waste treatment plan and schedules; and TRU mixed waste streams

  8. Federal Facilities Compliance Act, Draft Site Treatment Plan: Compliance Plan Volume. Part 2, Volume 2

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1994-08-31

    This document presents the details of the implementation of the Site Treatment Plan developed by Ames Laboratory in compliance with the Federal Facilities Compliance Act. Topics discussed in this document include: implementation of the plan; milestones; annual updates to the plan; inclusion of new waste streams; modifications of the plan; funding considerations; low-level mixed waste treatment plan and schedules; and TRU mixed waste streams.

  9. Radiotherapy Treatment Planning for Testicular Seminoma

    Energy Technology Data Exchange (ETDEWEB)

    Wilder, Richard B., E-mail: richardbwilder@yahoo.com [Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL (United States); Buyyounouski, Mark K. [Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA (United States); Efstathiou, Jason A. [Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA (United States); Beard, Clair J. [Department of Radiation Oncology, Dana-Farber/Brigham and Women' s Cancer Center, Boston, MA (United States)

    2012-07-15

    Virtually all patients with Stage I testicular seminoma are cured regardless of postorchiectomy management. For patients treated with adjuvant radiotherapy, late toxicity is a major concern. However, toxicity may be limited by radiotherapy techniques that minimize radiation exposure of healthy normal tissues. This article is an evidence-based review that provides radiotherapy treatment planning recommendations for testicular seminoma. The minority of Stage I patients who choose adjuvant treatment over surveillance may be considered for (1) para-aortic irradiation to 20 Gy in 10 fractions, or (2) carboplatin chemotherapy consisting of area under the curve, AUC = 7 Multiplication-Sign 1-2 cycles. Two-dimensional radiotherapy based on bony anatomy is a simple and effective treatment for Stage IIA or IIB testicular seminoma. Centers with expertise in vascular and nodal anatomy may consider use of anteroposterior-posteroanterior fields based on three-dimensional conformal radiotherapy instead. For modified dog-leg fields delivering 20 Gy in 10 fractions, clinical studies support placement of the inferior border at the top of the acetabulum. Clinical and nodal mapping studies support placement of the superior border of all radiotherapy fields at the top of the T12 vertebral body. For Stage IIA and IIB patients, an anteroposterior-posteroanterior boost is then delivered to the adenopathy with a 2-cm margin to the block edge. The boost dose consists of 10 Gy in 5 fractions for Stage IIA and 16 Gy in 8 fractions for Stage IIB. Alternatively, bleomycin, etoposide, and cisplatin chemotherapy for 3 cycles or etoposide and cisplatin chemotherapy for 4 cycles may be delivered to Stage IIA or IIB patients (e.g., if they have a horseshoe kidney, inflammatory bowel disease, or a history of radiotherapy).

  10. Reducing the sensitivity of IMPT treatment plans to setup errors and range uncertainties via probabilistic treatment planning

    International Nuclear Information System (INIS)

    Treatment plans optimized for intensity modulated proton therapy (IMPT) may be very sensitive to setup errors and range uncertainties. If these errors are not accounted for during treatment planning, the dose distribution realized in the patient may by strongly degraded compared to the planned dose distribution. The authors implemented the probabilistic approach to incorporate uncertainties directly into the optimization of an intensity modulated treatment plan. Following this approach, the dose distribution depends on a set of random variables which parameterize the uncertainty, as does the objective function used to optimize the treatment plan. The authors optimize the expected value of the objective function. They investigate IMPT treatment planning regarding range uncertainties and setup errors. They demonstrate that incorporating these uncertainties into the optimization yields qualitatively different treatment plans compared to conventional plans which do not account for uncertainty. The sensitivity of an IMPT plan depends on the dose contributions of individual beam directions. Roughly speaking, steep dose gradients in beam direction make treatment plans sensitive to range errors. Steep lateral dose gradients make plans sensitive to setup errors. More robust treatment plans are obtained by redistributing dose among different beam directions. This can be achieved by the probabilistic approach. In contrast, the safety margin approach as widely applied in photon therapy fails in IMPT and is neither suitable for handling range variations nor setup errors.

  11. FiR 1 reactor in service for boron neutron capture therapy (BNCT) and isotope production

    International Nuclear Information System (INIS)

    The FiR 1 reactor, a 250 kW Triga reactor, has been in operation since 1962. The main purpose for the existence of the reactor is now the Boron Neutron Capture Therapy (BNCT), but FiR 1 has also an important national role in providing local enterprises and research institutions in the fields of industrial measurements, pharmaceuticals, electronics etc. with isotope production and activation analysis services. In the 1990's a BNCT treatment facility was built at the FiR 1 reactor located at Technical Research Centre of Finland. A special new neutron moderator material FluentalTM (Al+AlF3+Li) developed at VTT ensures the superior quality of the neutron beam. Also the treatment environment is of world top quality after a major renovation of the whole reactor building in 1997. Recently the lithiated polyethylene neutron shielding of the beam aperture was modified to ease the positioning of the patient close to the beam aperture. Increasing the reactor power to 500 kW would allow positioning of the patient further away from the beam aperture. Possibilities to accomplish a safety analysis for this is currently under considerations. Over thirty patients have been treated at FiR 1 since May 1999, when the license for patient treatment was granted to the responsible BNCT treatment organization, Boneca Corporation. Currently three clinical trial protocols for tumours in the brain as well as in the head and neck region are recruiting patients. (author)

  12. Advantages of three-dimensional treatment planning in radiation therapy

    International Nuclear Information System (INIS)

    This study was designed to demonstrate the feasibility of three-dimensional (3-D) treatment planning in-patients maxilla, breast, bladder, and lung tumors to explore its potential therapeutic advantage over the traditional dimensional (2-D) approach in these diseases. Conventional two-dimensional (2-D) treatment planning was compared to three-dimensional (3-D) treatment planning. In five selected disease sites, plans calculated with both types of treatment planning were compared. The (3-D) treatment planning system used in this work TMS version 5.1 B from helax AB is based on a monte Carlo-based pencil beam model. The other treatment planning system (2-D 0, introduced in this study was the multi data treatment planning system version 2.35. For the volumes of interest; quality of dose distribution concerning homogeneity in the target volume and the isodose distribution in organs at risk, was discussed. Qualitative and quantitative comparisons between the two planning systems were made using dose volume histograms (DVH's) . For comparisons of dose distributions in real-patient cases, differences ranged from 0.8% to 6.4% for 6 MV, while in case of 18 MV photon, it ranged from 1,8% to 6.5% and was within -+3 standard deviations for the dose between the two planning systems.Dose volume histogram (DVH) shows volume reduction of the radiation-related organs at risk 3-D planning

  13. INEL BNCT Research Program, January/February 1993

    International Nuclear Information System (INIS)

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylaianine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed

  14. INEL BNCT Research Program, May/June 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1992-09-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylaianine (IBPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  15. INEL BNCT Research Program, March/April 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1992-09-01

    This report presents summaries for two months of current research for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murino screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor call culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronopheoylalanine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  16. INEL BNCT research program, July--August 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1992-10-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylalanine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  17. INEL BNCT Research Program, September--October 1992

    International Nuclear Information System (INIS)

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotain. carboranyl alanine, and liposome boron containing compounds. Pituitary tumor call culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophonylalanine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed

  18. INEL BNCT Research Program, May/June 1992

    International Nuclear Information System (INIS)

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylaianine (IBPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed

  19. INEL BNCT Research Program, January/February 1993

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1993-04-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylaianine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  20. INEL BNCT Research Program, September--October 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1992-12-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotain. carboranyl alanine, and liposome boron containing compounds. Pituitary tumor call culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophonylalanine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  1. Federal Facilities Compliance Act, Conceptual Site Treatment Plan. Part 1

    International Nuclear Information System (INIS)

    This Conceptual Site Treatment Plan was prepared by Ames Laboratory to meet the requirements of the Federal Facilities Compliance Act. Topics discussed in this document include: general discussion of the plan, including the purpose and scope; technical aspects of preparing plans, including the rationale behind the treatability groupings and a discussion of characterization issues; treatment technology needs and treatment options for specific waste streams; low-level mixed waste options; TRU waste options; and future waste generation from restoration activities

  2. Epithermal BNCT neutron beam design for a TRIGA II reactor

    International Nuclear Information System (INIS)

    In Finland a collaborative effort by Helsinki University Central Hospital, MAP Medical Technologies Inc. and VTT Reactor Laboratory has started aiming at BNCT of glioma patients. For this the capabilities of the FiR-1 TRIGA II 250 kW research reactor have been evaluated. The FiR-1 is located in the middle of the Otaniemi campus eight kilometers from the center of Helsinki and four kilometers from the Central Hospital. The power of the reactor was increased in 1965 to 250 kW and the instrumentation modernised in 1981. It is a pool reactor with graphite reflector and a core loading of 3 kg 20w% 235U in the special TRIGA uranium-zirconium hydride fuel (8-12 w% U, 91% Zr, 1% H). The advantages of using a TRIGA reactor for BNCT have already been pointed out earlier by Whittemore and have been verified in practice by the thermal neutron treatment work done at the Musashi 100 kW reactor. The advantages include a wide core face area and a wide spatial angle covered by the thermal-epithermal column system, large flux-per-Watt feature and inherent safety of the TRIGA fuel. Because of its wider applicability and less stringent requirements for clinical operation conditions, an epithermal neutron beam has been selected as the design goal. The epithermal flux should be sufficient for glioblastoma patient treatment: 109 epithermal neutrons/cm2/s with low enough fast neutron (-13Gy/epithermal n/cm2) and gamma contamination

  3. Cationized gelatin-HVJ envelope with sodium borocaptate improved the BNCT efficacy for liver tumors in vivo

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is a cell-selective radiation therapy that uses the alpha particles and lithium nuclei produced by the boron neutron capture reaction. BNCT is a relatively safe tool for treating multiple or diffuse malignant tumors with little injury to normal tissue. The success or failure of BNCT depends upon the 10B compound accumulation within tumor cells and the proximity of the tumor cells to the body surface. To extend the therapeutic use of BNCT from surface tumors to visceral tumors will require 10B compounds that accumulate strongly in tumor cells without significant accumulation in normal cells, and an appropriate delivery method for deeper tissues. Hemagglutinating Virus of Japan Envelope (HVJ-E) is used as a vehicle for gene delivery because of its high ability to fuse with cells. However, its strong hemagglutination activity makes HVJ-E unsuitable for systemic administration. In this study, we developed a novel vector for 10B (sodium borocaptate: BSH) delivery using HVJ-E and cationized gelatin for treating multiple liver tumors with BNCT without severe adverse events. We developed cationized gelatin conjugate HVJ-E combined with BSH (CG-HVJ-E-BSH), and evaluated its characteristics (toxicity, affinity for tumor cells, accumulation and retention in tumor cells, boron-carrying capacity to multiple liver tumors in vivo, and bio-distribution) and effectiveness in BNCT therapy in a murine model of multiple liver tumors. CG-HVJ-E reduced hemagglutination activity by half and was significantly less toxic in mice than HVJ-E. Higher 10B concentrations in murine osteosarcoma cells (LM8G5) were achieved with CG-HVJ-E-BSH than with BSH. When administered into mice bearing multiple LM8G5 liver tumors, the tumor/normal liver ratios of CG-HVJ-E-BSH were significantly higher than those of BSH for the first 48 hours (p < 0.05). In suppressing the spread of tumor cells in mice, BNCT treatment was as effective with CG-HVJ-E-BSH as with BSH

  4. Functional imaging in treatment planning of brain lesions

    International Nuclear Information System (INIS)

    Purpose: Explore the use of functional imaging data in radiation treatment planning of brain lesions. Methods and Materials: Compare the treatment-planning process with and without the use of functional brain imaging for clinical cases where functional studies using either single photon emission computed tomography or magnetic resonance imaging are available. Results: A method to register functional image data with planning image studies is needed for functional treatment planning. Functional volumes are not simply connected regions. One activation study may produce many isolated functional areas. After finding the functional volumes and registering the functional information with the planning imaging data, the tools used for conventional three-dimensional treatment planning are sufficient for functional treatment planning. However, the planning system must provide dose-volume histograms for volumes of interest that consist of isolated pieces. Treatment plans that spare functional brain while providing identical target coverage can be constructed for lesions situated near the functional volume. However, the dose to other areas of the brain may be increased. Conclusions: Functional imaging will make determination of dose response of eloquent areas of the brain possible when combined with volumetric dose information and neuropsychological evaluation prior to and after radiation therapy. Realizing the full potential of functional imaging studies will require improved delineation of activated volumes and determination of the uncertainties in functional volume delineation. Optimization of treatment plans by minimizing dose to volumes activated during functional imaging studies should be used cautiously, because the dose to ''silent,'' but possibly eloquent, brain may be increased

  5. Tumor development in field-cancerized tissue is inhibited by a double application of Boron neutron capture therapy (BNCT) without exceeding radio-tolerance

    International Nuclear Information System (INIS)

    Introduction: BNCT is based on the capture reaction between boron, selectively targeted to tumor tissue, and thermal neutrons which gives rise to lethal, short-range high linear energy transfer particles that selectively damage tumor tissue, sparing normal tissue. We previously evidenced a remarkable therapeutic success of a 'single' application of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-1(Na210B10H10) or (GB-10+BPA) to treat hamster cheek pouch tumors with no normal tissue radiotoxicity. Based on these results, we developed a model of precancerous tissue in the hamster cheek pouch for long-term studies. Employing this model we evaluated the long-term potential inhibitory effect on the development of second primary tumors from precancerous tissue and eventual radiotoxicity of a single application of BNCT mediated by BPA, GB-10 or (GB-10+BPA), in the RA-6. The clinical rationale of this study was to search for a BNCT protocol that is therapeutic for tumor, not radio-toxic for the normal tissue that lies in the neutron beam path, and exerts the desired inhibitory effect on the development of second primary tumors, without exceeding the radio-tolerance of precancerous tissue, the dose limiting tissue in this case. Second primary tumors that arise in precancerous tissue (also called locoregional recurrences) are a frequent cause of therapeutic failure in head and neck tumors. Aim: Evaluate the radiotoxicity and inhibitory effect of a 'double' application of the same BNCT protocols that were proved therapeutically successful for tumor and precancerous tissue, with a long term follow up (8 months). A 'double' application of BNCT is a potentially useful strategy for the treatment of tumors, in particular the larger ones, but the cost in terms of side-effects in dose-limiting tissues might preclude its application and requires cautious evaluation. Materials and methods: We performed a double application of 1) BPA-BNCT; 2) (GB- 10+BPA)-BNCT

  6. Dosimetry audit of radiotherapy treatment planning systems

    International Nuclear Information System (INIS)

    In radiotherapy Treatment Planning Systems (TPS) various calculation algorithms are used. The accuracy of dose calculations has to be verified. Numerous phantom types, detectors and measurement methodologies are proposed to verify the TPS calculations with dosimetric measurements. A heterogeneous slab phantom has been designed within a Coordinated Research Project (CRP) of the IAEA. The heterogeneous phantom was developed in the frame of the IAEA CRP. The phantom consists of frame slabs made with polystyrene and exchangeable inhomogeneity slabs equivalent to bone or lung tissue. Special inserts allow to position thermoluminescent dosimeters (TLD) capsules within the polystyrene slabs below the bone or lung equivalent slabs and also within the lung equivalent material. Additionally, there are inserts that allow to position films or ionisation chamber in the phantom. Ten Polish radiotherapy centres (of 30 in total) were audited during on-site visits. Six different TPSs and five calculation algorithms were examined in the presence of inhomogeneities. Generally, most of the results from TLD were within 5 % tolerance. Differences between doses calculated by TPSs and measured with TLD did not exceed 4 % for bone and polystyrene equivalent materials. Under the lung equivalent material, on the beam axis the differences were lower than 5 %, whereas inside the lung equivalent material, off the beam axis, in some cases they were of around 7 %. The TLD results were confirmed with the ionisation chamber measurements. The comparison results of the calculations and the measurements allow to detect limitations of TPS calculation algorithms. The audits performed with the use of heterogeneous phantom and TLD seem to be an effective tool for detecting the limitations in the TPS performance or beam configuration errors at audited radiotherapy departments. (authors)

  7. Current practices and future directions of therapeutic strategy in glioblastoma: Survival benefit and indication of BNCT

    International Nuclear Information System (INIS)

    Since 1998, we are performing clinical studies on treatment of GBM using conventional fractionated photon radiation therapy (CRT), proton beam therapy (PBT) or boron neutron capture therapy (BNCT). We investigated whether these radiation modalities improves the survival of patients with GBM. Sixty-eight cases of newly diagnosed GBM have been treated in our institution. After surgery, radiation therapy was performed using CRT with a dose of 60.0-61.2 Gy (n=36), hyperfractionated PBT concomitant with fractionated photon irradiation with a total dose of 96.6 Gy (n=17), or a single fraction of BNCT (n=15). In PBT, the surrounding volume of 2 cm from main tumor mass and the volume of perifocal edema were irradiated at dose of 75.6 and 60 Gy, respectively. The median OS time of the case series of BNCT for GBM has been reported as 13-20.7 M. In this study, the median OS and median time to MR change (TTM) for all patients were 25.7 and 11.9 M, respectively. The 1- and 2-year survival rates were 85.7% and 45.5%, respectively. On the other hand, in the patients who underwent CRT and ACNU-based chemotherapy, OS and 2-year survival rate were 14.2 M and 17.9%, respectively. In the patients who underwent high-dose PBT, OS and 2-year survival rate were 21.3 M and 38.5%, respectively. The present small case series of selected patients showed survival benefit after BNCT. The comparison using previously reported prognostic factor-based classifications suggest that outcome of BNCT in terms of survival appeared to have non-inferiority compared to the standard therapy. With respect to the case series as a high-dose radiation trial, the outcome (OS: 9.5-25 M) of previously reported may still be comparable to that of BNCT. Randomized trials of comparably selected patients are required to demonstrate conclusively that prolonged survival is a result of this tumor-selective radiotherapy.

  8. Quality control and quality assurance procedures at the THOR BNCT facility

    International Nuclear Information System (INIS)

    Various quality control (QC) and quality assurance (QA) procedures of the boron neutron capture therapy (BNCT) beam at the Tsing Hua Open-pool Reactor (THOR) are established to ensure beam availability and quality. The QC/QA methods mainly employ foil activation and paired ionization chambers, respectively, for beam intensity check and dose assessment. Beam intensity is monitored on-line by using three dead-time corrected fission chambers. In addition to the periodic QC/QA activities regarding beam quality and the monitoring system, the quick QC/QA performed in an all-in-one phantom will be executed less than 70 min before the clinical treatment to guarantee beam quality. The QC/QA procedures have been gradually established and the actual performance satisfied the preset criteria defined for the BNCT facility at THOR.

  9. Towards the final BSA modeling for the accelerator-driven BNCT facility at INFN LNL

    International Nuclear Information System (INIS)

    Some remarkable advances have been made in the last years on the SPES-BNCT project of the Istituto Nazionale di Fisica Nucleare (INFN) towards the development of the accelerator-driven thermal neutron beam facility at the Legnaro National Laboratories (LNL), aimed at the BNCT experimental treatment of extended skin melanoma. The compact neutron source will be produced via the 9Be(p,xn) reactions using the 5 MeV, 30 mA beam driven by the RFQ accelerator, whose modules construction has been recently completed, into a thick beryllium target prototype already available. The Beam Shaping Assembly (BSA) final modeling, using both neutron converter and the new, detailed, Be(p,xn) neutron yield spectra at 5 MeV energy recently measured at the CN Van de Graaff accelerator at LNL, is summarized here.

  10. The experience from the construction of BNCT facility at the LVR-15 reactor

    International Nuclear Information System (INIS)

    The BNCT project at LVR-15 reactor of NRI for treatment of human brain gliomas is before start of clinical trials. A survey of present conditions is included, the attention is devoted to BNCT facility with epithermal neutron beam first of all. The different materials for filter composition were studied, the calculational methods have been used for the determination of neutron and gamma rays in the reactor geometry. Some configurations were experimentally verified. The effort for improvement of epithermal neutron beam parameters in configuration 1998 was concentrated to block of filters remodelling, improvement of collimator-shutter geometry, the choice of optimal reactor core edge configuration. Awaited results from experiment in June 1999 are described. (author)

  11. Towards the final BSA modeling for the accelerator-driven BNCT facility at INFN LNL

    Energy Technology Data Exchange (ETDEWEB)

    Ceballos, C. [Centro de Aplicaciones Tecnlogicas y Desarrollo Nuclear, 5ta y30, Miramar, Playa, Ciudad Habana (Cuba); Esposito, J., E-mail: juan.esposito@lnl.infn.it [INFN, Laboratori Nazionali di Legnaro (LNL), via dell' Universita, 2, I-35020 Legnaro (PD) (Italy); Agosteo, S. [Politecnico di Milano, Dipartimento di Energia, Piazza Leonardo da Vinci 32, 20133 Milano (Italy)] [INFN, Sezione di Milano, via Celoria 16, 20133 Milano (Italy); Colautti, P.; Conte, V.; Moro, D. [INFN, Laboratori Nazionali di Legnaro (LNL), via dell' Universita, 2, I-35020 Legnaro (PD) (Italy); Pola, A. [Politecnico di Milano, Dipartimento di Energia, Piazza Leonardo da Vinci 32, 20133 Milano (Italy)] [INFN, Sezione di Milano, via Celoria 16, 20133 Milano (Italy)

    2011-12-15

    Some remarkable advances have been made in the last years on the SPES-BNCT project of the Istituto Nazionale di Fisica Nucleare (INFN) towards the development of the accelerator-driven thermal neutron beam facility at the Legnaro National Laboratories (LNL), aimed at the BNCT experimental treatment of extended skin melanoma. The compact neutron source will be produced via the {sup 9}Be(p,xn) reactions using the 5 MeV, 30 mA beam driven by the RFQ accelerator, whose modules construction has been recently completed, into a thick beryllium target prototype already available. The Beam Shaping Assembly (BSA) final modeling, using both neutron converter and the new, detailed, Be(p,xn) neutron yield spectra at 5 MeV energy recently measured at the CN Van de Graaff accelerator at LNL, is summarized here.

  12. Fast-neutron dose evaluation in BNCT with Fricke gel layer detectors

    Energy Technology Data Exchange (ETDEWEB)

    Gambarini, G., E-mail: grazia.gambarini@mi.infn.i [Universita degli Studi di Milano, Department of Physics, Via Celoria 16, 20133 Milano (Italy); INFN Sezione di Milano, via Celoria 16, 20133 Milano (Italy); Bartesaghi, G. [Universita degli Studi di Milano, Department of Physics, Via Celoria 16, 20133 Milano (Italy); INFN Sezione di Milano, via Celoria 16, 20133 Milano (Italy); Burian, J. [Department of Reactor Physics, Nuclear Research Institute Rez, Husinec - Rez 130, 250 68 Rez (Czech Republic); Carrara, M., E-mail: mauro.carrara@istitutotumori.mi.i [Medical Physics Unit, Fondazione IRCCS ' Istituto Nazionale Tumori' , via Venezian 1, 20133 Milano (Italy); Marek, M. [Department of Reactor Physics, Nuclear Research Institute Rez, Husinec - Rez 130, 250 68 Rez (Czech Republic); Negri, A. [Universita degli Studi di Milano, Department of Physics, Via Celoria 16, 20133 Milano (Italy); INFN Sezione di Milano, via Celoria 16, 20133 Milano (Italy); Pirola, L. [Universita degli Studi di Milano, Department of Physics, Via Celoria 16, 20133 Milano (Italy); Viererbl, L. [Department of Reactor Physics, Nuclear Research Institute Rez, Husinec - Rez 130, 250 68 Rez (Czech Republic)

    2010-12-15

    Boron neutron capture therapy (BNCT) is a cancer radiotherapy that uses epithermal and thermal neutron beams. The determination of the absorbed dose in healthy tissue, separating the various dose contributions having different radiobiological effectiveness (RBE) is of great importance for therapy planning. However, a standard code of practice has not yet been established because suitable methods for dosimetry in BNCT are still in progress. A study about the characterization of the epithermal column of the LVR-15 research reactor in Rez (CZ) has been performed, in particular concerning the fast-neutron dose. This dose is not negligible and its determination is important owing to its high RBE. Fast-neutron and photon dose distributions in a water phantom have been measured by means of Fricke gel layer dosimeters. Even if gel layer dosimetry is not yet standardized, it is presently the only method for obtaining images of each dose contribution in BNCT neutron fields. The results were compared with values measured with thermoluminescence detectors, twin ionization chambers data taken from literature and Monte Carlo simulations.

  13. Monitoring total boron in blood for BNCT by a novel atomic emission method

    International Nuclear Information System (INIS)

    In BNCT the duration and timing of the is adjusted by 10B concentrations in whole blood. Time-frame for determinations is less than 20 minutes. Therefore fast and accurate boron determinations are a prerequisite for BNCT. We present a method based on ICP-AES instrument for whole blood and plasma boron determinations with protein precipitation with trichloroacetic acid as sample pre-treatment and beryllium as an internal standard. The method was compared to established but tedious ICP-mass spectrometric method with wet ashing as a sample pre-treatment. The ICP-AES method is in good agreement (correlation coefficient 0.99) the ICP-MS. Within-day and between-day imprecisions were less than 3,5% CV for whole blood samples. Samples taken during and after BPA-F infusion (290 mg/kg) revealed an uneven distribution between plasma and erythrocytes. The present method is feasible and one of the fastest currently available for BNCT. Our results indicate that BPA-F or its metabolites do not seem to be tightly bound to plasma proteins. It also seems that determination of boron in plasma sample may be preferable than measuring boron in whole blood. (author)

  14. Quality assurance for BNCT at nuclear facilities. A necessary burden or the unavoidable seal of approval

    International Nuclear Information System (INIS)

    The BNCT clinical trial at the HFR Petten is performed on a completely multi-national basis. The irradiation facility is located in one country (The Netherlands), is operated by an international team of experts under the leadership of a radiotherapist from another country (Germany) and treats patients coming from different European countries. In gaining the necessary approval, it became apparent, especially in the many discussions with the (Dutch) Health authorities that Quality Assurance (QA) would be and is a critical aspect. This is even more so, in the case of BNCT, where it was not only a (relatively) new experimental treatment (in 1996/97) about to be performed for the first time in Europe, but it was to be performed in a non-hospital environment and furthermore in a nuclear research reactor. It was necessary therefore to comply, as closely as possible, with similarly accepted practices in conventional radiotherapy. Despite QA being a sometimes burdensome task, this paper nevertheless raises the issue as to whether it is necessary or whether it is the seal of approval for BNCT as an acceptable mode of treatment in mainstream radiotherapy. (author)

  15. Radioprotective agents to reduce BNCT (Boron Neutron Capture Therapy) induced mucositis in the hamster cheek pouch

    International Nuclear Information System (INIS)

    Introduction: BNCT is based on the capture reaction between boron, selectively targeted to tumor tissue, and thermal neutrons which gives rise to lethal, short-range high linear energy transfer particles that selectively damage tumor tissue, sparing normal tissue. We previously evidenced a remarkable therapeutic success of BNCT mediated by boronophenylalanine (BPA) in the hamster cheek pouch oral cancer and pre cancer model. Despite therapeutic efficacy, mucositis induced in premalignant tissue was dose limiting and favored, in some cases, tumor development. In a clinical scenario, oral mucositis limits the dose administered to head and neck tumors. Aim: Our aim was to evaluate the effect of the administration of different radioprotective agents, seeking to reduce BNCT-induced mucositis to acceptable levels in dose-limiting premalignant tissue; without compromising therapeutic effect evaluated as inhibition on tumor development in premalignant tissue; without systemic or local side effects; and without negative effects on the biodistribution of the boron compound used for treatment. Materials and methods: Cancerized hamsters with DMBA (dimethylbenzanthracene) were treated with BPA-BNCT 5 Gy total absorbed dose to premalignant tissue, at the RA-3 Nuclear Reactor, divided into different groups: 1-treated with FLUNIXIN; 2- ATORVASTATIN; 3-THALIDOMIDE; 4-HISTAMINE (two concentrations: Low -1 mg/ml- and High -5 mg/ml-); 5-JNJ7777120; 6-JNJ10191584; 7-SALINE (vehicle). Cancerized animals without any treatment (neither BNCT nor radioprotective therapy) were also analyzed. We followed the animals during one month and evaluated the percentage of animals with unacceptable/severe mucositis, clinical status and percentage of animals with new tumors post treatment. We also performed a preliminary biodistribution study of BPA + Histamine “low” concentration to evaluate the potential effect of the radioprotector on BPA biodistribution. Results: Histamine

  16. INEL BNCT Research Program annual report, 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1993-05-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1992. Contributions from all the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor targeting compounds, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, inductively coupled plasma-atomic emission spectroscopy (ICP-AES) analysis of biological samples), physics (radiation dosimetry software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of borocaptate sodium and boronophenylalanine is presented, results of 21 spontaneous-tumor-bearing dogs that have been treated with BNCT at the Brookhaven National Laboratory (BNL) Medical Research Reactor (BMRR) are discussed, and predictions for an epithermal-neutron beam at the Georgia Tech Research Reactor (GTRR) are shown. Cellular-level boron detection and localization by secondary ion mass spectrometry, sputter-initiated resonance ionization spectroscopy, low atomization resonance ionization spectroscopy, and alpha track are presented. Boron detection by ICP-AES is discussed in detail. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors with BNCT is presented. Measurement of the epithermal-neutron flux at BNL and comparison to predictions are shown. Calculations comparing the GTRR and BMRR epithermal-neutron beams are also presented. Individual progress reports described herein are separately abstracted and indexed for the database.

  17. INEL BNCT Research Program annual report, 1992

    International Nuclear Information System (INIS)

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1992. Contributions from all the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor targeting compounds, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, inductively coupled plasma-atomic emission spectroscopy (ICP-AES) analysis of biological samples), physics (radiation dosimetry software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of borocaptate sodium and boronophenylalanine is presented, results of 21 spontaneous-tumor-bearing dogs that have been treated with BNCT at the Brookhaven National Laboratory (BNL) Medical Research Reactor (BMRR) are discussed, and predictions for an epithermal-neutron beam at the Georgia Tech Research Reactor (GTRR) are shown. Cellular-level boron detection and localization by secondary ion mass spectrometry, sputter-initiated resonance ionization spectroscopy, low atomization resonance ionization spectroscopy, and alpha track are presented. Boron detection by ICP-AES is discussed in detail. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors with BNCT is presented. Measurement of the epithermal-neutron flux at BNL and comparison to predictions are shown. Calculations comparing the GTRR and BMRR epithermal-neutron beams are also presented. Individual progress reports described herein are separately abstracted and indexed for the database

  18. Development of a Tandem-ElectroStatic-Quadrupole accelerator facility for Boron Neutron Capture Therapy (BNCT)

    International Nuclear Information System (INIS)

    There is a generalized perception that the availability of suitable particle accelerators installed in hospitals, as neutron sources, may be crucial for the advancement of Boron Neutron Capture Therapy (BNCT). An ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based (AB)-BNCT is described here. The project goal is a machine capable of delivering 30 mA of 2.4-2.5 MeV protons to be used in conjunction with a neutron production target based on the 7Li(p,n)7Be reaction slightly beyond its resonance at 2.25 MeV. A folded tandem, with 1.20-1.25 MV terminal voltage, combined with an ESQ chain is being designed and constructed. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7Li(p,n)7Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is one of the technologically simplest and cheapest solutions for optimized AB-BNCT. At present there is no BNCT facility in the world with the characteristics presented in this work. For the accelerator, results on its design, construction and beam transport calculations are discussed. Taking into account the peculiarities of the expected irradiation field, the project also considers a specific study of the treatment room. This study aims at the design of the treatment room emphasizing aspects related to patient, personnel and public radiation protection; dose monitoring; patient positioning and room construction. The design considers both thermal (for the treatment of shallow tumors) and epithermal (for deep-seated tumors) neutron beams entering the room through a port connected to the accelerator via a moderation and neutron beam shaping assembly. Preliminary results of dose calculations for the treatment room design, using the MCNP program, are presented

  19. Monitoring Hazardous Fuels Treatments: Southeast Regional Plan

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — The purpose of this document is to provide technical guidance on monitoring activities to refuge staff involved in planning and conducting hazardous fuel...

  20. A Technique for Stereotactic Radiosurgery Treatment Planning with Helical Tomotherapy

    International Nuclear Information System (INIS)

    The purpose of this study was to develop an efficient and effective planning technique for stereotactic radiosurgery using helical tomotherapy. Planning CTs and contours of 20 patients, previously treated in our clinic for brain metastases with linac-based radiosurgery using circular collimators, were used to develop a robust TomoTherapy planning technique. Plan calculation times as well as delivery times were recorded for all patients to allow for an efficiency evaluation. In addition, conformation and homogeneity indices were calculated as metrics to compare plan quality with that which is achieved with conventional radiosurgery delivery systems. A robust and efficient planning technique was identified to produce plans of radiosurgical quality using the TomoTherapy treatment planning system. Dose calculation did not exceed a few hours and resulting delivery times were less than 1 hour, which allows the process to fit into a single day radiosurgery workflow. Plan conformity compared favorably with published results for gamma knife radiosurgery. In addition, plan homogeneity was similar to linac-based approaches. The TomoTherapy planning software can be used to create plans of acceptable quality for stereotactic radiosurgery in a time that is appropriate for a radiosurgery workflow that requires that planning and delivery occur within 1 treatment day.

  1. SU-D-BRD-04: The Impact of Automatic Radiation Therapy Plan Checks in Treatment Planning

    International Nuclear Information System (INIS)

    Purpose: The physics plan check verifies various aspects of a treatment plan after dosimetrists have finished creating the plan. Some errors in the plan which are caught by the physics check could be caught earlier in the departmental workflow. The purpose of this project was to evaluate a plan checking script that can be run within the treatment planning system (TPS) by the dosimetrists prior to plan approval and export to the record and verify system. Methods: A script was created in the Pinnacle TPS to automatically check 15 aspects of a plan for clinical practice conformity. The script outputs a list of checks which the plan has passed and a list of checks which the plan has failed so that appropriate adjustments can be made. For this study, the script was run on a total of 108 plans: IMRT (46/108), VMAT (35/108) and SBRT (27/108). Results: Of the plans checked by the script, 77/108 (71%) failed at least one of the fifteen checks. IMRT plans resulted in more failed checks (91%) than VMAT (51%) or SBRT (63%), due to the high failure rate of an IMRT-specific check, which checks that no IMRT segment < 5 MU. The dose grid size and couch removal checks caught errors in 10% and 14% of all plans – errors that ultimately may have resulted in harm to the patient. Conclusion: Approximately three-fourths of the plans being examined contain errors that could be caught by dosimetrists running an automated script embedded in the TPS. The results of this study will improve the departmental workflow by cutting down on the number of plans that, due to these types of errors, necessitate re-planning and re-approval of plans, increase dosimetrist and physician workload and, in urgent cases, inconvenience patients by causing treatment delays

  2. American brain tumor patients treated with BNCT in Japan

    International Nuclear Information System (INIS)

    The purpose of this work is to establish and maintain a database for patients from the United States who have received BNCT in Japan for malignant gliomas of the brain. This database will serve as a resource for the DOE to aid in decisions relating to BNCT research in the United States, as well as assisting the design and implementation of clinical trials of BNCT for brain cancer patients in this country. The database will also serve as an information resource for patients with brain tumors and their families who are considering this form of therapy

  3. An accelerator-based epithermal photoneutron source for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Nigg, D.W.; Mitchell, H.E.; Harker, Y.D.; Yoon, W.Y. [and others

    1995-11-01

    Therapeutically-useful epithermal-neutron beams for BNCT are currently generated by nuclear reactors. Various accelerator-based neutron sources for BNCT have been proposed and some low intensity prototypes of such sources, generally featuring the use of proton beams and beryllium or lithium targets have been constructed. This paper describes an alternate approach to the realization of a clinically useful accelerator-based source of epithermal neutrons for BNCT that reconciles the often conflicting objectives of target cooling, neutron beam intensity, and neutron beam spectral purity via a two stage photoneutron production process.

  4. American brain tumor patients treated with BNCT in Japan

    Energy Technology Data Exchange (ETDEWEB)

    Laramore, G.E.; Griffin, B.R.; Spence, A.

    1995-11-01

    The purpose of this work is to establish and maintain a database for patients from the United States who have received BNCT in Japan for malignant gliomas of the brain. This database will serve as a resource for the DOE to aid in decisions relating to BNCT research in the United States, as well as assisting the design and implementation of clinical trials of BNCT for brain cancer patients in this country. The database will also serve as an information resource for patients with brain tumors and their families who are considering this form of therapy.

  5. Optimization of the irradiation beam in the BNCT research facility at IEA-R1 reactor

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) is a radiotherapeutic technique for the treatment of some types of cancer whose useful energy comes from a nuclear reaction that occurs when thermal neutron impinges upon a Boron-10 atom. In Brazil there is a research facility built along the beam hole number 3 of the IEA-R1 research reactor at IPEN, which was designed to perform BNCT research experiments. For a good performance of the technique, the irradiation beam should be mostly composed of thermal neutrons with a minimum as possible gamma and above thermal neutron components. This work aims to monitor and evaluate the irradiation beam on the sample irradiation position through the use of activation detectors (activation foils) and also to propose, through simulation using the radiation transport code, MCNP, new sets of moderators and filters which shall deliver better irradiation fields at the irradiation sample position In this work, a simulation methodology, based on a MCNP card, known as wwg (weight window generation) was studied, and the neutron energy spectrum has been experimentally discriminated at 5 energy ranges by using a new set o activation foils. It also has been concluded that the BNCT research facility has the required thermal neutron flux to perform studies in the area and it has a great potential for improvement for tailoring the irradiation field. (author)

  6. Radiation field characterization of a BNCT research facility using Monte Carlo Method - Code MCNP-4B

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy - BNCT- is a selective cancer treatment and arises as an alternative therapy to treat cancer when usual techniques - surgery, chemotherapy or radiotherapy - show no satisfactory results. The main proposal of this work is to project a facility to BNCT studies. This facility relies on the use of an AmBe neutron source and on a set of moderators, filters and shielding which will provide the best neutron/gamma beam characteristic for these BNCT studies, i.e., high intensity thermal and/or epithermal neutron fluxes and with the minimum feasible gamma rays and fast neutrons contaminants. A computational model of the experiment was used to obtain the radiation field in the sample irradiation position. The calculations have been performed with the MCNP 4B Monte Carlo Code and the results obtained can be regarded as satisfactory, i.e., a thermal neutron fluency ΝΤ = 1,35x108 n/cm2, a fast neutron dose of 5,86x-10 Gy/ΝΤ and a gamma ray dose of 8,30x-14 Gy/ΝΤ. (author)

  7. The Trimeric Model: A New Model of Periodontal Treatment Planning

    OpenAIRE

    Azouni, Khalid G; Tarakji, Bassel

    2014-01-01

    Treatment of periodontal disease is a complex and multidisciplinary procedure, requiring periodontal, surgical, restorative, and orthodontic treatment modalities. Several authors attempted to formulate models for periodontal treatment that orders the treatment steps in a logical and easy to remember manner. In this article, we discuss two models of periodontal treatment planning from two of the most well-known textbook in the specialty of periodontics internationally. Then modify them to arri...

  8. Proposed Site Treatment Plan (PSTP). STP reference document

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1995-02-22

    The Department of Energy (DOE) is required by Section 3021(b) of the Resource Conservation and Recovery Act (RCRA), as amended by the Federal Facility Compliance Act (FFCAct), to prepare a plan describing the development of treatment capacities and technologies for treating mixed waste (hazardous/radioactive waste). DOE decided to prepare its site treatment plan in a three phased approach. The first phase, called the Conceptual Site Treatment Plan (CSTP), was issued in October 1993. At the Savannah River Site (SRS) the CSTP described mixed waste streams generated at SRS and listed treatment scenarios for each waste stream utilizing an onsite, offsite DOE, and offsite or onsite commercial or vendor treatment option. The CSTP is followed by the Draft Site Treatment Plan (DSTP), due to be issued in August 1994. The DSTP, the current activity., will narrow the options discussed in the CSTP to a preferred treatment option, if possible, and will include waste streams proposed to be shipped to SRS from other DOE facilities as well as waste streams SRS may send offsite for treatment. The SRS DSTP process has been designed to address treatment options for each of the site`s mixed waste streams. The SRS Proposed Site Treatment Plan (PSTP) is due to be issued in February 1995. The compliance order would be derived from the PSTP.

  9. Proposed Site Treatment Plan (PSTP). STP reference document

    International Nuclear Information System (INIS)

    The Department of Energy (DOE) is required by Section 3021(b) of the Resource Conservation and Recovery Act (RCRA), as amended by the Federal Facility Compliance Act (FFCAct), to prepare a plan describing the development of treatment capacities and technologies for treating mixed waste (hazardous/radioactive waste). DOE decided to prepare its site treatment plan in a three phased approach. The first phase, called the Conceptual Site Treatment Plan (CSTP), was issued in October 1993. At the Savannah River Site (SRS) the CSTP described mixed waste streams generated at SRS and listed treatment scenarios for each waste stream utilizing an onsite, offsite DOE, and offsite or onsite commercial or vendor treatment option. The CSTP is followed by the Draft Site Treatment Plan (DSTP), due to be issued in August 1994. The DSTP, the current activity., will narrow the options discussed in the CSTP to a preferred treatment option, if possible, and will include waste streams proposed to be shipped to SRS from other DOE facilities as well as waste streams SRS may send offsite for treatment. The SRS DSTP process has been designed to address treatment options for each of the site's mixed waste streams. The SRS Proposed Site Treatment Plan (PSTP) is due to be issued in February 1995. The compliance order would be derived from the PSTP

  10. Volume definition system for treatment planning

    International Nuclear Information System (INIS)

    Purpose: Volume definition is a difficult and time consuming task in 3D treatment planning. We have studied a systems approach for constructing an efficient and reliable set of tools for volume definition. Our intent is to automate body outline, air cavities and bone volume definition and accelerate definition of other anatomical structures. An additional focus is on assisting in definition of CTV and PTV. The primary goals of this work are to cut down the time used in contouring and to improve the accuracy of volume definition. Methods: We used the following tool categories: manual, semi-automatic, automatic, structure management, target volume definition, and visualization tools. The manual tools include mouse contouring tools with contour editing possibilities and painting tools with a scaleable circular brush and an intelligent brush. The intelligent brush adapts its shape to CT value boundaries. The semi-automatic tools consist of edge point chaining, classical 3D region growing of single segment and competitive volume growing of multiple segments. We tuned the volume growing function to take into account both local and global region image values, local volume homogeneity, and distance. Heuristic seeding followed with competitive volume growing finds the body outline, couch and air automatically. The structure management tool stores ICD-O coded structures in a database. The codes have predefined volume growing parameters and thus are able to accommodate the volume growing dissimilarity function for different volume types. The target definition tools include elliptical 3D automargin for CTV to PTV transformation and target volume interpolation and extrapolation by distance transform. Both the CTV and the PTV can overlap with anatomical structures. Visualization tools show the volumes as contours or color wash overlaid on an image and displays voxel rendering or translucent triangle mesh rendering in 3D. Results: The competitive volume growing speeds up the

  11. Recovery post treatment: plans, barriers and motivators

    OpenAIRE

    Duffy Paul; Baldwin Helen

    2013-01-01

    Abstract Background The increasing focus on achieving a sustained recovery from substance use brings with it a need to better understand the factors (recovery capital) that contribute to recovery following treatment. This work examined the factors those in recovery perceive to be barriers to (lack of capital) or facilitators of (presence of capital) sustained recovery post treatment. Methods A purposive sample of 45 participants was recruited from 11 drug treatment services in northern Englan...

  12. Reprint of Bioneutronics: Thermal scattering in organics tissues and its impact on BNCT dosimetry.

    Science.gov (United States)

    Ramos, R L; Sztejnberg Gonçalves-Carralves, M L; Cantargi, F

    2015-12-01

    Neutron transport calculation is a key factor in BNCT numerical dosimetry assessments where thermal neutron flux is intimately related to the neutron dose, specially, the therapeutic boron dose. In this work, numerical calculations in phantoms were performed to determine the importance of utilizing the appropriate thermal scattering treatment for different organic tissues. Two thermal treatments for the neutron scattering were included in the simulations: hydrogen bounded in bulk water and hydrogen bounded in a lipid like carbon chain (polyethylene). The results showed difference between both thermal treatments that can reach several percent points depending on the type of source and irradiated geometry. PMID:26515135

  13. Bioneutronics: Thermal scattering in organics tissues and its impact on BNCT dosimetry.

    Science.gov (United States)

    Ramos, R L; Gonçalves-Carralves, M L Sztejnberg; Cantargi, F

    2015-10-01

    Neutron transport calculation is a key factor in BNCT numerical dosimetry assessments where thermal neutron flux is intimately related to the neutron dose, specially, the therapeutic boron dose. In this work, numerical calculations in phantoms were performed to determine the importance of utilizing the appropriate thermal scattering treatment for different organic tissues. Two thermal treatments for the neutron scattering were included in the simulations: hydrogen bounded in bulk water and hydrogen bounded in a lipid like carbon chain (polyethylene). The results showed difference between both thermal treatments that can reach several percent points depending on the type of source and irradiated geometry. PMID:26141296

  14. Managing Health Care After Cancer Treatment: A Wellness Plan

    OpenAIRE

    Moye, Jennifer; Langdon, Maura; Jones, Janice M.; Haggstrom, David; Naik, Aanand D.

    2014-01-01

    Many patients and health care providers lack awareness of both the existence of, and treatments for, lingering distress and disability after treatment. A cancer survivorship wellness plan can help ensure that any referral needs for psychosocial and other restorative care after cancer treatment are identified.

  15. Automated treatment planning engine for prostate seed implant brachytherapy

    International Nuclear Information System (INIS)

    Purpose: To develop a computer-intelligent planning engine for automated treatment planning and optimization of ultrasound- and template-guided prostate seed implants. Methods and Materials: The genetic algorithm was modified to reflect the 2D nature of the implantation template. A multi-objective decision scheme was used to rank competing solutions, taking into account dose uniformity and conformity to the planning target volume (PTV), dose-sparing of the urethra and the rectum, and the sensitivity of the resulting dosimetry to seed misplacement. Optimized treatment plans were evaluated using selected dosimetric quantifiers, dose-volume histogram (DVH), and sensitivity analysis based on simulated seed placement errors. These dosimetric planning components were integrated into the Prostate Implant Planning Engine for Radiotherapy (PIPER). Results: PIPER has been used to produce a variety of plans for prostate seed implants. In general, maximization of the minimum peripheral dose (mPD) for given implanted total source strength tended to produce peripherally weighted seed patterns. Minimization of the urethral dose further reduced the loading in the central region of the PTV. Isodose conformity to the PTV was achieved when the set of objectives did not reflect seed positioning uncertainties; the corresponding optimal plan generally required fewer seeds and higher source strength per seed compared to the manual planning experience. When seed placement uncertainties were introduced into the set of treatment planning objectives, the optimal plan tended to reach a compromise between the preplanned outcome and the likelihood of retaining the preferred outcome after implantation. The reduction in the volatility of such seed configurations optimized under uncertainty was verified by sensitivity studies. Conclusion: An automated treatment planning engine incorporating real-time sensitivity analysis was found to be a useful tool in dosimetric planning for prostate

  16. Manpower Planning for Wastewater Treatment Plants.

    Science.gov (United States)

    Davies, J. Kenneth; And Others

    This document discusses the components necessary in the development of a forecasting process by which manpower needs can be determined and the development of action programs by which the projected needs may be satisfied. The primary focus of this manual is directed at that person in a state agency who has the responsibility for planning the…

  17. Biodistribution of Boron compounds in an experimental model of liver metastases for Boron Neutron Capture (BNCT) Studies

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality that involves the selective accumulation of 10B carriers in tumors followed by irradiation with thermal or epithermal neutrons. The high linear energy transfer alpha particles and recoiling 7Li nuclei emitted during the capture of a thermal neutron by a 10B nucleus have a short range and a high biological effectiveness. Thus, BNCT would potentially target neoplastic tissue selectively. In previous studies we demonstrated the therapeutic efficacy of different BNCT protocols in an experimental model of oral cancer. More recently we performed experimental studies in normal rat liver that evidenced the feasibility of treating liver metastases employing a novel BNCT protocol proposed by JEC based on ex-situ treatment and partial liver auto-transplant. The aim of the present study was to perform biodistribution studies with different boron compounds and different administration protocols to determine the protocols that would be therapeutically useful in 'in vivo' BNCT studies at the RA-3 Nuclear Reactor in an experimental model of liver metastases in rats. Materials and Methods. A total of 70 BDIX rats (Charles River Lab., MA, USA) were inoculated in the liver with syngeneic colon cancer cells DH/DK12/TRb (ECACC, UK) to induce the development of subcapsular metastatic nodules. 15 days post-inoculation the animals were used for biodistribution studies. A total of 11 protocols were evaluated employing the boron compounds boronophenylalanine (BPA) and GB-10 (Na210B1-0H10), alone or combined employing different doses and administration routes. Tumor, normal tissue and blood samples were processed for boron measurement by ICP-OES. Results. Several protocols proved potentially useful for BNCT studies in terms of absolute boron concentration in tumor and preferential uptake of boron by tumor tissue, i.e. BPA 15.5 mg 10B/kg iv + GB-10 50 mg 10B/kg iv; BPA 46.5 mg 10B/kg ip; BPA 46.5 mg 10B/kg ip + iv; BPA 46

  18. Measurement of thermal neutron flux for BNCT in JRR-2

    International Nuclear Information System (INIS)

    For Boron Neutron Capture Therapy (BNCT) on brain tumor, a medical irradiation facility has been installed in the Japan Research Reactor No.2 (JRR-2) in Japan Atomic Energy Research Institute (JAERI). The first BNCT using by this facility was performed in August 1990. Since then, irradiations for 15 BNCT were performed until March 1993 in JRR-2. Two kinds of devices has been equipped for the measurement of thermal neutron flux at the diseased part of patients. The one is for the measurement of activation of thin gold wire using β-γ coincidence equipment, and the other is for the simultaneous monitoring of neutron fluxes during BNCT using silicon semiconductor detectors. The measurements using these devices are reported in this paper. (author)

  19. Present status of BNCT at Kyoto University Research Reactor Institute

    International Nuclear Information System (INIS)

    At Kyoto University Research Reactor Institute, we have two facilities for BNCT such as a reactor-based and an accelerator-based neutron source. In this article, we will present the characteristics overview of both facilities. (author)

  20. Telemedicine in radiotherapy treatment planning: requirements and applications

    International Nuclear Information System (INIS)

    Telemedicine facilitates decentralized radiotherapy services by allowing remote treatment planning and quality assurance of treatment delivery. A prerequisite is digital storage of relevant data and an efficient and reliable telecommunication system between satellite units and the main radiotherapy clinic. The requirements of a telemedicine system in radiotherapy is influenced by the level of support needed. In this paper we differentiate between three categories of telemedicine support in radiotherapy. Level 1 features video conferencing and display of radiotherapy images and dose plans. Level 2 involves replication of selected data from the radiotherapy database - facilitating remote treatment planning and evaluation. Level 3 includes real-time, remote operations, e.g. target volume delineation and treatment planning performed by the team at the satellite unit under supervision and guidance from more experienced colleagues at the main clinic. (author)

  1. 300 Area waste acid treatment system closure plan. Revision 1

    International Nuclear Information System (INIS)

    This section provides a description of the Hanford Site, identifies the proposed method of 300 Area Waste Acid Treatment System (WATS) closure, and briefly summarizes the contents of each chapter of this plan

  2. Optimal partial-arcs in VMAT treatment planning

    CERN Document Server

    Wala, Jeremiah; Chen, Wei; Craft, David

    2012-01-01

    Purpose: To improve the delivery efficiency of VMAT by extending the recently published VMAT treatment planning algorithm vmerge to automatically generate optimal partial-arc plans. Methods and materials: A high-quality initial plan is created by solving a convex multicriteria optimization problem using 180 equi-spaced beams. This initial plan is used to form a set of dose constraints, and a set of partial-arc plans is created by searching the space of all possible partial-arc plans that satisfy these constraints. For each partial-arc, an iterative fluence map merging and sequencing algorithm (vmerge) is used to improve the delivery efficiency. Merging continues as long as the dose quality is maintained above a user-defined threshold. The final plan is selected as the partial arc with the lowest treatment time. The complete algorithm is called pmerge. Results: Partial-arc plans are created using pmerge for a lung, liver and prostate case, with final treatment times of 127, 245 and 147 seconds. Treatment times...

  3. A case of astrocytoma, 19 year history after BNCT

    International Nuclear Information System (INIS)

    A 39-year-old man had received Boron Neutron Capture Therapy (BNCT) in 1987 for a Grade II Astrocytoma. He gradually exacerbated and received a second operation in 1994. The mass taken in the second operation is almost competent with radiation necrosis. Following that, he shows no signs of recurrence. Currently, he has returned to full time employment in physical labor. This case suggests effectiveness of BNCT for rather low-grade astrocytomas. (author)

  4. Generating Treatment Plan in Medicine: A Data Mining Approach

    OpenAIRE

    Ahmad M. Razali; Shahriyah Ali

    2009-01-01

    This study reports on a research effort on generating treatment plan to handle the error and complexity of treatment process for healthcare providers. Focus has been given for outpatient and was based on data collected from various health centers throughout Malaysia. These clinical data were recorded using SOAP (Subjective, Objective, Assessment and Plan) format approach as being practiced in medicine and were recorded electronically via Percuro Clinical Information System (Percuro). Cross-In...

  5. Comparing Treatment Plan in All Locations of Esophageal Cancer

    OpenAIRE

    Lin, Jang-Chun; Tsai, Jo-Ting; Chang, Chih-Chieh; Jen, Yee-Min; Li, Ming-Hsien; Liu, Wei-Hsiu

    2015-01-01

    Abstract The aim of this study was to compare treatment plans of volumetric modulated arc therapy (VMAT) with intensity-modulated radiotherapy (IMRT) for all esophageal cancer (EC) tumor locations. This retrospective study from July 2009 to June 2014 included 20 patients with EC who received definitive concurrent chemoradiotherapy with radiation doses >50.4 Gy. Version 9.2 of Pinnacle3 with SmartArc was used for treatment planning. Dosimetric quality was evaluated based on doses to several or...

  6. Evolving treatment plan quality criteria from institution-specific experience

    International Nuclear Information System (INIS)

    Purpose: The dosimetric aspects of radiation therapy treatment plan quality are usually evaluated and reported with dose volume histogram (DVH) endpoints. For clinical practicality, a small number of representative quantities derived from the DVH are often used as dose endpoints to summarize the plan quality. National guidelines on reference values for such quantities for some standard treatment approaches are often used as acceptance criteria to trigger treatment plan review. On the other hand, treatment prescription and planning approaches specific to each institution warrants the need to report plan quality in terms of practice consistency and with respect to institution-specific experience. The purpose of this study is to investigate and develop a systematic approach to record and characterize the institution-specific plan experience and use such information to guide the design of plan quality criteria. In the clinical setting, this approach will assist in (1) improving overall plan quality and consistency and (2) detecting abnormal plan behavior for retrospective analysis. Methods: The authors propose a self-evolving methodology and have developed an in-house prototype software suite that (1) extracts the dose endpoints from a treatment plan and evaluates them against both national standard and institution-specific criteria and (2) evolves the statistics for the dose endpoints and updates institution-specific criteria. Results: The validity of the proposed methodology was demonstrated with a database of prostate stereotactic body radiotherapy cases. As more data sets are accumulated, the evolving institution-specific criteria can serve as a reliable and stable consistency measure for plan quality and reveals the potential use of the ''tighter'' criteria than national standards or projected criteria, leading to practice that may push to shrink the gap between plans deemed acceptable and the underlying unknown optimality. Conclusions: The authors have developed

  7. Treatment planning for heavy ion radiotherapy: clinical implementation and application

    International Nuclear Information System (INIS)

    The clinical implementation and application of a novel treatment planning system (TPS) for scanned ion beams is described, which is in clinical use for carbon ion treatments at the German heavy ion facility (GSI). All treatment plans are evaluated on the basis of biologically effective dose distributions. For therapy control, in-beam positron emission tomography (PET) and an online monitoring system for the beam intensity and position are used. The absence of a gantry restricts the treatment plans to horizontal beams. Most of the treatment plans consist of two nearly opposing lateral fields or sometimes orthogonal fields. In only a very few cases a single beam was used. For patients with very complex target volumes lateral and even distal field patching techniques were applied. Additional improvements can be achieved when the patient's head is fixed in a tilted position, in order to achieve sparing of the organs at risk. In order to test the stability of dose distributions in the case of patient misalignments we routinely simulate the effects of misalignments for patients with critical structures next to the target volume. The uncertainties in the range calculation are taken into account by a margin around the target volume of typically 2-3 mm, which can, however, be extended if the simulation demonstrates larger deviations. The novel TPS developed for scanned ion beams was introduced into clinical routine in December 1997 and was used for the treatment planning of 63 patients with head and neck tumours until July 2000. Planning strategies and methods were developed for this tumour location that facilitate the treatment of a larger number of patients with the scanned heavy ion beam in a clinical setting. Further developments aim towards a simultaneous optimization of the treatment field intensities and more effective procedures for the patient set-up. The results demonstrate that ion beams can be integrated into a clinical environment for treatment planning and

  8. 300 Area waste acid treatment system closure plan

    International Nuclear Information System (INIS)

    The Hanford Facility Dangerous Waste Permit Application is considered to be a single application organized into a General Information Portion (document number DOERL-91-28) and a Unit-Specific Portion. The scope of the Unit-Specific Portion includes closure plan documentation submitted for individual, treatment, storage, and/or disposal units undergoing closure, such as the 300 Area Waste Acid Treatment System. Documentation contained in the General Information Portion is broader in nature and could be used by multiple treatment, storage, and/or disposal units (e.g., the glossary provided in the General Information Portion). Whenever appropriate, 300 Area Waste Acid Treatment System documentation makes cross-reference to the General Information Portion, rather than duplicating text. This 300 Area Waste Acid Treatment System Closure Plan (Revision 2) includes a Hanford Facility Dangerous Waste Permit Application, Part A, Form 3. Information provided in this closure plan is current as of April 1999

  9. 300 Area waste acid treatment system closure plan

    Energy Technology Data Exchange (ETDEWEB)

    LUKE, S.N.

    1999-05-17

    The Hanford Facility Dangerous Waste Permit Application is considered to be a single application organized into a General Information Portion (document number DOERL-91-28) and a Unit-Specific Portion. The scope of the Unit-Specific Portion includes closure plan documentation submitted for individual, treatment, storage, and/or disposal units undergoing closure, such as the 300 Area Waste Acid Treatment System. Documentation contained in the General Information Portion is broader in nature and could be used by multiple treatment, storage, and/or disposal units (e.g., the glossary provided in the General Information Portion). Whenever appropriate, 300 Area Waste Acid Treatment System documentation makes cross-reference to the General Information Portion, rather than duplicating text. This 300 Area Waste Acid Treatment System Closure Plan (Revision 2) includes a Hanford Facility Dangerous Waste Permit Application, Part A, Form 3. Information provided in this closure plan is current as of April 1999.

  10. Planning of emergency medical treatment in nuclear power plant

    International Nuclear Information System (INIS)

    Medical staffs and health physicists have shown deep concerning at the emergency plans of nuclear power plants after the TMI nuclear accident. The most important and basic countermeasure for accidents was preparing appropriate and concrete organization and plans for treatment. We have planed emergency medical treatment for radiation workers in a nuclear power plant institute. The emergency medical treatment at institute consisted of two stages, that is on-site emergency treatment at facility medical service. In first step of planning in each stage, we selected and treatment at facility medical service. In first step of planning in each stage, we selected and analyzed all possible accidents in the institute and discussed on practical treatments for some possible accidents. The manuals of concrete procedure of emergency treatment for some accidents were prepared following discussion and facilities and equipment for medical treatment and decontamination were provided. All workers in the institute had periodical training and drilling of on-site emergency treatment and mastered technique of first aid. Decontamination and operation rooms were provided in the facillity medical service. The main functions at the facility medical service have been carried out by industrial nurses. Industrial nurses have been in close co-operation with radiation safety officers and medical doctors in regional hospital. (author)

  11. Sodium-Bearing Waste Treatment, Applied Technology Plan

    International Nuclear Information System (INIS)

    Settlement Agreement between the Department of Energy and the State of Idaho mandates treatment of sodium-bearing waste at the Idaho Nuclear Technology and Engineering Center within the Idaho National Engineering and Environmental Laboratory. One of the requirements of the Settlement Agreement is to complete treatment of sodium-bearing waste by December 31, 2012. Applied technology activities are required to provide the data necessary to complete conceptual design of four identified alternative processes and to select the preferred alternative. To provide a technically defensible path forward for the selection of a treatment process and for the collection of needed data, an applied technology plan is required. This document presents that plan, identifying key elements of the decision process and the steps necessary to obtain the required data in support of both the decision and the conceptual design. The Sodium-Bearing Waste Treatment Applied Technology Plan has been prepared to provide a description/roadmap of the treatment alternative selection process. The plan details the results of risk analyzes and the resulting prioritized uncertainties. It presents a high-level flow diagram governing the technology decision process, as well as detailed roadmaps for each technology. The roadmaps describe the technical steps necessary in obtaining data to quantify and reduce the technical uncertainties associated with each alternative treatment process. This plan also describes the final products that will be delivered to the Department of Energy Idaho Operations Office in support of the office's selection of the final treatment technology

  12. Sodium-Bearing Waste Treatment, Applied Technology Plan

    Energy Technology Data Exchange (ETDEWEB)

    Lance Lauerhass; Vince C. Maio; S. Kenneth Merrill; Arlin L. Olson; Keith J. Perry

    2003-06-01

    Settlement Agreement between the Department of Energy and the State of Idaho mandates treatment of sodium-bearing waste at the Idaho Nuclear Technology and Engineering Center within the Idaho National Engineering and Environmental Laboratory. One of the requirements of the Settlement Agreement is to complete treatment of sodium-bearing waste by December 31, 2012. Applied technology activities are required to provide the data necessary to complete conceptual design of four identified alternative processes and to select the preferred alternative. To provide a technically defensible path forward for the selection of a treatment process and for the collection of needed data, an applied technology plan is required. This document presents that plan, identifying key elements of the decision process and the steps necessary to obtain the required data in support of both the decision and the conceptual design. The Sodium-Bearing Waste Treatment Applied Technology Plan has been prepared to provide a description/roadmap of the treatment alternative selection process. The plan details the results of risk analyzes and the resulting prioritized uncertainties. It presents a high-level flow diagram governing the technology decision process, as well as detailed roadmaps for each technology. The roadmaps describe the technical steps necessary in obtaining data to quantify and reduce the technical uncertainties associated with each alternative treatment process. This plan also describes the final products that will be delivered to the Department of Energy Idaho Operations Office in support of the office's selection of the final treatment technology.

  13. The therapeutic ratio in BNCT: Assessment using the Rat 9L gliosarcoma brain tumor and spinal cord models

    International Nuclear Information System (INIS)

    During any radiation therapy, the therapeutic tumor dose is limited by the tolerance of the surrounding normal tissue within the treatment volume. The short ranges of the products of the 10B(n,α)7Li reaction produced during boron neutron capture therapy (BNCT) present an opportunity to increase the therapeutic ratio (tumor dose/normal tissue dose) to levels unprecedented in photon radiotherapy. The mixed radiation field produced during BNCT comprises radiations with different linear energy transfer (LET) and different relative biological effectiveness (RBE). The short ranges of the two high-LET products of the 'B(n,a)'Li reaction make the microdistribution of the boron relative to target cell nuclei of particular importance. Due to the tissue specific distribution of different boron compounds, the term RBE is inappropriate in defining the biological effectiveness of the 10B(n,α)7Li reaction. To distinguish these differences from true RBEs we have used the term open-quotes compound biological effectivenessclose quotes (CBE) factor. The latter can be defined as the product of the true, geometry-independent, RBE for these particles times a open-quotes boron localization factorclose quotes, which will most likely be different for each particular boron compound. To express the total BNCT dose in a common unit, and to compare BNCT doses with the effects of conventional photon irradiation, multiplicative factors (RBEs and CBEs) are applied to the physical absorbed radiation doses from each high-LET component. The total effective BNCT dose is then expressed as the sum of RBE-corrected physical absorbed doses with the unit Gray-equivalent (Gy-Eq)

  14. The therapeutic ratio in BNCT: Assessment using the Rat 9L gliosarcoma brain tumor and spinal cord models

    Energy Technology Data Exchange (ETDEWEB)

    Coderre, J.A.; Micca, P.L.; Nawrocky, M.M.; Fisher, C.D.; Bywaters, A. [Brookhaven National Lab., Upton, NY (United States); Morris, G.M.; Hopewell, J.W. [Univ. of Oxford (United Kingdom). CRC Normal Tissue Radiobiological Research Group

    1996-10-01

    During any radiation therapy, the therapeutic tumor dose is limited by the tolerance of the surrounding normal tissue within the treatment volume. The short ranges of the products of the {sup 10}B(n,{alpha}){sup 7}Li reaction produced during boron neutron capture therapy (BNCT) present an opportunity to increase the therapeutic ratio (tumor dose/normal tissue dose) to levels unprecedented in photon radiotherapy. The mixed radiation field produced during BNCT comprises radiations with different linear energy transfer (LET) and different relative biological effectiveness (RBE). The short ranges of the two high-LET products of the `B(n,a)`Li reaction make the microdistribution of the boron relative to target cell nuclei of particular importance. Due to the tissue specific distribution of different boron compounds, the term RBE is inappropriate in defining the biological effectiveness of the {sup 10}B(n,{alpha}){sup 7}Li reaction. To distinguish these differences from true RBEs we have used the term {open_quotes}compound biological effectiveness{close_quotes} (CBE) factor. The latter can be defined as the product of the true, geometry-independent, RBE for these particles times a {open_quotes}boron localization factor{close_quotes}, which will most likely be different for each particular boron compound. To express the total BNCT dose in a common unit, and to compare BNCT doses with the effects of conventional photon irradiation, multiplicative factors (RBEs and CBEs) are applied to the physical absorbed radiation doses from each high-LET component. The total effective BNCT dose is then expressed as the sum of RBE-corrected physical absorbed doses with the unit Gray-equivalent (Gy-Eq).

  15. Conservative treatment planning in veneer replacement.

    Science.gov (United States)

    Guzmán-Armstrong, Sandra; Maia, Rodrigo Rocha

    2016-04-01

    This clinical report describes a conservative treatment in veneer replacement where diastemas, malalignment, and midline shift were the main modifying factors. When replacement veneers are indicated, the definitive results can only be accurately predicted after an esthetic reanalysis of the existing restorations. PMID:26602148

  16. Characterisation of the TAPIRO BNCT thermal facility

    International Nuclear Information System (INIS)

    Dosimetry and spectrometry measurements have been carried out in the thermal column of the research fast reactor RSV-TAPIRO (ENEA-Casaccia, Rome) in order to investigate its suitability for irradiation of cells or mice, with a view to research in the interests of boron neutron capture therapy (BNCT). The thermal column consists of a graphite moderator (40 cm thick) containing a lead shield (13 cm thick) in order to shield reactor background. The irradiation volume, inside this structure, has cubic shape (18 x 18 x 18 cm3). Besides measurements of fluence and dose rates in air or in phantom performed with thermoluminescence dosemeters (TLDs) and using the activation technique, dose and fluence profiles have been generated using a method based on gel dosemeters analysed with optical imaging. To check the consistency of the results, spectrometry measurements in the same irradiation volume have been performed by means of bubble detectors. (authors)

  17. Radiological protection considerations during the treatment of glioblastoma patients by boron neutron capture therapy at the high flux reactor in Petten, The Netherlands

    International Nuclear Information System (INIS)

    A clinical trial of Boron Neutron Capture Therapy (BNCT) for glioblastoma patients has been in progress at the High Flux Reactor (HFR) at Petten since October 1997. The JRC (as licence holder of the HFR) must ensure that radiological protection measures are provided. The BNCT trial is a truly European trial, whereby the treatment takes place at a facility in the Netherlands under the responsibility of clinicians from Germany and patients are treated from several European countries. Consequently, radiological protection measures satisfy both German and Dutch laws. To respect both laws, a BNCT radioprotection committee was formed under the chairmanship of an independent radioprotection expert, with members representing all disciplines in the trial. A special nuance of BNCT is that the radiation is provided by a mixed neutron/gamma beam. The radiation dose to the patient is thus a complex mix due to neutrons, gammas and neutron capture in boron, nitrogen and hydrogen, which, amongst others, need to be correctly calculated in non-commercial and validated treatment planning codes. Furthermore, due to neutron activation, measurements on the patient are taken regularly after treatment. Further investigations along these lines include dose determination using TLDs and boron distribution measurements using on-line gamma ray spectroscopy. (author)

  18. BNCT for skin melanoma in extremities: Updated Argentine clinical results

    International Nuclear Information System (INIS)

    As part of phase I/II melanoma BNCT clinical trial conducted in Argentina in a cooperative effort of the Argentine Atomic Energy Commission (CNEA) and the Oncology Institute Angel H. Roffo (IOAHR), 7 patients (6 female-1 male) received eight treatment sessions covering ten anatomical areas located in extremities. Mean age of the patients was 64 years (51-74). The treatments were performed between October 2003 and June 2007. All patients presented multiple subcutaneous skin metastases of melanoma and received an infusion containing ∼14 gr/m2 of 10borophenyl-alanine (BPA) followed by the exposition of the area to a mixed thermal-epithermal neutron beam at the RA-6 reactor. The maximum prescribed dose to normal skin ranged from 16.5 to 24 Gy-Eq and normal tissue administered dose varied from 15.8 to 27.5 Gy-Eq. Considering evaluable nodules, 69.3% of overall response and 30.7% of no changes were seen. The toxicity was acceptable, with 3 out of 10 evaluable areas showing ulceration (30% toxicity grade 3).

  19. 78 FR 65675 - Proposed Collection; 60-Day Comment Request; Multidisciplinary Treatment Planning (MTP) Within...

    Science.gov (United States)

    2013-11-01

    ...; Multidisciplinary Treatment Planning (MTP) Within the National Cancer Institute (NCI) Community Cancer Centers... Collection: Multidisciplinary Treatment Planning (MTP) within the NCI Community Cancer Centers Program (NCI... Program (NCCCP) hospitals define, structure, and implement multidisciplinary treatment planning...

  20. Explicit and convex optimization of plan quality measures in intensity-modulated radiation therapy treatment planning

    CERN Document Server

    Engberg, Lovisa; Forsgren, Anders; Hårdemark, Björn

    2016-01-01

    Given the widespread agreement that doses-at-volume play important roles in quality assessment of radiation therapy treatment plans, planning objectives that correlate well with explicit dose-at-volume optimization are likely to correlate well with plan quality. In this study, planning objectives are formulated to explicitly either minimize or maximize convex approximations of dose-at-volume, namely, mean-tail-doses. This is in contrast to the conventionally used planning objectives, which are used to maximize clinical goal fulfilment by relating to deviations from dose-at-volume thresholds. Advantages of the proposed planning objectives are investigated through juxtaposition with conventional objectives in a computational study of two patient cases, each with three doses-at-volume to be minimized subject to PTV coverage. With proposed planning objectives, this is translated into minimizing three mean-tail-doses. Comparison with conventional objectives is carried out in the dose-at-volume domain and in the no...

  1. Quantitative evaluation of boron neutron capture therapy (BNCT) drugs for boron delivery and retention at subcellular scale resolution in human glioblastoma cells with imaging secondary ion mass spectrometry (SIMS)

    Science.gov (United States)

    Chandra, S.; Ahmad, T.; Barth, R. F.; Kabalka, G. W.

    2014-01-01

    low phenylalanine diet prior to the initiation of BNCT. Since BPA currently is used clinically for BNCT, our observations may have direct relevance to future clinical studies utilizing this agent and provides support for individualized treatment planning regimens rather than the use of fixed BPA infusion protocols. PMID:24684609

  2. Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases

    International Nuclear Information System (INIS)

    BNCT was proposed for the treatment of diffuse, non-resectable tumors in the lung. We performed boron biodistribution studies with 5 administration protocols employing the boron carriers BPA and/or GB-10 in an experimental model of disseminated lung metastases in rats. All 5 protocols were non-toxic and showed preferential tumor boron uptake versus lung. Absolute tumor boron concentration values were therapeutically useful (25–76 ppm) for 3 protocols. Dosimetric calculations indicate that BNCT at RA-3 would be potentially therapeutic without exceeding radiotolerance in the lung. - Highlights: • We performed experimental boron biodistribution studies for lung metastases. • 3 protocols employing BPA and GB-10 would be therapeutically useful. • BNCT at RA-3 would be potentially therapeutic for experimental lung metastases

  3. Influence of BNCT radiations on the blood-brain barrier in terms of boron-10 uptake

    International Nuclear Information System (INIS)

    A key issue is to determine whether fractionated BNCT is a feasible proposition. This issue has been reviewed by Dorn et al, who call for further experimental investigation of BNCT induced changes in the blood brain barrier and investigated by Hatanaka et al. In order to investigate the effect on BNCT, the authors measured 10B concentration and water content in the normal brain which has been subjected to BNCT regimen

  4. An international dosimetry exchange for BNCT part II: computational dosimetry normalizations.

    Science.gov (United States)

    Riley, K J; Binns, P J; Harling, O K; Albritton, J R; Kiger, W S; Rezaei, A; Sköld, K; Seppälä, T; Savolainen, S; Auterinen, I; Marek, M; Viererbl, L; Nievaart, V A; Moss, R L

    2008-12-01

    The meaningful sharing and combining of clinical results from different centers in the world performing boron neutron capture therapy (BNCT) requires improved precision in dose specification between programs. To this end absorbed dose normalizations were performed for the European clinical centers at the Joint Research Centre of the European Commission, Petten (The Netherlands), Nuclear Research Institute, Rez (Czech Republic), VTT, Espoo (Finland), and Studsvik, Nyköping (Sweden). Each European group prepared a treatment plan calculation that was bench-marked against Massachusetts Institute of Technology (MIT) dosimetry performed in a large, water-filled phantom to uniformly evaluate dose specifications with an estimated precision of +/-2%-3%. These normalizations were compared with those derived from an earlier exchange between Brookhaven National Laboratory (BNL) and MIT in the USA. Neglecting the uncertainties related to biological weighting factors, large variations between calculated and measured dose are apparent that depend upon the 10B uptake in tissue. Assuming a boron concentration of 15 microg g(-1) in normal tissue, differences in the evaluated maximum dose to brain for the same nominal specification of 10 Gy(w) at the different facilities range between 7.6 and 13.2 Gy(w) in the trials using boronophenylalanine (BPA) as the boron delivery compound and between 8.9 and 11.1 Gy(w) in the two boron sulfhydryl (BSH) studies. Most notably, the value for the same specified dose of 10 Gy(w) determined at the different participating centers using BPA is significantly higher than at BNL by 32% (MIT), 43% (VTT), 49% (JRC), and 74% (Studsvik). Conversion of dose specification is now possible between all active participants and should be incorporated into future multi-center patient analyses. PMID:19175101

  5. Neutron and gamma dose rates determined in a cell phantom at the Finnish BNCT facility

    International Nuclear Information System (INIS)

    Radiation dosimetry studies have played an essential role in the Finnish BNCT (Boron Neutron Capture Therapy) project. Various phantom studies have been carried out in the FiR I epithermal neutron beam to characterise the gamma and the neutron dose distributions involved in the patient treatment circumstances and to evaluate the beam model used for dose planning. During the summer 1999 cell-line phantom irradiations were done. Dose calculations and measurements were required to determine the dose delivered to the cells at the different locations in the phantom. A cylindrical water-filled polyethylene phantom was used in contact with the 14 cm diameter circular beam aperture. The phantom was modelled by deterministic DORT code. Activation detectors (MT-AI wires), twin (Mg and TE) ionisations chambers (IC) and TL detectors were used to establish the measured dose and 55Mn(n,γ) reaction rates compared to the calculated values. The measured (IC) and calculated gamma and neutron dose rates at three depths in the phantom will be presented. The measured gamma dose rates were about 10 % lower, and the neutron dose rates about 35% lower than the calculations. The difference between the measured 55Mn reaction rates and the calculations was insignificant (= 1%). During the measurements the reactor was operated at the nominal power of 250 kW. The measured (IC) gamma dose rates were in fair agreement with the calculated values but the neutron dose rates displayed considerable discrepancy. However, the activation results, having the best accuracy, were very consistent with the calculated 55Mn reaction rates and therefore the dose determination could be based on the simulated results (author)

  6. Assessment tool for planning fallback Tomotherapy treatment plans; Evaluacion de la herramienta fallback planning para planes de tratamiento de tomoterapia

    Energy Technology Data Exchange (ETDEWEB)

    Sanchez Rubio, P.; Rodriguez Romero, R.; Montes Uruen, A.

    2015-07-01

    Interruption of radiotherapy treatments in an increase the total time of the same to the detriment of tumour control. In centers that have a unique special unit as the TomoTherapy, is emphasized the difficulty to resume treatment at another unit, since the technique of helical TomoTherapy is not portable to conventional accelerators and therefore requires the planning of new dosimetry distributions emulating the initially obtained and accepted. This work evaluates the ability of an automatic planning tool to mimic TomoTherapy plans. (Author)

  7. Comparative study of conformal versus intensity modulated radiotherapy treatment plans

    International Nuclear Information System (INIS)

    Full text: In order to establish some early clinical experience in the use of intensity modulated radiotherapy (IMRT) as an alternative treatment method to conformal irradiation, we selected a number of specifically difficult clinical cases to compare. Complex tumour shapes located in the skull (two cases), close to the spinal cord (two cases) and one standard prostate case were chosen for this study. A Varian CadPlan system is used for the conformal treatment plans and Helios for the IMRT plans. In both these techniques, the linear accelerator multileaf collimator system is used to shape the beam about the target volume. The Royal North Shore Hospital Varian Clinac 600C/D linear accelerator also has dynamic multileaf collimator control (DMLC) capabilities for IMRT. The five cases reported here were planned by the radiation therapists for conformal treatment and then re-planned by physics using the CadPlan's Helios inverse planning option to produce an alternative IMRT plan. Both planners worked independently of each other. Treatment set-up errors were not considered as part of this study but it is apparent here that positional errors and immobilisation are particularly important factors to consider. An allowance for all errors must therefore be included for all critical organ outlines as well as the target volume for both the conformal or IMRT treatments. Visually, the covering of regularly shaped treatment volumes for the IMRT plans was improved marginally over the conformal plan. However, complex treatment volumes (such as the posterior orbital region with surrounding critical structures) showed very clear improvements. The IMRT dose drop-off at the edge of the target volume was not as sharp as the conformal equivalent. The dose-volume-histogram (DVH) provides a limited analytical tool to quantify these observations. The DVH generally indicated similar curves for the IMRT and conformal target volume but significant IMRT improvements in limiting the dose to

  8. Inclusion of organ movements in IMRT treatment planning via inverse planning based on probability distributions

    International Nuclear Information System (INIS)

    In this paper, we investigate an off-line strategy to incorporate inter-fraction organ motion in IMRT treatment planning. It was suggested that inverse planning could be based on a probability distribution of patient geometries instead of a single snap shot. However, this concept is connected to two intrinsic problems: first, this probability distribution has to be estimated from only a few images; and second, the distribution is only sparsely sampled over the treatment course due to a finite number of fractions. In the current work, we develop new concepts of inverse planning which account for these two problems

  9. Standardized treatment planning methodology for passively scattered proton craniospinal irradiation

    International Nuclear Information System (INIS)

    As the number of proton therapy centers increases, so does the need for studies which compare proton treatments between institutions and with photon therapy. However, results of such studies are highly dependent on target volume definition and treatment planning techniques. Thus, standardized methods of treatment planning are needed, particularly for proton treatment planning, in which special consideration is paid to the depth and sharp distal fall-off of the proton distribution. This study presents and evaluates a standardized method of proton treatment planning for craniospinal irradiation (CSI). We applied our institution’s planning methodology for proton CSI, at the time of the study, to an anatomically diverse population of 18 pediatric patients. We evaluated our dosimetric results for the population as a whole and for the two subgroups having two different age-specific target volumes using the minimum, maximum, and mean dose values in 10 organs (i.e., the spinal cord, brain, eyes, lenses, esophagus, lungs, kidneys, thyroid, heart, and liver). We also report isodose distributions and dose-volume histograms (DVH) for 2 representative patients. Additionally we report population-averaged DVHs for various organs. The planning methodology here describes various techniques used to achieve normal tissue sparing. In particular, we found pronounced dose reductions in three radiosensitive organs (i.e., eyes, esophagus, and thyroid) which were identified for optimization. Mean doses to the thyroid, eyes, and esophagus were 0.2%, 69% and 0.2%, respectively, of the prescribed dose. In four organs not specifically identified for optimization (i.e., lungs, liver, kidneys, and heart) we found that organs lateral to the treatment field (lungs and kidneys) received relatively low mean doses (less than 8% of the prescribed dose), whereas the heart and liver, organs distal to the treatment field, received less than 1% of the prescribed dose. This study described and evaluated

  10. Solid Mesh Registration for Radiotherapy Treatment Planning

    DEFF Research Database (Denmark)

    Noe, Karsten Østergaard; Sørensen, Thomas Sangild

    2010-01-01

    We present an algorithm for solid organ registration of pre-segmented data represented as tetrahedral meshes. Registration of the organ surface is driven by force terms based on a distance field representation of the source and reference shapes. Registration of internal morphology is achieved using...... a non-linear elastic finite element model. A key feature of the method is that the user does not need to specify boundary conditions (surface point correspondences) prior to the finite element analysis. Instead the boundary matches are found as an integrated part of the analysis. The method is...... seconds to complete. The proposed method has many potential uses in image guided radiotherapy (IGRT) which relies on registration to account for organ deformation between treatment sessions....

  11. Evaluation of IMRT plans of prostate carcinoma from four treatment planning systems based on Monte Carlo

    International Nuclear Information System (INIS)

    Objective: With the Monte Carlo method to recalculate the IMRT dose distributions from four TPS to provide a platform for independent comparison and evaluation of the plan quality.These results will help make a clinical decision as which TPS will be used for prostate IMRT planning. Methods: Eleven prostate cancer cases were planned with the Corvus, Xio, Pinnacle and Eclipse TPS. The plans were recalculated by Monte Carlo using leaf sequences and MUs for individual plans. Dose-volume-histograms and isodose distributions were compared. Other quantities such as Dmin (the minimum dose received by 99% of CTV/PTV), Dmax (the maximum dose received by 1% of CTV/PTV), V110%, V105%, V95% (the volume of CTV/PTV receiving 110%, 105%, 95% of the prescription dose), the volume of rectum and bladder receiving >65 Gy and >40 Gy, and the volume of femur receiving >50 Gy were evaluated. Total segments and MUs were also compared. Results: The Monte Carlo results agreed with the dose distributions from the TPS to within 3%/3 mm. The Xio, Pinnacle and Eclipse plans show less target dose heterogeneity and lower V65 and V40 for the rectum and bladder compared to the Corvus plans. The PTV Dmin is about 2 Gy lower for Xio plans than others while the Corvus plans have slightly lower female head V50 (0.03% and 0.58%) than others. The Corvus plans require significantly most segments (187.8) and MUs (1264.7) to deliver and the Pinnacle plans require fewest segments (82.4) and MUs (703.6). Conclusions: We have tested an independent Monte Carlo dose calculation system for dose reconstruction and plan evaluation. This system provides a platform for the fair comparison and evaluation of treatment plans to facilitate clinical decision making in selecting a TPS and beam delivery system for particular treatment sites. (authors)

  12. Computerized treatment planning systems for external photon beam radiotherapy

    International Nuclear Information System (INIS)

    Computerized treatment planning systems (TPSs) are used in external beam radiotherapy to generate beam shapes and dose distributions with the intent to maximize tumour control and minimize normal tissue complications. Patient anatomy and tumour targets can be represented as 3-D models. The entire process of treatment planning involves many steps and the medical physicist is responsible for the overall integrity of the computerized TPS to accurately and reliably produce dose distributions and associated calculations for external beam radiotherapy. The planning itself is most commonly carried out by a dosimetrist, and the plan must be approved by a radiation oncologist before implementation in actual patient treatments. Treatment planning prior to the 1970s was generally carried out through the manual manipulation of standard isodose charts on to patient body contours that were generated by direct tracing or lead wire representation, and relied heavily on the judicious choice of beam weight and wedging by an experienced dosimetrist. The simultaneous development of computed tomography (CT), along with the advent of readily accessible computing power from the 1970s on, led to the development of CT based computerized treatment planning, providing the ability to view dose distributions directly superimposed upon a patient's axial anatomy. The entire treatment planning process involves many steps, beginning from beam data acquisition and entry into the computerized TPS, through patient data acquisition, to treatment plan generation and the final transfer of data to the treatment machine. Successive improvements in treatment planning hardware and software have been most notable in the graphics, calculation and optimization aspects of current systems. Systems encompassing the 'Virtual Patient' are able to display beam's eye views (BEVs) of radiation beams and digitally reconstructed radiographs (DRRs) for arbitrary dose distributions. Dose calculations have evolved from

  13. Knowledge-based radiation therapy (KBRT) treatment planning versus planning by experts: validation of a KBRT algorithm for prostate cancer treatment planning

    International Nuclear Information System (INIS)

    A knowledge-based radiation therapy (KBRT) treatment planning algorithm was recently developed. The purpose of this work is to investigate how plans that are generated with the objective KBRT approach compare to those that rely on the judgment of the experienced planner. Thirty volumetric modulated arc therapy plans were randomly selected from a database of prostate plans that were generated by experienced planners (expert plans). The anatomical data (CT scan and delineation of organs) of these patients and the KBRT algorithm were given to a novice with no prior treatment planning experience. The inexperienced planner used the knowledge-based algorithm to predict the dose that the OARs receive based on their proximity to the treated volume. The population-based OAR constraints were changed to the predicted doses. A KBRT plan was subsequently generated. The KBRT and expert plans were compared for the achieved target coverage and OAR sparing. The target coverages were compared using the Uniformity Index (UI), while 5 dose-volume points (D10, D30, D50, D70 and D90) were used to compare the OARs (bladder and rectum) doses. Wilcoxon matched-pairs signed rank test was used to check for significant differences (p < 0.05) between both datasets. The KBRT and expert plans achieved mean UI values of 1.10 ± 0.03 and 1.10 ± 0.04, respectively. The Wilcoxon test showed no statistically significant difference between both results. The D90, D70, D50, D30 and D10 values of the two planning strategies, and the Wilcoxon test results suggests that the KBRT plans achieved a statistically significant lower bladder dose (at D30), while the expert plans achieved a statistically significant lower rectal dose (at D10 and D30). The results of this study show that the KBRT treatment planning approach is a promising method to objectively incorporate patient anatomical variations in radiotherapy treatment planning

  14. High neutronic efficiency, low current targets for accelerator-based BNCT applications

    International Nuclear Information System (INIS)

    The neutronic efficiency of target/filters for accelerator-based BNCT applications is measured by the proton current required to achieve a desirable neutron current at the treatment port (109 n/cm2/s). In this paper the authors describe two possible targeyt/filter concepts wihch minimize the required current. Both concepts are based on the Li-7 (p,n)Be-7 reaction. Targets that operate near the threshold energy generate neutrons that are close tothe desired energy for BNCT treatment. Thus, the filter can be extremely thin (∼ 5 cm iron). However, this approach has an extremely low neutron yield (n/p ∼ 1.0(-6)), thus requiring a high proton current. The proposed solutino is to design a target consisting of multiple extremely thin targets (proton energy loss per target ∼ 10 keV), and re-accelerate the protons between each target. Targets operating at ihgher proton energies (∼ 2.5 MeV) have a much higher yield (n/p ∼ 1.0(-4)). However, at these energies the maximum neutron energy is approximately 800 keV, and thus a neutron filter is required to degrade the average neutron energy to the range of interest for BNCT (10--20 keV). A neutron filter consisting of fluorine compounds and iron has been investigated for this case. Typically a proton current of approximately 5 mA is required to generate the desired neutron current at the treatment port. The efficiency of these filter designs can be further increased by incorporating neutron reflectors that are co-axial with the neutron source. These reflectors are made of materials which have high scattering cross sections in the range 0.1--1.0 MeV

  15. Bioneutronics: Thermal scattering in organics tissues and its impact on BNCT dosimetry

    International Nuclear Information System (INIS)

    Neutron transport calculation is a key factor in BNCT numerical dosimetry assessments where thermal neutron flux is intimately related to the neutron dose, specially, the therapeutic boron dose. In this work, numerical calculations in phantoms were performed to determine the importance of utilizing the appropriate thermal scattering treatment for different organic tissues. Two thermal treatments for the neutron scattering were included in the simulations: hydrogen bounded in bulk water and hydrogen bounded in a lipid like carbon chain (polyethylene). The results showed difference between both thermal treatments that can reach several percent points depending on the type of source and irradiated geometry. - Highlights: • The impact of the thermal scattering data in BNCT dosimetry calculations was studied. • Thermal treatment for H in bulk water and H in a carbon chain was considered. • Calculations of thermal neutron flux and dose profiles in phantoms were performed. • The results show differences between both thermal treatments. • The importance of utilizing the correct thermal data for tissues was determined

  16. Feasibility of BNCT radiobiological experiments at the HYTHOR facility

    Science.gov (United States)

    Esposito, J.; Ceballos, C.; Soncin, M.; Fabris, C.; Friso, E.; Moro, D.; Colautti, P.; Jori, G.; Rosi, G.; Nava, E.

    2008-06-01

    HYTHOR (HYbrid Thermal spectrum sHifter tapirO Reactor) is a new thermal-neutron irradiation facility, which was installed and became operative in mid 2005 at the TAPIRO (TAratura PIla Rapida potenza 0) fast reactor, in the Casaccia research centre (near Rome) of ENEA (Ente per le Nuove tecnologie Energia ed Ambiente). The facility has been designed for in vivo radiobiological studies. In HYTHOR irradiation cavity, 1-6 mice can be simultaneously irradiated to study skin melanoma treatments with the BNCT (boron neutron capture therapy). The therapeutic effects of HYTHOR radiation field on mouse melanoma has been studied as a preliminary investigation before studying the tumour local control due to boron neutron capture effect after boronated molecule injection. The method to properly irradiate small animals has been precisely defined. Results show that HYTHOR radiation field is by itself effective in reducing the tumour-growth rate. This finding has to be taken into account in studying the effectiveness of new 10B carriers. A method to properly measure the reduction of the tumour-growth rate is reported and discussed.

  17. Orthognathic Surgery: Planning and treatment with illustration on six cases

    International Nuclear Information System (INIS)

    Almost all conferences for plastic and maxillofacial surgery discuss reports on several methods of orthognathic surgery, planning, success results, and complications of the different procedures carried out to correct patient's soft and hard tissues frontal profiles and occlusal discrepancies. Various principles are involved in the diagnosis and treatment of facial deformities. However, the most important consideration, after all, is the final accepted aesthetic and functional requirements and stability of the moved segments. The objective of this paper is to give the basic principles of treatment planning for correcting facial discrepancies, surgical approach to different cases, and the methods to increase stability of the moved segments. Six cases are included to illustrate the different aspects of treatment planning, surgical management, and stabilization methods. (author)

  18. Collimator and shielding design for boron neutron capture therapy (BNCT) facility at TRIGA MARK II reactor

    International Nuclear Information System (INIS)

    The geometry of reactor core, thermal column, collimator and shielding system for BNCT application of TRIGA MARK II Reactor were simulated with MCNP5 code. Neutron particle lethargy and dose were calculated with MCNPX code. Neutron flux in a sample located at the end of collimator after normalized to measured value (Eid Mahmoud Eid Abdel Munem, 2007) at 1 MW power was 1.06 x 108 n/ cm2/ s. According to IAEA (2001) flux of 1.00 x 109 n/ cm2/ s requires three hours of treatment. Few modifications were needed to get higher flux. (Author)

  19. Determination of the irradiation field at the research reactor TRIGA Mainz for BNCT.

    Science.gov (United States)

    Nagels, S; Hampel, G; Kratz, J V; Aguilar, A L; Minouchehr, S; Otto, G; Schmidberger, H; Schütz, C; Vogtländer, L; Wortmann, B

    2009-07-01

    For the application of the BNCT for the excorporal treatment of organs at the TRIGA Mainz, the basic characteristics of the radiation field in the thermal column as beam geometry, neutron and gamma ray energies, angular distributions, neutron flux, as well as absorbed gamma and neutron doses must be determined in a reproducible way. To determine the mixed irradiation field thermoluminescence detectors (TLD) made of CaF(2):Tm with a newly developed energy-compensation filter system and LiF:Mg,Ti materials with different (6)Li concentrations and different thicknesses as well as thin gold foils were used. PMID:19380234

  20. IMRT treatment plans and functional planning with functional lung imaging from 4D-CT for thoracic cancer patients

    OpenAIRE

    Huang Tzung-Chi; Hsiao Chien-Yi; Chien Chun-Ru; Liang Ji-An; Shih Tzu-Ching; Zhang Geoffrey G

    2013-01-01

    Abstract Background and purpose Currently, the inhomogeneity of the pulmonary function is not considered when treatment plans are generated in thoracic cancer radiotherapy. This study evaluates the dose of treatment plans on highly-functional volumes and performs functional treatment planning by incorporation of ventilation data from 4D-CT. Materials and methods Eleven patients were included in this retrospective study. Ventilation was calculated using 4D-CT. Two treatment plans were generate...

  1. Neuro-Dynamic Programming for Radiation Treatment Planning

    OpenAIRE

    Ferris, Michael C.; Voelker, Meta M.

    2002-01-01

    In many cases a radiotherapy treatment is delivered as a series of smaller dosages over a period of time. Currently, it is difficult to determine the actual dose that has been delivered at each stage, precluding the use of adaptive treatment plans. However, new generations of machines will give more accurate information of actual dose delivered, allowing a planner to compensate for errors in delivery. We formulate a model of the day-to-day planning problem as a stochastic linear program and e...

  2. SU-D-BRD-03: Improving Plan Quality with Automation of Treatment Plan Checks

    International Nuclear Information System (INIS)

    Purpose: To evaluate the effectiveness of an automated plan check tool to improve first-time plan quality as well as standardize and document performance of physics plan checks. Methods: The Plan Checker Tool (PCT) uses the Eclipse Scripting API to check and compare data from the treatment planning system (TPS) and treatment management system (TMS). PCT was created to improve first-time plan quality, reduce patient delays, increase efficiency of our electronic workflow, and to standardize and partially automate plan checks in the TPS. A framework was developed which can be configured with different reference values and types of checks. One example is the prescribed dose check where PCT flags the user when the planned dose and the prescribed dose disagree. PCT includes a comprehensive checklist of automated and manual checks that are documented when performed by the user. A PDF report is created and automatically uploaded into the TMS. Prior to and during PCT development, errors caught during plan checks and also patient delays were tracked in order to prioritize which checks should be automated. The most common and significant errors were determined. Results: Nineteen of 33 checklist items were automated with data extracted with the PCT. These include checks for prescription, reference point and machine scheduling errors which are three of the top six causes of patient delays related to physics and dosimetry. Since the clinical roll-out, no delays have been due to errors that are automatically flagged by the PCT. Development continues to automate the remaining checks. Conclusion: With PCT, 57% of the physics plan checklist has been partially or fully automated. Treatment delays have declined since release of the PCT for clinical use. By tracking delays and errors, we have been able to measure the effectiveness of automating checks and are using this information to prioritize future development. This project was supported in part by P01CA059827

  3. SU-D-BRD-03: Improving Plan Quality with Automation of Treatment Plan Checks

    Energy Technology Data Exchange (ETDEWEB)

    Covington, E; Younge, K; Chen, X; Lee, C; Matuszak, M; Kessler, M; Acosta, E; Orow, A; Filpansick, S; Moran, J [University of Michigan Hospital and Health System, Ann Arbor, MI (United States); Keranen, W [Varian Medical Systems, Palo Alto, CA (United States)

    2015-06-15

    Purpose: To evaluate the effectiveness of an automated plan check tool to improve first-time plan quality as well as standardize and document performance of physics plan checks. Methods: The Plan Checker Tool (PCT) uses the Eclipse Scripting API to check and compare data from the treatment planning system (TPS) and treatment management system (TMS). PCT was created to improve first-time plan quality, reduce patient delays, increase efficiency of our electronic workflow, and to standardize and partially automate plan checks in the TPS. A framework was developed which can be configured with different reference values and types of checks. One example is the prescribed dose check where PCT flags the user when the planned dose and the prescribed dose disagree. PCT includes a comprehensive checklist of automated and manual checks that are documented when performed by the user. A PDF report is created and automatically uploaded into the TMS. Prior to and during PCT development, errors caught during plan checks and also patient delays were tracked in order to prioritize which checks should be automated. The most common and significant errors were determined. Results: Nineteen of 33 checklist items were automated with data extracted with the PCT. These include checks for prescription, reference point and machine scheduling errors which are three of the top six causes of patient delays related to physics and dosimetry. Since the clinical roll-out, no delays have been due to errors that are automatically flagged by the PCT. Development continues to automate the remaining checks. Conclusion: With PCT, 57% of the physics plan checklist has been partially or fully automated. Treatment delays have declined since release of the PCT for clinical use. By tracking delays and errors, we have been able to measure the effectiveness of automating checks and are using this information to prioritize future development. This project was supported in part by P01CA059827.

  4. Current calibration, treatment, and treatment planning techniques among institutions participating in the Children's Oncology Group

    International Nuclear Information System (INIS)

    Purpose: To report current technology implementation, radiation therapy physics and treatment planning practices, and results of treatment planning exercises among 261 institutions belonging to the Children's Oncology Group (COG). Methods and Materials: The Radiation Therapy Committee of the newly formed COG mandated that each institution demonstrate basic physics and treatment planning abilities by satisfactorily completing a questionnaire and four treatment planning exercises designed by the Quality Assurance Review Center. The planning cases are (1) a maxillary sinus target volume (for two-dimensional planning), (2) a Hodgkin's disease mantle field (for irregular-field and off-axis dose calculations), (3) a central axis blocked case, and (4) a craniospinal irradiation case. The questionnaire and treatment plans were submitted (as of 1/30/02) by 243 institutions and completed satisfactorily by 233. Data from this questionnaire and analyses of the treatment plans with monitor unit calculations are presented. Results: Of the 243 clinics responding, 54% use multileaf collimators routinely, 94% use asymmetric jaws routinely, and 13% use dynamic wedges. Nearly all institutions calibrate their linear accelerators following American Association of Physicists in Medicine protocols, currently 16% with TG-51 and 81% with TG-21 protocol. Treatment planning systems are relied on very heavily for all calculations, including monitor units. Techniques and results of each of the treatment planning exercises are presented. Conclusions: Together, these data provide a unique compilation of current (2001) radiation therapy practices in institutions treating pediatric patients. Overall, the COG facilities have the equipment and the personnel to perform high-quality radiation therapy. With ongoing quality assurance review, radiation therapy compliance with COG protocols should be high

  5. Draft Site Treatment Plan (DSTP), Volumes I and II

    International Nuclear Information System (INIS)

    Site Treatment Plans (STP) are required for facilities at which the DOE generates or stores mixed waste. This Draft Site Treatment Plan (DSTP) the second step in a three-phase process, identifies the currently preferred options for treating mixed waste at the Savannah River Site (SRS) or for developing treatment technologies where technologies do not exist or need modification. The DSTP reflects site-specific preferred options, developed with the state's input and based on existing available information. To the extent possible, the DSTP identifies specific treatment facilities for treating the mixed waste and proposes schedules. Where the selection of specific treatment facilities is not possible, schedules for alternative activities such as waste characterization and technology assessment are provided. All schedule and cost information presented is preliminary and is subject to change. The DSTP is comprised of two volumes: this Compliance Plan Volume and the Background Volume. This Compliance Plan Volume proposes overall schedules with target dates for achieving compliance with the land disposal restrictions (LDR) of RCRA and procedures for converting the target dates into milestones to be enforced under the Order. The more detailed discussion of the options contained in the Background Volume is provided for informational purposes only

  6. Draft Site Treatment Plan (DSTP), Volumes I and II

    Energy Technology Data Exchange (ETDEWEB)

    D`Amelio, J.

    1994-08-30

    Site Treatment Plans (STP) are required for facilities at which the DOE generates or stores mixed waste. This Draft Site Treatment Plan (DSTP) the second step in a three-phase process, identifies the currently preferred options for treating mixed waste at the Savannah River Site (SRS) or for developing treatment technologies where technologies do not exist or need modification. The DSTP reflects site-specific preferred options, developed with the state`s input and based on existing available information. To the extent possible, the DSTP identifies specific treatment facilities for treating the mixed waste and proposes schedules. Where the selection of specific treatment facilities is not possible, schedules for alternative activities such as waste characterization and technology assessment are provided. All schedule and cost information presented is preliminary and is subject to change. The DSTP is comprised of two volumes: this Compliance Plan Volume and the Background Volume. This Compliance Plan Volume proposes overall schedules with target dates for achieving compliance with the land disposal restrictions (LDR) of RCRA and procedures for converting the target dates into milestones to be enforced under the Order. The more detailed discussion of the options contained in the Background Volume is provided for informational purposes only.

  7. Physical and biological dosimetry at the RA-3 facility for small animal irradiation: preliminary BNCT studies in an experimental model of oral cancer

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality based on the capture reaction that occurs between thermal neutrons and boron-10 atoms that accumulate selectively in tumor tissue, emitting high linear energy transfer (LET), short range (5-9 microns) particles (alpha y 7Li). Thus, BNCT would potentially target tumor tissue selectively, sparing normal tissue. Herein we evaluated the feasibility of treating experimental oral mucosa tumors with BNCT at RA-3 (CAE) employing the hamster cheek pouch oral cancer model and characterized the irradiation field at the RA-3 facility. We evaluated the therapeutic effect on tumor of BNCT mediated by BPA in the hamster cheek pouch oral cancer model and the potential radio toxic effects in normal tissue. We evidenced a moderate biological response in tumor, with no radio toxic effects in normal tissue following irradiations with no shielding for the animal body. Given the sub-optimal therapeutic response, we designed and built a 6Li2CO3 shielding for the body of the animal to increase the irradiation dose to tumor, without exceeding normal tissue radio tolerance. The measured absolute magnitude of thermal neutron flux and the characterization of the beam with and without the shielding in place, suggest that the irradiation facility in the thermal column of RA-3 would afford an excellent platform to perform BNCT studies in vitro and in vivo in small experimental animals. The present findings must be confirmed and extended by performing in vivo BNCT radiobiological studies in small experimental animals, employing the shielding device for the animal body. (author)

  8. Dosimetric analysis of BNCT - Boron Neutron Capture Therapy - coupled to 252Cf brachytherapy

    International Nuclear Information System (INIS)

    The incidence of brain tumors is increasing in world population; however, the treatments employed in this type of tumor have a high rate of failure and in some cases have been considered palliative, depending on histology and staging of tumor. Its necessary to achieve the control tumor dose without the spread irradiation cause damage in the brain, affecting patient neurological function. Stereotactic radiosurgery is a technique that achieves this; nevertheless, other techniques that can be used on the brain tumor control must be developed, in order to guarantee lower dose on health surroundings tissues other techniques must be developing. The 252Cf brachytherapy applied to brain tumors has already been suggested, showing promising results in comparison to photon source, since the active source is placed into the tumor, providing greater dose deposition, while more distant regions are spared. BNCT - Boron Neutron Capture Therapy - is another technique that is in developing to brain tumors control, showing theoretical superiority on the rules of conventional treatments, due to a selective irradiation of neoplasics cells, after the patient receives a borate compound infusion and be subjected to a epithermal neutrons beam. This work presents dosimetric studies of the coupling techniques: BNCT with 252Cf brachytherapy, conducted through computer simulation in MCNP5 code, using a precise and well discretized voxel model of human head, which was incorporated a representative Glioblastoma Multiform tumor. The dosimetric results from MCNP5 code were exported to SISCODES program, which generated isodose curves representing absorbed dose rate in the brain. Isodose curves, neutron fluency, and dose components from BNCT and 252Cf brachytherapy are presented in this paper. (author)

  9. IMRT treatment plans and functional planning with functional lung imaging from 4D-CT for thoracic cancer patients

    Directory of Open Access Journals (Sweden)

    Huang Tzung-Chi

    2013-01-01

    Full Text Available Abstract Background and purpose Currently, the inhomogeneity of the pulmonary function is not considered when treatment plans are generated in thoracic cancer radiotherapy. This study evaluates the dose of treatment plans on highly-functional volumes and performs functional treatment planning by incorporation of ventilation data from 4D-CT. Materials and methods Eleven patients were included in this retrospective study. Ventilation was calculated using 4D-CT. Two treatment plans were generated for each case, the first one without the incorporation of the ventilation and the second with it. The dose of the first plans was overlapped with the ventilation and analyzed. Highly-functional regions were avoided in the second treatment plans. Results For small targets in the first plans (PTV  Conclusion Radiation treatments affect functional lung more seriously in large tumor cases. With compromise of dose to other critical organs, functional treatment planning to reduce dose in highly-functional lung volumes can be achieved

  10. TRU Management in the Site Treatment Plan at the INEEL

    International Nuclear Information System (INIS)

    The storage of any form of hazardous waste is prohibited unless the waste has available treatment to meet land disposal restriction (LDR) requirements in accordance with 40 CFR 268 of the Resource Conservation and Recovery Act (RCRA). In 1992, Congress passed the Federal Facility Compliance Act (FFCA), which allows for the storage of radioactive and hazardous mixed waste (mixed waste) until available treatment can be developed that meets the LDR requirements. Transuranic-contaminated mixed (TRU) waste is covered under the FFCA through the Site Treatment Plan (STP) since the implementation of the plan in November, 1995. The Idaho National Engineering and Environmental Laboratory (INEEL) STP required schedules and milestones for the treatment and shipment of TRU waste to the Waste Isolation Pilot Plant (WIPP). Potential enforcement actions for missing compliance milestones exist in the INEEL STP

  11. Uncertainty incorporated beam angle optimization for IMPT treatment planning

    OpenAIRE

    Cao, Wenhua; Gino J. Lim; Lee, Andrew; Li, Yupeng; Liu, Wei; Ronald Zhu, X.; Zhang, Xiaodong

    2012-01-01

    Purpose: Beam angle optimization (BAO) by far remains an important and challenging problem in external beam radiation therapy treatment planning. Conventional BAO algorithms discussed in previous studies all focused on photon-based therapies. Impact of BAO on proton therapy is important while proton therapy increasingly receives great interests. This study focuses on potential benefits of BAO on intensity-modulated proton therapy (IMPT) that recently began available to clinical cancer treatment.

  12. Novel tools for stepping source brachytherapy treatment planning: Enhanced geometrical optimization and interactive inverse planning

    Energy Technology Data Exchange (ETDEWEB)

    Dinkla, Anna M., E-mail: a.m.dinkla@amc.uva.nl; Laarse, Rob van der; Koedooder, Kees; Petra Kok, H.; Wieringen, Niek van; Pieters, Bradley R.; Bel, Arjan [Department of Radiation Oncology, Academic Medical Center Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ (Netherlands)

    2015-01-15

    Purpose: Dose optimization for stepping source brachytherapy can nowadays be performed using automated inverse algorithms. Although much quicker than graphical optimization, an experienced treatment planner is required for both methods. With automated inverse algorithms, the procedure to achieve the desired dose distribution is often based on trial-and-error. Methods: A new approach for stepping source prostate brachytherapy treatment planning was developed as a quick and user-friendly alternative. This approach consists of the combined use of two novel tools: Enhanced geometrical optimization (EGO) and interactive inverse planning (IIP). EGO is an extended version of the common geometrical optimization method and is applied to create a dose distribution as homogeneous as possible. With the second tool, IIP, this dose distribution is tailored to a specific patient anatomy by interactively changing the highest and lowest dose on the contours. Results: The combined use of EGO–IIP was evaluated on 24 prostate cancer patients, by having an inexperienced user create treatment plans, compliant to clinical dose objectives. This user was able to create dose plans of 24 patients in an average time of 4.4 min/patient. An experienced treatment planner without extensive training in EGO–IIP also created 24 plans. The resulting dose-volume histogram parameters were comparable to the clinical plans and showed high conformance to clinical standards. Conclusions: Even for an inexperienced user, treatment planning with EGO–IIP for stepping source prostate brachytherapy is feasible as an alternative to current optimization algorithms, offering speed, simplicity for the user, and local control of the dose levels.

  13. Novel tools for stepping source brachytherapy treatment planning: Enhanced geometrical optimization and interactive inverse planning

    International Nuclear Information System (INIS)

    Purpose: Dose optimization for stepping source brachytherapy can nowadays be performed using automated inverse algorithms. Although much quicker than graphical optimization, an experienced treatment planner is required for both methods. With automated inverse algorithms, the procedure to achieve the desired dose distribution is often based on trial-and-error. Methods: A new approach for stepping source prostate brachytherapy treatment planning was developed as a quick and user-friendly alternative. This approach consists of the combined use of two novel tools: Enhanced geometrical optimization (EGO) and interactive inverse planning (IIP). EGO is an extended version of the common geometrical optimization method and is applied to create a dose distribution as homogeneous as possible. With the second tool, IIP, this dose distribution is tailored to a specific patient anatomy by interactively changing the highest and lowest dose on the contours. Results: The combined use of EGO–IIP was evaluated on 24 prostate cancer patients, by having an inexperienced user create treatment plans, compliant to clinical dose objectives. This user was able to create dose plans of 24 patients in an average time of 4.4 min/patient. An experienced treatment planner without extensive training in EGO–IIP also created 24 plans. The resulting dose-volume histogram parameters were comparable to the clinical plans and showed high conformance to clinical standards. Conclusions: Even for an inexperienced user, treatment planning with EGO–IIP for stepping source prostate brachytherapy is feasible as an alternative to current optimization algorithms, offering speed, simplicity for the user, and local control of the dose levels

  14. A virtual model of the patient's head for BNCT

    International Nuclear Information System (INIS)

    The aim of the present work was creating a virtual phantom of a human head for BNCT, as a part of the BNCT programme project. This model is an amplification of the simple model described in earlier publications. It takes into account the major head organs as well as the scalp and skull. The chemical composition of all tissues was modelled according to the recommendations of the ICRP. The organs were parameterized using mathematical formulas based on the human head magnetic resonance images. The model was used for calculating the thermal neutron flux and the injuring (fast neutron, nitrogen and gamma) dose components for the head irradiated using the therapeutic neutron beam, whose parameters were obtained as the result of the modelling of the filter/moderator system for the BNCT therapeutic beam from the MARIA reactor. (authors)

  15. Protocols for BNCT of glioblastoma multiforme at Brookhaven: Practical considerations

    Energy Technology Data Exchange (ETDEWEB)

    Chanana, A.D.; Coderre, J.A.; Joel, D.D.; Slatkin, D.N.

    1996-12-31

    In this report we discuss some issues considered in selecting initial protocols for boron neutron capture therapy (BNCT) of human glioblastoma multiforme. First the tolerance of normal tissues, especially the brain, to the radiation field. Radiation doses limits were based on results with human and animal exposures. Estimates of tumor control doses were based on the results of single-fraction photon therapy and single fraction BNCT both in humans and experimental animals. Of the two boron compounds (BSH and BPA), BPA was chosen since a FDA-sanctioned protocol for distribution in humans was in effect at the time the first BNCT protocols were written and therapy studies in experimental animals had shown it to be more effective than BSH.

  16. Proceedings of neutron irradiation technical meeting on BNCT

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2000-10-01

    The 'Neutron Irradiation Technical Meeting for Boron Neutron Capture Therapy (BNCT)' was held on March 13, 2000 at Tokai Research Establishment. The Meeting is aimed to introduce the neutron beam facility for medical irradiation at JRR-4 to Japanese researchers widely, as well as providing an opportunity for young researchers, engineers, medical representatives such surgeons and doctors of pharmacology to present their research activities and to exchange valuable information. JAERI researcher presented the performance and the irradiation technology in the JRR-4 neutron beam facility, while external researchers made various and beneficial presentations containing such accelerator-based BNCT, spectrum-shifter, biological effect, pharmacological development and so on. In this meeting, a special lecture titled 'The Dawn of BNCT and Its Development.' was given by MD, Prof. Takashi Minobe, an executive director of Japan Foundation for Emergency Medicine. The 11 of the presented papers are indexed individually. (J.P.N.)

  17. [Treatment of removable partial dentures. 1. Legislation, rules of conduct, care plan and treatment plan

    NARCIS (Netherlands)

    Witter, D.J.; Brands, W.G.; Barl, J.C.; Creugers, N.H.J.

    2011-01-01

    An invasive treatment, such as the treatment involving a removable partial denture, requires a well-structured approach. Regulations governing the communication between a healthcare professional and a patient in the Netherlands can be found in the Dutch Medical Treatment Act and the Rules of Conduct

  18. [Endodontically treated teeth. Success--failure. Endorestorative treatment plan].

    Science.gov (United States)

    Zabalegui, B

    1990-01-01

    More and more often the general dentist is finding the presence of endodontically treated teeth during his treatment planning procedure. He has to ask himself if the endo-treated tooth functions and will continue to function function successfully, when deciding which final endo-restorative procedure to apply. For this reason the dentist or the endodontist with whom he works should clinically evaluate these teeth, establish a diagnostic criteria of their success or failure and a treatment plan according to the prognosis. The purpose of this article is to offer an organized clinical view of the steps to follow when evaluating an endodontically treated tooth and how to establish a final endo-restorative plan. PMID:2168732

  19. Development and validation of a treatment planning system for small animal radiotherapy: SmART-Plan

    International Nuclear Information System (INIS)

    Background and purpose: Image-guided equipment for precision irradiation of small animals for pre-clinical radiotherapy research became recently available. To enable downscaled radiotherapy studies that can be translated into human radiotherapy knowledge, a treatment planning system for pre-clinical studies is required. Material and methods: A dedicated treatment planning system (SmART-Plan) for small animal radiotherapy studies was developed. It is based on Monte Carlo simulation of particle transport in an animal. The voxel geometry is derived from the onboard cone beam CT imaging panel. SmART-Plan was validated using radiochromic film (RCF) dosimetry in various phantoms: uniform, multislab and a realistic plasticized mouse geometry. Results: Good agreement was obtained between SmART-Plan dose calculations and RCF dose measurements in all phantoms. For various delivered plans agreement was obtained within 10% for the majority of the targeted dose region, with larger differences between 10% and 20% near the penumbra regions and for the smallest 1 mm collimator. Absolute depth and lateral dose distributions showed better agreement for 5 and 15-mm collimators than for a 1-mm collimator, indicating that accurate dose prediction for the smallest field sizes is difficult. Conclusion: SmART-Plan offers a useful dose calculation tool for pre-clinical small animal irradiation studies

  20. Including the Consumer and Environment in Occupational Therapy Treatment Planning.

    Science.gov (United States)

    Brown, Catana; Bowen, Robin E.

    1998-01-01

    Occupational therapists (n=29) completed treatment plans based on case study data. Analysis indicated they often identified goals not addressed by the consumer/client. They significantly selected more simulated than real activities and more activities designed to change the person rather than the environment. (SK)

  1. Savannah River Site approved site treatment plan, 2000 annual update

    International Nuclear Information System (INIS)

    The Compliance Plan Volume (Volume 1) identifies project activity schedule milestones for achieving compliance with Land Disposal Restrictions. Information regarding the technical evaluation of treatment options for SRS mixed wastes is contained in the Background Volume (Volume 2) and is provided for information

  2. The effect of dose calculation accuracy on inverse treatment planning

    Science.gov (United States)

    Jeraj, Robert; Keall, Paul J.; Siebers, Jeffrey V.

    2002-02-01

    The effect of dose calculation accuracy during inverse treatment planning for intensity modulated radiotherapy (IMRT) was studied in this work. Three dose calculation methods were compared: Monte Carlo, superposition and pencil beam. These algorithms were used to calculate beamlets, which were subsequently used by a simulated annealing algorithm to determine beamlet weights which comprised the optimal solution to the objective function. Three different cases (lung, prostate and head and neck) were investigated and several different objective functions were tested for their effect on inverse treatment planning. It is shown that the use of inaccurate dose calculation introduces two errors in a treatment plan, a systematic error and a convergence error. The systematic error is present because of the inaccuracy of the dose calculation algorithm. The convergence error appears because the optimal intensity distribution for inaccurate beamlets differs from the optimal solution for the accurate beamlets. While the systematic error for superposition was found to be ~1% of Dmax in the tumour and slightly larger outside, the error for the pencil beam method is typically ~5% of Dmax and is rather insensitive to the given objectives. On the other hand, the convergence error was found to be very sensitive to the objective function, is only slightly correlated to the systematic error and should be determined for each case individually. Our results suggest that because of the large systematic and convergence errors, inverse treatment planning systems based on pencil beam algorithms alone should be upgraded either to superposition or Monte Carlo based dose calculations.

  3. Savannah River Site Approved Site Treatment Plan, 1998 Annual Update

    International Nuclear Information System (INIS)

    The Compliance Plan Volume (Volume I) identifies project activity schedule milestones for achieving compliance with Land Disposal Restrictions. Information regarding the technical evaluation of treatment options for SRS mixed wastes is contained in the Background Volume (Volume II) and is provided for information

  4. Savannah River Site approved site treatment plan, 2000 annual update

    Energy Technology Data Exchange (ETDEWEB)

    Lawrence, B.

    2000-04-20

    The Compliance Plan Volume (Volume 1) identifies project activity schedule milestones for achieving compliance with Land Disposal Restrictions. Information regarding the technical evaluation of treatment options for SRS mixed wastes is contained in the Background Volume (Volume 2) and is provided for information.

  5. Savannah River Site Approved Site Treatment Plan, 1998 Annual Update

    Energy Technology Data Exchange (ETDEWEB)

    Lawrence, B.

    1999-04-20

    The Compliance Plan Volume (Volume I) identifies project activity schedule milestones for achieving compliance with Land Disposal Restrictions. Information regarding the technical evaluation of treatment options for SRS mixed wastes is contained in the Background Volume (Volume II) and is provided for information.

  6. WE-A-BRD-01: Innovation in Radiation Therapy Planning I: Knowledge Guided Treatment Planning

    International Nuclear Information System (INIS)

    Intensity modulated radiation therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) offer the capability of normal tissues and organs sparing. However, the exact amount of sparing is often unknown until the plan is complete. This lack of prior guidance has led to the iterative, trial and-error approach in current planning practice. Even with this effort the search for patient-specific optimal organ sparing is still strongly influenced by planner's experience. While experience generally helps in maximizing the dosimetric advantages of IMRT/VMAT, there have been several reports showing unnecessarily high degree of plan quality variability at individual institutions and amongst different institutions, even with a large amount of experience and the best available tools. Further, when physician and physicist evaluate a plan, the dosimetric quality of the plan is often compared with a standard protocol that ignores individual patient anatomy and tumor characteristic variations. In recent years, developments of knowledge models for clinical IMRT/VMAT planning guidance have shown promising clinical potentials. These knowledge models extract past expert clinical experience into mathematical models that predict dose sparing references at patient-specific level. For physicians and planners, these references provide objective values that reflect best achievable dosimetric constraints. For quality assurance, applying patient-specific dosimetry requirements will enable more quantitative and objective assessment of protocol compliance for complex IMRT planning. Learning Objectives: Modeling and representation of knowledge for knowledge-guided treatment planning. Demonstrations of knowledge-guided treatment planning with a few clinical caanatomical sites. Validation and evaluation of knowledge models for cost and quality effective standardization of plan optimization

  7. 3718-F Alkali Metal Treatment and Storage Facility Closure Plan

    Energy Technology Data Exchange (ETDEWEB)

    None

    1991-12-01

    Since 1987, Westinghouse Hanford Company has been a major contractor to the U.S. Department of Energy-Richland Operations Office and has served as co-operator of the 3718-F Alkali Metal Treatment and Storage Facility, the waste management unit addressed in this closure plan. The closure plan consists of a Part A Dangerous waste Permit Application and a RCRA Closure Plan. An explanation of the Part A Revision (Revision 1) submitted with this document is provided at the beginning of the Part A section. The closure plan consists of 9 chapters and 5 appendices. The chapters cover: introduction; facility description; process information; waste characteristics; groundwater; closure strategy and performance standards; closure activities; postclosure; and references.

  8. 3718-F Alkali Metal Treatment and Storage Facility Closure Plan

    International Nuclear Information System (INIS)

    Since 1987, Westinghouse Hanford Company has been a major contractor to the U.S. Department of Energy-Richland Operations Office and has served as co-operator of the 3718-F Alkali Metal Treatment and Storage Facility, the waste management unit addressed in this closure plan. The closure plan consists of a Part A Dangerous waste Permit Application and a RCRA Closure Plan. An explanation of the Part A Revision (Revision 1) submitted with this document is provided at the beginning of the Part A section. The closure plan consists of 9 chapters and 5 appendices. The chapters cover: introduction; facility description; process information; waste characteristics; groundwater; closure strategy and performance standards; closure activities; postclosure; and references

  9. Treatment planning aspects for tumours in the region of parotid

    International Nuclear Information System (INIS)

    The treatment of carcinoma of parotid/external ear needs careful planning in respect of dose to the normal organs surrounding the tumour such as eye(s), pituitary and normal brain. In many centres, generally, manual contours are generated for a two dimensional planning, wherein Anterior-Posterior (A-P) oblique fields (patient in Lateral Position) are planned. However, such a field orientation is not always useful in terms of minimum possible dose to the said normal organs, especially for eye. In this centre, a different field arrangement has been attempted, which helps in dose reduction to the normal structures to a large extent in comparison with the conventional 2D planning method

  10. Automatic treatment plan re-optimization for adaptive radiotherapy guided with the initial plan DVHs

    International Nuclear Information System (INIS)

    Adaptive radiation therapy (ART) can reduce normal tissue toxicity and/or improve tumor control through treatment adaptations based on the current patient anatomy. Developing an efficient and effective re-planning algorithm is an important step toward the clinical realization of ART. For the re-planning process, manual trial-and-error approach to fine-tune planning parameters is time-consuming and is usually considered unpractical, especially for online ART. It is desirable to automate this step to yield a plan of acceptable quality with minimal interventions. In ART, prior information in the original plan is available, such as dose–volume histogram (DVH), which can be employed to facilitate the automatic re-planning process. The goal of this work is to develop an automatic re-planning algorithm to generate a plan with similar, or possibly better, DVH curves compared with the clinically delivered original plan. Specifically, our algorithm iterates the following two loops. An inner loop is the traditional fluence map optimization, in which we optimize a quadratic objective function penalizing the deviation of the dose received by each voxel from its prescribed or threshold dose with a set of fixed voxel weighting factors. In outer loop, the voxel weighting factors in the objective function are adjusted according to the deviation of the current DVH curves from those in the original plan. The process is repeated until the DVH curves are acceptable or maximum iteration step is reached. The whole algorithm is implemented on GPU for high efficiency. The feasibility of our algorithm has been demonstrated with three head-and-neck cancer IMRT cases, each having an initial planning CT scan and another treatment CT scan acquired in the middle of treatment course. Compared with the DVH curves in the original plan, the DVH curves in the resulting plan using our algorithm with 30 iterations are better for almost all structures. The re-optimization process takes about 30

  11. Automatic treatment plan re-optimization for adaptive radiotherapy guided with the initial plan DVHs

    Science.gov (United States)

    Li, Nan; Zarepisheh, Masoud; Uribe-Sanchez, Andres; Moore, Kevin; Tian, Zhen; Zhen, Xin; Jiang Graves, Yan; Gautier, Quentin; Mell, Loren; Zhou, Linghong; Jia, Xun; Jiang, Steve

    2013-12-01

    Adaptive radiation therapy (ART) can reduce normal tissue toxicity and/or improve tumor control through treatment adaptations based on the current patient anatomy. Developing an efficient and effective re-planning algorithm is an important step toward the clinical realization of ART. For the re-planning process, manual trial-and-error approach to fine-tune planning parameters is time-consuming and is usually considered unpractical, especially for online ART. It is desirable to automate this step to yield a plan of acceptable quality with minimal interventions. In ART, prior information in the original plan is available, such as dose-volume histogram (DVH), which can be employed to facilitate the automatic re-planning process. The goal of this work is to develop an automatic re-planning algorithm to generate a plan with similar, or possibly better, DVH curves compared with the clinically delivered original plan. Specifically, our algorithm iterates the following two loops. An inner loop is the traditional fluence map optimization, in which we optimize a quadratic objective function penalizing the deviation of the dose received by each voxel from its prescribed or threshold dose with a set of fixed voxel weighting factors. In outer loop, the voxel weighting factors in the objective function are adjusted according to the deviation of the current DVH curves from those in the original plan. The process is repeated until the DVH curves are acceptable or maximum iteration step is reached. The whole algorithm is implemented on GPU for high efficiency. The feasibility of our algorithm has been demonstrated with three head-and-neck cancer IMRT cases, each having an initial planning CT scan and another treatment CT scan acquired in the middle of treatment course. Compared with the DVH curves in the original plan, the DVH curves in the resulting plan using our algorithm with 30 iterations are better for almost all structures. The re-optimization process takes about 30 s using

  12. Dose calculations with SERA for the application of the BNCT at the TRIGA Mainz

    International Nuclear Information System (INIS)

    The BNCT shall be applied for an explantated organ with metastases at the TRIGA reactor Mainz, Germany. After the treatment of the patient with 10B pharmaceutical the liver will be explanted, irradiated in the thermal column and then implantated again (autotransplantation). This was first successfully done in 12/2001 for a 48 years old male patient at the TRIGA reactor in Pavia. For a treatment with BNCT it is necessary to determine the total dose and partial radiation doses like the boron and gamma dose. Since several parts of the dose can not be measured, calculations are necessary. For this procedure the program Simulation Environment for Radiotherapy Applications (SERA) developed by INEEL, Idaho, U.S., can be applied, which allows an individual dosimetry for the patient. The SERA program consists of a manual and semi-automated geometric modeling of the treatment objects like the liver derived from MRI, CT or other medical imaging modalities. The dose for these geometric models is calculated with the INEEL radiation transport computer code and the dose contouring is also derived. The SERA program was adapted at MHH to calculate the radiation dose in the case of liver autotransplantation. Also, the technical characteristics and the physical environment of the thermal column were programmed for SERA. For the first reactor model the core of the MHH TRIGA reactor and the thermal column of the Mainz TRIGA reactor were used. The thermal column was modulated with layers of bismuth and lead to minimize the gamma dose. (author)

  13. Optimizing global liver function in radiation therapy treatment planning

    Science.gov (United States)

    Wu, Victor W.; Epelman, Marina A.; Wang, Hesheng; Romeijn, H. Edwin; Feng, Mary; Cao, Yue; Ten Haken, Randall K.; Matuszak, Martha M.

    2016-09-01

    Liver stereotactic body radiation therapy (SBRT) patients differ in both pre-treatment liver function (e.g. due to degree of cirrhosis and/or prior treatment) and radiosensitivity, leading to high variability in potential liver toxicity with similar doses. This work investigates three treatment planning optimization models that minimize risk of toxicity: two consider both voxel-based pre-treatment liver function and local-function-based radiosensitivity with dose; one considers only dose. Each model optimizes different objective functions (varying in complexity of capturing the influence of dose on liver function) subject to the same dose constraints and are tested on 2D synthesized and 3D clinical cases. The normal-liver-based objective functions are the linearized equivalent uniform dose (\\ell \\text{EUD} ) (conventional ‘\\ell \\text{EUD} model’), the so-called perfusion-weighted \\ell \\text{EUD} (\\text{fEUD} ) (proposed ‘fEUD model’), and post-treatment global liver function (GLF) (proposed ‘GLF model’), predicted by a new liver-perfusion-based dose-response model. The resulting \\ell \\text{EUD} , fEUD, and GLF plans delivering the same target \\ell \\text{EUD} are compared with respect to their post-treatment function and various dose-based metrics. Voxel-based portal venous liver perfusion, used as a measure of local function, is computed using DCE-MRI. In cases used in our experiments, the GLF plan preserves up to 4.6 % ≤ft(7.5 % \\right) more liver function than the fEUD (\\ell \\text{EUD} ) plan does in 2D cases, and up to 4.5 % ≤ft(5.6 % \\right) in 3D cases. The GLF and fEUD plans worsen in \\ell \\text{EUD} of functional liver on average by 1.0 Gy and 0.5 Gy in 2D and 3D cases, respectively. Liver perfusion information can be used during treatment planning to minimize the risk of toxicity by improving expected GLF; the degree of benefit varies with perfusion pattern. Although fEUD model optimization is computationally inexpensive and

  14. A treatment planning study comparing Elekta VMAT and fixed field IMRT using the varian treatment planning system eclipse

    International Nuclear Information System (INIS)

    The newest release of the Eclipse (Varian) treatment planning system (TPS) includes an optimizing engine for Elekta volumetric-modulated arc therapy (VMAT) planning. The purpose of this study was to evaluate this new algorithm and to compare it to intensity-modulated radiation therapy (IMRT) for various disease sites by creating single- and double-arc VMAT plans. A total of 162 plans were evaluated in this study, including 38 endometrial, 57 head and neck, 12 brain, 10 breast and 45 prostate cancer cases. The real-life IMRT plans were developed during routine clinical cases using the TPS Eclipse. VMAT plans were generated using a preclinical version of Eclipse with tumor-region-specific optimizing templates without interference of the operator: with one full arc (1A) and with two full arcs (2A), and with partial arcs for breast and prostate with hip implant cases. All plans were evaluated based on target coverage, homogeneity and conformity. The organs at risk (OARs) were analyzed according to plan objectives, such as the mean and maximum doses. If one or more objectives were exceeded, the plan was considered clinically unacceptable, and a second VMAT plan was created by adapting the optimization penalties once. Compared to IMRT, single- and double-arc VMAT plans showed comparable or better results concerning the target coverage: the maximum dose in the target for 1A is the same as that for IMRT; for 2A, an average reduction of 1.3% over all plans was observed. The conformity showed a statistically significant improvement for both 1A (+3%) and 2A (+6%). The mean total body dose was statistically significant lower for the considered arc techniques (IMRT: 16.0 Gy, VMAT: 15.3 Gy, p < 0.001). However, the sparing of OARs shows individual behavior that depends strongly on the different tumor regions. A clear difference is found in the number of monitor units (MUs) per plan: VMAT shows a reduction of 31%. These findings demonstrate that based on optimizing templates with

  15. Conformal three dimensional radiotherapy treatment planning in Lund

    Energy Technology Data Exchange (ETDEWEB)

    Knoos, T.; Nilsson, P. [Lund Univ. (Sweden). Dept. of Radiation Physics; Anders, A. [Lund Univ. (Sweden). Dept. of Oncology

    1995-12-01

    The use of conformal therapy is based on 3-dimensional treatment planning as well as on methods and routines for 3-dimensional patient mapping, 3-dimensional virtual simulation and others. The management of patients at the Radiotherapy Department at the University Hospital in Lund (Sweden) is discussed. About 2100 new patients are annually treated with external radiotherapy using seven linear accelerators. Three of the accelerators have dual photon energies and electron treatment facilities. A multi-leaf collimator as well as an electronic portal imaging device are available on one machine. Two simulators and an in-house CT-scanner are used for treatment planning. From 1988 to 1992 Scandiplan (Umplan) was used. Since 1992, the treatment planning system is TMS (HELAX AB, Sweden), which is based on the pencil beam algorithm of Ahnesjo. The calculations use patient modulated accelerator specific energy fluence spectra which are compiled with pencil beams from Monte Carlo generated energy absorption kernels. Heterogeneity corrections are performed with results close to conventional algorithms. Irregular fields, either from standard or individual blocks and from multi-leaf collimators are handled by the treatment planning system. The field shape is determined conveniently using the beam`s eye view. The final field shape is exported electronically to either the block cutting machine or the multileaf collimator control computer. All patient fields are checked against the beam`s eye view during simulation using manual methods. Treatment verification is performed by portal films and in vivo dosimetry with silicon diodes or TL-dosimetry. Up to now, approximately 4400 patients have received a highly individualized 3-dimensional conformal treatment.

  16. Conformal three dimensional radiotherapy treatment planning in Lund

    International Nuclear Information System (INIS)

    The use of conformal therapy is based on 3-dimensional treatment planning as well as on methods and routines for 3-dimensional patient mapping, 3-dimensional virtual simulation and others. The management of patients at the Radiotherapy Department at the University Hospital in Lund (Sweden) is discussed. About 2100 new patients are annually treated with external radiotherapy using seven linear accelerators. Three of the accelerators have dual photon energies and electron treatment facilities. A multi-leaf collimator as well as an electronic portal imaging device are available on one machine. Two simulators and an in-house CT-scanner are used for treatment planning. From 1988 to 1992 Scandiplan (Umplan) was used. Since 1992, the treatment planning system is TMS (HELAX AB, Sweden), which is based on the pencil beam algorithm of Ahnesjo. The calculations use patient modulated accelerator specific energy fluence spectra which are compiled with pencil beams from Monte Carlo generated energy absorption kernels. Heterogeneity corrections are performed with results close to conventional algorithms. Irregular fields, either from standard or individual blocks and from multi-leaf collimators are handled by the treatment planning system. The field shape is determined conveniently using the beam's eye view. The final field shape is exported electronically to either the block cutting machine or the multileaf collimator control computer. All patient fields are checked against the beam's eye view during simulation using manual methods. Treatment verification is performed by portal films and in vivo dosimetry with silicon diodes or TL-dosimetry. Up to now, approximately 4400 patients have received a highly individualized 3-dimensional conformal treatment

  17. IRT-Sofia BNCT beam tube optimization study

    International Nuclear Information System (INIS)

    An optimization study of IRT-Sofia BNCT beam tube is presented. In the study we used the MIT/FCB experience. The enlarging of filter/moderator cross section dimensions and the decreasing of collimator length within the limits of the IRT-Sofia reactor design were analyzed. The influence of beam and reactor core axes non-coincidence on the beam properties was also evaluated. The irradiation resistance of polytetrafluoroethylene (Teflon®) was also evaluated. The results provide information for making decisions on the IRT-Sofia BNCT beam construction.

  18. IRT-Sofia BNCT beam tube optimization study

    Energy Technology Data Exchange (ETDEWEB)

    Belousov, S., E-mail: belousov@inrne.bas.bg [Institute for Nuclear Research and Nuclear Energy (INRNE) of the Bulgarian Academy of Sciences, Tsarigradsko 72, Sofia (Bulgaria); Mitev, M.; Ilieva, K. [Institute for Nuclear Research and Nuclear Energy (INRNE) of the Bulgarian Academy of Sciences, Tsarigradsko 72, Sofia (Bulgaria); Riley, K. [Radiation Monitoring Devices, Watertown, MA (United States); Harling, O. [Nuclear Science and Engineering Department, Massachusetts Institute of Technology, Cambridge, MA (United States)

    2011-12-15

    An optimization study of IRT-Sofia BNCT beam tube is presented. In the study we used the MIT/FCB experience. The enlarging of filter/moderator cross section dimensions and the decreasing of collimator length within the limits of the IRT-Sofia reactor design were analyzed. The influence of beam and reactor core axes non-coincidence on the beam properties was also evaluated. The irradiation resistance of polytetrafluoroethylene (Teflon{sup Registered-Sign }) was also evaluated. The results provide information for making decisions on the IRT-Sofia BNCT beam construction.

  19. Emergency assessment and treatment planning for traumatic dental injuries.

    Science.gov (United States)

    Moule, A; Cohenca, N

    2016-03-01

    Trauma involving the dentoalveolar region is a frequent occurrence which can result in the fracturing and displacement of teeth, crushing and/or fracturing of bone and soft tissue injuries including contusions, abrasions and lacerations. This review describes the assessment of patients with these injuries, not in a didactic sense by repeating excellent already published classifications and treatment options, but by addressing questions that arise during assessment. It covers trauma first aid, examination of the patient, factors that affect treatment planning decisions, and the importance of communicating treatment options and prognosis to traumatized patients. PMID:26923446

  20. Considerations for boron neutron capture therapy studies; Consideracoes sobre o estudo da BNCT (terapia de captura neutronica por boro)

    Energy Technology Data Exchange (ETDEWEB)

    Faria Gaspar, P. de

    1994-12-31

    Radiotherapy is indispensable as a mean to eradicate deeply or infiltrating tumor tissue that can not be removed surgically. Therefore, it is not selective and may also kill the surrounding health tissue. The principle of BNCT (Boron Neutron Capture Therapy) consist in targeting a tumor selectively with a boron-10 compound. This nuclide has a large capture cross section for thermal neutrons and the nuclear reaction and the delivered energy in locus will selective the tumor. Since its initial proposal in 1963 BNCT has made much progress, however it is not used in a routine treatment. In this work it was approached some complex procedures, as the obtention of selective boron compounds, the adequate set up of neutron beams, the biodistribution, the in vivo and in vitro studies, and also human patients treatments. This work provide fundamentals about BNCT to professional of different areas of knowledge since it comprises multidisciplinary study. It includes appendixes for the ones not related to the field for a better comprehension of the many aspects involved. It is also presented a glossary containing technical and basic aspects involved. It is also presented a glossary containing technical and basic terms referred in the work. (author). 174 refs, 1 fig, 12 apps.

  1. A simple planning technique of craniospinal irradiation in the eclipse treatment planning system

    Directory of Open Access Journals (Sweden)

    Hemalatha Athiyaman

    2014-01-01

    Full Text Available A new planning method for Craniospinal Irradiation by Eclipse treatment planning system using Field alignment, Field-in-Field technique was developed. Advantage of this planning method was also studied retrospectively for previously treated five patients of medulloblastoma with variable spine length. Plan consists of half beam blocked parallel opposed cranium, and a single posterior cervicospine field was created by sharing the same isocenter, which obviates divergence matching. Further, a single symmetrical field was created to treat remaining Lumbosacral spine. Matching between a inferior diverging edge of cervicospine field and superior diverging edge of a Lumbosacral field was done using the field alignment option. ′Field alignment′ is specific option in the Eclipse Treatment Planning System, which automatically matches the field edge divergence as per field alignment rule. Multiple segments were applied in both the spine field to manage with hot and cold spots created by varying depth of spinal cord. Plan becomes fully computerized using this field alignment option and multiple segments. Plan evaluation and calculated mean modified Homogeneity Index (1.04 and 0.1 ensured that dose to target volume is homogeneous and critical organ doses were within tolerance. Dose variation at the spinal field junction was verified using ionization chamber array (I′MatriXX for matched, overlapped and gap junction spine fields; the delivered dose distribution confirmed the ideal clinical match, over exposure and under exposure at the junction, respectively. This method is simple to plan, executable in Record and Verify mode and can be adopted for various length of spinal cord with only two isocenter in shorter treatment time.

  2. Computer calculations in interstitial seed therapy: I. Radiation treatment planning

    International Nuclear Information System (INIS)

    Interstitial seed therapy computers can be used for radiation treatment planning and for dose control after implantation. In interstitial therapy with radioactive seeds there are much greater differences between planning and carrying out radiation treatment than in teletherapy with cobalt-60 or X-rays. Because of the short distance between radioactive sources and tumour tissue, even slight deviations from the planned implantation geometry cause considerable dose deviations. Furthermore, the distribution of seeds in an actual implant is inhomogeneous. During implantation the spatial distribution of seeds cannot be examined exactly, though X-rays are used to control the operation. The afterloading technique of Henschke allows a more exact implantation geometry, but I have no experience of this method. In spite of the technical difficulty of achieving optimum geometry, interstitial therapy still has certain advantages when compared with teletherapy: the dose in the treated volume can be kept smaller than in teletherapy, the radiation can be better concentrated in the tumour volume, the treatment can be restricted to one or two operations, and localized inoperable tumours may be cured more easily. The latter may depend on an optimal treatment time, a relatively high tumour dose and a continuous exponentially decreasing dose rate during the treatment time. A disadvantage of interstitial therapy is the high personnel dose, which may be reduced by the afterloading technique of Henschke (1956). However, the afterloading method requires much greater personnel and instrumental expense than free implantation of radiogold seeds and causes greater trauma for the patient

  3. Dosimetric tests for treatment planning commissioning in 3DCRT

    International Nuclear Information System (INIS)

    The radiotherapy evolution from 2D treatments to 3D conformal treatments was possible after the advent the treatment planning systems commercially available and tridimensional images techniques like computed tomography. These systems have tools that allow delineate anatomical structures from tomographic images. Calculations dose tools allow the planner evaluate the dose received in the anatomical structures. When these systems are acquired or an upgrade is made many dosimetric and non-dosimetric tests need to be performed to know the system limitations and correct functioning and to verify the correct dosimetric data insertion. This study was based in International Atomic Energy Agency protocols, Task Groups documents from American Association of Physics in Medicine, and other papers. A dosimetric test set was done to commissioning the Eclipse 10.0.28 (Varian Medical Systems) treatments planning system This version has two photon calculation algorithm (Pencil Beam Convolution and Analytical Anisotropic Algorithm – AAA) and Gaussian Pencil Beam algorithm for electron beams. However, tests for AAA it was not performed. In this study was possible to conclude that the dosimetric data was correctly added in the treatment planning system. Some results allowed to understand the algorithm limitations to calculate dose distributions in specifics situations, that was not clinically relevant in our routine. (author)

  4. A 4D treatment planning tool for the evaluation of motion effects on lung cancer treatments

    International Nuclear Information System (INIS)

    In this study, a 4D treatment planning tool using an analytical model accounting for breathing motion is investigated to evaluate the motion effect on delivered dose for lung cancer treatments with three-dimensional conformal radiotherapy (3DCRT). The Monte Carlo EGS4/MCDOSE user code is used in the treatment planning dose calculation, and the patient CT data are converted into respective patient geometry files for Monte Carlo dose calculation. The model interpolates CT images at different phases of the breathing cycle from patient CT scans taken at end inspiration and end expiration phases and the chest wall position. Correlation between the voxels in a reference CT dataset and the voxels in the interpolated CT datasets at any breathing phases is established so that the dose to a voxel can be accumulated through the entire breathing cycle. Simulated lung tumors at different locations are used to demonstrate our model in 3DCRT for lung cancer treatments. We demonstrated the use of a 4D treatment planning tool in evaluating the breathing motion effect on delivered dose for different planning margins. Further studies are being conducted to use this tool to study the lung motion effect through large-scale analysis and to implement this useful tool for treatment planning dose calculation and plan evaluation for 4D radiotherapy

  5. Savannah River Site Approved Site Treatment Plan, 1998 Annual Update

    Energy Technology Data Exchange (ETDEWEB)

    Lawrence, B. [Westinghouse Savannah River Company, AIKEN, SC (United States); Berry, M.

    1998-03-01

    The U.S. Department of Energy, Savannah River Operations Office (DOE- SR),has prepared the Site Treatment Plan (STP) for Savannah River Site (SRS) mixed wastes in accordance with RCRA Section 3021(b), and SCDHEC has approved the STP (except for certain offsite wastes) and issued an order enforcing the STP commitments in Volume I. DOE-SR and SCDHEC agree that this STP fulfills the requirements contained in the FFCAct, RCRA Section 3021, and therefore,pursuant to Section 105(a) of the FFCAct (RCRA Section 3021(b)(5)), DOE`s requirements are to implement the plan for the development of treatment capacities and technologies pursuant to RCRA Section 3021.Emerging and new technologies not yet considered may be identified to manage waste more safely, effectively, and at lower cost than technologies currently identified in the plan. DOE will continue to evaluate and develop technologies that offer potential advantages in public acceptance, privatization, consolidation, risk abatement, performance, and life-cycle cost. Should technologies that offer such advantages be identified, DOE may request a revision/modification of the STP in accordance with the provisions of Consent Order 95-22-HW.The Compliance Plan Volume (Volume I) identifies project activity schedule milestones for achieving compliance with Land Disposal Restrictions (LDR). Information regarding the technical evaluation of treatment options for SRS mixed wastes is contained in the Background Volume (Volume II) and is provided for information.

  6. Approved Site Treatment Plan, Volumes 1 and 2. Revision 4

    Energy Technology Data Exchange (ETDEWEB)

    Helmich, E.H.; Molen, G.; Noller, D.

    1996-03-22

    The US Department of Energy, Savannah River Operations Office (DOE-SR), has prepared the Site Treatment Plan (STP) for Savannah River Site (SRS) mixed wastes in accordance with RCRA Section 3021(b), and SCDHEC has approved the STP (except for certain offsite wastes) and issued an order enforcing the STP commitments in Volume 1. DOE-SR and SCDHEC agree that this STP fulfills the requirements contained in the FFCAct, RCRA Section 3021, and therefore, pursuant to Section 105(a) of the FFCAct (RCRA Section 3021(b)(5)), DOE`s requirements are to implement the plan for the development of treatment capacities and technologies pursuant to RCRA Section 3021. Emerging and new technologies not yet considered may be identified to manage waste more safely, effectively, and at lower cost than technologies currently identified in the plan. DOE will continue to evaluate and develop technologies that offer potential advantages in public acceptance, privatization, consolidation, risk abatement, performance, and life-cycle cost. Should technologies that offer such advantages be identified, DOE may request a revision/modification of the STP in accordance with the provisions of Consent Order 95-22-HW. The Compliance Plan Volume (Volume 1) identifies project activity schedule milestones for achieving compliance with Land Disposal Restrictions (LDR). Information regarding the technical evaluation of treatment options for SRS mixed wastes is contained in the Background Volume (Volume 2) and is provided for information.

  7. Approved Site Treatment Plan, Volumes 1 and 2. Revision 4

    International Nuclear Information System (INIS)

    The US Department of Energy, Savannah River Operations Office (DOE-SR), has prepared the Site Treatment Plan (STP) for Savannah River Site (SRS) mixed wastes in accordance with RCRA Section 3021(b), and SCDHEC has approved the STP (except for certain offsite wastes) and issued an order enforcing the STP commitments in Volume 1. DOE-SR and SCDHEC agree that this STP fulfills the requirements contained in the FFCAct, RCRA Section 3021, and therefore, pursuant to Section 105(a) of the FFCAct (RCRA Section 3021(b)(5)), DOE's requirements are to implement the plan for the development of treatment capacities and technologies pursuant to RCRA Section 3021. Emerging and new technologies not yet considered may be identified to manage waste more safely, effectively, and at lower cost than technologies currently identified in the plan. DOE will continue to evaluate and develop technologies that offer potential advantages in public acceptance, privatization, consolidation, risk abatement, performance, and life-cycle cost. Should technologies that offer such advantages be identified, DOE may request a revision/modification of the STP in accordance with the provisions of Consent Order 95-22-HW. The Compliance Plan Volume (Volume 1) identifies project activity schedule milestones for achieving compliance with Land Disposal Restrictions (LDR). Information regarding the technical evaluation of treatment options for SRS mixed wastes is contained in the Background Volume (Volume 2) and is provided for information

  8. 4D Proton treatment planning strategy for mobile lung tumors

    International Nuclear Information System (INIS)

    Purpose: To investigate strategies for designing compensator-based 3D proton treatment plans for mobile lung tumors using four-dimensional computed tomography (4DCT) images. Methods and Materials: Four-dimensional CT sets for 10 lung cancer patients were used in this study. The internal gross tumor volume (IGTV) was obtained by combining the tumor volumes at different phases of the respiratory cycle. For each patient, we evaluated four planning strategies based on the following dose calculations: (1) the average (AVE) CT; (2) the free-breathing (FB) CT; (3) the maximum intensity projection (MIP) CT; and (4) the AVE CT in which the CT voxel values inside the IGTV were replaced by a constant density (AVERIGTV). For each strategy, the resulting cumulative dose distribution in a respiratory cycle was determined using a deformable image registration method. Results: There were dosimetric differences between the apparent dose distribution, calculated on a single CT dataset, and the motion-corrected 4D dose distribution, calculated by combining dose distributions delivered to each phase of the 4DCT. The AVERIGTV plan using a 1-cm smearing parameter had the best overall target coverage and critical structure sparing. The MIP plan approach resulted in an unnecessarily large treatment volume. The AVE and FB plans using 1-cm smearing did not provide adequate 4D target coverage in all patients. By using a larger smearing value, adequate 4D target coverage could be achieved; however, critical organ doses were increased. Conclusion: The AVERIGTV approach is an effective strategy for designing proton treatment plans for mobile lung tumors

  9. Comparative dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for brain tumors

    Energy Technology Data Exchange (ETDEWEB)

    Brandao, Samia de Freitas, E-mail: samiabrandao@gmail.com [Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG (Brazil). Departamento de Engenharia Nuclear; Campos, Tarcisio Passos Ribeiro de [Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG (Brazil)

    2013-06-15

    Objective: comparative analysis of dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for treatment of brain tumors. Materials and methods: simulations of intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT were performed with the MCNP5 code, modeling the treatment of a brain tumor on a voxel computational phantom representing a human head. Absorbed dose rates were converted into biologically weighted dose rates. Results: intracavitary balloon catheter brachytherapy with I-125 produced biologically weighted mean dose rates of 3.2E-11, 1.3E-10, 1.9E-11 and 6.9E-13 RBE.Gy.h{sup -1}.p{sup -1}.s, respectively, on the healthy tissue, on the balloon periphery and on the /{sub 1} and /{sub 2} tumor infiltration zones. On the other hand, Cf-252 brachytherapy combined with BNCT produced a biologically weighted mean dose rate of 5.2E-09, 2.3E-07, 8.7E-09 and 2.4E-09 RBE.Gy.h{sup -1}.p{sup -1}.s, respectively on the healthy tissue, on the target tumor and on the /{sub 1} and /{sub 2} infiltration zones. Conclusion: Cf-252 brachytherapy combined with BNCT delivered a selective irradiation to the target tumor and to infiltration zones, while intracavitary balloon catheter brachytherapy with I-125 delivered negligible doses on the tumor infiltration zones. (author)

  10. Comparative dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for brain tumors

    Directory of Open Access Journals (Sweden)

    Samia de Freitas Brandao

    2013-07-01

    Full Text Available Objective Comparative analysis of dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for treatment of brain tumors. Materials and Methods Simulations of intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT were performed with the MCNP5 code, modeling the treatment of a brain tumor on a voxel computational phantom representing a human head. Absorbed dose rates were converted into biologically weighted dose rates. Results Intracavitary balloon catheter brachytherapy with I-125 produced biologically weighted mean dose rates of 3.2E-11, 1.3E-10, 1.9E-11 and 6.9E-13 RBE.Gy.h-1.p-1.s, respectively, on the healthy tissue, on the balloon periphery and on the I 1 and I 2 tumor infiltration zones. On the other hand, Cf-252 brachytherapy combined with BNCT produced a biologically weighted mean dose rate of 5.2E-09, 2.3E-07, 8.7E-09 and 2.4E-09 RBE.Gy.h-1.p-1.s, respectively on the healthy tissue, on the target tumor and on the I 1 and I 2 infiltration zones. Conclusion Cf-252 brachytherapy combined with BNCT delivered a selective irradiation to the target tumor and to infiltration zones, while intracavitary balloon catheter brachytherapy with I-125 delivered negligible doses on the tumor infiltration zones.

  11. Comparative dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for brain tumors

    International Nuclear Information System (INIS)

    Objective: comparative analysis of dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for treatment of brain tumors. Materials and methods: simulations of intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT were performed with the MCNP5 code, modeling the treatment of a brain tumor on a voxel computational phantom representing a human head. Absorbed dose rates were converted into biologically weighted dose rates. Results: intracavitary balloon catheter brachytherapy with I-125 produced biologically weighted mean dose rates of 3.2E-11, 1.3E-10, 1.9E-11 and 6.9E-13 RBE.Gy.h-1.p-1.s, respectively, on the healthy tissue, on the balloon periphery and on the /1 and /2 tumor infiltration zones. On the other hand, Cf-252 brachytherapy combined with BNCT produced a biologically weighted mean dose rate of 5.2E-09, 2.3E-07, 8.7E-09 and 2.4E-09 RBE.Gy.h-1.p-1.s, respectively on the healthy tissue, on the target tumor and on the /1 and /2 infiltration zones. Conclusion: Cf-252 brachytherapy combined with BNCT delivered a selective irradiation to the target tumor and to infiltration zones, while intracavitary balloon catheter brachytherapy with I-125 delivered negligible doses on the tumor infiltration zones. (author)

  12. Review on Desing Beam Shaping Assembly Based on the D-T Reaction for BNCT

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) can be achieved using a compact high energy neutron generator, in which the neutron energy should be in the epithermal range (1 eV < E < 10 keV) with high epithermal flux for treating Glioblastoma Multiforme (GBM). For this purpose, a suitable Beam Shaping Assembly (BSA) of a D-T neutron source is required. A major advantage of a D-T neutron source is the low energy required for the deuteron beam, namely 400 keV. The BSA design consists of a neutron multiplier, a moderator, a reflector, a fast neutron filter, a thermal neutron filter, gamma shielding and a collimator. In this work, the simulation code MCNP-4C is used to simulate the suggested BSA design as given in the literature. Beam parameters obtained by the proposed BSA design for the D-T neutron generator are investigated based on the IAEA recommendation. The results will be presented and discussed, which can provide an appropriate neutron beam for BNCT and suitable for planning in-hospital installations.

  13. Implementation of three dimensional treatment planning system for external radiotherapy

    International Nuclear Information System (INIS)

    A three dimensional (3D) treatment planning system was installed at Apollo Cancer Hospital, Chennai, India in 1995. This paper gives a short description of the system including hardware components, calculation algorithm, measured data requirements and specific three dimensional features. The concept and the structure of the system are shortly described. The first impressions along with critical opinions and the experiences are gained during the data acquisition are mentioned. Some improvements in the user interface are suggested. It is emphasized that although a 3D system offers more detailed and accurate dose distributions compared to a 2D system, it also introduces a greatly increased workload for the planning staff. (author)

  14. Continuity of Care: Sharing the Medication Treatment Plan.

    Science.gov (United States)

    Spahni, Stéphane

    2016-01-01

    The shared medication treatment plan is a key element for supporting the continuity of care. Indeed a substantial amount of emergency hospitalization is linked to medication - 5% to 10% according to some studies. Methods and tools helping all healthcare providers to have a better knowledge of the complete medication plan are therefore required in order to limit side effects linked to an insufficient knowledge of what the patient is taking. The workshop intends to present various initiatives and open the discussion about the limits, pros and cons of various initiatives. PMID:27332315

  15. Monte Carlo conformal treatment planning as an independent assessment

    International Nuclear Information System (INIS)

    The wide range of possibilities available in Radiotherapy with conformal fields cannot be covered experimentally. For this reason, dosimetrical and planning procedures are based on approximate algorithms or systematic measurements. Dose distribution calculations based on Monte Carlo (MC) simulations can be used to check results. In this work, two examples of conformal field treatments are shown: A prostate carcinoma and an ocular lymphoma. The dose distributions obtained with a conventional Planning System and with MC have been compared. Some significant differences have been found. (orig.)

  16. Calculational evaluations of the proposal for a reference dosimetric phantom for BNCT

    International Nuclear Information System (INIS)

    Standard dosimetric phantoms are used in radiotherapy to compare irradiations under standard conditions. They provide volumes of tissue substitute for the measurement of absorbed dose and are large enough to ensure that full contribution to the absorbed dose from scattered radiation is received at the point of measurement. Aim of this study was to find out a recommendation for the boundary values of size of a reference phantom. These reference conditions for the reference measurement methods are created for 'A code of practise for dosimetry, of BNCT in Europe' project. The major objective of the project is to prepare detailed guidelines for the dosimetry of epithermal neutron beams to be used for treatment of cancer patients by Boron Neutron Capture Therapy (BNCT) at European research reactors and accelerators. For this objective Monte Carlo simulations have been carried out with MCNP 4B code in three different cubic phantoms for studying effect of different phantom sizes in important radiation components. These three phantoms are the proposed reference (measurement) phantom (20*20*20 cm), a phantom that was assumed to model an infinite phantom, and a smaller (15*15*15 cm) cubic phantom which exists in Petten BNCT facility in Netherlands. Function of the smallest phantom was to study acceptable lower limit to the phantom size to still reach the reference conditions. All the simulated phantoms were cubic water phantoms with one 0.5 cm thick (beam side) wall and three 1 cm thick walls of PMMA (polymethyl-methacrylate). The comparisons were done with calculations of the thermal, epithermal and fast neutron fluence rates in analogous points. The source specification of the MCNP runs were accordance of 250 kW FiR 1 research reactor neutron beam with 14 cm beam aperture. In order to minimise the statistical error of the Monte Carlo calculations, over 60*106 source particles were simulated for infinite and reference phantom cases. Calculation results were in good

  17. Orthodontic treatment plan changed by 3D images

    International Nuclear Information System (INIS)

    Clinical application of CBCT is most often enforced in dental phenomenon of impacted teeth, hyperodontia, transposition, ankyloses or root resorption and other pathologies in the maxillofacial area. The goal, we put ourselves, is to show how the information from 3D images changes the protocol of the orthodontic treatment. The material, we presented six our clinical cases and the change in the plan of the treatment, which has used after analyzing the information carried on the three planes of CBCT. These cases are casuistic in the orthodontic practice and require individual approach to each of them during their analysis and decision taken. The discussion made by us is in line with reveal of the impacted teeth, where we need to evaluate their vertical depth and mediodistal ratios with the bond structures. At patients with hyperodontia, the assessment is of outmost importance to decide which of the teeth to be extracted and which one to be arranged into the dental arch. The conclusion we make is that diagnostic information is essential for decisions about treatment plan. The exact graphs will lead to better treatment plan and more predictable results. (authors) Key words: CBCT. IMPACTED CANINES. HYPERODONTIA. TRANSPOSITION

  18. Boron Neutron Capture Therapty (BNCT) in an Oral Precancer Model: Therapeutic Benefits and Potential Toxicity of a Double Application of BNCT with a Six-Week Interval

    Energy Technology Data Exchange (ETDEWEB)

    Andrea Monti Hughes; Emiliano C.C. Pozzi; Elisa M. Heber; Silvia Thorp; Marcelo Miller; Maria E. Itoiz; Romina F. Aromando; Ana J. Molinari; Marcela A. Garabalino; David W. Nigg; Veronica A. Trivillin; Amanda E. Schwint

    2011-11-01

    Given the clinical relevance of locoregional recurrences in head and neck cancer, we developed a novel experimental model of premalignant tissue in the hamster cheek pouch for long-term studies and demonstrated the partial inhibitory effect of a single application of Boron Neutron Capture Therapy (BNCT) on tumor development from premalignant tissue. The aim of the present study was to evaluate the effect of a double application of BNCT with a 6 week interval in terms of inhibitory effect on tumor development, toxicity and DNA synthesis. We performed a double application, 6 weeks apart, of (1) BNCT mediated by boronophenylalanine (BPA-BNCT); (2) BNCT mediated by the combined application of decahydrodecaborate (GB-10) and BPA [(GB-10 + BPA)-BNCT] or (3) beam-only, at RA-3 nuclear reactor and followed the animals for 8 months. The control group was cancerized and sham-irradiated. BPA-BNCT, (GB- 10 + BPA)-BNCT and beam-only induced a reduction in tumor development from premalignant tissue that persisted until 8, 3, and 2 months respectively. An early maximum inhibition of 100% was observed for all 3 protocols. No normal tissue radiotoxicity was detected. Reversible mucositis was observed in premalignant tissue, peaking at 1 week and resolving by the third week after each irradiation. Mucositis after the second application was not exacerbated by the first application. DNA synthesis was significantly reduced in premalignant tissue 8 months post-BNCT. A double application of BPA-BNCT and (GB-10 + BPA)-BNCT, 6 weeks apart, could be used therapeutically at no additional cost in terms of radiotoxicity in normal and dose-limiting tissues.

  19. Boron Neutron Capture Therapy (BNCT) in an Oral Precancer Model: Therapeutic Benefits and Potential Toxicity of a Double Application of BNCT with a Six-Week Interval

    International Nuclear Information System (INIS)

    Given the clinical relevance of locoregional recurrences in head and neck cancer, we developed a novel experimental model of premalignant tissue in the hamster cheek pouch for long-term studies and demonstrated the partial inhibitory effect of a single application of Boron Neutron Capture Therapy (BNCT) on tumor development from premalignant tissue. The aim of the present study was to evaluate the effect of a double application of BNCT with a 6 week interval in terms of inhibitory effect on tumor development, toxicity and DNA synthesis. We performed a double application, 6 weeks apart, of (1) BNCT mediated by boronophenylalanine (BPA-BNCT); (2) BNCT mediated by the combined application of decahydrodecaborate (GB-10) and BPA ((GB-10 + BPA)-BNCT) or (3) beam-only, at RA-3 nuclear reactor and followed the animals for 8 months. The control group was cancerized and sham-irradiated. BPA-BNCT, (GB- 10 + BPA)-BNCT and beam-only induced a reduction in tumor development from premalignant tissue that persisted until 8, 3, and 2 months respectively. An early maximum inhibition of 100% was observed for all 3 protocols. No normal tissue radiotoxicity was detected. Reversible mucositis was observed in premalignant tissue, peaking at 1 week and resolving by the third week after each irradiation. Mucositis after the second application was not exacerbated by the first application. DNA synthesis was significantly reduced in premalignant tissue 8 months post-BNCT. A double application of BPA-BNCT and (GB-10 + BPA)-BNCT, 6 weeks apart, could be used therapeutically at no additional cost in terms of radiotoxicity in normal and dose-limiting tissues.

  20. INEL BNCT Program: Volume 5, No. 9. Bulletin, September 1991

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. [ed.

    1991-12-31

    This Bulletin presents a summary of accomplishments and highlights of the Idaho National Engineering Laboratory`s (INEL) Boron Neutron Capture Therapy (BNCT) Program for September 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, and updates to the animal data charts.

  1. Backgrounds of computer-assisted treatment planning in radiation therapy

    International Nuclear Information System (INIS)

    Interaction of ionising radiation and living materials causes biological damage of tempory or permanent nature. In radiation therapy this phenomenon is used in a controlled fashion in order to stop the proliferation of malignant cells, while at the same time limiting the permanent damage to healthy tissues and organs to at least tolerable levels. Because of the often relatively small differences in response of malignant growths and normal tissues, the margins between tolerable and intolerable are so small that the greatest precision in treatment planning and execution is required. The nature of this treatment agent implies that the radiation therapist has to rely very much on instrumentally obtained and processed information, in all phases of this medical activities around the patient. In this paper a description is given of the backgrounds of computer-assisted methods which have enabled modern individualised and optimised planning for therapy with high energy X- and gamma beams. (orig.)

  2. Treatment planning in radiosurgery: parallel Monte Carlo simulation software

    Energy Technology Data Exchange (ETDEWEB)

    Scielzo, G. [Galliera Hospitals, Genova (Italy). Dept. of Hospital Physics; Grillo Ruggieri, F. [Galliera Hospitals, Genova (Italy) Dept. for Radiation Therapy; Modesti, M.; Felici, R. [Electronic Data System, Rome (Italy); Surridge, M. [University of South Hampton (United Kingdom). Parallel Apllication Centre

    1995-12-01

    The main objective of this research was to evaluate the possibility of direct Monte Carlo simulation for accurate dosimetry with short computation time. We made us of: graphics workstation, linear accelerator, water, PMMA and anthropomorphic phantoms, for validation purposes; ionometric, film and thermo-luminescent techniques, for dosimetry; treatment planning system for comparison. Benchmarking results suggest that short computing times can be obtained with use of the parallel version of EGS4 that was developed. Parallelism was obtained assigning simulation incident photons to separate processors, and the development of a parallel random number generator was necessary. Validation consisted in: phantom irradiation, comparison of predicted and measured values good agreement in PDD and dose profiles. Experiments on anthropomorphic phantoms (with inhomogeneities) were carried out, and these values are being compared with results obtained with the conventional treatment planning system.

  3. Treatment planning in radiosurgery: parallel Monte Carlo simulation software

    International Nuclear Information System (INIS)

    The main objective of this research was to evaluate the possibility of direct Monte Carlo simulation for accurate dosimetry with short computation time. We made us of: graphics workstation, linear accelerator, water, PMMA and anthropomorphic phantoms, for validation purposes; ionometric, film and thermo-luminescent techniques, for dosimetry; treatment planning system for comparison. Benchmarking results suggest that short computing times can be obtained with use of the parallel version of EGS4 that was developed. Parallelism was obtained assigning simulation incident photons to separate processors, and the development of a parallel random number generator was necessary. Validation consisted in: phantom irradiation, comparison of predicted and measured values good agreement in PDD and dose profiles. Experiments on anthropomorphic phantoms (with inhomogeneities) were carried out, and these values are being compared with results obtained with the conventional treatment planning system

  4. Treatment planning of paraspinal tumors with CT-myelography

    International Nuclear Information System (INIS)

    Background and aim: Artifacts due to metal implants are an important problem in diagnostic radiology and radiotherapy planning in tumors such as chordoma of the spine. A strict differentiation between target and radiosensitive structures e.g. spinal cord is absolutely essential for high-dose radiotherapy. Up to now CT and MRI techniques have provided only limited image quality in such situations. We introduce an approach to facilitate segmentation by using the technique of CT-myelography for radiation treatment. Patient and method: A 48-year-old woman with multiple inoperable relapses of a chordoma in the lumbar spine and extensive metal instrumentation in this area was given to radiotherapy using IMRT-technique (intensity modulated). MRI- and CT-planning images did not allow differentiation between myelon, cauda equina, dural sac and tumor. In this situation we performed a CT-myelography with the patient in treatment position. Result: CT-myelographic images enabled precise differentiation between myelon, cauda equina and intraspinal tumor. A substantial improvement of the segmentation of the spinal cord was obtained. There was no compression of the dural sac along the spine. This information provided the basis for a precise radiotherapy planning in IMRT-technique. Conclusion: In situations where CT- and MRI-techniques are not able to generate precise images which allow differentiation between tumor, myelon and cauda equina because of metal artifacts, CT-myelography is a promising technique which may help the diagnostic radiologist and radiation oncologist in planning radiotherapy. (orig.)

  5. Electron arc therapy: physical measurement and treatment planning techniques

    Energy Technology Data Exchange (ETDEWEB)

    Leavitt, D.D.; Peacock, L.M.; Gibbs, F.A. Jr.; Stewart, J.R.

    1985-05-01

    An electron beam arc therapy technique has been developed for the treatment of the post-mastectomy chest wall using a clinical linear accelerator modified for arc therapy. The effects on the dose distribution of primary X ray collimators, secondary cerrobend blocks attached to the accelerator accessory tray, and tertiary cerrobend casting of the treatment area on the patient's thorax have been investigated. A computerized treatment planning program has been developed to aid in visualization and optimization of dose distributions. A simple technique to estimate the width variation in the secondary collimator necessary to compensate for radial patient thickness changes in the cephalocaudad direction is described. Electron beam energies of 6 MeV, 9 MeV, 12 MeV, 15 MeV, and 18 MeV have been studied. The physical measurements needed to implement this technique are described, and a comparison of electron arc therapy dose distributions with other standard treatment techniques is presented.

  6. Dosimetric verification of a commercial inverse treatment planning system

    Science.gov (United States)

    Xing, Lei; Curran, Bruce; Hill, Robert; Holmes, Tim; Ma, Lijun; Forster, Kenneth M.; Boyer, Arthur L.

    1999-02-01

    A commercial three-dimensional (3D) inverse treatment planning system, Corvusimages/0031-9155/44/2/013/img10.gif" ALIGN="TOP"/> (Nomos Corporation, Sewickley, PA), was recently made available. This paper reports our preliminary results and experience with commissioning this system for clinical implementation. This system uses a simulated annealing inverse planning algorithm to calculate intensity-modulated fields. The intensity-modulated fields are divided into beam profiles that can be delivered by means of a sequence of leaf settings by a multileaf collimator (MLC). The treatments are delivered using a computer-controlled MLC. To test the dose calculation algorithm used by the Corvus software, the dose distributions for single rectangularly shaped fields were compared with water phantom scan data. The dose distributions predicted to be delivered by multiple fields were measured using an ion chamber that could be positioned in a rotatable cylindrical water phantom. Integrated charge collected by the ion chamber was used to check the absolute dose of single- and multifield intensity modulated treatments at various spatial points. The measured and predicted doses were found to agree to within 4% at all measurement points. Another set of measurements used a cubic polystyrene phantom with radiographic film to record the radiation dose distribution. The films were calibrated and scanned to yield two-dimensional isodose distributions. Finally, a beam imaging system (BIS) was used to measure the intensity-modulated x-ray beam patterns in the beam's-eye view. The BIS-measured images were then compared with a theoretical calculation based on the MLC leaf sequence files to verify that the treatment would be executed accurately and without machine faults. Excellent correlation (correlation coefficients images/0031-9155/44/2/013/img11.gif" ALIGN="TOP"/>) was found for all cases. Treatment plans generated using intensity-modulated beams appear to be suitable for treatment of

  7. Generating Treatment Plan in Medicine: A Data Mining Approach

    Directory of Open Access Journals (Sweden)

    Ahmad M. Razali

    2009-01-01

    Full Text Available This study reports on a research effort on generating treatment plan to handle the error and complexity of treatment process for healthcare providers. Focus has been given for outpatient and was based on data collected from various health centers throughout Malaysia. These clinical data were recorded using SOAP (Subjective, Objective, Assessment and Plan format approach as being practiced in medicine and were recorded electronically via Percuro Clinical Information System (Percuro. Cross-Industry Standard Process for Data Mining (CRISP-DM model has been utilized for the entire research. We used data mining analysis through decision trees technique with C5 algorithm. The scopes that have been set are patients complaint, gender, age, race, type of plan and detailed item given to patient. Acute upper respiratory infection disease or identified as J06.9 in International Classification of Diseases 10 by World Health Organization has been selected as it was the most common problem encountered. The model created for J06.9 disease is that type of plan recommended through giving drug to patients without the need to consider patients complaint, gender, age and race, with accuracy obtained for the model is 94.73%. Inspite of that, we also identified detailed items that have been given to J06.9 patients and the occurancy of them. This can be as a guideline for future treatment with item recommendation is less than 0.078% compared to item inventory in Percuro database. The research is expected to aid healthcare provider as well as to minimize error during treatment process while benefited from technology information to increase the health care delivery.

  8. Patients with hip prosthesis: radiotherapy treatment planning considerations

    International Nuclear Information System (INIS)

    The number of patients with hip prosthesis undergoing radiotherapy for pelvic cancer worldwide is increasing. This might be of importance depending on the materials in the prosthesis and whether any of the treatment fields are involved in the prosthesis. Radiotherapy planning involving the pelvic region of patients having total hip prosthesis has been found to be difficult due to the effect of the prosthesis on the dose distribution. This review is intended to project dosimetric considerations and possible solutions to this uncommon problem

  9. Monte Carlo treatment planning for photon and electron beams

    Science.gov (United States)

    Reynaert, N.; van der Marck, S. C.; Schaart, D. R.; Van der Zee, W.; Van Vliet-Vroegindeweij, C.; Tomsej, M.; Jansen, J.; Heijmen, B.; Coghe, M.; De Wagter, C.

    2007-04-01

    During the last few decades, accuracy in photon and electron radiotherapy has increased substantially. This is partly due to enhanced linear accelerator technology, providing more flexibility in field definition (e.g. the usage of computer-controlled dynamic multileaf collimators), which led to intensity modulated radiotherapy (IMRT). Important improvements have also been made in the treatment planning process, more specifically in the dose calculations. Originally, dose calculations relied heavily on analytic, semi-analytic and empirical algorithms. The more accurate convolution/superposition codes use pre-calculated Monte Carlo dose "kernels" partly accounting for tissue density heterogeneities. It is generally recognized that the Monte Carlo method is able to increase accuracy even further. Since the second half of the 1990s, several Monte Carlo dose engines for radiotherapy treatment planning have been introduced. To enable the use of a Monte Carlo treatment planning (MCTP) dose engine in clinical circumstances, approximations have been introduced to limit the calculation time. In this paper, the literature on MCTP is reviewed, focussing on patient modeling, approximations in linear accelerator modeling and variance reduction techniques. An overview of published comparisons between MC dose engines and conventional dose calculations is provided for phantom studies and clinical examples, evaluating the added value of MCTP in the clinic. An overview of existing Monte Carlo dose engines and commercial MCTP systems is presented and some specific issues concerning the commissioning of a MCTP system are discussed.

  10. Boron neutron capture therapy for the treatment of oral cancer in the hamster cheek pouch model

    International Nuclear Information System (INIS)

    We have proposed and validated the hamster cheek pouch model of oral cancer for BNCT studies separately. We herein report the first evidence of the usefulness of BNCT for the treatment of oral cancer in an experimental model. We assessed the response of hamster cheek pouch tumors, precancerous tissue and normal oral tissue to BPA-mediated BNCT employing the thermalized epithermal beam of the RA-6 Reactor at the Bariloche Atomic Center. BNCT leads to complete remission by 15 days post-treatment in 78% of tumors and partial remission in a further 13% of tumors with virtually no damage to normal tissue. (author)

  11. Neutron flux measurements with Monte Carlo verification at the thermal column of a TRIGA MARK II reactor: Feasibility study for a BNCT facility

    International Nuclear Information System (INIS)

    The treatment of the malignant brain tumor through Boron Neutron Capture Therapy (BNCT) requires a high-flux neutron source. The Malaysian TRIGA Mark II reactor was investigated for a proposed BNCT facility. The neutron flux was measured along the central stringer of the thermal column and the outermost positions of the other stringers. The unfolding foil method was applied here. We have used Al, As, Au, Co, In, Mo, Ni and Re foils and Cd as a cover with 19 useful reactions in this study. The infinitely diluted foil activity was calculated and used in the SAND-II code (Spectrum Analysis by Neutron Detectors) to calculate the neutron flux. The reactor was also simulated using Monte Carlo code (MCNP5) and the neutron flux was calculated along the thermal column. The measured and calculated neutron flux along the thermal column show good agreement. The minimum epithermal neutron intensity required for BNCT is achieved up to position 22 with a mixed neutron-gamma beam. A suggested MCNP simulated modification of the reactor thermal column increased the neutron flux at distant positions from the reactor core but the epithermal neutron part was below the minimum requirement for a BNCT facility. The photon flux calculations along the thermal column show relatively high results which should be filtered. The calculation of the neutron and gamma dose in a head phantom (water) indicated that the available neutron spectrum requires modifications to increase the epithermal part of the neutrons and filter the gamma ray contamination. (author)

  12. Are high energy proton beams ideal for AB‐BNCT? A brief discussion from the viewpoint of fast neutron contamination control

    International Nuclear Information System (INIS)

    High energy proton beam (>8 MeV) is favorable for producing neutrons with high yield. However, the produced neutrons are of high energies. These high energy neutrons can cause severe fast neutron contamination and degrade the BNCT treatment quality if they are not appropriately moderated. Hence, this study aims to briefly discuss the issue, from the viewpoint of fast neutron contamination control, whether high energy proton beam is ideal for AB-BNCT or not. In this study, D2O, PbF4, CaF2, and Fluental™ were used standalone as moderator materials to slow down 1-, 6-, and 10-MeV parallelly incident neutrons. From the calculated results, we concluded that neutrons produced by high energy proton beam could not be easily moderated by a single moderator to an acceptable contamination level and still with reasonable epithermal neutron beam intensity. Hence, much more complicated and sophisticated designs of beam shaping assembly have to be developed when using high energy proton beams. - Highlights: • The fast neutron contamination profiles of 3 different moderator materials were discussed. • D2O, PbF4 and Fluental™ were tested as standalone moderators. • Standalone moderator cannot effectively suppress fast neutrons higher than 1 MeV. • AB-BNCT by high energy proton beam suffers serious fast neutron contamination. • The use of high energy protons (>8 MeV) for AB-BNCT should be carefully evaluated

  13. Radiation field characterization of a BNCT research facility using Monte Carlo method - code MCNP-4B

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy - BNCT - is a selective cancer treatment and arises as an alternative therapy to treat cancer when usual techniques - surgery, chemotherapy or radiotherapy - show no satisfactory results. The main proposal of this work is to project a facility to BNCT studies. This facility relies on the use of an Am Be neutron source and on a set of moderators, filters and shielding which will provide the best neutron/gamma beam characteristic for these Becton studies, i.e., high intensity thermal and/or epithermal neutron fluxes and with the minimum feasible gamma rays and fast neutrons contaminants. A computational model of the experiment was used to obtain the radiation field in the sample irradiation position. The calculations have been performed with the MCNP 4B Monte Carlo Code and the results obtained can be regarded as satisfactory, i.e., a thermal neutron fluencyNT = 1,35x108 n/cm , a fast neutron dose of 5,86x10-10 Gy/NT and a gamma ray dose of 8,30x10-14 Gy/NT. (author)

  14. Treatment planning for Hodgkin's Disease: a patterns of care study

    International Nuclear Information System (INIS)

    Purpose: To conduct a survey of the process of treatment planning for the radiation treatment of Hodgkin's Disease in the United States, and to compare survey results with consensus guidelines as determined by recognized experts. Methods and Materials: A consensus committee developed guidelines for the radiotherapeutic management of Hodgkin's Disease. A series of survey forms were designed to evaluate the standards of practice and compare these with the consensus guidelines. A total of 61 facilities divided evenly into the strata of academic, hospital based, and free standing had eligible Hodgkin's Disease cases. There were 275 eligible cases of Hodgkin's Disease evaluated. Data collected from the radiation oncology records included treatment-specific parameters such as energy, dose, blocking, and calculations, as well as treatment planning practices. Statistical analysis was performed on each data element and for all institution strata. Results: For a number of treatment parameters, there were some discrepancies noted between the current United States practice and the consensus guidelines. Some significant differences were found in practice between the stratified institution types. A representative sample of results are: the majority of Hodgkin's Disease patients are treated with x-ray energies in the recommended range, between 4 and 10 MV. Standard mantle (for upper extended field treatment) and modified spade (for lower extended field treatments) are the fields of choice for all types of facilities. The consensus guidelines recommended that dose calculations at multiple points be obtained; however, 15% of patients in the survey received only a single point calculation. Current irregular field dosimetry calculation software does not take account of inhomogeneities. Thirty percent of Hodgkin's Disease patients do not receive a gap calculation for the abutment of upper and lower extended fields. In 70% of treatment fields, no compensation is used. Very few patients

  15. Ultrafast treatment plan optimization for volumetric modulated arc therapy (VMAT)

    International Nuclear Information System (INIS)

    Purpose: To develop a novel aperture-based algorithm for volumetric modulated arc therapy (VMAT) treatment plan optimization with high quality and high efficiency. Methods: The VMAT optimization problem is formulated as a large-scale convex programming problem solved by a column generation approach. The authors consider a cost function consisting two terms, the first enforcing a desired dose distribution and the second guaranteeing a smooth dose rate variation between successive gantry angles. A gantry rotation is discretized into 180 beam angles and for each beam angle, only one MLC aperture is allowed. The apertures are generated one by one in a sequential way. At each iteration of the column generation method, a deliverable MLC aperture is generated for one of the unoccupied beam angles by solving a subproblem with the consideration of MLC mechanic constraints. A subsequent master problem is then solved to determine the dose rate at all currently generated apertures by minimizing the cost function. When all 180 beam angles are occupied, the optimization completes, yielding a set of deliverable apertures and associated dose rates that produce a high quality plan. Results: The algorithm was preliminarily tested on five prostate and five head-and-neck clinical cases, each with one full gantry rotation without any couch/collimator rotations. High quality VMAT plans have been generated for all ten cases with extremely high efficiency. It takes only 5-8 min on CPU (MATLAB code on an Intel Xeon 2.27 GHz CPU) and 18-31 s on GPU (CUDA code on an NVIDIA Tesla C1060 GPU card) to generate such plans. Conclusions: The authors have developed an aperture-based VMAT optimization algorithm which can generate clinically deliverable high quality treatment plans at very high efficiency.

  16. Power Burst Facility/Boron Neutron Capture Therapy Program for cancer treatment

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.); Dorn, R.V. III.

    1990-08-01

    This report discusses monthly progress in the Power Boron Facility/Boron Neutron Capture Therapy (PBF/BNCT) Program for Cancer Treatment. Highlights of the PBF/BNCT Program during August 1990 include progress within the areas of: Gross Boron Analysis in Tissue, Blood, and Urine, boron microscopic (subcellular) analytical development, noninvasive boron quantitative determination, analytical radiation transport and interaction modeling for BNCT, large animal model studies, neutron source and facility preparation, administration and common support and PBF operations.

  17. MO-C-BRF-01: Pediatric Treatment Planning I: Overview of Planning Strategies

    Energy Technology Data Exchange (ETDEWEB)

    Olch, A [Childrens Hospital of LA, Los Angeles, CA (United States); Hua, C [St. Jude Childrens Research Hospital, Memphis, TN (United States)

    2014-06-15

    Most Medical Physicists working in radiotherapy departments see few pediatric patients. This is because, fortunately, children get cancer at a rate nearly 100 times lower than adults. Children have not smoked, abused alcohol, or been exposed to environmental carcinogens for decades, and of course, have not fallen victim to the aging process. Children get very different cancers than adults. Breast or prostate cancers, typical in adults, are rarely seen in children but instead a variety of tumors occur in children that are rarely seen in adults; examples are germinomas, ependymomas and primitive neuroectodermal tumors, which require treatment of the child's brain or neuroblastoma, requiring treatment in the abdomen. The treatment of children with cancer using radiation therapy is one of the most challenging planning and delivery problems facing the physicist. This is because bones, brain, breast tissue, and other organs are more sensitive to radiation in children than in adults. Because most therapy departments treat mostly adults, when the rare 8 year-old patient comes to the department for treatment, the physicist may not understand the clinical issues of his disease which drive the planning and delivery decisions. Additionally, children are more prone than adults to developing secondary cancers after radiation. This fact has important implications for the choice of delivery techniques, especially when considering IMRT. For bilateral retinoblastoma for example, an irradiated child has a 50% chance of developing a second cancer by age 50. In the first presentation, an overview of childhood cancers and their corresponding treatment techniques will be given. These can be some of the most complex treatments that are delivered in the radiation therapy department. These cancers include leukemia treated with total body irradiation, medulloblastoma, treated with craniospinal irradiation plus a conformal boost to the posterior fossa, neuroblastoma, requiring focal

  18. MO-C-BRF-01: Pediatric Treatment Planning I: Overview of Planning Strategies

    International Nuclear Information System (INIS)

    Most Medical Physicists working in radiotherapy departments see few pediatric patients. This is because, fortunately, children get cancer at a rate nearly 100 times lower than adults. Children have not smoked, abused alcohol, or been exposed to environmental carcinogens for decades, and of course, have not fallen victim to the aging process. Children get very different cancers than adults. Breast or prostate cancers, typical in adults, are rarely seen in children but instead a variety of tumors occur in children that are rarely seen in adults; examples are germinomas, ependymomas and primitive neuroectodermal tumors, which require treatment of the child's brain or neuroblastoma, requiring treatment in the abdomen. The treatment of children with cancer using radiation therapy is one of the most challenging planning and delivery problems facing the physicist. This is because bones, brain, breast tissue, and other organs are more sensitive to radiation in children than in adults. Because most therapy departments treat mostly adults, when the rare 8 year-old patient comes to the department for treatment, the physicist may not understand the clinical issues of his disease which drive the planning and delivery decisions. Additionally, children are more prone than adults to developing secondary cancers after radiation. This fact has important implications for the choice of delivery techniques, especially when considering IMRT. For bilateral retinoblastoma for example, an irradiated child has a 50% chance of developing a second cancer by age 50. In the first presentation, an overview of childhood cancers and their corresponding treatment techniques will be given. These can be some of the most complex treatments that are delivered in the radiation therapy department. These cancers include leukemia treated with total body irradiation, medulloblastoma, treated with craniospinal irradiation plus a conformal boost to the posterior fossa, neuroblastoma, requiring focal

  19. State of the art of high energy photon treatment planning

    International Nuclear Information System (INIS)

    A virtual revolution in computer capability has occurred in the last few years, based largely on rapidly decreasing costs and increasing reliability of digital memory and mass-storage capability. These developments have now made it possible to consider the application of both computer and display technologies to a much broader range of problems in radiation therapy including dose computation, therapy planning and treatment verification. Various similar methods of three-dimensional dose computations in heterogeneous media capable of 2-3% accuracy are likely to be available, but significant work still remains especially for high energy X-rays where electron transport, and possibly pair production, needs to be considered. Innovative display and planning techniques are emerging and show great promise for the future. No doubt these advances will lead to substantially improved treatment planning systems in the next few years. However, it must be emphasized that for many of these applications a tremendous software and hardware development effort is required. Yet it is not clear whether the investments and efforts for improved capabilities and accuracies are warranted with respect to clinical outcome. The question must be addressed for the advancement in the practice of radiotherapy

  20. On the quality of treatment planning systems in radiation therapy

    International Nuclear Information System (INIS)

    Purpose: To assist in the design of quality assurance activities of 3D treatment planning systems (TPSs), a postal survey has been carried out, addressing TPS users on quality characteristics and their relative importance in clinical routine planning. Material and methods: The approach as described in ISO/IEC 9126 has been used to analyze TPS quality. Both TPS quality characteristics and how these may be used to establish a quality model are included. A questionnaire on ranking of these TPS quality characteristics has been sent out to the German DEGRO members in February 1997. Results: By the end of July 1997, 90 individual assessments (of 45 physicists, 35 physicians, and 10 radiographers) had been collected. On an importance scale from 1 (very important) to 6 (unimportant), weight factors of 1.71 (portability), 2.84 (maintainability), 3.18 (efficiency), 3.85 (usability), 4.52 (functionality) and 4.90 (reliability) have been determined from the data. From user satisfaction data also obtained from the questionnaire responses, baseline quality indices could be established from the quality model for the RTPs Cadplan, TMS Helax, and Voxelplan. Conclusion: The responses highlight the need for TPS quality assurance at the same time along the lines of safety-related, research-oriented, and interactive end-user software systems in radiotherapy treatment planning. Quality assurance activities must take this into account. Their effect can be monitored by using quality indices as derivable from the established quality model. (orig.)

  1. B Plant treatment, storage, and disposal (TSD) units inspection plan

    International Nuclear Information System (INIS)

    This inspection plan is written to meet the requirements of WAC 173-303 for operations of a TSD facility. Owners/operators of TSD facilities are required to inspection their facility and active waste management units to prevent and/or detect malfunctions, discharges and other conditions potentially hazardous to human health and the environment. A written plan detailing these inspection efforts must be maintained at the facility in accordance with Washington Administrative Code (WAC), Chapter 173-303, ''Dangerous Waste Regulations'' (WAC 173-303), a written inspection plan is required for the operation of a treatment, storage and disposal (TSD) facility and individual TSD units. B Plant is a permitted TSD facility currently operating under interim status with an approved Part A Permit. Various operational systems and locations within or under the control of B Plant have been permitted for waste management activities. Included are the following TSD units: Cell 4 Container Storage Area; B Plant Containment Building; Low Level Waste Tank System; Organic Waste Tank System; Neutralized Current Acid Waste (NCAW) Tank System; Low Level Waste Concentrator Tank System. This inspection plan complies with the requirements of WAC 173-303. It addresses both general TSD facility and TSD unit-specific inspection requirements. Sections on each of the TSD units provide a brief description of the system configuration and the permitted waste management activity, a summary of the inspection requirements, and details on the activities B Plant uses to maintain compliance with those requirements

  2. In-house quality check of external beam plans using 3D treatment planning systems - a DVH comparison.

    Science.gov (United States)

    Kumar, Ayyalasomayajula Anil; Akula, Roopa Rani; Ayyangar, Komanduri; P, Krishna Reddy; Vuppu, Srinivas; Narayana, P V Lakshmi; Rao, A Durga Prasada

    2016-01-01

    This paper presents a new approach towards the quality assurance of external beam plans using in-house-developed DICOM import and export software in a clinical setup. The new approach is different from what is currently used in most clinics, viz., only MU and point dose are verified. The DICOM-RT software generates ASCII files to import/export structure sets, treatment beam data, and dose-volume histo-grams (DVH) from one treatment planning system (TPS) to the other. An efficient and reliable 3D planning system, ROPS, was used for verifying the accuracy of treatment plans and treatment plan parameters. With the use of this new approach, treatment plans planned using Varian Eclipse planning system were exported to ROPS planning system. Important treatment and dosimetrical data, such as the beam setup accuracy, target dose coverage, and dose to critical structures, were also quantitatively verified using DVH comparisons. Two external beam plans with diverse photon energies were selected to test the new approach. The satisfactory results show that the new approach is feasible, easy to use, and can be used as an adjunct test for patient treatment quality check. PMID:27167271

  3. Sci—Thur PM: Planning and Delivery — 06: Real-Time Interactive Treatment Planning

    International Nuclear Information System (INIS)

    Purpose: To describe and evaluate a novel system for generalized Real-Time Interactive Planning (RTIP) applied to head and neck (H and N) VMAT. Methods: The clinician interactively manipulates dose distributions using DVHs, isodoses, or rate of dose fall-off, which may be subjected to user-defined constraints. Dose is calculated using a fast Achievable Dose Estimate (ADE) algorithm, which simulates the limits of what can be achieved during treatment. After each manipulation contributing fluence elements are modified and the dose distribution updates in effectively real-time. For H and N VMAT planning, structure sets for 11 patients were imported into RTIP. Each dose distribution was interactively modified to minimize OAR dose while constraining target DVHs. The resulting RTIP DVHs were transferred to the Eclipse™ VMAT optimizer, and conventional VMAT optimization was performed. Results: Dose calculation and update times for the ADE algorithm ranged from 2.4 to 22.6 milliseconds, thus facilitating effectively real-time manipulation of dose distributions. For each of the 11 H and N VMAT cases, the RTIP process took ∼2–10 minutes. All RTIP plans exhibited acceptable PTV coverage, mean dose, and max dose. 10 of 11 RTIP plans achieved substantially improved sparing of one or more OARs without compromising dose to targets or other OARs. Importantly, 10 of the 11 RTIP plans required only one or two post-RTIP optimizations. Conclusions: RTIP is a novel system for manipulating and updating achievable dose distributions in real-time. H and N VMAT plans generated using RTIP demonstrate improved OAR sparing and planning efficiency. Disclosures: One author has a commercial interest in the presented materials

  4. Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy

    Directory of Open Access Journals (Sweden)

    Bracko Matej

    2010-02-01

    Full Text Available Abstract Background Electrochemotherapy treats tumors by combining specific chemotherapeutic drugs with an intracellular target and electric pulses, which increases drug uptake into the tumor cells. Electrochemotherapy has been successfully used for treatment of easily accessible superficial tumor nodules. In this paper, we present the first case of deep-seated tumor electrochemotherapy based on numerical treatment planning. Methods The aim of our study was to treat a melanoma metastasis in the thigh of a patient. Treatment planning for electrode positioning and electrical pulse parameters was performed for two different electrode configurations: one with four and another with five long needle electrodes. During the procedure, the four electrode treatment plan was adopted and the patient was treated accordingly by electrochemotherapy with bleomycin. The response to treatment was clinically and radiographically evaluated. Due to a partial response of the treated tumor, the metastasis was surgically removed after 2 months and pathological analysis was performed. Results A partial response of the tumor to electrochemotherapy was obtained. Histologically, the metastasis showed partial necrosis due to electrochemotherapy, estimated to represent 40-50% of the tumor. Based on the data obtained, we re-evaluated the electrical treatment parameters in order to correlate the treatment plan with the clinical response. Electrode positions in the numerical model were updated according to the actual positions during treatment. We compared the maximum value of the measured electric current with the current predicted by the model and good agreement was obtained. Finally, tumor coverage with an electric field above the reversible threshold was recalculated and determined to be approximately 94%. Therefore, according to the calculations, a small volume of tumor cells remained viable after electrochemotherapy, and these were sufficient for tumor regrowth

  5. Boron neutron capture therapy as new treatment for clear cell sarcoma: Trial on different animal model

    International Nuclear Information System (INIS)

    Clear cell sarcoma (CCS) is a rare malignant tumor with a poor prognosis. In our previous study, the tumor disappeared under boron neutron capture therapy (BNCT) on subcutaneously-transplanted CCS-bearing animals. In the present study, the tumor disappeared under this therapy on model mice intramuscularly implanted with three different human CCS cells. BNCT led to the suppression of tumor-growth in each of the different model mice, suggesting its potentiality as an alternative to, or integrative option for, the treatment of CCS. - Highlights: • BNCT with the use of L-BPA was applied for three human clear cell sarcoma (CCS) cell lines. • BNCT trial was performed on a newly established intramuscularly CCS-bearing animal model. • A significant decrease of the tumor-volume was seen by single BNCT with the use of L-BPA. • A multiple BNCT application would be required for controlling the growth of any residual tumors

  6. 3D volume visualization in remote radiation treatment planning

    Science.gov (United States)

    Yun, David Y.; Garcia, Hong-Mei C.; Mun, Seong K.; Rogers, James E.; Tohme, Walid G.; Carlson, Wayne E.; May, Stephen; Yagel, Roni

    1996-03-01

    This paper reports a novel applications of 3D visualization in an ARPA-funded remote radiation treatment planning (RTP) experiment, utilizing supercomputer 3D volumetric modeling power and NASA ACTS (Advanced Communication Technology Satellite) communication bandwidths at the Ka-band range. The objective of radiation treatment is to deliver a tumorcidal dose of radiation to a tumor volume while minimizing doses to surrounding normal tissues. High performance graphics computers are required to allow physicians to view a 3D anatomy, specify proposed radiation beams, and evaluate the dose distribution around the tumor. Supercomputing power is needed to compute and even optimize dose distribution according to pre-specified requirements. High speed communications offer possibilities for sharing scarce and expensive computing resources (e.g., hardware, software, personnel, etc.) as well as medical expertise for 3D treatment planning among hospitals. This paper provides initial technical insights into the feasibility of such resource sharing. The overall deployment of the RTP experiment, visualization procedures, and parallel volume rendering in support of remote interactive 3D volume visualization will be described.

  7. DVHs evaluation in brain metastases stereotactic radiotherapy treatment plans

    International Nuclear Information System (INIS)

    Purpose: The aim of this work is to report a retrospective study of radiobiological indicators based on Dose-Volume Histograms analysis obtained by stereotactic radiotherapy treatments. Methods and materials: Fifty-five patients for a total of sixty-seven brain metastases with a mean target volume of 8.49 cc were treated by Dynamic Conformal Arc Therapy (DCAT) and Intensity-Modulated Stereotactic Radiotherapy (IMRST). The Delivered prescription dose was chosen on the basis of tumor size and location so as to ensure a 100% isodose coverage to the target volume. Results: The treatment plans reported a mean value of 10% and 2.19% for the inhomogeneity and conformal index, respectively. The F factor showed we overdosed sixty-three patients delivering an additional 7% dose more than calculated values. The radiobiological parameters: TCP and NTCP showed a complete tumor control limiting the organs at risk damage. Conclusion: One goal of stereotactic radiotherapy is to design a treatment plan in which the steep dose gradient achievable minimizes the amount of radiation delivered outside the tumor region. This technique allows to deliver a much larger dose to the target without exceeding the radiation-related tolerance of normal tissues and improving patients' quality of life

  8. A Monte Carlo dose calculation tool for radiotherapy treatment planning

    Science.gov (United States)

    Ma, C.-M.; Li, J. S.; Pawlicki, T.; Jiang, S. B.; Deng, J.; Lee, M. C.; Koumrian, T.; Luxton, M.; Brain, S.

    2002-05-01

    A Monte Carlo user code, MCDOSE, has been developed for radiotherapy treatment planning (RTP) dose calculations. MCDOSE is designed as a dose calculation module suitable for adaptation to host RTP systems. MCDOSE can be used for both conventional photon/electron beam calculation and intensity modulated radiotherapy (IMRT) treatment planning. MCDOSE uses a multiple-source model to reconstruct the treatment beam phase space. Based on Monte Carlo simulated or measured beam data acquired during commissioning, source-model parameters are adjusted through an automated procedure. Beam modifiers such as jaws, physical and dynamic wedges, compensators, blocks, electron cut-outs and bolus are simulated by MCDOSE together with a 3D rectilinear patient geometry model built from CT data. Dose distributions calculated using MCDOSE agreed well with those calculated by the EGS4/DOSXYZ code using different beam set-ups and beam modifiers. Heterogeneity correction factors for layered-lung or layered-bone phantoms as calculated by both codes were consistent with measured data to within 1%. The effect of energy cut-offs for particle transport was investigated. Variance reduction techniques were implemented in MCDOSE to achieve a speedup factor of 10-30 compared to DOSXYZ.

  9. Nevada Test Site Site Treatment Plan. Revision 2

    International Nuclear Information System (INIS)

    Treatment Plans (STPS) are required for facilities at which the US Department of Energy (DOE) or stores mixed waste, defined by the Federal Facility Compliance Act (FFCAct) as waste containing both a hazardous waste subject to the Resource Conservation and Recovery Act and a radioactive material subject to the Atomic Energy Act. On April 6, 1993, DOE published a Federal Register notice (58 FR 17875) describing its proposed process for developing the STPs in three phases including a Conceptual, a Draft, and a Proposed Site Treatment Plan (PSTP). All of the DOE Nevada Operations Office STP iterations have been developed with the state of Nevada's input. The options and schedules reflect a ''bottoms-up'' approach and have been evaluated for impacts on other DOE sites, as well as impacts to the overall DOE program. Changes may have occurred in the preferred option and associated schedules between the PSTP, which was submitted to the state of Nevada and US Environmental Protection Agency April 1995, and the Final STP (hereafter referred to as the STP) as treatment evaluations progressed. The STP includes changes that have occurred since the submittal of the PSTP as a result of state-to-state and DOE-to-state discussions

  10. Generic Planning Target Margin for Rectal Cancer Treatment Setup Variation

    International Nuclear Information System (INIS)

    Purpose: To calculate the generic planning target margin (GPTM) for patients receiving radiation therapy (RT) for rectal cancer placed in a prone position with a customized cradle for small-bowel exclusion. Methods and Materials: A total of 25 consecutive rectal cancer patients were treated for 25 or 28 fractions in a prone position using a cradle to maximize small bowel exclusion. Treatment planning computed tomography (CT) scans were used to create orthogonally digitally reconstructed radiographs (DRRs) for portal image registration, which were compared with daily portal images from an electronic portal-imaging device (EPID). Translation values needed to align the DRRs and EPIDs were recorded for the superior to inferior (SI), right to left (RL), and anterior to posterior (AP) directions, and used to calculate the GPTM using the four-parameter model. Age, weight, and body mass index were tested compared with the setup variation using a Pearson correlation and a t test for significance. Gender versus setup variation was compared with a t test. Results: A total of 1,723 EPID images were reviewed. The GPTM was 10 mm superior, 8 mm inferior, 7 mm RL and 10 mm AP. Age and gender were unrelated to setup variation. Weight was significantly associated with systematic AP variation (p < 0.05). BMI was significantly associated with systematic SI (p < 0.05) and AP (p < 0.01) variation and random RL variation (p < 0.05). Conclusions: The GPTM for rectal cancer is asymmetric with a maximum of 10 mm in the superior, anterior and posterior dimensions. Body mass index may effect setup variation. Research using advanced treatment planning should include these margins in the planning target volume definition.

  11. Treatment planning for children with attention-deficit/hyperactivity disorder: treatment utilization and family preferences

    Directory of Open Access Journals (Sweden)

    William B Brinkman

    2011-01-01

    Full Text Available William B Brinkman, Jeffery N EpsteinDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USABackground: Attention-deficit/hyperactivity disorder (ADHD is a common condition that often results in child and family functional impairments. Although there are evidence-based treatment modalities available, implementation of and persistence with treatment plans vary with patients. Family preferences also vary and may contribute to variability in treatment utilization.Objective: The objective of this study is to describe the evidence-based treatments available for ADHD, identify patterns of use for each modality, and examine patient and parent treatment preferences.Method: Literature review.Results: Treatment options differ on benefits and risks/costs. Therefore, treatment decisions are preference sensitive and depend on how an informed patient/parent values the tradeoffs between options. Literature on patient and parent ADHD treatment preferences is based on quantitative research assessing the construct of treatment acceptability and qualitative and quantitative research that assesses preferences from a broader perspective. After a child is diagnosed with ADHD, a variety of factors influence the initial selection of treatment modalities that are utilized. Initial parent and child preferences are shaped by their beliefs about the nature of the child's problems and by information (and misinformation received from a variety of sources, including social networks, the media, and health care providers. Subsequently, preferences become further informed by personal experience with various treatment modalities. Over time, treatment plans are revisited and revised as families work with their health care team to establish a treatment plan that helps their child achieve goals while minimizing harms and costs.Conclusions: Studies have not been able to determine the extent to which

  12. A study of computational dosimetry and boron biodistribution for ex – situ lung BNCT at RA-3 Reactor

    International Nuclear Information System (INIS)

    Within the context of the preclinical ex-situ BNCT Project for the treatment of diffuse lung metastases, we performed boron biodistribution studies in a sheep model and computational dosimetry studies in human lung to evaluate the potential therapeutic efficacy of the proposed technique. Herein we report preliminary data that supports the use of the sheep model as an adequate human surrogate in terms of boron kinetics and uptake in clinically relevant tissues. Furthermore, the estimation of the potential therapeutic efficacy of the proposed treatment in humans, based on boron uptake values in the large animal model, yields promising tumor control probability values even in the most conservative scenario considered. (author)

  13. 3-Dimentional radiotherapy versus conventional treatment plans for gastric cancer

    Directory of Open Access Journals (Sweden)

    Aghili M

    2010-11-01

    Full Text Available "n Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:Arial; mso-bidi-theme-font:minor-bidi;} Background: The current standard of adjuvant management for gastric cancer after curative resection based on the results of intergroup 0116 is concurrent chemoradiation. Current guidelines for designing these challenging fields still include two-dimensional simulation with simple AP-PA parallel opposed design. However, the implementation of radiotherapy (RT remains a concern. Our objective was to compare three-dimensional (3D techniques to the more commonly used AP-PA technique."n"nMethods: A total of 24 patients with stages II-IV adenocarcinoma of the stomach were treated with adjuvant postoperative chemoradiation with simple AP-PA technique, using Cobalt-60. Total radiation dose was 50.4Gy. Landmark-based fields were simulated to assess PTV coverage. For each patient, three additional radiotherapy treatment plans were generated using three-dimensional (3D technique. The four treatment plans were then compared for target volume coverage and dose to normal tissues (liver, spinal cord, kidneys using dose volume histogram (DVH analysis."n"nResults: The three-dimensional planning techniques provided 10% superior PTV coverage compared to conventional AP-PA fields (p<0.001. Comparative DVHs for the right kidney, left kidney

  14. Status of quality assurance of treatment planning systems in Europe

    International Nuclear Information System (INIS)

    Quality assurance, QA, of treatment planning systems, TPS, is generally performed by individual physicists directed to the specific needs of their own institution. In the past a number of tests has been performed by national societies mainly of the accuracy of dose calculation algorithms. Little information is available on national recommendations in the field of QA of TPS. A questionnaire was therefore distributed amongst European countries to review national activities in this field. From the 19 responding countries 7 indicated that only limited efforts are underway, 8 answered that a working group is evaluating their specific national requirements while in 4 countries a document is drafted or tested in various clinics. The main part of these reports concerns detailed descriptions of acceptance tests and constancy checks, including action levels and frequency tests. Additional information concerns recommendations for documentation and short descriptions of dose calculation algorithms. In some countries, having a large number of TPS of the same type, regular users meetings and/or close co-operation with the manufacturer are employed to exchange information concerning QA of their systems. Some of the working groups mentioned separate checks of 2-D and 3-D features of a TPS. Special attention should also be paid to monitor unit computation programs. The survey showed that currently not many countries in Europe have national recommendations on the QA of treatment planning systems. ESTRO and other international organizations, in co-operation with national societies and manufacturers, might therefore play an important role in stimulating the drafting of guidelines for QA of treatment planning systems

  15. IMRT Quality Assurance Using a Second Treatment Planning System

    International Nuclear Information System (INIS)

    We used a second treatment planning system (TPS) for independent verification of the dose calculated by our primary TPS in the context of patient-specific quality assurance (QA) for intensity-modulated radiation therapy (IMRT). QA plans for 24 patients treated with inverse planned dynamic IMRT were generated using the Nomos Corvus TPS. The plans were calculated on a computed tomography scan of our QA phantom that consists of three Solid Water slabs sandwiching radiochromic films, and an ion chamber that is inserted into the center slab of the phantom. For the independent verification, the dose was recalculated using the Varian Eclipse TPS using the multileaf collimator files and beam geometry from the original plan. The data was then compared in terms of absolute dose to the ion chamber volume as well as relative dose on isodoses calculated at the film plane. The calculation results were also compared with measurements performed for each case. When comparing ion chamber doses, the mean ratio was 0.999 (SD 0.010) for Eclipse vs. Corvus, 0.988 (SD 0.020) for the ionization chamber measurements vs. Corvus, and 0.989 (SD 0.017) for the ionization chamber measurements vs. Eclipse. For 2D doses with gamma histogram, the mean value of the percentage of pixels passing the criteria of 3%, 3 mm was 94.4 (SD 5.3) for Eclipse vs. Corvus, 85.1 (SD 10.6) for Corvus vs. film, and 93.7 (SD 4.1) for Eclipse vs. film; and for the criteria of 5%, 3 mm, 98.7 (SD 1.5) for Eclipse vs. Corvus, 93.0 (SD 7.8) for Corvus vs. film, and 98.0 (SD 1.9) for Eclipse vs. film. We feel that the use of the Eclipse TPS as an independent, accurate, robust, and time-efficient method for patient-specific IMRT QA is feasible in clinic.

  16. Treatment planning for children with attention-deficit/hyperactivity disorder: treatment utilization and family preferences

    OpenAIRE

    Brinkman, William B.; Epstein, Jeffery N.

    2011-01-01

    William B Brinkman, Jeffery N EpsteinDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USABackground: Attention-deficit/hyperactivity disorder (ADHD) is a common condition that often results in child and family functional impairments. Although there are evidence-based treatment modalities available, implementation of and persistence with treatment plans vary with patients. Family preferences also vary...

  17. Computer assisted treatment planning for 125I ophthalmic plaque radiotherapy

    International Nuclear Information System (INIS)

    This paper describes a computer program for planning the treatment of ocular tumors with 125I plaques. The program permits the input of the tumor configuration into a model eye and facilitates the viewing of the relative geometry of the tumor and various eye structures in different perspectives. Custom-designed 125I plaques can be localized onto the globe, and dose distributions can be calculated and superimposed on the eye structures in any plane or on the inner eye surface. The program allows efficient evaluation of the plaque design in terms of radiation dose distribution relative to the tumor and critical structures

  18. Conformal Radiotherapy: Physics, Treatment Planning and Verification. Proceedings book

    International Nuclear Information System (INIS)

    The goal of conformal radiotherapy is to establish radiation dose distributions that conform tightly to the target volume in view of limiting radiation to normal tissues. Conformal radiotherapy significantly improves both local control and palliation and thus contributes to increase survival and to improve the quality of life. The subjects covered by the symposium include : (1) conformal radiotherapy and multi-leaf collimation; (2) three dimensional imaging; (3) treatment simulation, planning and optimization; (4) quality assurance; and (5) dosimetry. The book of proceedings contains the abstracts of the invited lectures, papers and poster presentations as well as the full papers of these contributions

  19. Conformal Radiotherapy: Physics, Treatment Planning and Verification. Proceedings book

    Energy Technology Data Exchange (ETDEWEB)

    De Wagter, C. [ed.

    1995-12-01

    The goal of conformal radiotherapy is to establish radiation dose distributions that conform tightly to the target volume in view of limiting radiation to normal tissues. Conformal radiotherapy significantly improves both local control and palliation and thus contributes to increase survival and to improve the quality of life. The subjects covered by the symposium include : (1) conformal radiotherapy and multi-leaf collimation; (2) three dimensional imaging; (3) treatment simulation, planning and optimization; (4) quality assurance; and (5) dosimetry. The book of proceedings contains the abstracts of the invited lectures, papers and poster presentations as well as the full papers of these contributions.

  20. An electron beam treatment planning system based on CT images

    International Nuclear Information System (INIS)

    This is a report on the computerization of the electron beam treatment planning system at the Cancer Institute Hospital. The computer aided calculation of electron beam dose distributions utilizes table look-up and interpolation of measured central axis depth doses and off-center ratios (OCR). Inhomogeneity correction is applied by the absorption equivalent thickness (AET) method. When OCR is expressed as a function of x-L instead of x/L, OCR is nearly independent of field size and shape, where x is the distance of the point from the central axis and L is half width. (author)

  1. Plutonium Finishing Plan (PFP) Treatment and Storage Unit Interim Status Closure Plan

    International Nuclear Information System (INIS)

    This document describes the planned activities and performance standards for closing the Plutonium Finishing Plant (PFP) Treatment and Storage Unit. The PFP Treatment and Storage Unit is located within the 234-52 Building in the 200 West Area of the Hanford Facility. Although this document is prepared based upon Title 40 Code of Federal Regulations (CFR), Part 265, Subpart G requirements, closure of the unit will comply with Washington Administrative Code (WAC) 173-303-610 regulations pursuant to Section 5.3 of the Hanford Federal Facility Agreement and Consent Order (Tri-Party Agreement) Action Plan (Ecology et al. 1996). Because the PFP Treatment and Storage Unit manages transuranic mixed (TRUM) waste, there are many controls placed on management of the waste. Based on the many controls placed on management of TRUM waste, releases of TRUM waste are not anticipated to occur in the PFP Treatment and Storage Unit. Because the intention is to clean close the PFP Treatment and Storage Unit, postclosure activities are not applicable to this closure plan. To clean close the unit, it will be demonstrated that dangerous waste has not been left onsite at levels above the closure performance standard for removal and decontamination. If it is determined that clean closure is not possible or is environmentally impractical, the closure plan will be modified to address required postclosure activities. The PFP Treatment and Storage Unit will be operated to immobilize and/or repackage plutonium-bearing waste in a glovebox process. The waste to be processed is in a solid physical state (chunks and coarse powder) and will be sealed into and out of the glovebox in closed containers. The containers of immobilized waste will be stored in the glovebox and in additional permitted storage locations at PFP. The waste will be managed to minimize the potential for spills outside the glovebox, and to preclude spills from reaching soil. Containment surfaces will be maintained to ensure

  2. IMRT treatment plans and functional planning with functional lung imaging from 4D-CT for thoracic cancer patients

    International Nuclear Information System (INIS)

    Currently, the inhomogeneity of the pulmonary function is not considered when treatment plans are generated in thoracic cancer radiotherapy. This study evaluates the dose of treatment plans on highly-functional volumes and performs functional treatment planning by incorporation of ventilation data from 4D-CT. Eleven patients were included in this retrospective study. Ventilation was calculated using 4D-CT. Two treatment plans were generated for each case, the first one without the incorporation of the ventilation and the second with it. The dose of the first plans was overlapped with the ventilation and analyzed. Highly-functional regions were avoided in the second treatment plans. For small targets in the first plans (PTV < 400 cc, 6 cases), all V5, V20 and the mean lung dose values for the highly-functional regions were lower than that of the total lung. For large targets, two out of five cases had higher V5 and V20 values for the highly-functional regions. All the second plans were within constraints. Radiation treatments affect functional lung more seriously in large tumor cases. With compromise of dose to other critical organs, functional treatment planning to reduce dose in highly-functional lung volumes can be achieved

  3. Vega library for processing DICOM data required in Monte Carlo verification of radiotherapy treatment plans

    International Nuclear Information System (INIS)

    Monte Carlo (MC) methods provide the most accurate to-date dose calculations in heterogeneous media and complex geometries, and this spawns increasing interest in incorporating MC calculations into treatment planning quality assurance process. This involves MC dose calculations for clinically produced treatment plans. To perform these calculations, a number of treatment plan parameters specifying radiation beam

  4. Microwave digestion techniques applied to determination of boron by ICP-AES in BNCT program

    International Nuclear Information System (INIS)

    Recently, boron neutron capture therapy (BNCT) has merged as an interesting option for the treatment of some kind of tumors where established therapies show no success. A molecular boronated species, enriched in 10B is administrated to the subject; it localizes in malignant tissues depending the kind of tumor and localization. Therefore, a very important fact in BNCT research is the detection of boron at trace or ultra trace levels precisely and accurately. This is extremely necessary as boronated species do localize in tumoral tissue and also localize in liver, kidney, spleen, skin, membranes. By this way, before testing a boronated species, it is mandatory to determine its biodistribution in a statistically meaning population, that is related with managing of a great number of samples. In the other hand, it is necessary to exactly predict when to begin the irradiation and to determine the magnitude of radiation to obtain the desired radiological dose for a specified mean boron concentration. This involves the determination of boron in whole blood, which is related with boron concentration in the tumor object of treatment. The methodology selected for the analysis of boron in whole blood and tissues must join certain characteristics: it must not be dependant of the chemical form of boron, it has to be fast and capable to determine boron accurately and precisely in a wide range of concentrations. The design and validation of experimental models involving animals in BNCT studies and the determination of boron in blood of animals and subjects upon treatment require reliable analytical procedures to determine boron quantitatively in those biologic materials. Inductively coupled plasma-atomic emission spectrometry (ICP-AES) using pneumatic nebulization is one of the most promising methods for boron analysis, but the sample must be liquid and have low solid concentration. In our case, biological tissues and blood, it is mandatory to mineralize and/or dilute samples

  5. Recent developments in radiation therapy planning and treatment optimization

    International Nuclear Information System (INIS)

    Radiation therapy of cancer is today going through a very dynamic development with the introduction of a large number of new treatment principles, new types of treatment units and new radiobiologically based optimization algorithms for treatment planning. All of these make use of the recent developments in three dimensional tumor diagnostics, molecular biology of cancer, the fractionation sensitivity of different tissues and most recently predictive assays of radiation sensitivity. The most efficient but also least developed area of treatment optimization is to use a few non uniform radiation beams directed towards the tumor. Today patient individual collimation with beam blocks or multi leaf collimators protect organs at risk laterally outside the tumor volume. Non uniform dose delivery also allows protection of normal tissues anterior, posterior and even inside the target volume by shaping the isodoses tightly around the tumor tissues and thereby also allowing longitudinal protection of normal tissues. Some of the most advanced new algorithms are even treating therapy optimization as an inverse problem where the optimal incident beam shapes are determined directly from the location of gross disease, presumed microscopic tumor spread and organs at risk. The optimization is then performed such that the probability, P+, to eradicate all clonogenic tumor cells without severely damaging healthy normal tissues is as high as possible. Already with a few non uniform beams the treatment outcome is within a few percent of what can be achieved with infinitely many co-planar beams in a dynamic mood. With such optimized non uniform treatments it should be possible to improve the treatment outcome by as much as 20% and more, particularly in patients with a local complex spread of the disease or several organs at risk. 78 refs., 1 tab., 7 figs

  6. Image correlation: meaning in clinical radioimmunotherapy dosimetry for treatment planning

    International Nuclear Information System (INIS)

    Image correlation has many potential applications in Nuclear Medicine: the combination of the high resolution anatomical delineation of structures as achievable with MRI/CT and the less spatially resolved but functional biochemical images from SPECT, benefits both modalities and is successful in clinical applications. In particular this is fundamental to obtain 1) the volume determination of tumours and normal organs and 2) the quantitation of the activity of radiolabelled antibodies in tumours and normal organs, necessary for the development of treatment strategies. Clinical reports of treatment planning in cerebral gliomas are showed in this paper: the modalities used are CT and SPECT with DTPA. The last has the property of showing the contour of the skull allowing an easier correlation by comparing it to the one that is even more visible by CT. This suggests to use anatomic markers or even surface fitting (Pellizzari algorithm)

  7. Patient-specific dosimetric endpoints based treatment plan quality control in radiotherapy

    International Nuclear Information System (INIS)

    In intensity modulated radiotherapy (IMRT), the optimal plan for each patient is specific due to unique patient anatomy. To achieve such a plan, patient-specific dosimetric goals reflecting each patient’s unique anatomy should be defined and adopted in the treatment planning procedure for plan quality control. This study is to develop such a personalized treatment plan quality control tool by predicting patient-specific dosimetric endpoints (DEs). The incorporation of patient specific DEs is realized by a multi-OAR geometry-dosimetry model, capable of predicting optimal DEs based on the individual patient’s geometry. The overall quality of a treatment plan is then judged with a numerical treatment plan quality indicator and characterized as optimal or suboptimal. Taking advantage of clinically available prostate volumetric modulated arc therapy (VMAT) treatment plans, we built and evaluated our proposed plan quality control tool. Using our developed tool, six of twenty evaluated plans were identified as sub-optimal plans. After plan re-optimization, these suboptimal plans achieved better OAR dose sparing without sacrificing the PTV coverage, and the dosimetric endpoints of the re-optimized plans agreed well with the model predicted values, which validate the predictability of the proposed tool. In conclusion, the developed tool is able to accurately predict optimally achievable DEs of multiple OARs, identify suboptimal plans, and guide plan optimization. It is a useful tool for achieving patient-specific treatment plan quality control. (paper)

  8. Patient-specific dosimetric endpoints based treatment plan quality control in radiotherapy

    Science.gov (United States)

    Song, Ting; Staub, David; Chen, Mingli; Lu, Weiguo; Tian, Zhen; Jia, Xun; Li, Yongbao; Zhou, Linghong; Jiang, Steve B.; Gu, Xuejun

    2015-11-01

    In intensity modulated radiotherapy (IMRT), the optimal plan for each patient is specific due to unique patient anatomy. To achieve such a plan, patient-specific dosimetric goals reflecting each patient’s unique anatomy should be defined and adopted in the treatment planning procedure for plan quality control. This study is to develop such a personalized treatment plan quality control tool by predicting patient-specific dosimetric endpoints (DEs). The incorporation of patient specific DEs is realized by a multi-OAR geometry-dosimetry model, capable of predicting optimal DEs based on the individual patient’s geometry. The overall quality of a treatment plan is then judged with a numerical treatment plan quality indicator and characterized as optimal or suboptimal. Taking advantage of clinically available prostate volumetric modulated arc therapy (VMAT) treatment plans, we built and evaluated our proposed plan quality control tool. Using our developed tool, six of twenty evaluated plans were identified as sub-optimal plans. After plan re-optimization, these suboptimal plans achieved better OAR dose sparing without sacrificing the PTV coverage, and the dosimetric endpoints of the re-optimized plans agreed well with the model predicted values, which validate the predictability of the proposed tool. In conclusion, the developed tool is able to accurately predict optimally achievable DEs of multiple OARs, identify suboptimal plans, and guide plan optimization. It is a useful tool for achieving patient-specific treatment plan quality control.

  9. A novel implementation of mARC treatment for non-dedicated planning systems using converted IMRT plans

    International Nuclear Information System (INIS)

    The modulated arc (mARC) technique has recently been introduced by Siemens as an analogue to VMAT treatment. However, up to now only one certified treatment planning system supports mARC planning. We therefore present a conversion algorithm capable of converting IMRT plans created by any treatment planning system into mARC plans, with the hope of expanding the availability of mARC to a larger range of clinical users and researchers. As additional advantages, our implementation offers improved functionality for planning hybrid arcs and provides an equivalent step-and-shoot plan for each mARC plan, which can be used as a back-up concept in institutions where only one linac is equipped with mARC. We present a feasibility study to outline a practical implementation of mARC plan conversion using Philips Pinnacle and Prowess Panther. We present examples for three different kinds of prostate and head-and-neck plans, for 6 MV and flattening-filter-free (FFF) 7 MV photon energies, which are dosimetrically verified. It is generally more difficult to create good quality IMRT plans in Pinnacle using a large number of beams and few segments. We present different ways of optimization as examples. By careful choosing the beam and segment arrangement and inversion objectives, we achieve plan qualities similar to our usual IMRT plans. The conversion of the plans to mARC format yields functional plans, which can be irradiated without incidences. Absolute dosimetric verification of both the step-and-shoot and mARC plans by point dose measurements showed deviations below 5% local dose, mARC plans deviated from step-and-shoot plans by no more than 1%. The agreement between GafChromic film measurements of planar dose before and after mARC conversion is excellent. The comparison of the 3D dose distribution measured by PTW Octavius 729 2D-Array with the step-and-shoot plans and with the TPS is well above the pass criteria of 90% of the points falling within 5% local dose and 3 mm distance

  10. Modeling the Agility MLC in the Monaco treatment planning system.

    Science.gov (United States)

    Snyder, Michael; Halford, Robert; Knill, Cory; Adams, Jeffrey N; Bossenberger, Todd; Nalichowski, Adrian; Hammoud, Ahmad; Burmeister, Jay

    2016-01-01

    We investigate the relationship between the various parameters in the Monaco MLC model and dose calculation accuracy for an Elekta Agility MLC. The vendor-provided MLC modeling procedure - completed first with external vendor participation and then exclusively in-house - was used in combination with our own procedures to investigate several sets of MLC modeling parameters to determine their effect on dose distributions and point-dose measurements. Simple plans provided in the vendor procedure were used to elucidate specific mechanical characteristics of the MLC, while ten complex treatment plans - five IMRT and five VMAT - created using TG-119-based structure sets were used to test clinical dosimetric effects of particular parameter choices. EDR2 film was used for the vendor fields to give high spatial resolution, while a combination of MapCHECK and ion chambers were used for the in-house TG-119-based proced-ures. The vendor-determined parameter set provided a reasonable starting point for the MLC model and largely delivered acceptable gamma pass rates for clinical plans - including a passing external evaluation using the IROC H&N phantom. However, the vendor model did not provide point-dose accuracy consistent with that seen in other treatment systems at our center. Through further internal testing it was found that there existed many sets of MLC parameters, often at opposite ends of their allowable ranges, that provided similar dosimetric characteristics and good agreement with planar and point-dose measurements. In particular, the leaf offset and tip leakage parameters compensated for one another if adjusted in opposite directions, which provided a level curve of acceptable parameter sets across all plans. Interestingly, gamma pass rates of the plans were less dependent upon parameter choices than point-dose measurements, suggesting that MLC modeling using only gamma evaluation may be generally an insufficient approach. It was also found that exploring all

  11. Volume rendering in treatment planning for moving targets

    International Nuclear Information System (INIS)

    Advances in computer technologies have facilitated the development of tools for 3-dimensional visualization of CT-data sets with volume rendering. The company Fovia has introduced a high definition volume rendering engine (HDVR trademark by Fovia Inc., Palo Alto, USA) that is capable of representing large CT data sets with high user interactivity even on standard PCs. Fovia provides a software development kit (SDK) that offers control of all the features of the rendering engine. We extended the SDK by functionalities specific to the task of treatment planning for moving tumors. This included navigation of the patient's anatomy in beam's eye view, fast point-and-click measurement of lung tumor trajectories as well as estimation of range perturbations due to motion by calculation of (differential) water equivalent path lengths for protons and carbon ions on 4D-CT data sets. We present patient examples to demonstrate the advantages and disadvantages of volume rendered images as compared to standard 2-dimensional axial plane images. Furthermore, we show an example of a range perturbation analysis. We conclude that volume rendering is a powerful technique for the representation and analysis of large time resolved data sets in treatment planning

  12. Integrated Waste Treatment Unit GFSI Risk Management Plan

    International Nuclear Information System (INIS)

    This GFSI Risk Management Plan (RMP) describes the strategy for assessing and managing project risks for the Integrated Waste Treatment Unit (IWTU) that are specifically within the control and purview of the U.S. Department of Energy (DOE), and identifies the risks that formed the basis for the DOE contingency included in the performance baseline. DOE-held contingency is required to cover cost and schedule impacts of DOE activities. Prior to approval of the performance baseline (Critical Decision-2) project cost contingency was evaluated during a joint meeting of the Contractor Management Team and the Integrated Project Team for both contractor and DOE risks to schedule and cost. At that time, the contractor cost and schedule risk value was $41.3M and the DOE cost and schedule risk contingency value is $39.0M. The contractor cost and schedule risk value of $41.3M was retained in the performance baseline as the contractor's management reserve for risk contingency. The DOE cost and schedule risk value of $39.0M has been retained in the performance baseline as the DOE Contingency. The performance baseline for the project was approved in December 2006 (Garman 2006). The project will continue to manage to the performance baseline and change control thresholds identified in PLN-1963, ''Idaho Cleanup Project Sodium-Bearing Waste Treatment Project Execution Plan'' (PEP)

  13. Dosimetric evaluation of 3D treatment planning system

    International Nuclear Information System (INIS)

    The computerized treatment planning system plays a major role in radiation therapy in delivering correct radiation dose to the patients with in 65% as recommended by the ICRU. A Plato V2.7.2 Treatment Planning System (Nucletron B.V.) was installed at Dr. Kamakshi Memorial Hospital with external and brachytherapy software. It is connected with Siemens CT scan (Emotion Duo) via Ocriten anatomical Modeling system. The present paper investigates the Dosimetric performance of the TPS with three-Dimensional dose calculation algorithm using the basic beam data measured for 6MV X-rays. Nine numbers of test cases were created according to the TRS 430 and are used to test the TPS, in a homogeneous water phantom. These cases involve simple field arrangements as well as the presence of a low-density material in the beam to resemble an air inhomogeneity. Absolute dose measurements were performed for the each case with the MU calculation given by the TPS, the measured dose is compared with that of the corresponding TPS calculations yields difference with in 3.39% for all simple test cases, for complex test cases in the presence of inhomogeneity or beam modifiers a maximum deviation of 6.25% was observed. In conclusion, observed deviations are well with in the set tolerance level

  14. Integrated Waste Treatment Unit GFSI Risk Management Plan

    Energy Technology Data Exchange (ETDEWEB)

    W. A. Owca

    2007-06-21

    This GFSI Risk Management Plan (RMP) describes the strategy for assessing and managing project risks for the Integrated Waste Treatment Unit (IWTU) that are specifically within the control and purview of the U.S. Department of Energy (DOE), and identifies the risks that formed the basis for the DOE contingency included in the performance baseline. DOE-held contingency is required to cover cost and schedule impacts of DOE activities. Prior to approval of the performance baseline (Critical Decision-2) project cost contingency was evaluated during a joint meeting of the Contractor Management Team and the Integrated Project Team for both contractor and DOE risks to schedule and cost. At that time, the contractor cost and schedule risk value was $41.3M and the DOE cost and schedule risk contingency value is $39.0M. The contractor cost and schedule risk value of $41.3M was retained in the performance baseline as the contractor's management reserve for risk contingency. The DOE cost and schedule risk value of $39.0M has been retained in the performance baseline as the DOE Contingency. The performance baseline for the project was approved in December 2006 (Garman 2006). The project will continue to manage to the performance baseline and change control thresholds identified in PLN-1963, ''Idaho Cleanup Project Sodium-Bearing Waste Treatment Project Execution Plan'' (PEP).

  15. Biodistribution of phenylboric acid derivative entrapped lipiodol and 4-borono-2-18F-fluoro-L-phenylalanine-fructose in GP7TB liver tumor bearing rats for BNCT

    International Nuclear Information System (INIS)

    A new phenylboric acid derivative entrapped lipiodol (PBAD-lipiodol) was developed as a boron carrier for the boron neutron capture therapy (BNCT) of hepatoma in Taiwan. The biodistribution of both PBAD-lipiodol and BPA-fructose was assayed in GP7TB hepatoma-bearing rat model. The highest uptake of PBAD-lipiodol was found at 2 h post injection. The application of BNCT for the hepatoma treatment in tumor-bearing rats is suggested to be 2-4 h post PBAD-lipiodol injection.

  16. Biodistribution of phenylboric acid derivative entrapped lipiodol and 4-borono-2-{sup 18}F-fluoro-L-phenylalanine-fructose in GP7TB liver tumor bearing rats for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Liao, A.H. [Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong St., Bei-tou, 112 Taipei, Taiwan (China); Chou, F.I. [Institute of Nuclear Engineering and Science, National Tsing-Hua University, Hsinchu, Taiwan (China); Kuo, Y.C. [Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong St., Bei-tou, 112 Taipei, Taiwan (China); Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan (China); Chen, H.W. [Department of Radiation Oncology and Hospice Center, Mackay Memorial Hospital, Taipei, Taiwan (China); Kai, J.J. [Institute of Nuclear Engineering and Science, National Tsing-Hua University, Hsinchu, Taiwan (China); Chang, C.W. [Department of Nuclear Medicine, Veterans General Hospital, Taipei, Taiwan (China); Chen, F.D. [Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong St., Bei-tou, 112 Taipei, Taiwan (China); Hwang, J.J. [Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong St., Bei-tou, 112 Taipei, Taiwan (China)], E-mail: jjhwang@ym.edu.tw

    2010-03-15

    A new phenylboric acid derivative entrapped lipiodol (PBAD-lipiodol) was developed as a boron carrier for the boron neutron capture therapy (BNCT) of hepatoma in Taiwan. The biodistribution of both PBAD-lipiodol and BPA-fructose was assayed in GP7TB hepatoma-bearing rat model. The highest uptake of PBAD-lipiodol was found at 2 h post injection. The application of BNCT for the hepatoma treatment in tumor-bearing rats is suggested to be 2-4 h post PBAD-lipiodol injection.

  17. Dose calculation accuracy of lung planning with a commercial IMRT treatment planning system.

    Science.gov (United States)

    McDermott, Patrick N; He, Tongming; DeYoung, A

    2003-01-01

    The dose calculation accuracy of a commercial pencil beam IMRT planning system is evaluated by comparison with Monte Carlo calculations and measurements in an anthropomorphic phantom. The target volume is in the right lung and mediastinum and thus significant tissue inhomogeneities are present. The Monte Carlo code is an adaptation of the MCNP code and the measurements were made with TLD and film. Both the Monte Carlo code and the measurements show very good agreement with the treatment planning system except in regions where the dose is high and the electron density is low. In these regions the commercial system shows doses up to 10% higher than Monte Carlo and film. The average calculated dose for the CTV is 5% higher with the commercial system as compared to Monte Carlo. PMID:14604424

  18. Registration and planning of radiotherapy and proton therapy treatment

    International Nuclear Information System (INIS)

    Within the frame of an update and renewal project, the Orsay Proton Therapy Centre of the Curie Institute (IPCO) renews its software used for the treatment of patients by proton therapy, a radiotherapy technique which uses proton beams. High energies used in these treatments and the precision provided by proton particle characteristics require a more precise patient positioning than conventional radiotherapy: proton therapy requires a precision of about a millimetre. Thus, markers are placed on the skull which are generally well accepted by patients, but are a problem in the case of paediatric treatment, notably for the youngest children whose skull is still growing. The first objective of this research is thus to use only intrinsic information from X-ray images used when positioning the patient. A second objective is to make the new software (TPS Isogray) perfectly compatible with IPCO requirements by maintaining the strengths of the previous TPS (Treatment Planning System) and being prepared to the implementation of a new installation. After a presentation of the context and state of the art in radiotherapy and patient positioning, the author proposes an overview of 2D registration methods, presents a new method for 2x2D registration, and addresses the problem of 3D registration. Then, after a presentation of proton therapy, the author addresses different specific issues and aspects: the compensator (simulation, calculation, and tests), dose calculation, the 'Pencil-Beam' algorithm, tests, and introduced improvements

  19. 4D FDG-PET based treatment planning for IGRT in the treatment of lung cancer

    Directory of Open Access Journals (Sweden)

    AlexanderChi

    2014-08-01

    Full Text Available 18F fluorodeoxyglucose positron emission tomography (FDG-PET has changed the staging of, and the treatment response assessment for lung cancer over the past decades dramatically. The improved accuracy in tumor identification with FDG-PET has led to its increased utilization in target volume delineation for radiotherapy treatment planning in the treatment of lung cancer. Despite the increased ability to distinguish tumor and normal tissue with the help of PET/CT registration, how to best delineate the PET avid tumor volume continues to be controversial as the PET intensity can be influenced by multiple machine and patient related factors. One major factor influencing the PET intensity and image resolution in the thorax is respiratory motion. This problem may be minimized by 4D FDG-PET based treatment planning, which can further improve the resolution of tumor extent, and the delineation of the internal target volume. Here, we offer our perspectives on the utilization of 4D FDG-PET based treatment planning for thoracic image-guided radiotherapy.

  20. The refinement of dose assessment of the THOR BNCT beam

    International Nuclear Information System (INIS)

    A refined dose assessment method has been used now in the THOR BNCT facility, which takes into account more delicate corrections, carefully handled calibration factors, and the spectrum- and kerma-weighted kt value. The refined method solved the previous problem of negative derived neutron dose in phantom at deeper positions. With the improved dose assessment, the calculated and measured gamma-ray dose rates match perfectly in a 15×15×15 cm3 PMMA phantom.

  1. Optimization of the application of BNCT to undifferentiated thyroid cancer

    International Nuclear Information System (INIS)

    The possible increase in BNCT efficacy for undifferentiated thyroid carcinoma (UTC) using BPA plus BOPP and nicotinamide (NA) as a radiosensitizer on the BNCT reaction was analyzed. In these studies nude mice were transplanted with the ARO cells and after 14 days they were treated as follows: 1) Control; 2) NCT (neutrons alone); 3) NCT plus NA (100 mg/kg bw/day for 3 days); 4) BPA (350 mg/kg bw) + neutrons; 5) BPA+ NA+ neutrons; 6) BPA+BOPP (60 mg/kg bw) + neutrons. The flux of hyperthermal neutrons was 2.8 108 during 85 min. Neutrons alone or with NA caused some tumor growth delay, while in the BPA, BPA+NA and BPA+BOPP groups a 100% halt of tumor growth was observed. When the initial tumor volume was 50 mm3 or less a complete cure was found in BPA+NA (2/2); BPA (1/4); BPA+BOPP (7/7). After 90 days of complete regression, recurrence of tumor was observed in 2/2 BPA/NA (2/2) and BPA+BOPP (1/7). Caspase 3 activity was increased in BPA+NA (p<0.05 vs controls). BPA plus NA increased tumor apoptosis but only the combination of BPA+BOPP increased significantly BNCT efficiency. (author)

  2. Clinical results of BNCT for malignant brain tumors in children

    International Nuclear Information System (INIS)

    It is very difficult to treat the patients with malignant brain tumor in children, especially under 3 years, because the conventional irradiation cannot be applied due to the damage of normal brain tissue. However, boron neutron capture therapy (BNCT) has tumor selectivity such that it can make damage only in tumor cells. We evaluated the clinical results and courses in patients with malignant glioma under 15 years. Among 183 patients with brain tumors treated by our group using BSH-based intra-operative BNCT, 23 patients were under 15 years. They included 4 patients under 3 years. There were 3 glioblastomas (GBM), 6 anaplastic astrocytomas(AAS), 7 primitive neuroectodermal tumors (PNET), 6 pontine gliomas and 1 anaplastic ependymoma. All GBM and PNET patients died due to CSF and/or CNS dissemination without local tumor regrowth. All pontine glioma patients died due to regrowth of the tumor. Four of 6 anaplastic astrocytoma and 1 anaplastic ependymoma patients alive without tumor recurrence. BNCT can be applied to malignant brain tumors in children, especially under 3 years instead of conventional radiation. Although it can achieve the local control in the primary site, it cannot prevent CSF dissemination in patients with glioblastoma.

  3. Clinical results of BNCT for malignant brain tumors in children

    Energy Technology Data Exchange (ETDEWEB)

    Nakagawa, Yoshinobu [Department of Neurosurgery, Kagawa National Children' s Hospital, Kagawa 765-8501 (Japan)], E-mail: ynakagawa0517@yahoo.co.jp; Kageji, Teruyoshi; Mizobuchi, Yoshifumi [Department of Neurosurgery, University of Tokushima, Tokushima 770-8503 (Japan); Kumada, Hiroaki [Department of Research Reactor, Japan Atomic Energy Research Institute, Ibaragi 319-1195 (Japan); Nakagawa, Yoshiaki [Department of Medical Informatics, Post Graduated School, Kyoto University, Kyoto (Japan)

    2009-07-15

    It is very difficult to treat the patients with malignant brain tumor in children, especially under 3 years, because the conventional irradiation cannot be applied due to the damage of normal brain tissue. However, boron neutron capture therapy (BNCT) has tumor selectivity such that it can make damage only in tumor cells. We evaluated the clinical results and courses in patients with malignant glioma under 15 years. Among 183 patients with brain tumors treated by our group using BSH-based intra-operative BNCT, 23 patients were under 15 years. They included 4 patients under 3 years. There were 3 glioblastomas (GBM), 6 anaplastic astrocytomas(AAS), 7 primitive neuroectodermal tumors (PNET), 6 pontine gliomas and 1 anaplastic ependymoma. All GBM and PNET patients died due to CSF and/or CNS dissemination without local tumor regrowth. All pontine glioma patients died due to regrowth of the tumor. Four of 6 anaplastic astrocytoma and 1 anaplastic ependymoma patients alive without tumor recurrence. BNCT can be applied to malignant brain tumors in children, especially under 3 years instead of conventional radiation. Although it can achieve the local control in the primary site, it cannot prevent CSF dissemination in patients with glioblastoma.

  4. Comparison of the radiobiological effects of Boron neutron capture therapy (BNCT) and conventional Gamma Radiation

    International Nuclear Information System (INIS)

    BNCT is an experimental radiotherapeutic modality that uses the capacity of the isotope 10B to capture thermal neutrons leading to the production of 4He and 7Li, particles with high linear energy transfer (LET). The aim was to evaluate and compare in vitro the mechanisms of response to the radiation arising of BNCT and conventional gamma therapy. We measured the survival cell fraction as a function of the total physical dose and analyzed the expression of p27/Kip1 and p53 by Western blotting in cells of colon cancer (ARO81-1). Exponentially growing cells were distributed into the following groups: 1) BPA (10 ppm 10B) + neutrons; 2) BOPP (10 ppm 10B) + neutrons; 3) neutrons alone; 4) gamma-rays. A control group without irradiation for each treatment was added. The cells were irradiated in the thermal neutron beam of the RA-3 (flux= 7.5 109 n/cm2 sec) or with 60Co (1Gy/min) during different times in order to obtain total physical dose between 1-5 Gy (±10 %). A decrease in the survival fraction as a function of the physical dose was observed for all the treatments. We also observed that neutrons and neutrons + BOPP did not differ significantly and that BPA was the more effective compound. Protein extracts of irradiated cells (3Gy) were isolated to 24 h and 48 h post radiation exposure. The irradiation with neutrons in presence of 10BPA or 10BOPP produced an increase of p53 at 24 h maintain until 48 h. On the contrary, in the groups irradiated with neutrons alone or gamma the peak was observed at 48 hr. The level of expression of p27/Kip1 showed a reduction of this protein in all the groups irradiated with neutrons (neutrons alone or neutrons plus boron compound), being more marked at 24 h. These preliminary results suggest different radiobiological response for high and low let radiation. Future studies will permit establish the role of cell cycle in the tumor radio sensibility to BNCT. (author)

  5. Audit of 3D conformal radiotherapy treatment planning systems

    International Nuclear Information System (INIS)

    Background. Treatment planning systems (TPSs) are an essential part of modern radiotherapy equipment where radiation dose distribution and number of Monitor Units (MU) necessary to achieve it are calculated. Therefore, proper commissioning, implementation and application of TPSs are essential to ensure accurate dose delivery to the patient, and to minimize the possibility of accidental exposure. IAEA is supporting national and sub-regional TPS audit activities as a new initiative to improve the quality and safety of radiotherapy in Member States. The audit methodology is based on the outcome of the IAEA coordinated research project E2.40.13 'Development of procedures for quality assurance for dosimetry calculation in radiotherapy'. The pilot runs have been conducted in the Baltic States and Hungarian hospitals. Methodology. The methodology for the audit focuses on the dosimetric aspects of the treatment planning and delivery processes of radiotherapy, for high-energy photon beams. It assesses the important part of the external beam radiotherapy workflow - from patient data acquisition and treatment planning to dose delivery. The audit procedure is based on the use of a CIRS thorax phantom Model 002LFC (Norfolk, VA). The phantom has a body made of plastic water, lung equivalent material and bone equivalent material sections and has 10 holes to hold interchangeable rod inserts for an ionization chamber. The phantom has a set of calibrated electron density reference plugs that enable the verification of the Hounsfield units/electron density (HU/ ED) conversion procedure. Computed tomography (CT) is used to image the phantom and the images are transferred to a TPS where planning and dose calculations take place. The clinical test cases cover a range of basic treatment techniques used in 3D conformal radiotherapy (CRT). The tests are structured so that at first, the dose distributions for single beams are considered, then standard multiple field techniques are used, and

  6. A new method for commissioning Monte Carlo treatment planning systems

    Science.gov (United States)

    Aljarrah, Khaled Mohammed

    2005-11-01

    The Monte Carlo method is an accurate method for solving numerical problems in different fields. It has been used for accurate radiation dose calculation for radiation treatment of cancer. However, the modeling of an individual radiation beam produced by a medical linear accelerator for Monte Carlo dose calculation, i.e., the commissioning of a Monte Carlo treatment planning system, has been the bottleneck for the clinical implementation of Monte Carlo treatment planning. In this study a new method has been developed to determine the parameters of the initial electron beam incident on the target for a clinical linear accelerator. The interaction of the initial electron beam with the accelerator target produces x-ray and secondary charge particles. After successive interactions in the linac head components, the x-ray photons and the secondary charge particles interact with the patient's anatomy and deliver dose to the region of interest. The determination of the initial electron beam parameters is important for estimating the delivered dose to the patients. These parameters, such as beam energy and radial intensity distribution, are usually estimated through a trial and error process. In this work an easy and efficient method was developed to determine these parameters. This was accomplished by comparing calculated 3D dose distributions for a grid of assumed beam energies and radii in a water phantom with measurements data. Different cost functions were studied to choose the appropriate function for the data comparison. The beam parameters were determined on the light of this method. Due to the assumption that same type of linacs are exactly the same in their geometries and only differ by the initial phase space parameters, the results of this method were considered as a source data to commission other machines of the same type.

  7. Evaluation of plan quality assurance models for prostate cancer patients based on fully automatically generated Pareto-optimal treatment plans

    Science.gov (United States)

    Wang, Yibing; Breedveld, Sebastiaan; Heijmen, Ben; Petit, Steven F.

    2016-06-01

    IMRT planning with commercial Treatment Planning Systems (TPSs) is a trial-and-error process. Consequently, the quality of treatment plans may not be consistent among patients, planners and institutions. Recently, different plan quality assurance (QA) models have been proposed, that could flag and guide improvement of suboptimal treatment plans. However, the performance of these models was validated using plans that were created using the conventional trail-and-error treatment planning process. Consequently, it is challenging to assess and compare quantitatively the accuracy of different treatment planning QA models. Therefore, we created a golden standard dataset of consistently planned Pareto-optimal IMRT plans for 115 prostate patients. Next, the dataset was used to assess the performance of a treatment planning QA model that uses the overlap volume histogram (OVH). 115 prostate IMRT plans were fully automatically planned using our in-house developed TPS Erasmus-iCycle. An existing OVH model was trained on the plans of 58 of the patients. Next it was applied to predict DVHs of the rectum, bladder and anus of the remaining 57 patients. The predictions were compared with the achieved values of the golden standard plans for the rectum D mean, V 65, and V 75, and D mean of the anus and the bladder. For the rectum, the prediction errors (predicted–achieved) were only  ‑0.2  ±  0.9 Gy (mean  ±  1 SD) for D mean,‑1.0  ±  1.6% for V 65, and  ‑0.4  ±  1.1% for V 75. For D mean of the anus and the bladder, the prediction error was 0.1  ±  1.6 Gy and 4.8  ±  4.1 Gy, respectively. Increasing the training cohort to 114 patients only led to minor improvements. A dataset of consistently planned Pareto-optimal prostate IMRT plans was generated. This dataset can be used to train new, and validate and compare existing treatment planning QA models, and has been made publicly available. The OVH model was highly

  8. Evaluation of plan quality assurance models for prostate cancer patients based on fully automatically generated Pareto-optimal treatment plans.

    Science.gov (United States)

    Wang, Yibing; Breedveld, Sebastiaan; Heijmen, Ben; Petit, Steven F

    2016-06-01

    IMRT planning with commercial Treatment Planning Systems (TPSs) is a trial-and-error process. Consequently, the quality of treatment plans may not be consistent among patients, planners and institutions. Recently, different plan quality assurance (QA) models have been proposed, that could flag and guide improvement of suboptimal treatment plans. However, the performance of these models was validated using plans that were created using the conventional trail-and-error treatment planning process. Consequently, it is challenging to assess and compare quantitatively the accuracy of different treatment planning QA models. Therefore, we created a golden standard dataset of consistently planned Pareto-optimal IMRT plans for 115 prostate patients. Next, the dataset was used to assess the performance of a treatment planning QA model that uses the overlap volume histogram (OVH). 115 prostate IMRT plans were fully automatically planned using our in-house developed TPS Erasmus-iCycle. An existing OVH model was trained on the plans of 58 of the patients. Next it was applied to predict DVHs of the rectum, bladder and anus of the remaining 57 patients. The predictions were compared with the achieved values of the golden standard plans for the rectum D mean, V 65, and V 75, and D mean of the anus and the bladder. For the rectum, the prediction errors (predicted-achieved) were only  -0.2  ±  0.9 Gy (mean  ±  1 SD) for D mean,-1.0  ±  1.6% for V 65, and  -0.4  ±  1.1% for V 75. For D mean of the anus and the bladder, the prediction error was 0.1  ±  1.6 Gy and 4.8  ±  4.1 Gy, respectively. Increasing the training cohort to 114 patients only led to minor improvements. A dataset of consistently planned Pareto-optimal prostate IMRT plans was generated. This dataset can be used to train new, and validate and compare existing treatment planning QA models, and has been made publicly available. The OVH model was highly accurate

  9. Improvements at the biological shielding of BNCT research facility in the IEA-R1 reactor; Projeto e implantacao de melhorias na blindagem biologica da instalacao para estudos em BCNT

    Energy Technology Data Exchange (ETDEWEB)

    Souza, Gregorio Soares de

    2011-07-01

    The technique of neutron capture in boron is a promising technique in cancer treatment, it uses the high LET particles from the reaction {sup 10}B (n, {alpha}) {sup 7}Li to destroy cancer cells.The development of this technique began in the mid-'50s and even today it is the object of study and research in various centers around the world, Brazil has built a facility that aims to conduct research in BNCT, this facility is located next to irradiation channel number three at the research nuclear reactor IEA-R1 and has a biological shielding designed to meet the radiation protection standards. This biological shielding was developed to allow them to conduct experiments with the reactor at maximum power, so it is not necessary to turn on and off the reactor to irradiate samples. However, when the channel is opened for experiments the background radiation in the experiments salon increases and this background variation makes it impossible to perform measurements in a neutron diffraction research that utilizes the irradiation channel number six. This study aims to further improve the shielding in order to minimize the variation of background making it possible to perform the research facility in BNCT without interfering with the action of the research group of the irradiation channel number six. To reach this purpose, the code MCNP5, dosimeters and activation detectors were used to plan improvements in the biological shielding. It was calculated with the help of the code an improvement that can reduce the average heat flow in 71.2% {+-} 13 and verified experimentally a mean reduce of 70 {+-} 9% in dose due to thermal neutrons. (author)

  10. Specification and acceptance testing of radiotherapy treatment planning systems

    International Nuclear Information System (INIS)

    Quality assurance (QA) in the radiation therapy treatment planning process is essential to ensure accurate dose delivery to the patient and to minimize the possibility of accidental exposure. The computerized radiotherapy treatment planning systems (RTPSs) are now widely available in industrialized and developing countries and it is of special importance to support hospitals in Member States in developing procedures for acceptance testing, commissioning and QA of their RTPSs. Responding to these needs, a group of experts developed an IAEA publication with such recommendations, which was published in 2004 as IAEA Technical Reports Series No. 430. This report provides a general framework and describes a large number of tests and procedures that should be considered by the users of new RTPSs. However, small hospitals with limited resources or large hospitals with high patient load and limited staff are not always able to perform complete characterization, validation and software testing of algorithms used in RTPSs. Therefore, the IAEA proposed more specific guidelines that provide a step-by-step recommendation for users at hospitals or cancer centres how to implement acceptance and commissioning procedures for newly purchased RTPSs. The current publication was developed in the framework of the Coordinated Research Project on Development of Procedures for Quality Assurance for Dosimetry Calculations in Radiotherapy and uses the International Electrotechnical Commission (IEC) standard IEC 62083, Requirements for the Safety of Radiotherapy Treatment Planning Systems as its basis. The report addresses the procedures for specification and acceptance testing of RTPSs to be used by both manufacturers and users at the hospitals. Recommendations are provided for specific tests to be performed at the manufacturing facility known as type tests, and for acceptance tests to be performed at the hospital known as site tests. The purpose of acceptance testing is to demonstrate to the

  11. 3718-F Alkali Metal Treatment and Storage Facility Closure Plan

    International Nuclear Information System (INIS)

    The Hanford Site, located northwest of the city of Richland, Washington, houses reactors, chemical-separation systems, and related facilities used for the production of special nuclear materials, as well as for activities associated with nuclear energy development. The 300 Area of the Hanford Site contains reactor fuel manufacturing facilities and several research and development laboratories. The 3718-F Alkali Metal Treatment and Storage Facility (3718-F Facility), located in the 300 Area, was used to store and treat alkali metal wastes. Therefore, it is subject to the regulatory requirements for the storage and treatment of dangerous wastes. Closure will be conducted pursuant to the requirements of the Washington Administrative Code (WAC) 173-303-610 (Ecology 1989) and 40 CFR 270.1. Closure also will satisfy the thermal treatment facility closure requirements of 40 CFR 265.381. This closure plan presents a description of the 3718-F Facility, the history of wastes managed, and the approach that will be followed to close the facility. Only hazardous constituents derived from 3718-F Facility operations will be addressed

  12. PhoNeS: A novel approach to BNCT with conventional radiotherapy accelerators

    International Nuclear Information System (INIS)

    PhoNeS (Photo Neutron Source) is an INFN project devoted to the optimization of the neutron production and moderation in radiotherapy linear accelerators. LinAcs producing high energy (15-25MeV) photon beams are becoming widespread. At this energy neutron photo-production is unavoidable and the neutron dose must be controlled and reduced during normal radiotherapy. A technique known as BNCT (Boron Neutron Capture Therapy) uses neutrons for radiotherapic treatments: the cells are given a drug containing B10 which undergoes fission after neutron capture, inducing heavy damages to the DNA of the cell itself. This paper will describe the moderator developed by PhoNeS and the results in terms of neutron flux and spectrum and photon contamination of the measurements performed on several radiotherapy accelerators

  13. The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation

    Energy Technology Data Exchange (ETDEWEB)

    Yamamoto, T., E-mail: tetsu_tsukuba@yahoo.co.jp [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan)] [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Nakai, K. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Nariai, T. [Department of Neurosurgery, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, Tokyo (Japan); Kumada, H.; Okumura, T.; Mizumoto, M.; Tsuboi, K. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Zaboronok, A.; Ishikawa, E.; Aiyama, H.; Endo, K.; Takada, T.; Yoshida, F.; Shibata, Y.; Matsumura, A. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan)

    2011-12-15

    The phase II trial has been prepared to assess the effectiveness of BPA (250 mg/kg)-based NCT combined with X-ray irradiation and temozolomide (75 mg/m{sup 2}) for the treatment of newly diagnosed GBM. BPA uptake is determined by {sup 18}F-BPA-PET and/or {sup 11}C-MET-PET, and a tumor with the lesion to normal ratio of 2 or more is indicated for BNCT. The maximum normal brain point dose prescribed was limited to 13.0 Gy or less. Primary end point is overall survival.

  14. Treatment planning for radiotherapy with very high-energy electron beams and comparison of VHEE and VMAT plans

    Energy Technology Data Exchange (ETDEWEB)

    Bazalova-Carter, Magdalena; Qu, Bradley; Palma, Bianey; Jensen, Christopher; Maxim, Peter G., E-mail: Peter.Maxim@Stanford.edu, E-mail: BWLoo@Stanford.edu; Loo, Billy W., E-mail: Peter.Maxim@Stanford.edu, E-mail: BWLoo@Stanford.edu [Department of Radiation Oncology, Stanford University, Stanford, California 94305 (United States); Hårdemark, Björn; Hynning, Elin [RaySearch Laboratories AB, Stockholm SE-103 65 (Sweden)

    2015-05-15

    Purpose: The aim of this work was to develop a treatment planning workflow for rapid radiotherapy delivered with very high-energy electron (VHEE) scanning pencil beams of 60–120 MeV and to study VHEE plans as a function of VHEE treatment parameters. Additionally, VHEE plans were compared to clinical state-of-the-art volumetric modulated arc therapy (VMAT) photon plans for three cases. Methods: VHEE radiotherapy treatment planning was performed by linking EGSnrc Monte Carlo (MC) dose calculations with inverse treatment planning in a research version of RayStation. In order to study the effect of VHEE treatment parameters on VHEE dose distributions, a MATLAB graphical user interface (GUI) for calculation of VHEE MC pencil beam doses was developed. Through the GUI, pediatric case MC simulations were run for a number of beam energies (60, 80, 100, and 120 MeV), number of beams (13, 17, and 36), pencil beam spot (0.1, 1.0, and 3.0 mm) and grid (2.0, 2.5, and 3.5 mm) sizes, and source-to-axis distance, SAD (40 and 50 cm). VHEE plans for the pediatric case calculated with the different treatment parameters were optimized and compared. Furthermore, 100 MeV VHEE plans for the pediatric case, a lung, and a prostate case were calculated and compared to the clinically delivered VMAT plans. All plans were normalized such that the 100% isodose line covered 95% of the target volume. Results: VHEE beam energy had the largest effect on the quality of dose distributions of the pediatric case. For the same target dose, the mean doses to organs at risk (OARs) decreased by 5%–16% when planned with 100 MeV compared to 60 MeV, but there was no further improvement in the 120 MeV plan. VHEE plans calculated with 36 beams outperformed plans calculated with 13 and 17 beams, but to a more modest degree (<8%). While pencil beam spacing and SAD had a small effect on VHEE dose distributions, 0.1–3 mm pencil beam sizes resulted in identical dose distributions. For the 100 MeV VHEE pediatric

  15. SU-D-BRD-01: Cloud-Based Radiation Treatment Planning: Performance Evaluation of Dose Calculation and Plan Optimization

    International Nuclear Information System (INIS)

    Purpose: To report the first experience on the development of a cloud-based treatment planning system and investigate the performance improvement of dose calculation and treatment plan optimization of the cloud computing platform. Methods: A cloud computing-based radiation treatment planning system (cc-TPS) was developed for clinical treatment planning. Three de-identified clinical head and neck, lung, and prostate cases were used to evaluate the cloud computing platform. The de-identified clinical data were encrypted with 256-bit Advanced Encryption Standard (AES) algorithm. VMAT and IMRT plans were generated for the three de-identified clinical cases to determine the quality of the treatment plans and computational efficiency. All plans generated from the cc-TPS were compared to those obtained with the PC-based TPS (pc-TPS). The performance evaluation of the cc-TPS was quantified as the speedup factors for Monte Carlo (MC) dose calculations and large-scale plan optimizations, as well as the performance ratios (PRs) of the amount of performance improvement compared to the pc-TPS. Results: Speedup factors were improved up to 14.0-fold dependent on the clinical cases and plan types. The computation times for VMAT and IMRT plans with the cc-TPS were reduced by 91.1% and 89.4%, respectively, on average of the clinical cases compared to those with pc-TPS. The PRs were mostly better for VMAT plans (1.0 ≤ PRs ≤ 10.6 for the head and neck case, 1.2 ≤ PRs ≤ 13.3 for lung case, and 1.0 ≤ PRs ≤ 10.3 for prostate cancer cases) than for IMRT plans. The isodose curves of plans on both cc-TPS and pc-TPS were identical for each of the clinical cases. Conclusion: A cloud-based treatment planning has been setup and our results demonstrate the computation efficiency of treatment planning with the cc-TPS can be dramatically improved while maintaining the same plan quality to that obtained with the pc-TPS. This work was supported in part by the National Cancer Institute (1

  16. SU-D-BRD-01: Cloud-Based Radiation Treatment Planning: Performance Evaluation of Dose Calculation and Plan Optimization

    Energy Technology Data Exchange (ETDEWEB)

    Na, Y; Kapp, D; Kim, Y; Xing, L [Stanford University School of Medicine, Stanford, CA (United States); Suh, T [Catholic UniversityMedical College, Seoul, Seoul (Korea, Republic of)

    2014-06-01

    Purpose: To report the first experience on the development of a cloud-based treatment planning system and investigate the performance improvement of dose calculation and treatment plan optimization of the cloud computing platform. Methods: A cloud computing-based radiation treatment planning system (cc-TPS) was developed for clinical treatment planning. Three de-identified clinical head and neck, lung, and prostate cases were used to evaluate the cloud computing platform. The de-identified clinical data were encrypted with 256-bit Advanced Encryption Standard (AES) algorithm. VMAT and IMRT plans were generated for the three de-identified clinical cases to determine the quality of the treatment plans and computational efficiency. All plans generated from the cc-TPS were compared to those obtained with the PC-based TPS (pc-TPS). The performance evaluation of the cc-TPS was quantified as the speedup factors for Monte Carlo (MC) dose calculations and large-scale plan optimizations, as well as the performance ratios (PRs) of the amount of performance improvement compared to the pc-TPS. Results: Speedup factors were improved up to 14.0-fold dependent on the clinical cases and plan types. The computation times for VMAT and IMRT plans with the cc-TPS were reduced by 91.1% and 89.4%, respectively, on average of the clinical cases compared to those with pc-TPS. The PRs were mostly better for VMAT plans (1.0 ≤ PRs ≤ 10.6 for the head and neck case, 1.2 ≤ PRs ≤ 13.3 for lung case, and 1.0 ≤ PRs ≤ 10.3 for prostate cancer cases) than for IMRT plans. The isodose curves of plans on both cc-TPS and pc-TPS were identical for each of the clinical cases. Conclusion: A cloud-based treatment planning has been setup and our results demonstrate the computation efficiency of treatment planning with the cc-TPS can be dramatically improved while maintaining the same plan quality to that obtained with the pc-TPS. This work was supported in part by the National Cancer Institute (1

  17. Technical Basis for Radiological Emergency Plan Annex for WTD Emergency Response Plan: West Point Treatment Plant

    Energy Technology Data Exchange (ETDEWEB)

    Hickey, Eva E.; Strom, Daniel J.

    2005-08-01

    Staff of the King County Wastewater Treatment Division (WTD) have concern about the aftermath of a radiological dispersion event (RDE) leading to the introduction of significant quantities of radioactive material into the combined sanitary and storm sewer system in King County, Washington. Radioactive material could come from the use of a radiological dispersion device (RDD). RDDs include "dirty bombs" that are not nuclear detonations but are explosives designed to spread radioactive material (National Council on Radiation Protection and Measurements (NCRP) 2001). Radioactive material also could come from deliberate introduction or dispersion of radioactive material into the environment, including waterways and water supply systems. This document, Volume 3 of PNNL-15163 is the technical basis for the Annex to the West Point Treatment Plant (WPTP) Emergency Response Plan related to responding to a radiological emergency at the WPTP. The plan primarily considers response to radioactive material that has been introduced in the other combined sanitary and storm sewer system from a radiological dispersion device, but is applicable to any accidental or deliberate introduction of materials into the system.

  18. Confirmation of a realistic reactor model for BNCT dosimetry at the TRIGA Mainz

    Energy Technology Data Exchange (ETDEWEB)

    Ziegner, Markus, E-mail: Markus.Ziegner.fl@ait.ac.at [AIT Austrian Institute of Technology GmbH, Vienna A-1220, Austria and Institute of Atomic and Subatomic Physics, Vienna University of Technology, Vienna A-1020 (Austria); Schmitz, Tobias; Hampel, Gabriele [Institut für Kernchemie, Johannes Gutenberg-Universität, Mainz DE-55128 (Germany); Khan, Rustam [Pakistan Institute of Engineering and Applied Sciences (PIEAS), Islamabad PK-44000 (Pakistan); Blaickner, Matthias [AIT Austrian Institute of Technology GmbH, Vienna A-1220 (Austria); Palmans, Hugo [Acoustics and Ionising Radiation Division, National Physical Laboratory, Teddington TW11 0LW, United Kingdom and Medical Physics Group, EBG MedAustron GmbH, Wiener Neustadt A-2700 (Austria); Sharpe, Peter [Acoustics and Ionising Radiation Division, National Physical Laboratory, Teddington TW11 0LW (United Kingdom); Böck, Helmuth [Institute of Atomic and Subatomic Physics, Vienna University of Technology, Vienna A-1020 (Austria)

    2014-11-01

    Purpose: In order to build up a reliable dose monitoring system for boron neutron capture therapy (BNCT) applications at the TRIGA reactor in Mainz, a computer model for the entire reactor was established, simulating the radiation field by means of the Monte Carlo method. The impact of different source definition techniques was compared and the model was validated by experimental fluence and dose determinations. Methods: The depletion calculation code ORIGEN2 was used to compute the burn-up and relevant material composition of each burned fuel element from the day of first reactor operation to its current core. The material composition of the current core was used in a MCNP5 model of the initial core developed earlier. To perform calculations for the region outside the reactor core, the model was expanded to include the thermal column and compared with the previously established ATTILA model. Subsequently, the computational model is simplified in order to reduce the calculation time. Both simulation models are validated by experiments with different setups using alanine dosimetry and gold activation measurements with two different types of phantoms. Results: The MCNP5 simulated neutron spectrum and source strength are found to be in good agreement with the previous ATTILA model whereas the photon production is much lower. Both MCNP5 simulation models predict all experimental dose values with an accuracy of about 5%. The simulations reveal that a Teflon environment favorably reduces the gamma dose component as compared to a polymethyl methacrylate phantom. Conclusions: A computer model for BNCT dosimetry was established, allowing the prediction of dosimetric quantities without further calibration and within a reasonable computation time for clinical applications. The good agreement between the MCNP5 simulations and experiments demonstrates that the ATTILA model overestimates the gamma dose contribution. The detailed model can be used for the planning of structural

  19. Groups as a part of integrated treatment plans : Inpatient psychotherapy for outpatients?

    NARCIS (Netherlands)

    Staats, H

    2005-01-01

    Group psychotherapy in Germany is well established as part of an integrative treatment plan in inpatient treatment. Outpatient group psychotherapy, however, is conceptualized as a separate treatment option in competition with individual therapy. German guidelines for outpatient psychotherapy exclude

  20. Development of low cost computerized radiation treatment planning systems. 131

    International Nuclear Information System (INIS)

    With the development of computer technology in the last few years, there has been a tremendous reduction in cost and improvement in performance. For example, many personal computers use 16 bit microprocessors (8086, 68000) resulting in high performance low cost systems. The manufacturers of radiation treatment planning systems have yet to take advantage of this technology in order to pass the benefit of low cost to the radiotherapy centres. This paper discusses the feasibility of developing more advanced TPS at perhaps one fourth the cost of current TPS systems using microprocessor technology. Apart from the cost, the very nature of the latest systems is that they incorporate totally interactive software technology making it extremely easy for physicists and radiotherapists to use computers without having to learn about computers. Perhaps, time has come when TPS would become part of routine radiotherapy procedures in any centre, rather than restricted to a few privileged large centres. 11 refs.; 1 table

  1. The 300 area waste acid treatment system closure plan

    International Nuclear Information System (INIS)

    The 300 Area Waste Acid Treatment System (WATS) is located within operable units 300-FF-2 (source) and 300-FF-5 (groundwater), as designated in the Hanford Federal Facility Agreement and Consent Order (Tri-Party Agreement) . Operable units 300-FF-2 and 300-FF-5 are scheduled to be remediated using the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) Remedial Investigation/Feasibility Study (RI/FS) process. Thus, any remediation of the 300 Area WATS with respect to contaminants not produced by those facilities and soils and groundwater will be deferred to the CERCLA RI/FS process. Final closure activities will be completed in 3 phases and certified in accordance with the 300 Area WATS closure plan by the Washington State Department of Ecology (Ecology) and the U.S. Environmental Protection Agency (EPA). It is anticipated that the 300 Area WATS closure would take 2 years to complete

  2. CBCT analysis of three implant cases for treatment planning

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Jae Duk; Kim, Kwang Won; Lim, Sung Hoon [Chosun Univ. School of Dentistry, Gwangju (Korea, Republic of)

    2007-09-15

    The role of radiographic imaging in determining the size, numbers and the position of implants is very important. To perform the implant procedure, the dentist needs to evaluate the bone pathology and bone density, and to know the precise height, width, and contour of the alveolar process, as well as its relationship to the maxillary sinus and mandibular canal. The author analyzed 3 implant cases for treatment planning with the cone beam CT. All axial, panoramic, serial and buccolingual-sectioned images of 3 cases with stent including vertical marker were taken by using Mercury (Hitachi, Japan). When the curved line drawn intentionally did nor include dot image of a vertical marker on the axial image of CBCT, the image of the vertical marker was deformed on its buccolingually sectioned image. There was wide discrepancy in inclination between the alveolar bone and tooth on buccolingually sectioned image.

  3. Optimal radiotherapy treatment planning using minimum entropy models

    CERN Document Server

    Barnard, Richard; Herty, Michael

    2011-01-01

    We study the problem of finding an optimal radiotherapy treatment plan. A time-dependent Boltzmann particle transport model is used to model the interaction between radiative particles with tissue. This model allows for the modeling of inhomogeneities in the body and allows for anisotropic sources modeling distributed radiation---as in brachytherapy---and external beam sources---as in teletherapy. We study two optimization problems: minimizing the deviation from a spatially-dependent prescribed dose through a quadratic tracking functional; and minimizing the survival of tumor cells through the use of the linear-quadratic model of radiobiological cell response. For each problem, we derive the optimality systems. In order to solve the state and adjoint equations, we use the minimum entropy approximation; the advantages of this method are discussed. Numerical results are then presented.

  4. A DVH-guided IMRT optimization algorithm for automatic treatment planning and adaptive radiotherapy replanning

    Energy Technology Data Exchange (ETDEWEB)

    Zarepisheh, Masoud; Li, Nan [Department of Radiation Medicine and Applied Sciences and Center for Advanced Radiotherapy Technologies, University of California San Diego, La Jolla, California 92037-0843 (United States); Long, Troy; Romeijn, H. Edwin [Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor, Michigan 48109-2117 (United States); Tian, Zhen; Jia, Xun; Jiang, Steve B., E-mail: Steve.Jiang@UTSouthwestern.edu [Department of Radiation Medicine and Applied Sciences and Center for Advanced Radiotherapy Technologies, University of California San Diego, La Jolla, California 92037-0843 and Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8542 (United States)

    2014-06-15

    Purpose: To develop a novel algorithm that incorporates prior treatment knowledge into intensity modulated radiation therapy optimization to facilitate automatic treatment planning and adaptive radiotherapy (ART) replanning. Methods: The algorithm automatically creates a treatment plan guided by the DVH curves of a reference plan that contains information on the clinician-approved dose-volume trade-offs among different targets/organs and among different portions of a DVH curve for an organ. In ART, the reference plan is the initial plan for the same patient, while for automatic treatment planning the reference plan is selected from a library of clinically approved and delivered plans of previously treated patients with similar medical conditions and geometry. The proposed algorithm employs a voxel-based optimization model and navigates the large voxel-based Pareto surface. The voxel weights are iteratively adjusted to approach a plan that is similar to the reference plan in terms of the DVHs. If the reference plan is feasible but not Pareto optimal, the algorithm generates a Pareto optimal plan with the DVHs better than the reference ones. If the reference plan is too restricting for the new geometry, the algorithm generates a Pareto plan with DVHs close to the reference ones. In both cases, the new plans have similar DVH trade-offs as the reference plans. Results: The algorithm was tested using three patient cases and found to be able to automatically adjust the voxel-weighting factors in order to generate a Pareto plan with similar DVH trade-offs as the reference plan. The algorithm has also been implemented on a GPU for high efficiency. Conclusions: A novel prior-knowledge-based optimization algorithm has been developed that automatically adjust the voxel weights and generate a clinical optimal plan at high efficiency. It is found that the new algorithm can significantly improve the plan quality and planning efficiency in ART replanning and automatic treatment

  5. A DVH-guided IMRT optimization algorithm for automatic treatment planning and adaptive radiotherapy replanning

    International Nuclear Information System (INIS)

    Purpose: To develop a novel algorithm that incorporates prior treatment knowledge into intensity modulated radiation therapy optimization to facilitate automatic treatment planning and adaptive radiotherapy (ART) replanning. Methods: The algorithm automatically creates a treatment plan guided by the DVH curves of a reference plan that contains information on the clinician-approved dose-volume trade-offs among different targets/organs and among different portions of a DVH curve for an organ. In ART, the reference plan is the initial plan for the same patient, while for automatic treatment planning the reference plan is selected from a library of clinically approved and delivered plans of previously treated patients with similar medical conditions and geometry. The proposed algorithm employs a voxel-based optimization model and navigates the large voxel-based Pareto surface. The voxel weights are iteratively adjusted to approach a plan that is similar to the reference plan in terms of the DVHs. If the reference plan is feasible but not Pareto optimal, the algorithm generates a Pareto optimal plan with the DVHs better than the reference ones. If the reference plan is too restricting for the new geometry, the algorithm generates a Pareto plan with DVHs close to the reference ones. In both cases, the new plans have similar DVH trade-offs as the reference plans. Results: The algorithm was tested using three patient cases and found to be able to automatically adjust the voxel-weighting factors in order to generate a Pareto plan with similar DVH trade-offs as the reference plan. The algorithm has also been implemented on a GPU for high efficiency. Conclusions: A novel prior-knowledge-based optimization algorithm has been developed that automatically adjust the voxel weights and generate a clinical optimal plan at high efficiency. It is found that the new algorithm can significantly improve the plan quality and planning efficiency in ART replanning and automatic treatment

  6. Treatment planning using MRI data: an analysis of the dose calculation accuracy for different treatment regions

    International Nuclear Information System (INIS)

    Because of superior soft tissue contrast, the use of magnetic resonance imaging (MRI) as a complement to computed tomography (CT) in the target definition procedure for radiotherapy is increasing. To keep the workflow simple and cost effective and to reduce patient dose, it is natural to strive for a treatment planning procedure based entirely on MRI. In the present study, we investigate the dose calculation accuracy for different treatment regions when using bulk density assignments on MRI data and compare it to treatment planning that uses CT data. MR and CT data were collected retrospectively for 40 patients with prostate, lung, head and neck, or brain cancers. Comparisons were made between calculations on CT data with and without inhomogeneity corrections and on MRI or CT data with bulk density assignments. The bulk densities were assigned using manual segmentation of tissue, bone, lung, and air cavities. The deviations between calculations on CT data with inhomogeneity correction and on bulk density assigned MR data were small. The maximum difference in the number of monitor units required to reach the prescribed dose was 1.6%. This result also includes effects of possible geometrical distortions. The dose calculation accuracy at the investigated treatment sites is not significantly compromised when using MRI data when adequate bulk density assignments are made. With respect to treatment planning, MRI can replace CT in all steps of the treatment workflow, reducing the radiation exposure to the patient, removing any systematic registration errors that may occur when combining MR and CT, and decreasing time and cost for the extra CT investigation

  7. Investigating the robustness of ion beam therapy treatment plans to uncertainties in biological treatment parameters

    CERN Document Server

    Boehlen, T T; Dosanjh, M; Ferrari, A; Fossati, P; Haberer, T; Mairani, A; Patera, V

    2012-01-01

    Uncertainties in determining clinically used relative biological effectiveness (RBE) values for ion beam therapy carry the risk of absolute and relative misestimations of RBE-weighted doses for clinical scenarios. This study assesses the consequences of hypothetical misestimations of input parameters to the RBE modelling for carbon ion treatment plans by a variational approach. The impact of the variations on resulting cell survival and RBE values is evaluated as a function of the remaining ion range. In addition, the sensitivity to misestimations in RBE modelling is compared for single fields and two opposed fields using differing optimization criteria. It is demonstrated for single treatment fields that moderate variations (up to +/-50\\%) of representative nominal input parameters for four tumours result mainly in a misestimation of the RBE-weighted dose in the planning target volume (PTV) by a constant factor and only smaller RBE-weighted dose gradients. Ensuring a more uniform radiation quality in the PTV...

  8. 45 CFR 146.180 - Treatment of non-Federal governmental plans.

    Science.gov (United States)

    2010-10-01

    ... 45 Public Welfare 1 2010-10-01 2010-10-01 false Treatment of non-Federal governmental plans. 146... § 146.180 Treatment of non-Federal governmental plans. (a) Requirements subject to exemption—(1) Basic... record of compliance, gravity of the violation and whether a plan corrects the failure, as...

  9. Automation and Intensity Modulated Radiation Therapy for Individualized High-Quality Tangent Breast Treatment Plans

    International Nuclear Information System (INIS)

    Purpose: To demonstrate the large-scale clinical implementation and performance of an automated treatment planning methodology for tangential breast intensity modulated radiation therapy (IMRT). Methods and Materials: Automated planning was used to prospectively plan tangential breast IMRT treatment for 1661 patients between June 2009 and November 2012. The automated planning method emulates the manual steps performed by the user during treatment planning, including anatomical segmentation, beam placement, optimization, dose calculation, and plan documentation. The user specifies clinical requirements of the plan to be generated through a user interface embedded in the planning system. The automated method uses heuristic algorithms to define and simplify the technical aspects of the treatment planning process. Results: Automated planning was used in 1661 of 1708 patients receiving tangential breast IMRT during the time interval studied. Therefore, automated planning was applicable in greater than 97% of cases. The time for treatment planning using the automated process is routinely 5 to 6 minutes on standard commercially available planning hardware. We have shown a consistent reduction in plan rejections from plan reviews through the standard quality control process or weekly quality review multidisciplinary breast rounds as we have automated the planning process for tangential breast IMRT. Clinical plan acceptance increased from 97.3% using our previous semiautomated inverse method to 98.9% using the fully automated method. Conclusions: Automation has become the routine standard method for treatment planning of tangential breast IMRT at our institution and is clinically feasible on a large scale. The method has wide clinical applicability and can add tremendous efficiency, standardization, and quality to the current treatment planning process. The use of automated methods can allow centers to more rapidly adopt IMRT and enhance access to the documented

  10. Scanned ion beam therapy for prostate carcinoma. Comparison of single plan treatment and daily plan-adapted treatment

    International Nuclear Information System (INIS)

    Intensity-modulated particle therapy (IMPT) for tumors showing interfraction motion is a topic of current research. The purpose of this work is to compare three treatment strategies for IMPT to determine potential advantages and disadvantages of ion prostate cancer therapy. Simulations for three treatment strategies, conventional one-plan radiotherapy (ConvRT), image-guided radiotherapy (IGRT), and online adaptive radiotherapy (ART) were performed employing a dataset of 10 prostate cancer patients with six CT scans taken at one week intervals. The simulation results, using a geometric margin concept (7-2 mm) as well as patient-specific internal target volume definitions for IMPT were analyzed by target coverage and exposure of critical structures on single fraction dose distributions. All strategies led to clinically acceptable target coverage in patients exhibiting small prostate motion (mean displacement < 4 mm), but IGRT and especially ART led to significant sparing of the rectum. In 20 % of the patients, prostate motion exceeded 4 mm causing insufficient target coverage for ConvRT (V95mean = 0.86, range 0.63-0.99) and IGRT (V95mean = 0.91, range 0.68-1.00), while ART maintained acceptable target coverage. IMPT of prostate cancer demands consideration of rectal sparing and adaptive treatment replanning for patients exhibiting large prostate motion. (orig.)

  11. Demonstration of the importance of a dedicated neutron beam monitoring system for BNCT facility.

    Science.gov (United States)

    Chao, Der-Sheng; Liu, Yuan-Hao; Jiang, Shiang-Huei

    2016-01-01

    The neutron beam monitoring system is indispensable to BNCT facility in order to achieve an accurate patient dose delivery. The neutron beam monitoring of a reactor-based BNCT (RB-BNCT) facility can be implemented through the instrumentation and control system of a reactor provided that the reactor power level remains constant during reactor operation. However, since the neutron flux in reactor core is highly correlative to complicated reactor kinetics resulting from such as fuel depletion, poison production, and control blade movement, some extent of variation may occur in the spatial distribution of neutron flux in reactor core. Therefore, a dedicated neutron beam monitoring system is needed to be installed in the vicinity of the beam path close to the beam exit of the RB-BNCT facility, where it can measure the BNCT beam intensity as closely as possible and be free from the influence of the objects present around the beam exit. In this study, in order to demonstrate the importance of a dedicated BNCT neutron beam monitoring system, the signals originating from the two in-core neutron detectors installed at THOR were extracted and compared with the three dedicated neutron beam monitors of the THOR BNCT facility. The correlation of the readings between the in-core neutron detectors and the BNCT neutron beam monitors was established to evaluate the improvable quality of the beam intensity measurement inferred by the in-core neutron detectors. In 29 sampled intervals within 16 days of measurement, the fluctuations in the mean value of the normalized ratios between readings of the three BNCT neutron beam monitors lay within 0.2%. However, the normalized ratios of readings of the two in-core neutron detectors to one of the BNCT neutron beam monitors show great fluctuations of 5.9% and 17.5%, respectively. PMID:26595774

  12. Functional and molecular image guidance in radiotherapy treatment planning optimization.

    Science.gov (United States)

    Das, Shiva K; Ten Haken, Randall K

    2011-04-01

    Functional and molecular imaging techniques are increasingly being developed and used to quantitatively map the spatial distribution of parameters, such as metabolism, proliferation, hypoxia, perfusion, and ventilation, onto anatomically imaged normal organs and tumor. In radiotherapy optimization, these imaging modalities offer the promise of increased dose sparing to high-functioning subregions of normal organs or dose escalation to selected subregions of the tumor as well as the potential to adapt radiotherapy to functional changes that occur during the course of treatment. The practical use of functional/molecular imaging in radiotherapy optimization must take into cautious consideration several factors whose influences are still not clearly quantified or well understood including patient positioning differences between the planning computed tomography and functional/molecular imaging sessions, image reconstruction parameters and techniques, image registration, target/normal organ functional segmentation, the relationship governing the dose escalation/sparing warranted by the functional/molecular image intensity map, and radiotherapy-induced changes in the image intensity map over the course of treatment. The clinical benefit of functional/molecular image guidance in the form of improved local control or decreased normal organ toxicity has yet to be shown and awaits prospective clinical trials addressing this issue. PMID:21356479

  13. An efficient framework for photon Monte Carlo treatment planning.

    Science.gov (United States)

    Fix, Michael K; Manser, Peter; Frei, Daniel; Volken, Werner; Mini, Roberto; Born, Ernst J

    2007-10-01

    Currently photon Monte Carlo treatment planning (MCTP) for a patient stored in the patient database of a treatment planning system (TPS) can usually only be performed using a cumbersome multi-step procedure where many user interactions are needed. This means automation is needed for usage in clinical routine. In addition, because of the long computing time in MCTP, optimization of the MC calculations is essential. For these purposes a new graphical user interface (GUI)-based photon MC environment has been developed resulting in a very flexible framework. By this means appropriate MC transport methods are assigned to different geometric regions by still benefiting from the features included in the TPS. In order to provide a flexible MC environment, the MC particle transport has been divided into different parts: the source, beam modifiers and the patient. The source part includes the phase-space source, source models and full MC transport through the treatment head. The beam modifier part consists of one module for each beam modifier. To simulate the radiation transport through each individual beam modifier, one out of three full MC transport codes can be selected independently. Additionally, for each beam modifier a simple or an exact geometry can be chosen. Thereby, different complexity levels of radiation transport are applied during the simulation. For the patient dose calculation, two different MC codes are available. A special plug-in in Eclipse providing all necessary information by means of Dicom streams was used to start the developed MC GUI. The implementation of this framework separates the MC transport from the geometry and the modules pass the particles in memory; hence, no files are used as the interface. The implementation is realized for 6 and 15 MV beams of a Varian Clinac 2300 C/D. Several applications demonstrate the usefulness of the framework. Apart from applications dealing with the beam modifiers, two patient cases are shown. Thereby

  14. Inverse treatment planning for spinal robotic radiosurgery: an international multi-institutional benchmark trial.

    Science.gov (United States)

    Blanck, Oliver; Wang, Lei; Baus, Wolfgang; Grimm, Jimm; Lacornerie, Thomas; Nilsson, Joakim; Luchkovskyi, Sergii; Palazon Cano, Isabel; Shou, Zhenyu; Ayadi, Myriam; Treuer, Harald; Viard, Romain; Siebert, Frank-Andre; Chan, Mark K H; Hildebrandt, Guido; Dunst, Jürgen; Imhoff, Detlef; Wurster, Stefan; Wolff, Robert; Romanelli, Pantaleo; Lartigau, Eric; Semrau, Robert; Soltys, Scott G; Schweikard, Achim

    2016-01-01

    Stereotactic radiosurgery (SRS) is the accurate, conformal delivery of high-dose radiation to well-defined targets while minimizing normal structure doses via steep dose gradients. While inverse treatment planning (ITP) with computerized optimization algorithms are routine, many aspects of the planning process remain user-dependent. We performed an international, multi-institutional benchmark trial to study planning variability and to analyze preferable ITP practice for spinal robotic radiosurgery. 10 SRS treatment plans were generated for a complex-shaped spinal metastasis with 21 Gy in 3 fractions and tight constraints for spinal cord (V14Gy 95%). The resulting plans were rated on a scale from 1 to 4 (excellent-poor) in five categories (constraint compliance, optimization goals, low-dose regions, ITP complexity, and clinical acceptability) by a blinded review panel. Additionally, the plans were mathemati-cally rated based on plan indices (critical structure and target doses, conformity, monitor units, normal tissue complication probability, and treatment time) and compared to the human rankings. The treatment plans and the reviewers' rankings varied substantially among the participating centers. The average mean overall rank was 2.4 (1.2-4.0) and 8/10 plans were rated excellent in at least one category by at least one reviewer. The mathematical rankings agreed with the mean overall human rankings in 9/10 cases pointing toward the possibility for sole mathematical plan quality comparison. The final rankings revealed that a plan with a well-balanced trade-off among all planning objectives was preferred for treatment by most par-ticipants, reviewers, and the mathematical ranking system. Furthermore, this plan was generated with simple planning techniques. Our multi-institutional planning study found wide variability in ITP approaches for spinal robotic radiosurgery. The participants', reviewers', and mathematical match on preferable treatment plans and ITP

  15. Treatment planning with functional MRI; Strahlentherapieplanung mit der funktionellen MRT

    Energy Technology Data Exchange (ETDEWEB)

    Georg, P. [EBG MedAustron GmbH, Wiener Neustadt (Austria); Medizinische Universitaet Wien, Christian Doppler Labor fuer die Medizinische Strahlenforschung, Wien (Austria); Andrzejewski, P.; Georg, D. [Medizinische Universitaet Wien, Christian Doppler Labor fuer die Medizinische Strahlenforschung, Wien (Austria); Medizinische Universitaet Wien, Abteilung fuer medizinische Strahlenphysik, Univ. Klinik fuer Strahlentherapie, Wien (Austria); Pinker, K. [Medizinische Universitaet Wien, Christian Doppler Labor fuer die Medizinische Strahlenforschung, Wien (Austria); Medizinische Universitaet Wien, Abteilung fuer molekulare Bildgebung, Univ. Klinik fuer Radiologie und Nuklearmedizin, Wien (Austria)

    2015-12-15

    The aim of magnetic resonance imaging (MRI) guided radiotherapy is high precision in treatment delivery. With new developments it is possible to focus the high dose irradiation on the tumor while sparing the surrounding tissue. The achievements in precision of the treatment planning and delivery warrant equally precise tumor definition. In conventional radiation therapy it is necessary to carry out a planning computed tomography (CT). For many tumors there is also need for an additional morphological MRI because of more accurate tumor definition. In standard radiotherapy the tumor volume is irradiated with a homogeneous dose. The aim of functional multiparametric MRI is to visualize and quantify biological, physiological and pathological processes at the cellular and molecular levels. Based on this information it is possible to elucidate tumor biology and identify subvolumes of more aggressive behavior. They are often radiotherapy-resistant, leading to tumor recurrence thus requiring further dose escalation. The concept of inhomogeneous tumor irradiation according to its biological behavior is called dose painting. Dose painting is technically feasible. The expected clinical benefit is motivated by selective treatment adaptations based on biological tumor characteristics. Tumors show variable response to therapy underlining the need for individual treatment plans. This approach may lead not only to higher local control but also to better sparing of normal surrounding tissue. With the clinical implementation of dose painting, improvements in the therapeutic outcome can be expected. Due to the existing technical challenges, extensive collaboration between radiation oncologists, radiologists, medical physicists and radiation biologists is needed. (orig.) [German] Die Strahlentherapieplanung mit der funktionellen Magnetresonanztomographie (fMRT) zielt auf eine Hochpraezisionsradiotherapie ab. Mit den modernen Technologien ist es moeglich, die Strahlentherapie nahezu

  16. Sci—Thur PM: Planning and Delivery — 02: Treatment planning workflow for very high-energy electron beam radiotherapy

    Energy Technology Data Exchange (ETDEWEB)

    Bazalova, Magdalena; Qu, Bradley; Palma, Bianey; Maxim, Peter; Loo, Billy [Stanford University, Stanford, CA (United States); Hårdemark, Bjorn; Hynning, Elin [RaySearch Laboratories AB, Stockholm (Sweden)

    2014-08-15

    Purpose: To develop treatment planning workflow for rapid radiotherapy delivered with very-high energy electron (VHEE) scanning beam. Methods: VHEE radiotherapy treatment planning was performed by linking Monte Carlo (MC) dose calculations with inverse optimization in a research version of RayStation. In order to study a number of treatment parameters, a Matlab graphical user interface (GUI) for calculation of VHEE beamlet dose was developed. Through the GUI, EGSnrc MC simulations were run for a number of beam energies, number of beams, beamlet spot and grid sizes, and machine bore sizes. VHEE plans for a pediatric patient with a 4.3 cm{sup 3} brain target optimized with spot-scanning algorithm in RayStation were compared to the clinically delivered 6 MV VMAT plan. Results and Discussion: VHEE beam energy had the largest effect on the quality of dose distributions. For the same target dose, the mean doses to critical organs decreased by 10–15% when planned with 100 MeV compared to 60 MeV. VHEE plans calculated with 36 beams outperformed plans calculated with 13 and 17 beams. While beamlet spacing and bore size had a small effect on VHEE dose distributions, 0.1-3mm beamlet sizes resulted in identical dose distributions. Critical organ doses were by up to 70% lower in the best VHEE plan compared to the clinical 6 MV VMAT plan. Conclusions: We have developed a GUI for MC beamlet generation for treatment planning of VHEE radiotherapy. We have demonstrated that pediatric VHEE plans resulted in significant critical organ dose sparing compared to the clinical VMAT plan.

  17. Assessments for High Dose Radionuclide Therapy Treatment Planning

    International Nuclear Information System (INIS)

    Advances in the biotechnology of cell-specific targeting of cancer, and the increased number of clinical trials involving treatment of cancer patients with radiolabeled antibodies, peptides, and similar delivery vehicles have led to an increase in the number of high-dose radionuclide therapy procedures. Optimized radionuclide therapy for cancer treatment is based on the concept of absorbed dose to the dose-limiting normal organ or tissue. The limiting normal tissue is often the red marrow, but it may sometimes be lungs, liver, intestinal tract, or kidneys. Appropriate treatment planning requires assessment of radiation dose to several internal organs and tissues, and usually involves biodistribution studies in the patient using a tracer amount of radionuclide bound to the targeting agent and imaged at sequential time points using a planar gamma camera. Time-activity curves are developed from the imaging data for the major organs tissues of concern, for the whole body, and sometimes for selected tumors. Patient-specific factors often require that dose estimates be customized for each patient. The Food and Drug Administration regulates the experimental use of investigational new drugs and requires reasonable calculation of radiation absorbed dose to the whole body and to critical organs using methods prescribed by the Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine. Review of high-dose studies in the U.S. and elsewhere shows that (1) some studies are conducted with minimal dosimetry, (2) the marrow dose is difficult to establish and is subject to large uncertainties, and (3) despite the general availability of MIRD software, internal dosimetry methods are often inconsistent from one clinical center to another

  18. Assessments for high dose radionuclide therapy treatment planning

    International Nuclear Information System (INIS)

    Advances in the biotechnology of cell specific targeting of cancer and the increased number of clinical trials involving treatment of cancer patients with radiolabelled antibodies, peptides, and similar delivery vehicles have led to an increase in the number of high dose radionuclide therapy procedures. Optimised radionuclide therapy for cancer treatment is based on the concept of absorbed dose to the dose limiting normal organ or tissue. The limiting normal tissue is often the red marrow, but it may sometimes be the lungs, liver, intestinal tract, or kidneys. Appropriate treatment planning requires assessment of radiation dose to several internal organs and tissues, and usually involves biodistribution studies in the patient using a tracer amount of radionuclide bound to the targeting agent and imaged at sequential timepoints using a planar gamma camera. Time-activity curves are developed from the imaging data for the major organ tissues of concern, for the whole body and sometimes for selected tumours. Patient specific factors often require that dose estimates be customised for each patient. In the United States, the Food and Drug Administration regulates the experimental use of investigational new drugs and requires 'reasonable calculation of radiation absorbed dose to the whole body and to critical organs' using the methods prescribed by the Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine. Review of high dose studies shows that some are conducted with minimal dosimetry, that the marrow dose is difficult to establish and is subject to large uncertainties. Despite the general availability of software, internal dosimetry methods often seem to be inconsistent from one clinical centre to another. (author)

  19. Implementation of hypoxia imaging into treatment planning and delivery

    International Nuclear Information System (INIS)

    Purpose: To review the current status of implementation of functional hypoxia imaging in radiotherapy (RT) planning and treatment delivery. Methods: Before biological imaging techniques such as positron emission tomography (PET) or magnetic resonance (MR) can be used for individual RT adaptation, three main requirements have to be fulfilled. First, tissue parameters have to be derived from the imaging data that correlate with individual therapy outcome. Then, the spatial and temporal stability of hypoxia PET images needs to be established. Finally, the dose painting (DP) concepts have to be practically feasible to be used as a basis for clinical trials. Results: A number of recent clinical studies could show the correlation of hypoxia PET imaging with different tracers and RT outcome. Most of the studies revealed a correlation between mean or maximum values and parameters assessed from the PET avid volume and treatment success, only few investigations used quantitative imaging. Multiparametric imaging seems to be very valuable. Recently, the spatial and temporal stability of hypoxia PET attracted attention. Temporal changes in the distribution of functional tumour properties were reported. Furthermore, technical feasibility of DP by contours (DPC) as well as DP by numbers (DPBN) was shown by several investigators. The challenge is now to design clinical studies in order to prove the impact of DP treatments on individual therapy success. Conclusion: A patient-specific adaptation of RT based on functional hypoxia imaging with PET is possible and promising. Conceptual feasibility could be shown for DPBN whereas to date, only DPC seems to be plausible and feasible in a clinical context.

  20. Neutron field characterization in the installation for BNCT study in the IEA-R1 reactor; Caracterizacao do campo de neutrons na instalacao para estudo em BNCT no reator IEA-R1

    Energy Technology Data Exchange (ETDEWEB)

    Carneiro Junior, Valdeci

    2008-07-01

    This work aims to characterize the mixed neutron and gamma field, in the sample irradiation position, in a research installation for Boron Neutron Capture Therapy (BNCT), in the IPEN IEA-R1 reactor. The BNCT technique has been studied as a safe and selective option in the treatment of resistant cancerigenous tumors or considered non-curable by the conventional techniques, for example, the Glioblastoma Multiform - a brain cancerigenous tumor. Neutron flux measurements were carried out: thermal, resonance and fast, as well as neutron and gamma rays doses, in the sample position, using activation foils detectors and thermoluminescent dosimeters. For the determination of the neutron spectrum and intensity, a set of different threshold activation foils and gold foils covered and uncovered with cadmium irradiated in the installation was used, analyzed by a high Pure Germanium semiconductor detector, coupled to an electronic system suitable for gamma spectrometry. The results were processed with the SAND-BP code. The doses due to gamma and neutron rays were determined using thermoluminescent dosimeters TLD 400 and TLD 700 sensitive to gamma and TLD 600, sensitive to neutrons. The TLDs were selected and used for obtaining the calibration curves - dosimeter answer versus dose - from each of the TLD three types, which were necessary to calculate the doses due to neutron and gamma, in the sample position. The radiation field, in the sample irradiation position, was characterized flux for thermal neutrons of 1.39.10{sup 8} {+-} 0,12.10{sup 8} n/cm{sup 2}s the doses due to thermal neutrons are three times higher than those due to gamma radiation and confirm the reproducibility and consistency of the experimental findings obtained. Considering these results, the neutron field and gamma radiation showed to be appropriated for research in BNCT. (author)

  1. SU-E-T-575: Isocenter Shifts in Treatment Planning and Its Clinical Implications

    Energy Technology Data Exchange (ETDEWEB)

    Ahmed, Y; Damiani, S; Cao, Y; Jamshidi, A [Long Island Jewish Medical Center, New Hyde Park, NY (United States)

    2014-06-01

    Purpose: To investigate causes of isocenter shifts in treatment planning and its clinical impact on patient treatment efficiency and safety. Methods/Materials: Treatment planning data of 340 patients under treatment over 8 weeks period were gathered to identify isocenter shifts according to site of the treatment, types of treatment plan or types of the machine used. Treatment plans included inversed and forward IMRT, as well as 3D plans. Treatment sites included pelvis, chest, abdomen, breasts, head and necks and extremities. Re-planning were performed without the isocenter shift for pelvis and chest plans, the dosimetric parameters such as PTV coverage, and dose sparing of OARs of these plans were analyzed and compared. Results/Discussions: Results showed that the isocenter shift was always necessary for some of sites such as breasts, two or more distinctive PTVs, or special cases such as large PTV treated with enhanced dynamic wedge. Many other cases, the re-planning results indicated 53% of the plans that the same quality of the plan can be achieved without the shift of the isocenter. Repositioning patients on a daily basis demanded unambiguous instructions for therapists for patient setups, and additional time to perform the shifts before treatment. Opportunities for error propagation exist during the communication and hand-over of such plans. Conclusion: Isocenter shifts demanded unambiguous instructions and times for therapists for daily patient setups, therefore it impacted both safety and efficiency of the patient treatment. Based on the analysis, the isocenter shifts were unavoidable for cases such as treatment of multiple sites, overcoming limitations of treatment machines, and/or sometime better dosimetry. However, we found many initially proposed shifts may have been eliminated either by careful planning or by improved CT simulation process such as detailed review of the images and localization of the PTV during simulation.

  2. Safety Improvement in Radiotherapy Treatment Plan. Planning vs Redundant Check vs in vivo Dosimetry

    International Nuclear Information System (INIS)

    In Cuba it is mandatory to have an independent monitor units check before any radiotherapy treatment is started. The main objective of this paper is to enhance the safety of the radiotherapy planning by developing and testing a practical tool to double check the monitor units calculation for external beam high energy photon therapy. A software for monitor units (MUs) verification was designed and coded. It considers the common in clinical practice isocentric set-ups. The in vivo dosimetry measurements were done with a silicon diode system for 6 MV photon beams to support the validation of the software. The results show a discrepancy within 5% between the 3 methods which is in accordance with international recommendations. (Author)

  3. Cell death following BNCT: A theoretical approach based on Monte Carlo simulations

    International Nuclear Information System (INIS)

    In parallel to boron measurements and animal studies, investigations on radiation-induced cell death are also in progress in Pavia, with the aim of better characterisation of the effects of a BNCT treatment down to the cellular level. Such studies are being carried out not only experimentally but also theoretically, based on a mechanistic model and a Monte Carlo code. Such model assumes that: (1) only clustered DNA strand breaks can lead to chromosome aberrations; (2) only chromosome fragments within a certain threshold distance can undergo misrejoining; (3) the so-called 'lethal aberrations' (dicentrics, rings and large deletions) lead to cell death. After applying the model to normal cells exposed to monochromatic fields of different radiation types, the irradiation section of the code was purposely extended to mimic the cell exposure to a mixed radiation field produced by the 10B(n,α) 7Li reaction, which gives rise to alpha particles and Li ions of short range and high biological effectiveness, and by the 14N(n,p)14C reaction, which produces 0.58 MeV protons. Very good agreement between model predictions and literature data was found for human and animal cells exposed to X- or gamma-rays, protons and alpha particles, thus allowing to validate the model for cell death induced by monochromatic radiation fields. The model predictions showed good agreement also with experimental data obtained by our group exposing DHD cells to thermal neutrons in the TRIGA Mark II reactor of University of Pavia; this allowed to validate the model also for a BNCT exposure scenario, providing a useful predictive tool to bridge the gap between irradiation and cell death.

  4. Cell death following BNCT: A theoretical approach based on Monte Carlo simulations

    Energy Technology Data Exchange (ETDEWEB)

    Ballarini, F., E-mail: francesca.ballarini@pv.infn.it [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy); Bakeine, J. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy); Bortolussi, S. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy); Bruschi, P. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy); Cansolino, L.; Clerici, A.M.; Ferrari, C. [University of Pavia, Department of Surgery, Experimental Surgery Laboratory, Pavia (Italy); Protti, N.; Stella, S. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy); Zonta, A.; Zonta, C. [University of Pavia, Department of Surgery, Experimental Surgery Laboratory, Pavia (Italy); Altieri, S. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy)

    2011-12-15

    In parallel to boron measurements and animal studies, investigations on radiation-induced cell death are also in progress in Pavia, with the aim of better characterisation of the effects of a BNCT treatment down to the cellular level. Such studies are being carried out not only experimentally but also theoretically, based on a mechanistic model and a Monte Carlo code. Such model assumes that: (1) only clustered DNA strand breaks can lead to chromosome aberrations; (2) only chromosome fragments within a certain threshold distance can undergo misrejoining; (3) the so-called 'lethal aberrations' (dicentrics, rings and large deletions) lead to cell death. After applying the model to normal cells exposed to monochromatic fields of different radiation types, the irradiation section of the code was purposely extended to mimic the cell exposure to a mixed radiation field produced by the {sup 10}B(n,{alpha}) {sup 7}Li reaction, which gives rise to alpha particles and Li ions of short range and high biological effectiveness, and by the {sup 14}N(n,p){sup 14}C reaction, which produces 0.58 MeV protons. Very good agreement between model predictions and literature data was found for human and animal cells exposed to X- or gamma-rays, protons and alpha particles, thus allowing to validate the model for cell death induced by monochromatic radiation fields. The model predictions showed good agreement also with experimental data obtained by our group exposing DHD cells to thermal neutrons in the TRIGA Mark II reactor of University of Pavia; this allowed to validate the model also for a BNCT exposure scenario, providing a useful predictive tool to bridge the gap between irradiation and cell death.

  5. Cell death following BNCT: a theoretical approach based on Monte Carlo simulations.

    Science.gov (United States)

    Ballarini, F; Bakeine, J; Bortolussi, S; Bruschi, P; Cansolino, L; Clerici, A M; Ferrari, C; Protti, N; Stella, S; Zonta, A; Zonta, C; Altieri, S

    2011-12-01

    In parallel to boron measurements and animal studies, investigations on radiation-induced cell death are also in progress in Pavia, with the aim of better characterisation of the effects of a BNCT treatment down to the cellular level. Such studies are being carried out not only experimentally but also theoretically, based on a mechanistic model and a Monte Carlo code. Such model assumes that: (1) only clustered DNA strand breaks can lead to chromosome aberrations; (2) only chromosome fragments within a certain threshold distance can undergo misrejoining; (3) the so-called "lethal aberrations" (dicentrics, rings and large deletions) lead to cell death. After applying the model to normal cells exposed to monochromatic fields of different radiation types, the irradiation section of the code was purposely extended to mimic the cell exposure to a mixed radiation field produced by the (10)B(n,α) (7)Li reaction, which gives rise to alpha particles and Li ions of short range and high biological effectiveness, and by the (14)N(n,p)(14)C reaction, which produces 0.58 MeV protons. Very good agreement between model predictions and literature data was found for human and animal cells exposed to X- or gamma-rays, protons and alpha particles, thus allowing to validate the model for cell death induced by monochromatic radiation fields. The model predictions showed good agreement also with experimental data obtained by our group exposing DHD cells to thermal neutrons in the TRIGA Mark II reactor of the University of Pavia; this allowed to validate the model also for a BNCT exposure scenario, providing a useful predictive tool to bridge the gap between irradiation and cell death. PMID:21481595

  6. On-line neutron beam monitoring of the Finnish BNCT facility

    International Nuclear Information System (INIS)

    A Boron Neutron Capture Therapy (BNCT) facility has been built at the FiR 1 research reactor of VTT Chemical Technology in Espoo, Finland. The facility is currently undergoing dosimetry characterisation and neutron beam operation research for clinical trials. The healthy tissue tolerance study, which was carried out in the new facility during spring 1998, demonstrated the reliability and user-friendliness of the new on-line beam monitoring system designed and constructed for BNCT by VTT Chemical Technology. The epithermal neutron beam is monitored at a bismuth gamma shield after an aluminiumfluoride-aluminium moderator. The detectors are three pulse mode U235-fission chambers for epithermal neutron fluence rate and one current mode ionisation chamber for gamma dose rate. By using different detector sensitivities the beam intensity can be measured over a wide range of reactor power levels (0.001-250 kW). The detector signals are monitored on-line with a virtual instrumentation (LabView) based PC-program, which records and displays the actual count rates and total counts of the detectors in the beam. Also reactor in-core power instrumentation and control rod positions can be monitored via another LabView application. The main purpose of the monitoring system is to provide a dosimetric link to the dose in a patient during the treatment, as the fission chamber count rates have been calibrated to the induced thermal neutron fluence rate and to the absorbed dose rate at reference conditions in a tissue substitute phantom

  7. On-line neutron beam monitoring of the Finnish BNCT facility

    Science.gov (United States)

    Tanner, Vesa; Auterinen, Iiro; Helin, Jori; Kosunen, Antti; Savolainen, Sauli

    1999-02-01

    A Boron Neutron Capture Therapy (BNCT) facility has been built at the FiR 1 research reactor of VTT Chemical Technology in Espoo, Finland. The facility is currently undergoing dosimetry characterisation and neutron beam operation research for clinical trials. The healthy tissue tolerance study, which was carried out in the new facility during spring 1998, demonstrated the reliability and user-friendliness of the new on-line beam monitoring system designed and constructed for BNCT by VTT Chemical Technology. The epithermal neutron beam is monitored at a bismuth gamma shield after an aluminiumfluoride-aluminium moderator. The detectors are three pulse mode U 235-fission chambers for epithermal neutron fluence rate and one current mode ionisation chamber for gamma dose rate. By using different detector sensitivities the beam intensity can be measured over a wide range of reactor power levels (0.001-250 kW). The detector signals are monitored on-line with a virtual instrumentation (LabView) based PC-program, which records and displays the actual count rates and total counts of the detectors in the beam. Also reactor in-core power instrumentation and control rod positions can be monitored via another LabView application. The main purpose of the monitoring system is to provide a dosimetric link to the dose in a patient during the treatment, as the fission chamber count rates have been calibrated to the induced thermal neutron fluence rate and to the absorbed dose rate at reference conditions in a tissue substitute phantom.

  8. Generalizable Class Solutions for Treatment Planning of Spinal Stereotactic Body Radiation Therapy

    International Nuclear Information System (INIS)

    Purpose: Spinal stereotactic body radiation therapy (SBRT) continues to emerge as an effective therapeutic approach to spinal metastases; however, treatment planning and delivery remain resource intensive at many centers, which may hamper efficient implementation in clinical practice. We sought to develop a generalizable class solution approach for spinal SBRT treatment planning that would allow confidence that a given plan provides optimal target coverage, reduce integral dose, and maximize planning efficiency. Methods and Materials: We examined 91 patients treated with spinal SBRT at our institution. Treatment plans were categorized by lesion location, clinical target volume (CTV) configuration, and dose fractionation scheme, and then analyzed to determine the technically achievable dose gradient. A radial cord expansion was subtracted from the CTV to yield a planning CTV (pCTV) construct for plan evaluation. We reviewed the treatment plans with respect to target coverage, dose gradient, integral dose, conformality, and maximum cord dose to select the best plans and develop a set of class solutions. Results: The class solution technique generated plans that maintained target coverage and improved conformality (1.2-fold increase in the 95% van’t Riet Conformation Number describing the conformality of a reference dose to the target) while reducing normal tissue integral dose (1.3-fold decrease in the volume receiving 4 Gy (V4Gy) and machine output (19% monitor unit (MU) reduction). In trials of planning efficiency, the class solution technique reduced treatment planning time by 30% to 60% and MUs required by ∼20%: an effect independent of prior planning experience. Conclusions: We have developed a set of class solutions for spinal SBRT that incorporate a pCTV metric for plan evaluation while yielding dosimetrically superior treatment plans with increased planning efficiency. Our technique thus allows for efficient, reproducible, and high-quality spinal SBRT

  9. Automated planning of ablation targets in atrial fibrillation treatment

    Science.gov (United States)

    Keustermans, Johannes; De Buck, Stijn; Heidbüchel, Hein; Suetens, Paul

    2011-03-01

    Catheter based radio-frequency ablation is used as an invasive treatment of atrial fibrillation. This procedure is often guided by the use of 3D anatomical models obtained from CT, MRI or rotational angiography. During the intervention the operator accurately guides the catheter to prespecified target ablation lines. The planning stage, however, can be time consuming and operator dependent which is suboptimal both from a cost and health perspective. Therefore, we present a novel statistical model-based algorithm for locating ablation targets from 3D rotational angiography images. Based on a training data set of 20 patients, consisting of 3D rotational angiography images with 30 manually indicated ablation points, a statistical local appearance and shape model is built. The local appearance model is based on local image descriptors to capture the intensity patterns around each ablation point. The local shape model is constructed by embedding the ablation points in an undirected graph and imposing that each ablation point only interacts with its neighbors. Identifying the ablation points on a new 3D rotational angiography image is performed by proposing a set of possible candidate locations for each ablation point, as such, converting the problem into a labeling problem. The algorithm is validated using a leave-one-out-approach on the training data set, by computing the distance between the ablation lines obtained by the algorithm and the manually identified ablation points. The distance error is equal to 3.8+/-2.9 mm. As ablation lesion size is around 5-7 mm, automated planning of ablation targets by the presented approach is sufficiently accurate.